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Pharmaceutical Innovation & Knowledge Management Abstract 
ABSTRACT 
Pharmaceutical innovation is a complex task that is reliant upon the availability of 
relevant information and knowledge. To date, the aspects of how, when and where 
this information and knowledge is applied throughout the drug development 
processes, has been lightly researched. Furthermore, the science of Knowledge 
Management can potentially aid the drug development processes and allow an 
organisation to reduce the time and costs associated with innovative drug 
development. This thesis examines these issues in greater depth through a series of 
case studies conducted within the innovative pharmaceutical organisation 
AstraZeneca. The end result of this research is a Knowledge Management tool set 
which is capable of driving pharmaceutical innovation. 
The thesis firstly explores the literature associated with innovation, pharmaceutical 
innovation, Knowledge Management and Intellectual Capital. The second aspect of 
the research used the literature review to develop a novel research framework with 
which to examine pharmaceutical innovation in greater detail. The third stage of the 
research utilised the results of the previous stages to develop a novel Innovation and 
Knowledge Management focused model. The fourth stage of this research utilised the 
research findings to develop a Knowledge Management tool set that can be used to 
drive innovation. This tool set is comprised of three distinct levels of functionality, 
namely: the social and collaborative level, the information assimilation and 
dissemination level and a level that encourages the capture of knowledge. The final 
stage of the research concludes with a discussion on evaluating Knowledge 
Management and its use in driving pharmaceutical innovation. 
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CHAPTERI 
INTRODUCTION TO THE REA SEARCH 
1.0 INTRODUCTION 
This thesis has developed from a three year collaborative research project with 
Loughborough University and the Clinical Department of AstraZeneca, R&D, UK. 
The research focuses upon the use of Knowledge Management tools and strategies to 
drive pharmaceutical innovation and evaluates the rise to prominence of Knowledge 
Management as a strategy to drive innovation. 
This chapter places the research into context and introduces the concepts associated 
with pharmaceutical innovation and Knowledge Management. It continues to 
introduce the case study organisation of AstraZcneca and the rationale behind the 
research, before concluding with an outline of the thesis structure. 
1.1 BACKGROUND TO THE RESEARCH 
The pharmaceutical industry is a unique and challenging environment where the 
process of launching a new drug product takes between 10 and 14 years and incurs 
substantial expense (Davis, 2001). Faced with the challenges associated with this 
lengthy process and the spiralling upward costs of modem R&D, pharmaceutical 
companies are exploring ways to cut the time and resource required to release a new 
medical drug. Couple high R&D costs with fierce external competition from rivals 
and generic manufacturers, and it becomes clear that pharmaceutical companies are 
justified to worry about where their future profits are coming from (DiMasi et al. 
1991). The days of large pharmaceutical companies dominating the R&D market are 
gone with the arrival of small agile competitors from the biotechnology field now 
supplying the majority of innovation within the pharmaceutical field (Schweizer, 
2005). Pharmaceutical companies are being forced to take stock and address the very 
basis of innovation and look at how they can streamline the drug development 
processes. 
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Due to the complexities of drug development the requirements for knowledge and 
information are great. As Zack (1999) states, the trend of pharmaceutical companies 
merging and acquiring competitors and biotechnology companies is resulting in the 
wholesale distribution of the knowledge required to drive the development processes. 
Reining in, capturing and disseminating this knowledge thus becomes a major 
problem for pharmaceutical companies as the sheer scope and wealth of knowledge 
and information sources required to innovate are vast. However, in the stark 
competitive reality of pharmaceutical R&D, companies are being driven to address 
these issues and one such approach that has been suggested, is the use of the 
emergent science of Knowledge Management. 
Knowledge Management is concerned with allowing employees to collaborate and 
innovate by providing them with the necessary knowledge to effectively fulfil their 
role (Havens & Knapp, 1999). Translating the benefits of Knowledge Management to 
the pharmaceutical industry, should equate, in theory, to the provision of a 
competitive advantage through retaining and building upon corporate knowledge 
(Wang, 2006). The progression of a chemical compound to a marketable drug that 
acts on a disease is a complex series of interacting processes, and when faced with 
challenges such as these it is not surprising that few drugs progress beyond the R&D 
lab: 
"Pharmaceutical R&D is like juggling snakes--you must ensure that a drug can be 
readilyformulated, remains stable when stored, resists destruction by stomach acids, 
gets into patients' bloodstreams, and doesn't break down into toxic compounds when 
metabolised. It's almost unheard-offor a randomly selected compound to meet all 
these requirements without major tinkering that takes months to years. " (Stipp, 2005) 
Thus it would seem that serendipity plays a small part in the initial development 
processes. At present, little is known on how these processes occur and how the 
pharmaceutical R&D employees locate the knowledge required to drive innovation 
and produce a workable and valuable drug over the 12 years of intense work 
(Dougherty, 2006). 
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Few studies have conclusively addressed these aspects and little academic literature 
can offer guidance to an organisation as it attempts to manage and apply its 
knowledge more effectively. This is largely due to the complex web of interrelated 
processes that support each other. Furthermore, each drug development process poses 
problems and beneath these problems will be a further set of problems that require 
further answers in order to progress (Bouthillier & Shearer, 2002). Research by du 
Plessis (2005) suggests that Knowledge Management would be the ideal vehicle to 
unravel and shed light upon these processes: 
"Knowledge Management takes aim at evolving people's attitudes and work 
behaviours to effect new heights of collaboration-the international sharing of ideas, 
information, knowledge, and work itsel(-in support of a business need It is about 
changing people's value paradigm from "my information is power " to "sharing is 
power". It's about large-scale cultural change, new incentive systems and 
performance metrics, and learning and education. It focuses on (re)shaping the 
attitudes and behaviours of people so they can ensure the ready availability and 
resolute application of both personal and institutional knowledge. " (du Plessis, 
2005) 
The potential of Knowledge Management to deliver these benefits has not escaped 
the notice of the pharmaceutical companies. Research by Hung et al., (2006), Wang 
(2005), Davenport & Peitsch (2005) and Metaxiotis & Psarras (2005), amongst 
others, espouse the virtues of adopting pharmaceutical Knowledge Management, but' 
conclude that Knowledge Management in practice is a rather subdued affair and 
rarely fulfils on its promise. Pharmaceutical studies by Hung et al. (2005) suggest that 
although Knowledge Management technology is in place within major companies, 
the cohesive integration of Knowledge Management practices falls behind and may 
even hinder knowledge exchange. 
Critics of Knowledge Management are quick to point out that it is, in reality, a 
management fad representing little more than a revamped facet of infort-nation 
management (Wilson, 2002). 
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However, the sheer wealth of published Knowledge Management literature within 
other industries (e. g. Un & Cuervo-Cazurra, 2004) and the interest in Knowledge 
Management within the pharmaceutical industry organisations, such as AstraZeneca 
(Roth, 2003), suggests fad or not, Knowledge Management is at least worthy of 
attention. This is particularly emphasised by research from The Association of British 
Pharmaceutical Industry (2006) which i' ndicates that British pharmaceutical 
manufacturers invested E3.2 billion in 2004 in R&D alone. With the average drug 
requiring L550 million of investment and with no guarantee of success, the appeal of 
cutting development times and using employee knowledge more efficiently is 
obvious. Yes, the advances in drug development technology (e. g. High Throughput 
Screening) and computing power are improving the capture and analysis of 
information and data (Donelly, 2003), but the impact of Knowledge Management on 
the knowledge required to utilise and act on this data and information within the drug 
development processes is rather less apparent. 
The slow shift in the approach of Knowledge Management from the management of 
the tacit knowledge of the employee, to a holistic organisational 'capability' approach 
(Argote et al. 2003) would appear to hold promise. However, assigning metrics to 
measure and validate the performance of a Knowledge Management strategy still 
remains ambiguous and notoriously difficult (Marr & Starovic, 2003). As Knowledge 
Management is evolving, the means to measure knowledge is also evolving in 
tandem. The Intellectual Capital approach favoured by authors such as Kaplan & 
Norton (2001) and Edvinsson & Malone (1997) assigns measurable value to 
knowledge driven activities, yet to date, little work has been conducted that 
specifically targets pharmaceutical innovation and drug development. 
The research project described in this thesis has been commissioned to address some 
of the issues raised above and pays particular attention to the relationship between 
pharmaceutical innovation and Knowledge Management. 
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The research seeks to clarify the importance of Knowledge Management through the 
use of metrics, and to shed light upon the knowledge and information needs of the 
employees. 
1.2 INDUSTRIAL SPONSOR 
AstraZeneca is one of the world's leading pharmaceutical companies with an 
operating profit of $6.5 billion and a total sales figure of $24 billion. The company 
portfolio operates over a variety of disease areas and top growth medications include: 
Arimidex (cancer), Crestor (cardiovascular), Nexium (gastrointestinal disease), 
Seroquel (schizophrenia) and Symbicort (asthma and chronic obstructive pulmonary 
disease). The company employs over 12,000 R&D personnel and invests a total of 
$14 million a day into the development of new medicines across the group. Within 
the UK its R&D functions are situated across eight sites with the research described 
in this thesis conducted primarily at the Chamwood R&D site in Leicestershire. 
The Charnwood site concentrates upon the development of medicines that target 
asthma, chronic bronchitis, emphysema and rheumatoid arthritis and osteoarthritis. 
The case study is focused upon the Clinical function which acts as the centre of 
excellence for the company's clinical inflammation knowledge. The company prides 
itself on its creativity and its innovative approach to drug development, the mantra 
taken from the AstraZeneca website reads: 
"At AstraZeneca, innovation is about more than just research. We aim to stimulate 
continued creativity throughout our organisation by maintaining a culture in which 
our people feel valued, energised and rewardedfor their ideas and contribution to 
our success - ideas which can make a difference in all aspects of our business. 
(AstraZeneca, 2006). 
Throughout the business, collaboration is regarded in high esteem and as such, during 
the research, the business underwent restructuring to encourage cross-project working 
and collaboration. 
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The results of this restructuring are discussed in later chapters, but were intended to 
produce a flatter organisational structure replacing the previous hierarchical structure 
that was deemed to inhibit effective drug development. 
The company has responded to external competition and changes in the value of its 
portfolio, as a number of key products face patent expiry over the next decade, by 
nominating a number of new chemical entities into Phase III trials in 2005. Building 
upon and developing a long term drug development pipeline by maximising short 
term growth within the early stages of the internal R&D processes is a priority. The 
organisation is also increasing its focus upon the external acquisition of innovation 
through in-licensing and biotechnology buy outs, and is actively working upon 
expanding its current four therapy areas to five with the development of a New 
Opportunities group, specifically created to spearhead innovative work. 
1.3 RESEARCH RATIONALE 
AstraZeneca R&D Clinical at Chamwood is committed to producing high quality 
medicines and recognised that Knowledge Management may be able to offer a 
tangible benefit within the Clinical environment of the company. A number of 
Knowledge Management schemes have been running within the company and in 
recent years a long term Knowledge Management (KM) and Information Systems 
(IS) strategy is in the process of being implemented across the R&D function within 
the UK. The Knowledge Management strategy was developed from a variety of pilot 
schemes in operation that lacked focus and cohesion and hence IS management 
deemed it was necessary to take ownership of the various schemes and ensure they 
represented the interests of AstraZeneca. This research was commissioned to analyse 
the impact of Knowledge Management activities on innovation and knowledge 
sharing within the organisation. In light of this, a key component of the research is to 
analyse the IS/ KM strategy and suggest the means to improve, standardise and 
measure the value of Knowledge Management throughout the organisation. The 
following section outlines the structure of the thesis with regards to the areas of 
Knowledge Management and innovation within AstraZeneca. 
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1.4 STRUCTURE OF THE THESIS 
The thesis chapters and scope are outlined in the following section with reference to 
the papers and reports on which the chapters are based. 
1.4.1 CHAPTER 1: INTRODUCTION 
This Chapter provides a brief introduction to the research scope, the rationale behind 
the research, the case study organisation and the structure of the thesis. 
1.4.2 CHAPTER 2: RESEARCH AIINI AND OBJECTIVES 
Chapter 2 gives a synopsis of the research Aims and Objectives concerned with the 
main research theme of Knowledge Management and pharmaceutical innovation. 
1.4.3 CHAPTER 3: LITERATURE REVIEW 
This chapter provides an in-depth analysis of the problem scope through a review of 
the published academic and practitioner based work within the fields of Knowledge 
Management, innovation, pharmaceutical drug development and Intellectual Capital 
research. The chapter highlights areas for future research and reviews the initial aim 
and objectives, thus ensuring that the research is worthwhile and addresses the gaps 
in the current knowledge of the topic, The chapter is based in part, upon a paper 
submitted and presented at the IRMA Conference, San Diego 2005 (Parsons et al. 
2005b). 
1.4.4 CHAPTER 4: METHODOLOGY 
Chapter 4 gives review of research methods and the rationale behind the choice of the 
interpretive case study as the research philosophy. 
1.4.5 CHAPTER 5: A KNOWLEDGE AND INNOVATION FRAMEWORK 
Chapter 5 details a pilot study of innovation and Knowledge Management within 
AstraZencca. This chapter was based upon a paper presented at the EuroIMSA 2005 
conference (Parsons et al. 2005a). 
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1.4.6 CHAPTER 6: THE KNOWLEDGE AND INNOVATION CRITERIA 
Chapter 6 covers the generic innovation drivers that are not specific to AstraZeneca. 
1.4.7 CHAPTER 7: ASTRAZENECA AND AN NNOVATION CULTURE 
Chapter 7 covers the innovation drivers from an AstraZeneca-specific perspective and 
concentrates upon the culture of the organisation. 
1.4.8 CHAPTER 8: KNOWLEDGE MANAGEMENT AND INNOVATION 
Chapter 8 examines the use of Knowledge Management within AstraZeneca. 
1.4.9 CHAPTER 9: AN INNOVATION CASE STUDY 
Chapter 9 details a case study conducted within AstraZeneca with regard to 
innovation and Knowledge Management 
1.4.10 CHAPTER 10: DEFINING A KM AND INNOVATION FRAMEWORK 
Chapter 10 discusses the results of the research and develops an innovation and 
Knowledge Management based framework. 
1.4.11 CHAPTER 11: DEVELOPMENT OF THE KM TOOL SET 
Chapter II discusses the development of a Knowledge Management tool set and its 
potential use to drive innovation within AstraZeneca. 
1.4.12 CHAPTER 12: EVALUATING KNOWLEDGE MANAGEMENT 
Chapter 12 discusses the evaluation of Knowledge Management and suggests the 
means to assess the worth of Knowledge Management as a tool to drive innovation. 
1.4.13 CHAPTER 13: CONCLUSION 
Chapter 13 concludes with the main findings of the research, the implications and 
areas of further research. 
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1.5 CONCLUSION 
The background and rationale to the research have been covered within this chapter. 
The following chapter details the research aims and objectives and indicates how the 
challenges associated with this research will be overcome. 
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CHAPTER2 
RESEARCH AIMS AND OBJECTIVES 
2.0 INTRODUCTION 
This chapter defines the aims and objectives on which the research described in this 
thesis is based. The objectives are broken down into a number of tasks which define 
individual actions and deliverables. 
2.1 THE RESEARCH AM 
The aim of the research project is to contribute to the research and knowledge 
surrounding the use of Knowledge Management for pharmaceutical innovation. 
Therefore the main aim of the research is: 
To create and evaluate a Knowledge Management tool set to enhance innovation 
within AstraZeneca. 
The tool set is intended to be used across AstraZeneca global sites to provide greater 
access to the knowledge and information required by innovators who are responsible 
for producing innovative drugs. It is believed the tool set will also be applicable to 
other innovative organisations that are reliant upon knowledge and information to 
innovate. 
2.2 OBJECTIVES 
The aim of the study was clarified by using the following high level objectives. Each 
objective was assigned specific stages that combine to support the overall aim of the 
project: 
Objective 1: Identify the general views associated with innovation and 
pharmaceutical innovation. 
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The first objective covers the initial investigation stages where the scope and area of 
the problem is defined. The objective is broken down into two stages that address 
individual areas of the objective: 
4o Conduct a review of the literature to identify and understand the general views 
on innovation and innovative processes within the literature. This stage will 
identify what constitutes innovation and what processes are thought to support 
innovation 
Conduct an exploratory case study on innovation within AstraZeneca to 
identify the departments and principle innovative employees across 
AstraZeneca R&D. This will take the form of a qualitative case study utilising 
semi-structured interviews 
Objective 2: Identify the drivers, the criteria for innovation, the outputs of the 
innovation and the themes associated with innovation specifically within 
AstraZeneca. 
The second objective aims to pinpoint what exactly drives pharmaceutical innovation 
within AstraZeneca and identify the knowledge and information required to support 
innovation. The objective is broken down into three stages that address individual 
areas of the objective: 
Conduct a series of detailed case studies to identify the knowledge and 
information needs of the innovative employees and departments within 
AstraZeneca. These will form a set of innovation and knowledge criteria, 
drivers, outputs and themes to be used to develop the Knowledge 
Management tool set 
Produce a model of pharmaceutical innovation that reflects what is occurring 
within AstraZeneca based upon: the identified themes, criteria, outputs and 
drivers of innovation 
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Clarify and compare the innovative practices of these departments and 
innovators across AstraZeneca with the literature concerning pharmaceutical 
innovation 
Objective 3: Examine and evaluate the Knowledge Management strategy and 
existing tools in use across AstraZeneca R&D. 
The third objective will clarify the existing Knowledge Management tools and 
strategies in use across the organisation, with a view to identifying areas of success, 
weaknesses and gaps in the current tools and strategies employed within 
AstraZeneca: 
Conduct a review of the academic and practitioner's literature to identify 
Knowledge Management methods, tools and strategies 
9 Define how the value of knowledge and Knowledge Management is assessed 
within the literature 
Conduct a qualitative case study and consult with employees within 
AstraZeneca, to identify Knowledge Management tools that are being used to 
support innovation 
* Examine how Knowledge Management is and could be evaluated within 
AstraZeneca 
Objective 4: Examine potential Knowledge Management tools that could be used to 
support innovation in AstraZeneca and evaluate their potential use and impact to 
enhance innovation. 
The fourth objective intends to analyse potential Knowledge Management and 
information based tools that may be employed to enhance phannaceutical innovation: 
Produce a model of Knowledge Management that could be used to drive 
pharmaceutical innovation within AstraZeneca 
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Develop a Knowledge Management tool set from the previous review of the 
literature and the existing Knowledge Management tools within AstraZeneca. 
This will identify the worth of the tool based upon the previously identified 
innovation and knowledge criteria within Objective 2 
Objective 5: Test the validity of the Knowledge Management tool set and research 
by publishing the results within Astra. Zeneca and producing peer-reviewed 
conference proceedings: 
Evaluate the results of the research and the Knowledge Management 
recommendations by conducting a series of interviews to seek the opinions of 
the employees responsible for innovating within AstraZeneca 
o Publish peer reviewed conference papers and present the results to promote 
discussion 
The fifth objective seeks to validate the research with both AstraZeneca and 
academia. 
Objective 6: Deliver the tool set to AstraZeneca R&D. 
The final objective requires the implementation of the Knowledge Management 
toolset so that AstraZeneca may derive value from the research and the evaluation of 
the toolset as it is found to work in practice in the company environment: 
* Facilitate the implementation of the Knowledge Management tool set 
9 Evaluate the Knowledge Management tool set through a series of systematic 
surveys and further case studies. 
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2.3 CONCLUSION 
The research aim of enhancing pharmaceutical innovation through the use of 
Knowledge Management tools will be addressed by undertaking the objectives 
outlined in Section 2.2. Each objective is supported by a number of stages which 
emphasises the role knowledge and information plays within pharmaceutical 
innovation. Every effort will be made to fulfil the objectives described within this 
chapter and produce a working and beneficial Knowledge Management tool set that 
addresses the needs of the innovators within AstraZeneca. 
The next chapter will discuss the wealth and breadth of academic literature that 
focuses upon Knowledge Management, innovation and intellectual capital across a 
broad range of environments. 
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CHAPTER3 
LITERATURE RE VIEW 
3.0 INTRODUCTION 
The following chapter concentrates on providing the justification and background 
to the proposed research, by identifying the gaps in the literature on Knowledge 
Management, pharmaceutical innovation and Intellectual Capital. 
The chapter begins with an analysis of published work on innovation, creativity 
and pharmaceutical innovation. The chapter then proceeds to review the literature 
on Knowledge Management and Knowledge Management tools. It is important to 
define the applicable areas of Knowledge Management at an early stage, so as to 
enlighten the reader as to how and why Knowledge Management may have a role 
in enhancing pharmaceutical innovation. Both pharmaceutical innovation and 
Knowledge Management are broad topics. Hence the aim of this chapter is to 
condense the available material, so as to note similarities and familiarise the 
reader with how the two research components of Knowledge Management and 
pharmaceutical innovation interrelate. 
The final stage of the literature review addresses the models and strategies to 
evaluate Intellectual Capital. In order to develop the Knowledge Management tool 
kit suggested in Objective 4, it is important to address the Knowledge 
Management frameworks and strategies already in place within innovative 
industries and address their successes and failings. Innovation has experienced a 
rise in prominence of late. Whether the innovative process is concerned with new 
product development, incremental or process based innovation, knowledge plays a 
crucial role in the ability of an organisation to innovate. The growing practitioner 
and academic interest in finally tracking down what drives innovation, is reflected 
by the wealth of published strategies and theories available for review. The 
following critical review will cover these areas that are most applicable to the 
research question and address whether Knowledge Management can theoretically 
drive pharmaceutical innovation. 
15 
Chapter 3- Literature Review 
3.1 INNOVATION 
3.1.1 INTRODUCTION 
The subject of innovation and the associated processes of innovation management 
have attracted over 50 academic titles that specialise in the exploration of 
innovative processes within a broad range of fields. However, discrepancy lies in 
the research approaches and areas studied within such literature, and as such, a 
common standard of applied thought and consensus is lacking within the field. 
The following review aims to answer the questions suggested by Objectives 1,2 
and 3 and provide a comprehensive guide to innovation within the pharmaceutical 
business environment. Firstly the concepts involved within the terminology will 
be explored and a definition related to drug development and innovation within 
the firm proposed. Further sections of the review will discuss the importance of 
innovation within the business of pharmaceutical drug development, before 
continuing to examine the potential application of Knowledge Management 
techniques and strategies to enhance these processes, later within Section 3.6 of 
the chapter. 
3.1.2 DEFINING INNOVATION 
The innovation literature is awash with definitions and concepts which are 
distinct, yet inexorably linked through the use of key themes and are alike in 
many ways to the ambiguous definitions surrounding Knowledge Management. 
Innovation is perceived to be connected with areas such as competitive advantage, 
risk management, technological management, collaborative activity, creativity and 
Knowledge Management amongst other related fields (Tidd et al, 2001; Nieto, 
2004; Dosi, 1998). It is therefore wise to attempt to define the principles of 
innovation by utilising key literature sources from these areas. Proceeding with a 
business based view; the work of Hausman & Fontenot (1999) suggests 
innovation produces a competitive advantage, via the adaptation of a firm's 
resource to satisfy customer demands within a rapidly changing commercial 
enviro=ent. 
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Undeniably the application of an organisation's resource allows the firm to attain 
a competitive advantage over rival companies (Sundgren & Styhre, 2004); 
however, the authors suggested view neglects to address the concept of what 
actually constitutes innovation. Innovation is commonly referred to as the creation 
of value through the use of assets, whether they are intangible or tangible assets, 
yet in many senses innovation relates to the creation of a tangible product 
(Nonaka & Takeuchi, 1995). 
Although innovation may be described as the formation of a tangible product 
(Cooper, 2003), innovation may also be construed as a strategic concept, where 
the option to improve the organisation and therefore induce a competitive 
advantage through the use of innovative business practices (Montes, Moreno & 
Morales, 2005). Assigning innovation as a strategy and not as a tangible end 
product, suggests innovation has constituent parts that lead to an innovation. 
Tether's (2003) work questions the view (e. g. Hausman & Fontenot, 1999) that 
innovation must create a new product and provides a framework to assess how an 
innovation may be reached and how types of innovation may enhance the firm's 
competitiveness. The three concepts of innovation as proposed by Tether (2003) 
are: 
1. Innovation as a technological achievement 
2. Innovation as a consequence of technological achievement 
3. Innovation as a result of a firm's dynamic capabilities 
The view of innovation as a technological achievement, consists of the classical 
representation of innovation as a ground breaking invention, examples of this 
include the jet engine, the telephone and the semiconductor. These inventions 
possess the characteristics of a unique solution and possess a great impact upon 
their respective field, while their innovativeness is weighted upon the uniqueness 
of their market application (Lee & O'Connor, 2003). Essentially they have 
provided the 'significant leap forward' to overcome a technological block or 
readdress an existing problem or strategy and provide a solution. 
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The second stance views innovation as a natural progression of a technological 
achievement or inventions, it is the evolution of an initial concept or invention 
that attains greatness and the characteristics of an innovation over time (Tether, 
2003). This process may occur through the adoption of a risk based strategy, on 
which a company gambles that a rough concept may be taken through to a 
competitive product and hence a commercial advantage (Rothwell, 1983) or 
through a continuous process of improvement and prototyping of an established 
invention. The final concept penned by Tether's (2003) views innovation as a 
process that is driven by an organisation's dynamic capabilities. Here innovation 
is not simply the achievement, invention or new product, it is instead the 
organisational practices and strategies which merge to form an original stand 
point or a differentiated product from that of their rivals (Holt, 1999). 
Tether's (2003) third view of innovation is of most relevance to the research, but 
unfortunately the least clearly defined. The view implies that it is not the end 
product of a new drug that solely typifies pharmaceutical innovation. Instead the 
organisational processes within AstraZeneca which lead to a new medical product 
may also be regarded as innovations in their own right. However, collating the 
published innovation literature reveals a variety of theories regarding this view. 
For example an organisation may label an innovative process as a ground 
breaking technical achievement, while another firm may consider the same 
innovation to be the result of incremental steps and hence a consequence of a 
technological achievement (Hitt et al. 1998). Work by Garcia et al. (2002) 
suggests the literature interplays the terminology of 'innovation' and 
'innovativeness'. This may explain the confused view where innovation is viewed 
as both a new Product and a process. Evidently it is important to the research aim 
and objectives to define innovation. In light of the literature and the research 
direction, the definition offered by Damanpour (199 1) appears fitting: 
"Innovation is the adoption of an internally generated, system, policy, program, 
process, product or service that is new to the adopting organisation " 
The definition is broad, yet the rudimentary basis suggests that an innovation 
occurs only when a company encompasses a new direction or process and hence 
foresees value from adopting a particular approach. 
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Freeman (1991) notes that process driven innovation may only be labelled as an 
innovation after the process has generated value. Likewise Garcia (2002) suggests 
a product that does not progress to market is merely an invention. This supports 
the aspiration that innovation is intrinsically linked to value and a marketable 
product. Garcia (2002) also suggests that the innovativeness of a company is also 
a valuable and hence marketable commodity. 
Viewing innovation as a series of process based iterative steps recognises that a 
company possesses the ability to progress an invention to a marketable product 
and may be used as a measure of a company's innovativeness (Tether, 2003; Hitt 
et al. 1998). Nieto (2004) defines process based innovation as "technological 
innovation" whereby the set of activities which contribute to the overall new 
goods, services or new forms of production are considered to be the innovation. 
Pluskowski (2003) aligns innovation with the adoption of change within the 
organisation, the process of change having resulted from recognising the need to 
adapt and developing a solution or solutions to these needs, which is again a 
stance focused upon the process and the end result rather than the end product 
alone. 
As the research area is primarily considering how to enhance drug development 
through applying Knowledge Management techniques and strategies, innovation 
will be viewed as a series of processes that yield a new medical drug, aligning 
most strongly with Nieto's (2003) and Tether's (2003) concept that innovation 
may be perceived as process and not a tangible end product. 
3.1.3 INNOVATION, CREATIVITY AND KNOWLEDGE 
The term innovation is certainly popular and is becoming progressively more 
widespread within the Knowledge Management literature, when illustrating a 
Knowledge Management system few authors neglect to emit innovation as a key 
benefit and output of using their system - (e. g. Park & Kim, 2005). Indeed 
innovation has attained considerable importance, yet is important to firstly analyse 
where innovation stems from, so as to identify the drivers of innovation within 
AstraZenecas's processes of pharmaceutical innovation and satisfy Objectives I 
and 2. 
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The principle driver of innovation has long been regarded as creativity (Cothrel & 
Williams, 1999). Creativity is described by Mumford & Gustafon (1988) as the 
generation and emergence of new ideas and is akin to the generation of ideas 
through the "thinking out of the box" analogy. However, creativity may also be 
construed in a number of other ways. Tomas (1999) ascertains creativity stems 
from original thought, while Shalley & Perry Smith (2001) advocate true 
creativity is not only focused upon original thought, but also rests upon the 
processes of implementing the thoughts. It is evident that confusion reigns 
concerning the terminology of creativity and innovation. Shalley & Perry Smith's 
(2001) view, essentially ties in with Tether's (2003) view of innovation. Yet what 
may be grasped from the literature is that creativity is the production of the idea or 
concept that leads to an innovative process (Mumford & Gustafon, 1988; Handzic 
& Chaimungkalanont, 2004). Ford (2000) labels these processes as 'creative 
thinking' and is said to be a response to a complex or ill defined problem that has 
arisen within an organization. The development of creative solutions to these 
complex problems and issues may then be defi4ed as innovations. In light of 
pharmaceutical innovation this would equate to the processes under study in 
Objectives 1,2 and 3, so how are organisation's addressing problems? 
Mumford et al. (2002) note that the initial definition of the organisational problem 
is driven by the appliance of a conceptual structure to the problem scenario. This 
structure serves to define the problem within the boundaries of the orgarýisation. 
Handzic & Chaimungkalanont (2004) conclude that creativity then stems from the 
organisation's employees once the problem has an organisational context. This 
implies that the employee' is directly responsible for the appliance of their 
knowledge and information to defining and solving a problem (Reiter-Palmon & 
Illies, 2004). Perez-Bustamante (1999) suggests that the initial driver of 
innovation is information, where the information defining a problem is first 
outlined, before the employees are then able to apply their knowledge to tackle the 
problem through creative thinking. 
Above all, it is clear that innovation is reliant upon the knowledge and expertise 
of the employees. Yet as Mumford et al (2002) note, the complexities of a typical 
organisation demand multiple expertise areas. 
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It is largely agreed that employees no longer have the skills, expertise or resource 
to address complex problem scenarios on their own (Scott, 2000), particularly 
with regards to the processes of drug development. Terziovski & Morgan (2004) 
describe the biomedical innovation processes as: 
"A process of creating and developing new products or services through 
collaborative team processes and mechanisms that utilise and empower the skills 
and knowledge of the people ". 
Here we witness the use of teams of employees to overcome creative problems 
that arise within the organisation, reinforcing the idea that creativity and hence 
innovation, stems from the ability of the employees to combine or create problem 
solving ideas in a unique form (Reiter-Palmon & Illies, 2004). Ford (2000) 
advocates the need to provide a creative culture within the organisation, one 
where innovation progresses from creative inception, to application and then 
dissemination. The idea that an innovative culture is indicative of a desire to share 
knowledge is widespread within the Knowledge Management literature (e. g. 
Mahesh and Suresh, 2004; Gunnlaugsdottir, 2003). An organisational culture rich 
in knowledge is a powerful resource, while possessing knowledge allows 
employees to learn, to understand, to solve problems, preserve traditions, create 
competency and allow innovation (Liao, 2003). Innovation can be seen as the 
bridging of the gap between the current platform of knowledge and the target 
knowledge required to develop the new product (Hall & Andriani, 2002). 
However, in practice a company often does not know what is required or may be 
required to achieve innovation. This implies that complex problems often demand 
complex solutions that span an organisation. As Adler (2002) notes, cross 
organisational innovation requires diversity across the employees involved within 
innovative work, where the process of development and R&D commences with 
the creativity of the employees and is reliant upon the quirks and acquired 
knowledge of the employees and the cultural confines the organisation operates 
within. Within this complex environment, innovative knowledge is said to exist 
on a modular basis, scattered over the organisation as a whole, requiring 
innovators to collaborate and form networks in order to acquire the knowledge 
(Baldwin & Clark, 2000). 
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However, predicting and mapping the knowledge requirements of staff across 
such a network and providing an elaborate Knowledge Management system to 
provide this is daunting (Laudon & Laudon, 2002). 
The proviso of such an environment that allows and encourages innovation has 
attracted a great deal of research and interest from the academic community, yet 
remains an elusive goal. What is clear is that organisational innovation is driven 
by collaborative practices and the formation of collaborative networks (Bougain 
& Haudeville, 2002). The stereotypical vision of the innovative maverick is 
though to be far removed from the practice found within a R&D led organisation. 
The focal point of creativity no longer rests with the individual but with the 
employees across the organisation (Gatignon et al. 2002). Throughout the 
innovation literature, knowledge is viewed as an essential aspect of innovation 
and it would seem that the research aim of encouiaging pharmaceutical innovation 
through Knowledge Management is plausible. However, Schultz & Leidner 
(2002) acknowledge that too much knowledge causes staid business practices, 
while too little knowledge leads to inefficiency. Evidently a balance is required 
that drives creativity through to innovation and as Brown & Eisenhardt (1995) 
note, this process of product and competency development is essential for the very 
survival of the organisation. 
The review will now discuss pharmaceutical innovation in line with published 
literature on innovation, drug development and organisational knowledge and 
detail the growing role and awareness of knowledge within the innovative 
processes. 
3.1.4 PHARMACEUTICAL INNOVATION 
The following section provides the context to the thesis, detailing the steps of 
innovation within the pharmaceutical industry and outlining the areas that may 
benefit from Knowledge Management. The review will concentrate upon the drug 
development process within AstraZeneca so as to provide a basis for 
understanding the research within Chapter 5 of the thesis. Figure 3.1 demonstrates 
that the processes and stages required to develop a drug from a chemical to a 
marketable drug product, are wide and varied: 
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Figure 3.1: AstraZeneca Drug Development Processes 
To try and gain a clearer picture, the complexity of the drug development process 
within AstraZeneca is conceptually outlined in the following paragraphs using 
internal AstraZeneca data and published research literature (Davis, 2001; 
Sundgren & Styhre, 2004). 
The drug development process begins within the Discovery wing of the company, 
where knowledge is applied to identify worthwhile biological targets for the 
company to develop a New Chemical Entity (NCE) to act upon. The NCE is a 
chemical compound designed to have a pharmacologically active effect on a 
disease, the scientists responsible for developing a NCE aim to relieve symptoms 
of a disease, such as lowering blood pressure, or attack the root of the disease and 
provide a cure. A useful analogy to explain the action of an NCE on a biological 
target is a lock and key. 
The target acts as the lock and the NCE provides the key, the key allows a change 
in the behaviour of the biological target and this in turn produces a 'knock on 
effect' and allows regulation of the disease or its symptoms. 
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Central to the development of an NCE, is the knowledge of the scientists within 
the Discovery wing of the company. The scientists are required to develop NCEs 
that are both pharmacologically active against the target and are unique in their 
chemical structure. Suitable NCEs are then forwarded within the organisation to 
the Clinical wing as a Candidate Drug (CD). The safety credentials of the 
compound are verified with regards to their performance within biological 
models, before finally being forwarded to a marketable position as a New Medical 
Entity (NME) or new drug. 
The process of testing and transferring a NCE to a CD is equivalent to the 
validation of an invention. From a theoretical perspective the NCE lives up to the 
defined chemical expectations of Discovery and is a potential marketable drug. 
The Discovery organisation may pass on many 10s of NCEs to the Clinical wing, 
all of which have the potential to be marketable drugs, however the Clinical wing 
is then responsible for confirming that these compounds are safe and effective 
within a biological system. Within these stages of Clinical validation, almost all of 
the CDs will fail to meet the stringent criteria defined by the organisation and 
external regulatory bodies. This process is labelled as attrition and effectively 
equates to a maximum of four CDs a year, being forwarded by the relevant 
Clinical areas of AstraZeneca by the Discovery wing. The complex series of 
tollgates and milestones associated with developing a compound, which is 
pharmacologically active against a biological target, to a marketable drug takes up 
to 14 years. It is not uncommon for the identification of a CD to take up to 5 years 
and the time to market release of the drug taking a further 6 years. Hence the long 
time scales from innovation to product release. This is at odds with the majority of 
other R&D taking place within businesses such as the semi-conductor industry 
(Davis, 2001). The slow evolution of products means failure at any point is 
financially dire. Hence a pharmaceutical company must invest a considerable 
amount of resource in its R&D activities in order to provide the company with 
future products up to a decade from their original inception. 
Cutting the rate of attrition and ensuring that an initial NCE stands a higher 
chance of progressing from a CD to a marketable drug, is the principle underlying 
aim of the research. 
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3.1.5 THE DRIVERS OF PHARMACEUTICAL INNOVATION 
Zeller (2002) acknowledges that intensified global competition and the strong 
oligopolies of Western pharmaceutical companies has forced companies to 
increase innovative output. As a result, financial pressures and not medical need is 
driving drug research. Innovative products enable a pharmaceutical company to 
create wealth. Within the development pathways to making the end product, there 
are innumerable innovative processes, all of which link together and all of which 
requires innovative behaviour that is backed by accurate knowledge. Tether 
(2003) concludes that very few ground breaking pharmaceutical drugs are 
released. The majority are a gradual redefinition of an existing family of chemical 
compounds in order to produce a new marketable drug. Therefore, viewing 
pharmaceutical innovation as outright technical achievement is less relevant to the 
research. A more conducive stance would be to focus upon the processes of 
innovation, creativity and strategy which coexist to support the release of a drug. 
This stance would then clarify and build upon the existing published literature that 
takes this viewpoint (e. g. Handzic & Chaimungkalanont, 2004) 
In order to provide further context to the research and ascertain the drivers of 
pharmaceutical innovation, it is important to outline the financial and commercial 
environment AstraZeneca operates within. As is similar to other high technology 
industries, the pharmaceutical industry is reliant upon protecting its innovations 
and financial resource through patenting (Pearce, 2005). A patent confers to its 
owner the sole rights of manufacture and the offering for sale of the patented 
product (Levin, 1986). From a financial perspective, the patent is critical to 
maintaining a market position and allows the company to recoup the initial R&D 
investment required to develop and release a drug. To put the importance of 
patents into context, the average revenue of a market leading drug, such as 
Prilosec or Claritin equates to $2.6 million per day. 
Hence protecting the intellectual property of a drug and retaining sole 
manufacturing rights, not only sustains a company in the short term and recoups 
the initial R&D investment, but also provides the basis for further R&D 
expenditure (Pearce, 2005). 
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However, competition is fierce within the industry and rival manufacturers 
produce drugs that act upon the same disease areas. Competition also stems from 
the generic pharmaceutical industry, which specialises in manufacturing drug 
products that have expired patents. Due to the lack of initial R&D costs, generic 
manufacturers are able to offer these drugs at significantly lower costs than the 
initial developer and the company who initially invented the drug will quickly 
lose market revenue. Thus an R&D focused pharmaceutical company that fails to 
develop new patentable products and finds itself having to rely upon its existing 
product portfolio, will rapidly founder (Chataway et al. 2003). Historically 
pharmaceutical innovation has focused upon in-house R&D where organisational 
innovation stems from the research ability of the employees (Rosenberg & 
Birdzell, 1990). Yet, in recent years a study by Bottazzi et al. (2001) across 150 
pharmaceutical firms has drawn the conclusion that the differentiation between 
the tiers of R&D focused companies is widening. The syndicate of top R&D 
organisations, such as AstraZeneca, are strategically positioning themselves to 
develop new and 'first to market drugs' across similar therapeutic areas. The 
secondary R&D organisations are increasingly focusing upon expired patent drugs 
and drugs that are manufactured under licence (Bottazzi et al. 2001). 
Unfortunately these strategies are generating a deficit in innovative practice as a 
new drug must be truly remarkable to be granted a patent. Additionally when it is 
released it must show considerable medical benefit over its rivals to gain a market 
share (Heller & Eisenberg, 1998). 
To further complicate the problem, Terziovski & Morgan (2004) note the 
innovative R&D work is moving from the in-house R&D pharmaceutical 
departments, such as the Discovery wing at AstraZeneca, to external 
biotechnology companies and smaller research establishments. However, the 
extent of this shift is unclear within the literature. Branca (2002) suggests large 
pharmaceutical companies will come to rely upon sequestering the products of the 
smaller firms as their own in house innovative capabilities become diminished. 
Large pharmaceutical companies (e. g. Pfizer) are also acquiring larger marketing 
forces in an attempt to quickly assert market dominance. 
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This is leading to an inevitable down turn in innovative activity, as resource is 
diverted away from R&D to marketing (Branca, 2002). There is an increasing 
awareness of this within the literature (e. g. Terziovski & Morgan, 2004; Coombs 
& Metcalfe, 2002) yet little notion of how such an environment may be countered 
and innovative work may be increased in this envirom-nent. Yet what is clear is 
that this trend is set to escalate. Work by Cardinal & Hatfield (2000) observes the 
paradigm shift from in-house R&D to a collaborative outsourced model is 
occurring rapidly. An unwelcome consequence of this, is that pharmaceutical 
organisations are increasingly realising that the knowledge involved in 'buying in' 
innovation is difficult to elucidate and capture. However, is essential in order to 
understand how the purchased innovation may be eventually be realised as a 
marketable drug (Dixon, 2000). Factors such as financial resource, trust, 
intellectual property rights, patent rights and access to technology, equates to 
many quantifiable hurdles that must be addressed in order to successfully acquire 
an innovative product that may be marketed (Zeller, 2002). 
The pharmaceutical industry has long held the view that innovation is a linear 
scientific process begun in house, one where R&D develops products which are 
eventually passed to marketing (Trott, 2002). The realisation that the 
initial 
innovative R&D may be external is slowly being realised. The previous 
acknowledgement that Pfizer are purchasing marketing forces over investing in 
their in-house R&D capabilities, lends weight to this observation. Taking this one 
step further, Koberstein et al. (2002) suggests that feedback from the Marketing 
department which is derived from client contact, may be used to influence and 
drive the R&D and innovative processes. In effect R&D responds to market 
characteristics rather than scientific criteria alone (Becker & Lillemark, 2006). 
Although this concept is plausible, supporting research within this field is scant 
and the linear model of drug innovation, as advocated in Figure 3.1 is still widely 
exercised within pharmaceutical innovation (Becker & Lillemark, 2006). A 
clearer strategy revolves around the use of networked collaboration to drive R&D 
and innovation. This process involves the collaboration of a number of 
organisations; with the resulting innovation or product being progressed by 
research driven collaboration Gemser et al. (1996). 
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This changing model of pharmaceutical innovation rather undermines the 
assumption that a pharmaceutical prganisations in-house R&D, is a measure of an 
organisations financial value (Achilladelis & Antonakis, 2001). The developing 
trend towards the 'buy-in' of innovation also effectively negates valuation of the 
company by the filing of patents (Sakakibara & Branstetter, 2001). As many drug 
patents are now filed outside the organisation in smaller biotechnology or 
universities. Yet as Garcia & Calantone (2002) notes, a company's valuation is 
rarely measured upon its ability to innovate. In the case of the pharmaceutical 
industry, the measure of value is increasingly being aligned with the ability of the 
organisation to manage the innovative processes that occur after the nomination of 
a CD and not the initial R&D behind discovering an NCE (Hara, 2003). 
3.1.6 SUMMARY 
The proposition that value is linked to the management of innovative processes 
inevitably returns to the application of the organisation's knowledge (Penrose, 
1959; Ford, 2000). Undeniably AstraZeneca is a world leader in a number of 
therapeutic areas, yet the company's leading drugs have been developed over a 
decade previously. In order to maintain market position, the company is adapting 
to the external commercial pressures and attempting to redefine its existing 
working practices through the embrace of Knowledge Management practices 
(Zeller, 2002; Roth, 2003). As knowledge is at the crux of the pharmaceutical 
development process and the knowledge required to innovate is a main asset of an 
organisation (Nahapiet & Ghoshal, 1998; Kandampully, 2002), AstraZeneca is 
keen to harness the competitive advantage Knowledge Management may offer. 
Whether innovation is acquired externally, through collaboration or developed in- 
house, the knowledge within these processes is creating value for the organisation. 
Knowledge Management would to all intents and purposes, appear to be an ideal 
vehicle with which to reduce the amount of resource involved with the laborious 
process of developing a new drug and capture the knowledge intemally and 
extemalIy. Knowledge Management is intended to curtail the resource costs 
involved with developing a new product (Snowden, 2002; Lemon & Sahota, 
2004) and should ultimately allow a process or organisation to operate more 
effectively. 
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However, the physical process of managing the knowledge and providing a viable 
return is still shrouded in ambiguity (Stacey, 2001). Davenport & Marchand 
(1999) suggest Knowledge Management may help to create new knowledge 
through active management of the knowledge use of the staff within the business 
environment. Authors such as Jennex & Weiss (2002) and Hendrike (1999) 
recognise that Knowledge Management will aid a research-based organisation. 
However, to date, little academic research targets the practical applicability of 
Knowledge Management tools and strategies specifically within pharmaceutical 
innovation. One of the main aims of the research is to address this issue. To 
achieve this, the review will now move on to discuss Knowledge Management, 
Knowledge Management strategies and the tools which are available to help 
promote innovation and knowledge sharing across their organisation. 
3.2 KNOWLEDGE MANAGEMENT 
3.2.1 INTRODUCTION 
Knowledge Management has emerged as a popular and important area of 
academic and practitioner research. The principle reason behind the rise in 
popularity is that authors such as Drucker (1993) have assigned a value to the 
knowledge within an organisation. Due to this, organisations are becoming 
increasingly aware of the need to actively manage the knowledge of their 
employees. Largely in response as their operating strategies of utilising modem 
cross functional and cross team working practices (Argote et al. 2003). Large 
multinational organisations have long valued the use of technology to facilitate 
organisational learning and knowledge behaviour. Yet the smaller organisations 
are also recognising the value Knowledge Management may impart to their 
operating models (Baum & Greve, 2001). The growth of awareness in recognising 
knowledge as a valuable asset and the need for organisational learning has been 
coupled with the rapid growth of information technology. Together these areas 
have merged into the science of Knowledge Management. 
The following review of the Knowledge Management literature relates to 
Objectives 3 and 4. 
T9 
Chapter 3- Literature Review 
These objectives require the analysis of the Knowledge Management strategies 
and tools that are currently in use within AstraZeneca and the suggestion of 
potential new Knowledge Management approaches. 
3.2.2 KNOWLEDGE MANAGEMENT AS A CONCEPT 
Defining KM is itself a detailed problem and one, that the researches believes, 
may never be truly answered as perspectives and opinions on what Knowledge 
Management denotes are wide and varied. What is clear is that Knowledge 
Management may be viewed from a multitude of perspectives. Either as a high 
level strategy, a practical IT based approach or one that attempts to view 
knowledge from an employee's perspective. Ultimately each perspective supports 
the research aim, and seeks to enhance the use, creation and the exploitation of 
knowledge within the workplace. Newman & Conrad (1999) define Knowledge 
Management as: 
"A discipline that seeks to improve the performance of individuals and 
organizations by maintaining and leveraging the present andfuture value of 
knowledge assets ". 
Newman & Conrad (1999) acknowledge that Knowledge Management is not a 
new approach, but an integration of many disciplines that are linked by the 
guiding principle of deriving value from managing organisational knowledge. The 
advent of Knowledge Management has introduced a wide range of strategies and 
methodologies, all of which proclaim to be the definitive answer to knowledge 
sharing and creation within the business environment. Academic literature widely 
acknowledges that Knowledge Management creates value from the exploitation of 
the organisations knowledge and intangible assets (Alavi, 2000). Although how an 
organisation may achieve this and what constitutes an intangible or tangible asset, 
is often far from clear. It is also fair to say that Knowledge Management is in a 
state of continuous flux. As it has undergone a transition from the management of 
technology to the management of the social aspects of the organisation, where the 
focus upon what employees do with their knowledge has taken precedent over the 
provision of tools to capture the employee's knowledge (Darroch, 2005). 
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Knowledge Management literature is quick to point out that the processes of inter 
and intra organisational knowledge exchange is the driving factors behind the 
success of R&, D strategies and the innovative performance of the organisation 
(Faems et al. 2005). However, what is less clear, is the relationship between 
adopting a certain Knowledge Management strategy and the potential benefits on 
driving innovation. A factor that is largely due to the obscure nature of 
organisational knowledge. 
Lerner & Merges (1997) describes how the unpatented intellectual property or 
unpatented core technology of the organisation can be described as 'know how', 
which when captured and applied, allows the development of innovation. It is 
evident that the bundled 'know how' does lie within all organisations, but it is 
only through tackling the problems and inertia that revolve around the processes 
and application of this knowledge can the benefits by realised. In this way 
Knowledge Management creates value not through the management of the 
knowledge itself, but through the management and creation of a culture that is 
favourable to knowledge sharing and knowledge interactions (Walczak, 2005). 
The examination and improvement of the processes within a business have long 
been a source of academic research, continuous improvement, benchmarking and 
reengineering may be regarded as the fore runners of Knowledge Management 
(Hammer & Champy, 1993). Yet largely due to the promise of a tangible financial 
gain, Knowledge Management has leapt to the forefront and is now proclaimed as 
an essential facet of a successful business strategy (Drew, 1999). 
Since the meteoric rise to fame of Knowledge Management in the late 1990's, the 
process based reengineering methodologies have been relegated. This is due in 
part, to the emergence of the concept of an organisation's capability (Dosi, 1988). 
An organisation's capabilities directly relates to the ability of an organisation to 
manage its own internal resources or content to create innovation (Argote et al. 
2003). In this case, the content or resources invariably translates to organisational 
knowledge and the 'know how' of the employees. Drucker (1993) was amongst 
the first to ascertain that the knowledge content within an organisation's many 
processes can be measured as a tangible resource. 
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The intangible value of the organisation's 'know how' equates to a tangible 
financial value which may be measured and evaluated. This shifts the focus from 
the organisation as a whole, to a dissection of the processes that generate 
knowledge. Techniques such as Business Process Reengineering required the 
entire organisational structure and operating models to be realigned and largely 
failed due to the prohibitive costs (Hall et al. 1994). Knowledge Management is 
said to offer a more direct approach by identifying specific areas that require 
consideration. Drucker's (1993) work stated the possession of relevant knowledge 
and expertise infers value to an organisation. Yet scant regard has been paid to 
establishing a rigid terminology within Knowledge Management and little 
deliberation has been given to the study of where and how Knowledge 
Management can impart a positive influence upon an organisation. In an attempt 
to address this, the following literature review intends to shed light upon the 
terminology and concepts surrounding Knowledge Management. In addition to 
clarifying the environments in which Knowledge Management may be harnessed, 
in order to bring value to AstraZeneca and fulfil the research aim and objectives. 
3.2.3 A THEORETICAL PERSPECTIVE ON KNOWLEDCE AND KM 
Knowledge Management aspires to address and exploit the knowledge within an 
organisation, yet there is considerable ambiguity over the definitions surrounding 
knowledge. The present state of confusion persists through the poor definition of 
knowledge. In accordance with Polanyi (1967) and Davenport & Prusak (1998) 
knowledge is said to be construed of both tacit and explicit knowledge. These 
terms are a cornerstone of Knowledge Management and in simplistic terms: tacit 
knowledge refers to the expertise, insights and intuition of the organisations 
workforce. Explicit knowledge is construed to be the organisation's knowledge 
that is committed to storage, such as documents, words and archives. 
These two hierarchical types exhibit a degree of interchange ability and the 
knowledge of an organisation is interpreted as a combination of the two types 
(Davenport & Prusak, 1998). Due to this complexity, the majority of Knowledge 
Management literature fails to categorically outline the knowledge interactions 
that are being studied, preferring in the main to offer ambiguity, in the form of a 
generic framework or knowledge black box (e. g. Leonard-Barton, 1995). 
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In light of the lack of clarity within the field, it is prudent to clarify the research 
aim and objectives in relation to the largely ill-defined field of Knowledge 
Management. A fitting point to start would be the definition of knowledge. 
Knowledge is a commonly referenced term within the literature sources, yet what 
does the term 'knowledge' imply and how does this differ from the overlapping 
areas of information? 
An attempt to answer such a question from a philosophical pitch is beyond the 
scope of the review, and would raise untold arguments and counter arguments, 
many of which date from discussions surrounding the work of the Greek 
philosophers Plato. However, the research aim squarely focuses upon the use of 
knowledge within an organisational context and hence falls in line with the 
majority of published Knowledge Management literature. As Alavi & Leidner 
(2001) note, Knowledge Management lacks a true accepted definition of 
knowledge. Instead the academics and practitioners rely upon the premise that 
knowledge is an entity, over which a degree of control may be exerted (Lamberts 
& Shanks, 1997). From an organisational Knowledge Management perspective, 
Saberhal & Saberhal (2005) view knowledge as: 
"The set ofjustifted heliefs that enhance afirm's capabilityfor effective action. " 
Unfortunately the term 'belief' implies that Knowledge Management seeks to 
manage an unknown and indefinable entity or essence. Together these beliefs 
provide the drivers behind an organisation's performance. Inevitably confusion 
reigns within the classification of these drivers and consequently information may 
at times, be construed as a driver (Fukuhara, 2003). The definition of knowledge 
and information are a stumbling block of Knowledge Management and authors 
such as Wilson (2002) suspect Knowledge Management is simply Information 
Management under a different guise. Wilson's (2002) research demonstrates how 
confusion reigns concerning the terms information and knowledge. In particular 
noting that the practitioner's view of knowledge differs greatly from the academic 
perspective, yet all fall under the notion of Knowledge Management. An 
academic definition offered by Gunnlaugsdottir (2003) looks upon the knowledge 
within the organisation as "information with a contextual element. " 
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Importantly the definition applies to all knowledge within the organisation, 
regardless of whether the knowledge consists of tacit or explicit knowledge. 
Gunnlaugsdottir (2003) states that the contextual element of knowledge is 
important, as it will provide the facility for critical understanding. Ibis allows the 
information to be placed within a logical and intelligible sense within the 
organisation. 
Gunnlaugsdottir's (2003) definition of knowledge evolves from the capture of 
information with the accompanying and relevant contextual data. Gurmlaugsdottir 
(2003) identifies that the information within the knowledge, is itself composed of 
data, which has been organised, analysed and interpreted to become usable 
information. The lower level of the three tiers consists of data, which remains at 
the factual level where the role and context are ambiguous. Essentially, the 
meaning of data is entirely subjective until processing or an interpretation is 
applied to form a meaningful construct and render information (Gunnlaugsdottir, 
2003). 
The three tiers of knowledge, information and data demonstrate how knowledge 
holds great importance to the commercial organisation and is viewed as the basis 
of an organisation's commercial ability (Davenport, 1998). Although knowledge 
creation, manipulation and reuse are the drivers behind an organisation's 
innovative ability, knowledge alone must be supplemented and derived from 
information and data within the organisation in order to drive innovation (Goh, 
2005). It is raýe to read a Knowledge Management paper that does not advocate 
that the application of knowledge, information and data will ultimately leads to 
innovation (e. g. Stewart, 1997). Yet if knowledge itself is widely recogniscd to be 
intangible (Hall, 1992), how may an organisation apply its knowledge? 
It is easy to accept that information and data are captured in tangible stores such 
as IT software, databases and documents and their application is relatively 
straightforward, yet knowledge is a more elusive entity. Stewart's (1997) work 
suggests the very nature of knowledge is an intangible asset or resource that lies 
within the employee. This consists of the employee's knowledge, experience and 
experience within the organisational culture in which they act. 
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Presenting the opportunity for an employee to act and apply their knowledge 
appears to be at the crux of obtaining value from a Knowledge Management 
approach. However, this process is rarely straightforward. 
Gopal & Gagnon (1995) acknowledge that the knowledge within the employee is 
inherently difficult to capture and store. Over a decade has passed since their work 
and no satisfactory Knowledge Management frameworks or strategies are widely 
in place as yet. In an attempt to answer this, the Knowledge Management 
literature has adopted an interesting juxtaposition with regard to managing 
knowledge and there are two distinct arenas of thought. Firstly, knowledge may 
be viewed as an intangible asset held within the minds and actions of the 
organisation's employees (Nonaka & Takeuchi, 1995). Secondly, knowledge may 
also take the form of a tangible asset that may be manipulated through technology 
(Nonaka & Takeuchi, 1995). These views return to Polanyi's (1967) notion of 
explicit and tacit knowledge, yet little research successfully addresses the balance 
and relationship between the utilisation of the two forms within an organisation 
(Tiwana, 2000), let alone with regard to pharmaceutical innovation. What is clear 
is that these areas are intertwined, as the effective management of the employee 
directly influences the success of the socio-cognitive technological strategies 
(Ahonen, 2000). 
An alternative view of Knowledge Management, offered by Montano et al. 
(2001), focuses upon allowing the organisation to target the constituent 
knowledge within the organisation's business processes through the use of 
technology. The social aspect of knowledge is addressed by modelling an 
organisational environment that is conducive to the application of knowledge. 
Hence although Knowledge Management purports to manage knowledge, the 
existence of knowledge, information and data within a typical business process 
illustrates that Knowledge Management is not only addressing the notions of 
knowledge, but is also encompassing the information and data within these 
processes. The confusion surrounding Knowledge Management frameworks (e. g. 
Rubenstein-Montano et al. 2001) is concerning and would negate a large body of 
Knowledge Management work that confuses knowledge with information. 
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However, Gunnlaugsdottir's (2003) definition of knowledge as information with a 
context implies that information management tools will also fall under the 
umbrella of Knowledge Management tools, providing that can capture the 
additional contextual elements successfully. This argument is far from conducive, 
Allee (1997) states that knowledge may not be designed or processed or managed 
from an Information Management perspective. Instead knowledge requires a 
different approach. Although Allee (1997) does not successfully explain how to 
achieve this approach, it is implied that Knowledge Management seeks to 
organise, analyse and interpret organisational knowledge in order to provide 
usable knowledge that may be used to encourage creativity and innovation. 
Therefore Knowledge Management is addressing the practical aspects of the 
application of knowledge within the organisation (Kirchner, 1997). Svieby (1997) 
suggests that this returns to the exploitation of the knowledge that is held within 
the mind of the individual. A notion that implies that knowledge can only be 
released through social interaction. Due to the social aspect, Nomura (2002) 
suggests organisational Knowledge Management may be viewed simply as 
knowledge based management, rather than the management of physical 
knowledge. 
As can be seen Knowledge Management research is rarely clear. An uneasy 
balance exists within the Knowledge Management literature as to the relative 
importance of the social cognitive aspects and the technological focus of 
knowledge. Bresnen et al. 's (2003) research notes that even though explicit and 
tacit knowledge may be articulated and captured. The exploitation of this 
knowledge may then be hindered by the lack of suitable shared resources. This 
suggests that Knowledge Management must address both social and technical 
aspects in order to be valuable. Evidently this balance remains a contentious issue 
and further research within this thesis will shed light upon this area with regard to 
pharmaceutical innovation. However, the message is that technology should 
supply a means by which knowledge's context and understanding may be 
disseminated (Davenport & Prusak, 1998). 
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Unfortunately the complexities of social and technical Knowledge Management 
pale when compared to the fundamental stumbling block of understanding the role 
tacit knowledge holds within the company. Tacit knowledge underpins the 
majority of business transactions and while considerable efforts have been made 
to visualise and store tacit knowledge, there remains a substantial amount of 
knowledge that will stay within the heads of the business's employees (Nonaka et 
al. 2001). The management trend of "downsizing" illustrated the importance of 
tacit knowledge within the organisation. Knowledge accumulated by the time 
served employees was lost and the information that remained within the 
organisational databases was of little use, without the experience of these 
'downsized' staff to interpret and apply it (Martensson, 2000). As organisations 
realised this, Knowledge Management emerged as a tool to reverse and prevent 
this loss of knowledge from reoccurring. In a maelstrom of hype, large scale 
Knowledge Management schemes were specifically created to tackle these issues 
of tacit knowledge loss. Anderson Consulting chose the "Knowledge Manager" 
system and Price Waterhouse used "Knowledge View". However, Davenport & 
Prusak (1998) found that both schemes suffered from scant forward planning and 
the systems resulted in the wholesale storage of data and not applicable 
knowledge. Davenport & Prusak (1998) concluded that these schemes failed 
because the knowledge and business processes they were designed to capture 
rapidly became redundant as the key actors within the processes left the 
organisation. Hence with little or no contextual element, the knowledge lacked the 
authority, trust and verifiability which an employee, unfamiliar with a process, 
needed to make a reasoned decision and hence the existing business processes 
were quickly superseded. 
This example demonstrates that information management tools are unlikely to 
offer the correct means to store knowledge. This is because they do not take in to 
account the tacit knowledge transactions that occur when the experienced 
employee utilises the information or data (Nonaka & Takeuchi, 1995; Ruggles, 
1997; Silver, 2000; Gunnlaugsdottir, 2003). Nonaka et al. (2001) suggest tacit 
knowledge is personal, it may have meaning to a group, department or individual, 
and attempting to communicate the essence of the knowledge captured is essential 
to the success of a Knowledge Management system. 
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Even though Knowledge Management has evolved, the concept of organisational 
knowledge taking one of the dual classifications of tacit and explicit knowledge 
has remained predominant. It is rare to read a Knowledge Management paper that 
neglects to mention tacit or explicit knowledge management. However, Collins 
(1993) & latterly Blackler (1995), suggests that instead, knowledge possesses five 
facets. Knowledge may be embodied, encultured, embrained, embedded and 
encoded. Knowledge within the organisation is represented by the following 
definitions in Table 3.1: 
Table 3.1: The Components of Knowledge 
Knowledge Types Description 
Embrained Knowledge The inherent knowledge of the 
individual where the employee is the 
focus of the organisations knowledge. 
Embodied Knowledge A representation of the know-how 
derived from an employee's experience 
and the action based processes of the 
organisation. 
Encultured Knowledge The knowledge that is shared 
throughout the social structure of the 
organisation. 
Embedded Knowledge The knowledge held within the 
Knowledge Management systems and 
documented processes of the 
organisation. 
Encoded Knowledge Embedded knowledge that is accessible 
only to those who are familiar with the 
codification strategy of the knowledge. 
Of the five areas, three relate to the knowledge within the individual and may be 
generally construed under the banner of tacit knowledge. Dougherty (1999) and 
Allee (1997) offer further insight and proclaim that embraincd and embodied 
knowledge describes the rich subjective knowledge of the organisation. 
38 
Chapter 3- Literature Review 
However, to pigeonhole knowledge within categories alludes to an acceptance 
that knowledge can be specifically identified as holding characteristics of type X 
or Y. Yet within an organisation, knowledge resources may lie within and across 
these hypothetical boundaries (Allee, 1997). Scant empirical research is available 
to enlighten how the operational aspects of the five types of knowledge interact. 
Let alone divulging how a Knowledge Manager may apply the various types of 
knowledge once they are recognised. Although the five distinctions are fuzzy, 
they provide a higher level of detail over the duality of tacit and explicit 
knowledge. An encouraging point to note for this research is that little, if any, 
study has been carried out on the types of knowledge necessary for 
pharmaceutical innovation and as yet no studies have linked these knowledge 
types to Knowledge Management tools. 
3.2.4 SUMMARY 
Even at the early stages of Knowledge Management work Reich (1992) noted that 
research on the operational side of applying and capturing the types of knowledge 
was progressing slowly. Petty & Guthrie (2003) suggest that capturing 
organisational knowledge requires strong hierarchical control and guidance by 
management. Alternatively, authors such as Ndlela & Toit (2001) suggest 
Knowledge Management is dependent upon undertaking a series of reiterations, 
from the focus upon technology to a focus upon the assessment of the human 
factors within the organisation. Work by Balafas et al. (2003) and Heisig (2001) 
suggests Knowledge Management should address the business processes of an 
organisation. However, there is little doubt that Knowledge Management has 
undergone a shift in emphasis from the technology based Knowledge 
Management to an analysis of the knowledge within the business processes of the 
organisation. 
It is feasible that knowledge which falls within the categories defined by Collins 
(1993), Blackler (1995) and Dougherty (1999) when identified, may be supported 
through the application of Knowledge Management systems and tools (Jashapara, 
2004). 
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The following sections of the literature review will now turn to address the tools 
and practical approaches advocated by Knowledge Management academics and 
practitioner. Seeking to highlight Knowledge Management tools that may be used 
to enhance knowledge sharing and support the research aims and objectives. 
3.3 KNOWLEDGE MANAGEMENT TOOLS & STRATEGIES 
Knowledge Management is proclaimed by many authors to offer the key to a 
successful business and appears to offer an organisation the 'magic bullet' of 
increased productivity, efficiency and profitability (Choo & Bontis, 2002). 
Unfortunately, achieving these results is a somewhat grey area; the early rush of 
interest in Knowledge Management meant that many systems were 
enthusiastically introduced in many organisations and fell flatly out of use 
(Gartner Group, 2003). This is largely due to the scope of the field, Knowledge 
Management may be viewed from both an academic and a practitioner based 
view. A practitioner aims to create an environment conducive to knowledge 
sharing and is largely reliant upon the implementation of technology to support 
such knowledge interaction (Richardson, 2001). On the other hand, the academic 
arena approaches Knowledge Management from a conceptual angle, seeking to 
analyse the underlying basis of knowledge and create an environment conducive 
to knowledge sharing without the emphasis upon technology (Sullivan, 2000; 
Nomura, 2002). 
The two fields do agree that the basis of a successful Knowledge Management 
schema is an appreciation of the cultural and people centred aspects of the 
organisation (Rubenstein-Montano et al. 2001). Knowledge Management 
literature exhibits a fascinating degree of variability with regards to the 
acceptance of technology as a basis for a Knowledge Management strategy. 
Authors such as Alavi & Leidner (2001) advise the practitioner to view 
knowledge as a manageable entity and refrain from philosophical discussion. 
Work by Zack (1999) focuses upon knowledge as a codifiable and hence 
manageable entity. However, few authors will describe how these processes can 
be carried out and implemented. In the case of Yu et al. (2003), a set of step-by- 
step guides relating Knowledge Management to the creation, collection, 
codification, personalisation and dissemination of knowledge are suggested. 
TO 
Chapter 3- Literature Review 
Yet when analysed further, the steps fail to provide further infonnation with 
regards to practical application. 
However, Knowledge Management is a forward looking discipline and seeks to 
build upon the foundation of Information Management and establish its 
credibility. As previously mentioned, Wilson's (2002) argument that Knowledge 
Management is little more than Information Management appears to hold true on 
occasion. Indeed, as far as Knowledge Management tools are concerned it appears 
exceptionally well founded. Wang & Ariguzo's (2004) study indicates that the 
majority of Knowledge Management tools or Knowledge Management Systems 
(KMS) are in fact based upon the framework of an Information Management tool. 
A survey and review of these tools indicates there are four defined categories of 
Knowledge Management systems and tools (Ruggles, 1997). Jashapara (2004) & 
Benbya et al. (2004) suggests the four categories comprise of the following types 
of tools: 
1. Content management tools allow the codification, classify and capture of 
knowledge 
2. Knowledge sharing tools support the sharing of knowledge 
3. Knowledge search and retrieval systems allow the discovery of knowledge 
4. General Knowledge Management systems that attempt to answer a firm's 
knowledge needs in one package. 
The four definitions cover the majority of KMS within use, but substituting 
'knowledge' for 'information' still conveys meaning. It is odd to include type one, 
as the majority of content management tools are primarily based upon the 
management of documents and information (Jashapara, 2004). Accepting that a 
Knowledge Management System may in reality be an Information Management 
system unfortunately appears to be necessary. The confusion may be answered by 
the work of Polis et al. (2001) emphasises that companies seek to introduce a 
Knowledge Management system that encompasses all of the four categories. 
While few organisation's view Knowledge Management tools as distinct subsets 
(Rubenstein-Montano et al. 2001). 
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Hence a KMS may have many components including an information based tool, 
indeed Benbya et al. (2004) final recommendation is an amalgamation of the 
aforementioned concepts under the guise of a Knowledge Management System. 
Duffy (2001) states that a KMS is said to possess the capability to create 
knowledge and guide the use of these knowledge sources. Yet there remains a 
tenuous argument in the definition of a Knowledge Management and Information 
Management tools. Alavi & Leidner (2001), Gunnlaugsdottir (2003), Wilson 
(2002) and Scarborough et al. (2005) propose that the archetypal Knowledge 
Management System is an Information System. With the tag of KMS, being 
attributed to the concept of external guidance and management surrounding the 
information based systems. Holsapple & Joshi's (2002) study within the Delphi 
organisation places considerable emphasis on the dynamics of the knowledge 
activities within the organisation. Such knowledge related activities occur through 
the social interaction of individuals, the communities and the organisation, and to 
all intent a KMS should serve as a framework upon which these activities 
progress (Choo & Bontis, 2002). 
Evidently the knowledge aspect of the KMS stems from the aim of imposing a 
structure upon the knowledge led organisation, and in doing so provides 
clarification of the role and boundaries relating to the use and introduction of a 
KMS. However, deploying a KMS framework that produces value is rarely an 
easy task. Work by Rubenstein-Montano et at. (2001) notes that no single 
unifying Knowledge Management framework has been developed. Instead the 
authors define two co-existing frameworks, namely the prescriptive and the 
descriptive. The prescriptive framework is widely deployed and suggests that one 
should undertake defined actions in order to acquire, disseminate and amass 
knowledge. The prescriptive framework suggests a defined methodology with 
supporting KMS tools and is widely found throughout the literature (e. g. Alavi, 
2000, Tiwana, 2002; Jashapara, 2004). Although case study evidence suggests the 
likelihood of failure of prescriptive frameworks within an organisation is of 
concern (Malhotra, 2004). 
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A descriptive framework contrasts the rigidity of a set Knowledge Management 
methodology, by focusing on providing components of a Knowledge Management 
strategy. Although descriptive frameworks act as a hypothetical guide by 
highlighting areas to be addressed before implementing a Knowledge 
Management strategy, the physical implementation of tools and associated 
strategy aspect is lacking (Malhotra, 2004). There also appears to be little 
consensus concerning the standardisation of the traits associated with the 
prescriptive and descriptive frameworks (Earl, 2001). Furthermore, as 
collaboration takes place within the physical and technological realm of the 
organisation, it is implied that the practitioner will include both prescriptive and 
descriptive elements within a Knowledge Management strategy that are derived 
from multiple frameworks (Rubenstein-Montano et al., 2001). 
The issue of identifying what KMS framework to deploy certainly lacks a clear 
focus. Authors rarely adopt a homogenous tool set and this confusion represents a 
clear avenue for further research, particularly within the pharmaceutical 
environment. To illustrate this Nonaka et al. (2001) and Lindvall et al. (2003) 
signify that a KMS is a means to capture, codify and generate knowledge and is 
reliant upon information based principles. In contrast Holsapple & Joshi's (2002) 
and Wenger & Snyder (2000) work targets the adoption of a KMS to promote 
collaboration. This begs the reader to question how and what is meant by a KMS? 
Certainly there is a technological aspect, but what is meant by this? Hansen et al. 
(1999) rapidly concluded Knowledge Management requires the provision of 
information technology (IT) as a means to store knowledge through codification 
or as a means to provide the user with a personalised view of knowledge. Yet in 
this respect, little additional work has clarified this viewpoint. The Knowledge 
Management literature remains obstinately divided as to whether Knowledge 
Management should (or can) be deployed through tools and systems or whether it 
is an organisational dilemma alone (Horwitch & Armacost, 2002). Such a notion 
returns to the idea that of whether the individual is the sole provider of knowledge 
(Tsoukas & Vladimirou, 2001), or whether technology has its place to act as the 
facilitator of knowledge between individuals (Hansen & Haas, 200 1). 
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Additionally there appears to be a delicate balance between the culture and 
Knowledge Management tools. Earlier Knowledge Management research often 
assigns greater importance to the creation of a culture that is pervasive to 
knowledge exchange and interaction, over the introduction of tools to facilitate 
such interaction (DeLong & Fahey, 2000). In spite of this, the majority of 
Knowledge Management literature is based upon the notion of tangible 
prescriptive frameworks and it would be foolish to dismiss technologies role as an 
enabler of knowledge creation (Rubenstein-Montano et al., 2001). 
Knowledge Management literature can regard information technology as a 
separate entity and strategy. With an often dismissive attitude, prevalent within 
the Knowledge Management academic circle and literature, when IT driven 
Knowledge Management strategies are proposed (Un & Cuervo-Cazurra, 2004). 
Such views may stem from early research by authors such as Earl (1996) who 
championed the introduction of IT systems to support knowledge activities, yet 
disregarded the cultural aspects associated with the organisation. 
A more rounded approach details Knowledge Management and IT in tandem with 
the culture and strategy of the organisation. Rubenstein-Montano et al. (2001) 
noted this lack of an appreciation of the strategic element associated with IT 
hampers the introduction of Knowledge Management Systems. The cautionary 
taIe of KMS failure provided by Odom & Stams (2003), dispels the myth that a 
prescriptive IT led KMS framework will always provide tangible value. Instead 
Rubenstein-Montano et al. (2001) conclude Knowledge Management frameworks 
should be approached from a systems thinking concept. This links the people, 
their knowledge, the organisational culture, the organisational strategy and the 
technological infrastructure as a whole integrated system, while seeking to 
provide mechanisms for double loop leaming. 
Double loop learning implies the organisation actively challenges assumptions 
and processes rather that simply reacting to a challenge, as describes single loop 
learning (Agyris & Schon, 1978; Rubenstein-Montano et aL, 2001). While 
Rubenstein-Montano et al. 's (2001) work was conducted five years previously, 
little further work has focused upon addressing all the components of Rubenstein- 
Montano et al. 's (2001) framework. 
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The concepts of strategically aligning IT with Knowledge Management, is gaining 
acceptance as organisations realise information technology may facilitate 
Knowledge Management success (Kankanhalli et al. 2003). 
The shift from the IT led perspective to a knowledge led perspective has 
continued to fuel debate concerning IT and culture. As mentioned previously, the 
generations of Knowledge Management noted by Malhotra (2005) are in reality 
turning full cycle, returning to IT as a basis for Knowledge Management and 
collaborative activities. The re-emergence of technology as a key facet to address 
knowledge activities within R&D and innovation is being promoted by a new 
wave of innovation driven KMS systems that takes account of the knowledge 
required by innovators (e. g. Park & Kim, 2005). Hoadley & Kilner (2005) 
describes this as an 'information to knowledge' cascade. Whereby knowledge is 
constructed, shared and reconstructed by individuals from varying knowledge 
sources. Where the primary role of the KMS is to provide the knowledge sources 
on which an employee may act (Brown & Duguid, 200 1). 
3.3.1 STRATEGIES FOR KM & INNOVATION 
As the review has witnessed, the Knowledge Management literature can portray 
the use of Information Technology as a necessary evil, although as Malhotra 
(2005) notes, IT plays an important role when deployed in conjunction with the 
business processes and strategy of the organisation. In this light, strategy, 
innovation and Knowledge Management are closely linked concepts (Un & 
Cuervo-Cazurra, 2004). The concept of strategy and innovation or 'strategic 
innovation' is defined by Drejer (2006) as the ability to create and revitalise the 
business ideas and concepts of the company. This is achieved by addressing the 
market, the competencies and business systems of the company in such a way as 
to develop these areas across the entire organisation. However, the concept is also 
very similar to the ideals that Knowledge Management strives to achieve, as 
suggested by Scarborough (2002). Although strategic innovation is said to focus 
upon developing a differentiation strategy that allows innovative behaviour and 
hence may be of use to the overall research aim, it is still unclear what exactly the 
focus should be upon. 
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Drejer (2006) suggests that the current strategic literature is overly concerned with 
the operational aspects of the organisation, yet to an extent a strategy must address 
the operational aspects of the organisation in order to be successful (Un & 
Cuervo-Cazurra, 2004). 
Strategy or not, the very basis of an organisation's competence and ability stems 
from managing the employees and their knowledge and ensuring the 
organisational strategy reflects these aims (Benbya ct al. 2004). Nonaka & 
Takeuchi (1995) suggest that the primary means of achieving a successful strategy 
is through social interactions, which may, as we have previously witnessed, be 
encouraged through KMS technology. Returning to the topic of technology, an 
empirical study by Mustonen-Ollila & Lyytinen (2003) concerning the adoption 
of information systems, suggests it is prudent to identify the correct technologies 
to support the application areas. Interestingly their study assigned little 
importance to the cultural and social factors, such as strong management support, 
visibility of product champions and cost effectiveness. When the overall success 
of a strategy is considered these are areas that are key to the implementation of a 
successful strategy (Drejer, 2006). An earlier study by Thomas et al. (2001) 
concluded it is the social factors which hold the true weight of success. 
Ascertaining that Knowledge Management is concerned with the human aspects 
of the organisation and it is simply a matter of getting the right knowledge, to the 
right person, at the right time. 
In order to shed light upon these points and provide examples of KMS tools, the 
review will now look at the physical implementation of the Information Systems 
tools within Knowledge Management and outline how they may be used within an 
organisation. 
3.3.2 KNOWLEDGE MANAGEMENT TOOLS 
In compiling this review, the researcher realised there is such a wide variety of 
Knowledge Management based software tools available that to review each one is 
beyond the scope of the review. There is however, an arbitrary classification of 
the tools relative to the four classifications suggested by Jashapara (2004) and 
Benbya et at. (2004), cited earlier within Section 3.3. 
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These categories are broad in dimcnsion, but Saito et al. (2006) have compiled a 
more accurate overview that is based upon the tools associated with Knowledge 
Management and provides examples at the component level. This differs from the 
four categories previously discussed, in that software systems form the basis of 
each category. 
Table 3.2,3.3 and 3.4 illustrates the current software system components 
available, drawing examples primarily from Saito et al. (2006) but also Liao 
(2003), Gunnlaugsdottir (2003) and Wiig et al. (1997). 
Table 3.2: Content Management Tools 
Content Management Tools Allow the codification, classify and 
capture of knowledge 
Storage Databases, repositories, file-servers, 
data warehouses & data marts 
Authoring Office suites, desktop publishing, 
graphic suites & multimedia 
Table 3.3: Knowledge Sharing Tools 
Knowledge Sharing Tools Support the sharing of Knowledge & 
Information 
Distribution Web, intranets, extranets, enterprise 
portals, personalisation, syndication & 
audio/video streaming 
Connectivity Internet, security, authentication, 
wireless networking, mobile computing 
& peer-to-peer 
E-leaming Interactive multimedia, computer-based 
training, web seminars, simulations & 
learning objects 
Collaboration Calendaring, file sharing, meeting 
support, application sharing, groupware 
& decision support technology 
Community Community management, Web Logs 
(Blogs), Wikis & social network 
analysis 
Creativity Cognitive mapping & idea geneEation 
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Table 3.4: Knowledge Search & Retrieval Systems 
Knowledge Search & Retrieval Allow the discovery of knowledge & 
Systems information 
Search Search engines, search agents, 
indexing, glossaries, thesauri, 
taxonomies, ontologies, collaborative 
filtering & the Semantic Web 
Analytics Querying, reporting, multi-dimensional 
analysis & on-line analytical processing 
Workflow Process modelling & process engines 
Data mining Statistical techniques, multi- 
dimensional analysis & neural networks 
Text mining Semantic analysis, Bayesian inference 
& natural language processing 
Web mining Collaborative profiling & intelligent 
agents 
Visualisation 2D and 3D navigation & geographic 
mapping, 
Organisation Ontology development, Ontology 
acquisition, taxonomies, glossaries & 
thesauri 
Reasoning Rule-based expert systems, case-based 
reasoning, knowledge-bases, machine 
leaming & fuzzy logic. 
Table 3.2,3.3 and 3.4 illustrate the complexity and breadth of Knowledge 
Management component technologies available. When viewed from the 
previously mentioned categories of Jashapara (2004) and Benbya et al. (2004), it 
is evident that category four encompasses many of the available components. 
Citing the widely used Knowledge Management portal as a typical example, we 
witness that this contains an element of content management, knowledge sharing 
and search and retrieval components (Benbya et al. 2004). Many of the 
Knowledge Management technologies listed by Saito et al. (2006) may be 
fundamentally described as information systems. Yet it is only upon application of 
the information within these systems that knowledge is created (Liao, 2003). Thus 
the inclusion of information based software under the Knowledge Management 
umbrella certainly lends credibility to the protagonists of Knowledge 
Management, such as Wilson (2002). Knowledge Management based systems 
were originally said to stem from the field of Artificial Intelligence, whereby 
researchers attempted to capture and display human knowledge (Wiig, 1997). 
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It is evident however that this label has been extended to include a variety of 
further systems. However, true knowledge representation is apparent within the 
use of reasoning and semantic systems although the majority of Knowledge 
Management tools simply offer an information or data store (Berners-Lee et al. 
2001). The following section covers the semantic web that has been described as 
the future of pharmaceutical Knowledge Management (Davenport & Peitsch, 
2005), and provides an overview of the application and scope of the technology 
with relation to Knowledge Management systems and activities. 
3.3.3 THE SEMANTIC WEB AND KNOWLEDGE MANAGEMENT 
The semantic web is an emerging concept that creates a framework around 
information and knowledge stores. It is rapidly gaining acceptance as a credible 
knowledge and information retrieval approach (McGuiness, 2003). The semantic 
web is reliant upon the creation of domain ontologies to represent, map and search 
the information and knowledge within the organisation (Ding et al. 2002). 
Domain ontologies are a formal, explicit specification of a shared conceptual 
model (Gruber, 1993; Ding et al. 2002). The ontology models phenomena within 
a domain and explicitly defines the concepts and relationships within the model 
and hence the domain as a whole, may be understood, mapped and searched. The 
formality of Gruber's (1993) definition is associated with the machine readability 
aspect of the model, which is largely written within MVIL or an RDF/ XML 
framework (Anagnostakis et al. 2005). The concept of a shared and machine 
readable model of an organisational domain has not escaped the interest of the 
pharmaceutical industry. Gardner (2005) notes the semantic web offers 
pharmaceutical R&D industries the means to: 
1. Generate information that may be harnessed 
2. Distribute the generated information in a structured manner in order to 
generate knowledge 
3. Provide the ability to search across information sources 
4. Integrate the diverse ranges of information sources across an R&D 
organisation. 
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The semantic concept effectively tags encoded information with descriptors which 
describe the relation of the encoded information to other encoded information 
within the domain (Chiang et al. 200 1). However, as Chiang et al. (200 1) note, the 
semantic web suffers from a need to create and then actively manage the domain 
ontologies which are required for its success. 
Ontologies within a rapidly changing domain, such as drug R&D, must reflect 
current knowledge and thinking to provide the valuable relationships between 
terminologies and project work (Goble ct al. 2005). Public domain ontologies 
such as WordNet consist of 100,000 concepts and require considerable 
management (Fenscl et al. 2000). The management aspect makes it clear that the 
pharmaceutical domain ontologies are also expected to pose similar problems 
(Goble et al. 2005). Due to this, Gardner (2005) concludes that the semantic web 
is reliant upon accurately mapping the nomenclature and terminology found 
within the organisation and domain. As such this requires considerable investment 
over traditional free text search structures and information management systems. 
Early pioneers of the semantic web note the semantic structure may offer 
considerable benefit in the codification and retrieval of knowledge and 
information within the life sciences. In particular Goble et al. (2005) notes the 
semantic web addresses the issues of information search and retrieval across 
multiple life science domains, which is a commonly cited failing of Knowledge 
Management technology (Nonaka et al. 2001). 
3.3.4 REFLECTIONS ON KNOWLEDGE, INFORMATION AND 
SYSTEMS 
The intrinsic principles of the semantic web are linked with those of Knowledge 
Management. This link may provide an important tool with which to manage and 
locate an organisation's knowledge across multiple domains. Although the 
semantic concept is in its infancy, it would appear to offer considerable 
advantages through the linking of information and knowledge as a series of 
interrelated concepts. Information without searchable context is ambiguous in 
meaning and draws a parallel with unanalysed data (Gunnlaugsdottir, 2003), yet 
the semantic web may be used to provide the all important contextual element. 
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In reality though, too few KMSs or Knowledge Management papers address this 
issue and hence lack the contextual support, often simply rehashing an 
information tool under the guise of Knowledge Management (Chua, 2004). The 
reasoning behind this stems from a lack of specificity, few authors will tailor 
Knowledge Management tools to a specific environment, preferring instead to 
provide a multi-environment prescriptive framework that is based upon 
commercially available tools that will function in a variety of industries (Tiwana, 
2002). Hence tools are rarely built to exploit the knowledge of a particular 
environment and become 'generalist'. This is odd, as the basis of Knowledge 
Management is to extract and use the knowledge that is within the organisation 
(Stewart, 1997) which implies that specificity is preferable. The research aim will 
address this within the R&D pharmaceutical environment, but this trend maybe 
attributed to the acknowledgeable gap between the knowledge held within a 
Knowledge Management System and the application of knowledge by a human 
expert (Skyrme, 1999; Cooper, 2003). Such a gap often appears insurmountable 
and authors such as Havens & Knapp (1999) believe that rather than attempting to 
capture the knowledge of the employee's within a system, Knowledge 
Management should instead encourage collaboration and provoke discussion 
across knowledge sources, although Roberts' (2000) concedes that such a system 
may never manage to emulate a face to face environment. 
Theoretical research carried out by Chua (2004), reviewed established KM 
methodologies that purport to bridge the gap between the elusive organisational 
tacit knowledge and the existing Knowledge Management technology. From these 
models Chua (2004) outlined a KMS architecture, which drew upon three distinct 
service areas. Namely: 
* The infrastructure services such as knowledge storage and communication 
9 The knowledge services that deal with the creation, sharing and reuse of 
knowledge 
* The area of presentation, where the visualisation and personalisation of the 
knowledge occurs. 
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Altogether these aspects combine to form a theoretical basis to address the 
balance of technology in relation to organisational knowledge processes. 
However, it is apparent that the proposed system fails at grasping the importance 
of intangible knowledge and represents a clear example of the confusion between 
the terminology of knowledge and information. When describing the contents of 
the knowledge storage service Chua (2004) proposes that 'a knowledge repository 
could either be populated with data or documents', hence in effect the grounds of 
the 'Knowledge Management' system is firmly based within the realms of 
document and information management. This trend is apparent throughout the 
Knowledge Management literature and little explanation is offered as to the how 
the feat of intangible knowledge capture may be carried out. In reading papers 
such as these, it becomes apparent that although Knowledge Management 
research is established and varied, few people have attempted to apply their 
theoretical work within industry (Mouritsen & Thorsgaard-Larsen, 2005). 
A survey carried out by the Knowledge Management Consortium International 
(KMCI, 2003) in late 2003, questioned 110 KM professionals. From these 
discussions it emerged that KM practitioners are looking for and failing to find 
insight into how companies can physically implement KM within the workplace. 
The studies sample population revealed few studies provided practical instruction, 
while the associated standard means of operating a Knowledge Management 
schema were also shown to be lacking. Many Knowledge Management 
practitioners are in reality baffled by the scope and application of Knowledge 
Management within an organisation. As an example, Dilnutt (2002) has authored 
one of the few academic studies of Knowledge Management in practice. He 
describes three case study scenarios where Knowledge Management has aided a 
problem domain. The first is within a large bank call centre, where the introduced 
Knowledge Management system provided staff with a taxonomy that provided 
details of the knowledge required to carry out procedures, its location and the 
form of the knowledge. The second and third Knowledge Management schemas 
took place in a fund management company and a govemment office, and both also 
revolved around the same principles of providing access to the required 
knowledge, its location and its format. 
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Although this example provides a valuable illustration of knowledge and 
information manipulation, it denotes Knowledge Management at its most basic 
level and may readily be construed as information management. The implemented 
Knowledge Management systems revolved around a Lotus Notes system 
employed to classify and record information based best practice documents and 
guidelines as knowledge, in a similar respect to Chua's (2004) system. 
The Knowledge Management aspect of Dilnutt's (2002) research derived from the 
mapping of the employee's knowledge requirements and the gap analysis required 
to develop a taxonomy to map an organisation's information. The tangible 
benefits of the scheme did not stem from providing the employees with greater 
access to information, such as best practices and use case scenario, but from 
educating the organisation and employees to recognise and nurture the knowledge 
within themselves and the operating procedures of the organisation (Dilnutt, 
2002). A side effect of this action, was an elucidation of the knowledge structures 
within the organisation, which when identified was assigned ownership within an 
individual's job description (Dilnutt, 2002). Indeed authors such as Blair (2002), 
suggest mapping of an organisation's knowledge may help an organisation's best 
practice and decision support systems, but it does not replace an employee's tacit 
knowledge. It is the concept of knowing within an employee, which only begins 
with understanding and often reflects upon experience that differs from the 
capability of knowledge captured within a machine (Ghandi, 2004). 
3.3.5 SUMMARY 
Darroch & McNaughton (2002) propose Knowledge Management seeks to create 
or locate local knowledge. Therefore from a theoretical perspective a logical 
framework to capture knowledge within a machine may appear effective at 
recording the organisation's knowledge (Mayo, 1998). Yet the subsequent reuse is 
often limited by the lack of a contextual element (Gunnlaugsdottir, 2003). From 
this, the key to an effective Knowledge Management system appears to be 
providing the employee with an understanding of the captured knowledge from 
which to form reasoned judgements (Cooper, 2003). 
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Knowledge Management literature largely focuses upon the capture of an 
organisation's tacit knowledge into an explicit form in a KMS (Ghandi, 2004). 
This action detracts from the fact that an organisation's innovative knowledge can 
take a variety of forms. 
Albino et al. (2001) conclude knowledge is created through employee interactions 
and the tumultuous mix of knowledge and information that occurs within a 
business process. They also warn that ill formed attempts to compartmentalise 
such knowledge may hamper this reaction. From a pharmaceutical perspective, 
authors such as Roth (2003) advocate the use of multi skilled teams within 
pharmaceutical R&D and a Knowledge Management system in tandem. Authors 
such as Hoadley & Enyedy (1999) conclude that although information systems 
promote knowledge creation, the primary means of knowledge creation is through 
employee dialog that is centred upon and supported through information sources. 
The mention of dialog turns to the concept of the Community of Practice as a 
Knowledge Management tool. Watson (1999) notes the capture of knowledge 
within an organisation is not the only crucial aspect, it is the subsequent 
application of the knowledge within an organisational community that yields 
value. Deciding upon how to address how to encourage communities where 
knowledge is exchanged is where the challenge for Knowledge Management lies, 
and has so far yielded few methodologies or strategies. Of the few methodologies 
reviewed, the Community of Practice model occupies a prominent position within 
the Knowledge Management literature as a strategy to capture and disseminate the 
tacit and explicit knowledge of the organisation (Nahapiet & Ghoshal, 1998; 
Hoadley & Kilner, 2005). The review will now discuss the Community of Practice 
and its applicability to Knowledge Management and innovation within an 
organisation. 
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3.4 THE COMMUNITY OF PRACTICE 
3.4.1 INTRODUCTION 
As the review has previously noted, the advent of the knowledge based economy 
has caused great interest to be taken in the phygical and psychological aspects of 
knowledge sharing and creation (Drucker, 1993). A large amount of academic and 
practical based research has focused upon how the knowledge within an 
organisation is shared and this has led to the evolution of the term a Community 
of Practice (CoP) (Wenger & Snyder, 2000). The following section discusses the 
nature and deployment of the CoP and aims to clarify the accuracy and extent to 
which a community may be used within the innovative arena. The study aims to 
throw light upon the ambiguity present within current research, which sees co- 
operative groups falling under many different names and guises. All of which can 
seemingly be construed to be under the larger banner of a Community of Practice. 
Firstly the review will examine the theoretical basis of the CoP, before continuing 
to analyse their application and their impact on decision making, knowledge 
sharing and knowledge generation within an innovative business environment. 
3.4.2 DEFINING THE COMMUNITY OF PRACTICE 
The literature is extensive in scope and depth upon the subject of Communities of 
Practice, yet there are believed to be a number of factors which form to constitute 
the definition of a valid CoP. The key factor appears to be a shared or common 
interest centred upon a particular subject area (Davenport & Hall, 200 1). Research 
by authors such as Lave and Wenger (1991) has elucidated that the knowledge 
sharing processes involved within the organisation are dependent upon the 
formation of communities. In this light Lave & Wenger (199 1) define the CoP as: 
"An activity or system that includes individuals who are united in action and 
meaning, to provide reasonfor the larger collective or community. " 
Similarly the definitions offered by Wick (2000) and Cortada & Woods (2000) 
share a common knowledge creation theme, in that they encourage active 
participation and a fostered team work ethic, which is intended to complement 
and mirror the standard working practices of the organisation. 
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Such communities are often centred upon specific projects and focus on 
answering a specific project related task or a business process that is often the 
crux point of an innovative process, with the end results realising a step towards 
new product development or innovation (Collier & Esteban, 1999). Hence the 
CoP appears to be focused upon specific business processes and these include 
innovative and project related work. 
When looking to further define a CoP it is wise to look at the meaning attributed 
to the community aspect of the term. Drawing upon the view point of Heller 
(1989), we begin to see a focus upon interaction and participation where a 
community is characterised by the relational interactions or social ties which bind 
people together. This view ties in well with the definition of a CoP as penned by 
Lave & Wenger (1991). Although, Rothaermel & Sugiyamas (2001) believe a 
CoP allows people to come together to share knowledge and collaborate only 
when centred upon a technological framework or a Knowledge Management 
system. Earlier literature by Gusfeld (1975) focuses upon the existence of two 
different types of community - both a geographical and a relational community. 
Here the sense of close spatial proximity is inherent within the definition of the 
community, countering many of the definitions of a distributed community that is 
commonly associated with a CoP within a Knowledge Management system. 
However, to a large extent, the CoP associated with the technical realm is deemed 
non-geographical and independent of time (Markus et al., 2000) and hence not 
bound by the traditional restraints associated with a physical community more in 
keeping with Gusfeld's (1975) traditional definition. 
At this stage it must be noted that the CoP may exist both within the realm of the 
traditional physical work place and the virtual realm of technology backed 
interaction. The distinction defines a Community of Practice to involve physical 
interaction, while the virtual Community of Practice allows faceless interaction 
over a communicative medium (Rheingold, 1994; Palloff & Pratt, 1999). As both 
virtual and physical communities occur within the pharmaceutical innovative 
domains the research will cover both types, although the Knowledge Management 
literature is on the whole more concerned with the application of the virtual CoP, 
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The online or virtual CoP may be regarded as a predetermined situated learning or 
collaborative environment, where the instigators and practitioners are physically 
free from constraints such as their geographic location and provided they can gain 
access to the service, remain tentatively linked through their online relationships 
to form a working community (Nonaka & Takeuchi, 1995). The work of 
Davenport & Hall (2001) proclaims that a CoP will display three traits. These 
traits are based upon the organisation and virtual interaction of participants, rather 
than the spatial awareness and proximity of the participants: 
1. Firstly a group is said to display situated actions based upon a specific 
problem 
2. Secondly there is situated learning where both novices and experts learn 
and exchange knowledge when located within the same virtual space and 
context 
3. The third and final trait is distributed cognition where the phenomenon of 
learning as a collective is deemed to be greater than that possible by the 
individual. 
As the community evolves, the structure and rules associated with the 
accumulation of knowledge and the traits are said to be adapted and developed by 
the group, creating an environment that is specifically adapted to solving specific 
process driven requirements within the organisation (von Krogh & Kleine, 1998). 
Johnson's (2001) review of CoP literature provides ftirther clarification into the 
definition and scope of the CoP, where the author notes that these characteristic 
traits and definitions merge to support the view of a the CoP working on a shared 
goal or consensus. Johnson (2001) also implies that CoPs are based upon the 
principles of constructivism. Where the term constructivism denotes that we learn 
from our own experience, hence meaning and understanding of an issue are 
inferred by applying a community's current knowledge to a problem and then 
constructing their own meaning to suit each problem area. 
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Viewing the CoP in such a way allows us to comprehend their value within a 
business environment. By allowing and promoting the interactions of individuals 
who apply their knowledge and experience to a problem area, in the hope of 
ultimately devolving a meaning and solution to their quandary. 
The main points raised by Johnson's (2001) literature review on the means and 
application of a CoP to promote organisational learning and knowledge creation 
are: 
A CoP will evolve and challenge ill-structured problems which have 
defied traditional attempts to solve, such as commercial problems which 
are complex and ill-suited to be solved by generalised concepts found 
within a traditional rigid working pattern. 
Teams are paramount to the CoP and the emphasis is on attacking a 
problem with multiples of knowledge and experience in the hope of 
divulging a rationale outcome. 
The ultimate goals and answers are shared and all participants are working 
towards the effective resolution of a scenario. CoPs demand negotiation 
and discussion, which further promote a sense of ownership and interest 
amongst the participants. 
o CoPs often utilise a facilitator or advisor to guide rather than instruct the 
participants to a novel solution. 
Perhaps the most important feature raised by Johnson (2001) is the use of a CoP 
to organise and categorise knowledge through the use of a communities within the 
organisation. Although communities may naturally categorise knowledge across 
an organisation, little explanation is provided concerning the technology required 
to achieve and manage this knowledge. Rather it is implied that the process of 
learning how to create relationships across the organisation will foster knowledge 
and interaction across the organisation (Newell, et al., 2002). Here the value of the 
knowledge surrounding the formation and instigation of ties between employees 
may outweigh the knowledge contained within the community itself (Crampton, 
2001). 
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This point acknowledges that the formation of community is a valid approach to 
problem solving, as a group discussion or consensus formulates the knowledge 
within the community. Yet Huysman (2004) believes that organisations may be 
unaware of the CoPs that operate within its boundaries and even less aware of the 
learning and knowledge that occurs within them. Further to this, is the interaction 
of like minded communities that interact to form Communities of Interest that 
span multiple CoPs and multiple domains across an organisation (Fischer, 2002), 
further clouding the decision and knowledge processes of the organisation. 
Thus a Community of Interest differs from the process or practice based CoP and 
provides a wider group that has the capability to address a broader range of topics 
(Liedka, 1999). Fischer (2002) also argues that due to this a Community of 
Interest displays a potentially increased return due to the increased levels of 
interaction. If a CoP centred upon a process lacks the required number of 
participants to function effectively, the conglomerate of CoPs within a 
Community of Interest may offer a greater return. The literature suggests that the 
tight knit CoPs within an organisation may be used to form a larger framework of 
Communities of Interest throughout an organisation (Johnson, 2001). 
Unfortunately the specific Knowledge Management strategies and tools to achieve 
a viable Community of Interest are unclear. What is also unclear is the precise 
definition of a Community of Interest. A Community of Interest is described as a 
large CoP by many authors, yet each type of community appears important to the 
organisation and should be considered to meet the research aim. The problem of 
ill definition can affect how an organisation reacts and manages such 
communities. Kankanhalli et al. (2003) describes how companies such as Shell 
extract value through the deployment of discussion and collaboration tools to 
encourage communication across the organisation. This in effect, describe a 
Community of Interest, yet the reader may only assume that the base CoPs 
providing the basis for interaction, stem from similar groupware tools. 
flence the deployment, management and framework of communities within an 
organisation is a key Knowledge Management strategy. 
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Although they are driven to produce a similar tangible result, CoPs differ from the 
classical notion of an organisational team which has assignable and measurable 
deliverables (O'Donnell et al., 2003). Teams are formally identified and explicitly 
supported by an organisation's structure and software tools (Cabrera & Cabrera, 
2002). CoPs on the other hand, are often outside of the organisation's structure 
and lack allocated resources. Rather than this being a disadvantage, authors such 
as O'Donell et al. (2003) proclaim that organisational teams are too rigid and 
solely driven by management goals, and instead it is the CoP that offers: 
"Ae opportunities to learn, to share and to critically evaluate what the 
participant's discover and what may unexpectedly emerge ". 
It is interesting to note that author's (e. g Kirkman et al., 2001) focus upon the 
organisational team as the ideal medium in which to achieve this, identifying that 
the label of the CoP is a relatively recent term. Iqdeed Johnson (2001) notes a CoP 
may itself consist of teams, although the precise definition of these teams and 
whether their origins were within the established organisational structures or 
resulted as a result of the formation of a CoP is unclear. ZArraga-Oberty & De 
Sad-Nrez (2006) attempt to clarify this anomaly by differentiating the CoP from 
the work team, they conclude: 
"Communities ofpractice are not a new type of organizational unit, but rather a 
different "section" of the structure of the organization that emphasizes the joint 
learning ofthe individuals, rather than the unit to which they are accountable ". 
The CoP would appear to form in response to a defined need that cannot be 
addressed via the traditional organisational team. Such formation links the basis of 
a CoP to the Knowledge Management principles of innovation, intellectual capital 
creation, trust, common understandings and a mutual climate of knowledge 
sharing and trust (O'Donell et al., 2003; ZArraga-Obcrty & De SaA-Pdrez, 2006). 
Although Vangen & Huxham (2005) note the creation of such a collaborative 
environment requires substantial management and strategy. The Community of 
Interest would also appear to possess these facets of Knowledge Management. 
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Essentially, by extending the domain of the traditional CoP both internally and 
externally, across the organisation by creating 'communities of communities' 
(Brown & Duguid, 1991). Murray's (2002) research supports such a notion that 
'communities of communities' are common in organisations and those centred 
upon biotechnology companies are supporting innovation within this field. 
Overall the literature is unclear as to the strategic similarities and software 
components that may support the CoP, Community of Interest and the work team 
respectively. In addition the introduction of technology to encourage the 
collaborative activity between actors is less defined, with few case studies 
addressing the necessary components to facilitate such interactions. Murray 
(2002) suggests that the majority of collaboration is still via face to face meetings 
and hence spatial proximity plays an important role in initially establishing a CoP. 
As the review has discussed, the scope of the CoP is rather broad and it would 
appear that transient teams and occasional mass participation of employees can be 
included within the ambiguous realm of the CoP. The research aim and objectives 
are all concerned with enhancing knowledge sharing and pharmaceutical 
innovation. Hence the use of the CoP would appear to be a useful model to 
include within the tool set of Objective 4, particularly with regards to improving 
decision making and encouraging collaboration. 
3.4.3 IMPLEMENTING A COMMUNITY OF PRACTICE 
The work of Wenger (1998) and Johnson (2001) describes the virtual CoP as the 
designed community, where the community evolves as the result of users 
interacting with the technology. In order to believe this view, the practitioner 
inevitably questions what constitutes the underlying framework of a virtual 
community and how may a practitioner encourage the formation of a CoP? 
The commonest form of virtual community springs from a web or intranet 
medium with a text based interface. From a Human Computer Interface 
perspective, Kollock (1998) argues we should aim to recreate traditional 
community values within the virtual community. Through avoiding the use of 
flashy graphics and instead focusing upon persistence of identity, coherence and 
ritual within the community space in order to identify users with the community. 
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The basis of CoP software is also discussed by Whitaker & Parker (2000) and 
Godwin (1994) and they include ensuring that the software chosen, suits the needs 
of the users by using a customisable knowledge sharing environment. However, 
specific frameworks detailing the requirements necessary for implementing a CoP 
are lacking within established literature (Stacey, 2001). 
Preece et al. (2003) have conducted a review of community software. The earliest 
identified community technology focused upon Listservers that contain a simple 
list of topics that are commonly truncated into an emailed digest, which is then 
emailed to users. Technology was then used to map physical bulletin boards to the 
virtual realm, allowing users to post and respond to information and questions in 
defined hierarchies and categories. The aforementioned technologies are 
asynchronous in nature, allowing users to post a query or information that may not 
elicit an immediate response. Yet the post remains as a permanent record that 
users may view and contribute to as they wish (Hammond, 2000). Synchronous 
communication mediums that may be used to form a CoP, include live chat 
systems, video conferencing, whiteboards and instant messaging technology that 
require respondents to be online (Preece et al. 2003; Park & Kim, 2005). 
The inclusion of an instant messaging system within accepted CoP tools, suggests 
that the deftition of a community may be somewhat stretched. Research by 
Cameron & Webster (2005) suggests a critical mass of instant messaging 
participants is required to form a valid CoP. On the whole, users prefer to use the 
technology on a personal one-to-one basis to quickly reach colleagues, instead of 
on a community level. However, what may be implied from Cameron & 
Webster's (2005) research is that although communication largely occurs between 
two actors, the participants do form a viable Community of Practice via personal 
social networks. Furthermore the information of this network may be captured 
within an instant messaging system (Segerstad & Ljungstrand, 2002). 
Interestingly instant messaging technology allows users to immediately access a 
colleague above other communication mediums such as email and the telephone. 
Unfortunately, instant messaging also appears to invoke an appreciable sense of 
disruption to an employee's productivity (Cameron & Webster, 2005). 
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A finding that is akin to Jackson et al. 's (2003) research concerning the negative 
impact of email interruptions on employee productivity. 
A common finding throughout the study of instant communicative media is the 
lack of richness of context and meaning associated with the face to face meeting 
(Cameron & Webster, 2005). This collaborative aspect is regarded by Park & Kim 
(2005) to form an important component of a Knowledge Management system that 
is intended to enhance R&D functionality and innovation. Instant messaging has 
been envisaged by some to supplement email and face to face meetings (e. g. 
Segerstad & Ljungstrand, 2002). Although research by Smith & Fiore (2001) 
suggests that visualisation tools such as graphical timelines and content trees are 
also to replace face-to-face communication. 
3.4.4 CREATING A SUCCESSFUL COMMUNITY OF PRACTICE 
The Knowledge Management literature is awash with how a CoP can enhance 
human interaction and the virtual CoP aims to promote human interaction through 
the use of computer mediated technology (e. g. Cortada & Woods, 2000; Liedtka, 
1999) The ultimate aim is the proliferation and dispersion of knowledge and there 
is widespread belief that adopting such a practice will automatically confer these 
benefits to the participants (Wenger & Snyder, 2000). However knowledge 
sharing within a community is a delicate balance of participation and coercion 
(Adichvill et al. 2003). Werry (1999) is a noted author on CoPs and believes the 
value of a community is linked to the number of participants, thus the greater the 
number of participants the richer the tapestry of knowledge created. 
However, Werry (1999) does little to mention which parties and people should be 
involved within the community, in order to gain the correct balance and return on 
knowledge creation. This is an important point which is largely passed over by 
literature which, on the whole, expects a community model to be successful 
regardless of the environment it is deployed within. 
Therefore in order to solve an innovative problem, knowledge must flow from the 
participants and it stands to reason that unless a CoP is deployed and managed so 
as to reach key contributors then the return will be low (Cox et al. 2003). 
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Hayes & Walsham (2000) take this premise further by implying that the 
technology supporting the capture of explicit knowledge may never truly impart 
the true nature of the knowledge. Ibis factor suggests that the discussions 
occurring within a virtual CoP must then be followed by face-to-face 
communication, to successfully convert the explicit knowledge within the 
community to useable tacit knowledge. This supports Cook & Brown's (1999) 
observation that creating worthwhile knowledge, from which an organisation may 
learn, relies upon both the interaction of physical (e. g. explicit) and social (e. g. 
tacit) knowledge. 
Work by William & Cothrel (2000) propose three management strategies for 
introducing and maintaining a successful CoP. Members must be encouraged and 
developed, the community must be actively managed as an asset and the organiser 
must strive to build and foster community relationships. Methodologies and 
strategies for achieving these three strategies, theorised by Ardichvilli et al. 
(2003) and Hayes & Walsham (2000), focus upon promoting interaction between 
the users, managers and strategists within the organisation, and engaging 
participants in live chats, Q&A sessions and providing feedback on postings. 
The answer to successful knowledge creation and innovation via CoPs is elusive 
and is certainly dependent upon the aim of the community and the individual 
participants taking part. Additional research by Wenger (1998), Werry (1999) and 
Ardichvilli et al. (2003) notes that a 'champion' or leader is required to promote a 
CoPs use and focus the aim. In addition to a 'champion figure' a strong 
supporting organisational culture must exist to allow the community participants 
and champions to exert a bearing influence on the proceedings (Ardichvilli et al. 
2003). 
An interesting conceptual idea by Koh & Kim (2004), recommends participants 
subscribe to a CoP to attain the status and behaviour of citizens and within this 
concept a crucial percentage of users contribute without a formal reward. The 
notion of reward generates heated debate throughout the literature. Kankanhalli's 
(2003) study of organisational practice noted both Buckman Laboratories and 
Ernst & Young offer a monetary reward for contributing to a discussion forum 
based CoP. 
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On the contrary, academic literature focuses upon the intangible benefits an 
employee will encounter by regularly contributing knowledge to a community 
environment (Kwok & Gao, 2004). Kollock's (1998) cites that the factors driving 
users to participate are: the expectation of helpful research in return, contributing 
will increase the user's personal reputation and greater contributions will increase 
the sense of belonging within the community. Flower (1999) on the other hand 
recommends monetary reward as the only sure means to ensure users contributed 
knowledge to community software, which focused upon capturing innovative 
practices. 
3.4.5 SUMMARY 
The CoP literature review has been useful in outlining the role a CoP plays within 
a business environment. Conceptual literature is wide spread there are many case 
studies that support the viability and role of a CoP. However, there is a lack of 
applied research towards the commercial tangible evaluation of the CoP. Johnson 
(200 1) notes that a business based CoP, promotes knowledge across a broad range 
of groups. Effectively creating value by allowing a "knowledge network" to form 
and promote the conversion of the explicit knowledge, held within the community 
software, to tacit knowledge through employee interactions. However, there is 
little evidence that this occurs as a matter of course or what strategies should be 
employed to achieve this, particularly with regards to enhancing innovation and 
drug development. 
A key role of the CoP appears to be as a facilitator to remove the barriers that 
impede the formation of relationships across work groups, companies and cross 
company teams. In this respect the CoP seemingly is an ideal Knowledge 
management tool. Yet the reality is convoluted, in that a KM professional must 
actively promote, manage and guide the CoP to success which requires resource. 
Ilence there must be a tangible benefit which outweighs the time and efforts 
required to instil and maintain such a successful community, The excessive hype 
surrounding the appeal and application of a CoP which dominated the literature 
previously (e. g. Wenger & Snyder, 2000), is now being replaced by tentative steps 
to evaluate the active management and problems associated with their use Martin 
(2004). 
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However, there remains scope for extensive study into how informal learning and 
knowledge interaction spawns knowledge generation within a CoP, particularly 
regarding how the Knowledge Management professional can encourage and 
enhances these processes. 
Wick (2000) surmises that "the effective management of the employee's 
knowledge becomes the value creating element within the company". This lends 
weight to the use of the CoP as an important component of a Knowledge 
Management strategy. Although perhaps the most important feature raised by 
Johnson (2001), is the use of a CoP to organise and categorise knowledge through 
the use of communities across the organisation. Although communities may 
naturally categorise knowledge, little explanation is provided concerning the 
technology required to achieve and manage this knowledge. In addition there is 
little information regarding their use in driving pharmaceutical research. Hence 
research leading to the development of a Knowledge Management framework or 
tool set that includes CoPs within an organisation would undoubtedly be useful 
research. The principles of Knowledge Management require knowledge and 
information reuse and while the CoP and community model may encourage such 
bchaviours, there remains many unclear areas. 
The review now tums to focus upon measuring and evaluating the knowledge and 
the myriad of Knowledge Management technologies that are available. Seeking to 
clarify the extent and success of the techniques employed to measure the 
intangible nature of organisational knowledge. . 
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3.5 INTELLECTUAL CAPITAL 
3.5.1 INTRODUCTION 
Supporting the deployment of a Knowledge Management system and strategy is 
an intricate balancing act of tangible costs weighed up with the intangibility of 
perceived benefits. Establishing a measurable return on a Knowledge 
Management investment has had, or can have, on a business area, is often 
essential to sway the opinions of staff that the scheme is having a positive benefit 
and is worth persevering with (Milis & Mercken, 2004; Wilcocks & Lester, 
1996). 
Knowledge Management within an organisation undergoes a slow process of 
evolution. From the basic building blocks of system appraisal and the analysis of 
the problem scope, to the introduction of a proposed strategy and the associated 
technology, the process occurs over a lengthy period of time. Mouritsen & 
Thorsgaard Larsen (2005) propose Knowledge Management has evolved from the 
first wave that viewed the employee as the central source of knowledge within the 
organisation. To a second wave that addresses the knowledge resources of the 
organisation in terms of both the employees and the organisation as a whole. The 
results of introducing Knowledge Management to target multiple stakeholders and 
knowledge across an organisation will be immediately visible in terms of access 
to explicit knowledge. Yet the indoctrination of the system within the 
organisational culture of the organisation will be less evident and leads many 
organisations to question the true worth of a Knowledge Management strategy 
(Mahesh & Suresh, 2004). 
The field of intellectual capital and intangible metrics essentially aims to assign a 
value to the use of knowledge within an organisation. Furthermore, it is 
increasingly linked to the area of Knowledge Management activities (Bukh et al. 
2001). On first glance, measuring knowledge and- Knowledge Management 
activity would appear a difficult process and the multitude of available 
methodologies to achieve this confirms this prognosis (e. g. Kuczmarski, 2000; 
Marr et al. 2004). 
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After all how can one assign a value to the intangible processes of knowledge 
generation and the subsequent processes of utilisation, storage and retrieval? 
A wealth of literature assures the reader that companies who embrace newer 
technology will gain a distinct and measurable financial advantage over their 
competitors (Barney, 1991). Measuring the means and objectives behind a 
successful strategy should be considered within the first stages of a KM schema 
(Marr & Starovic, 2003). Only once this aspect has been addressed, can an 
organisation truly value the benefits a Knowledge Management schema has 
bought to the working practices of the company (Havens & Knapp, 1999). 
The following sections aim to provide a detailed analysis of the concept of 
intellectual capital in relation to innovative activities within the modem 
knowledge creating organisation. The section concludes with recommendations 
that apply to evaluating the knowledge requirements within the area of 
pharmaceutical innovation. 
3.5.2 QUANTIFIABLE KNOWLEDGE 
The traditional view of knowledge creation championed by authors such as 
Nonaka (1991) typifies a chain of events, when linked together allows the 
continuous interaction of tacit and explicit knowledge within the company. Ille 
key actors within this process are the employees who are deemed to carry out this 
process on a daily basis and this in turn generates organisational and innovative 
knowledge. Further work by Nonaka & Takaeuchi (1995) discusses these 
interactions in greater detail. Firstly tacit to tacit knowledge, which occurs on the 
social level is often observed within the corridors or rest areas of a company. The 
second type of interaction covers the explicit to explicit level of knowledge 
interchange, which allows the combination and reappraisal of knowledge confined 
within the operating and technological layers of the company. The third type of 
interaction is tacit to explicit knowledge conversion or externalisation, where 
knowledge is captured from employees and by such processes may then be 
deemed to be accessible to the company on a whole. 
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The final type suggested by Nonaka (1991) is a reverse of the third process and 
results in explicit to tacit knowledge being interrialised within the company. These 
processes of knowledge externalisation and internalisation are deemed by Albino 
et al. (2001) to be the crux of knowledge creation as they necessitate a change in 
the nature of knowledge. From this an inference is made, which argues knowledge 
will be retained by the workforce when processed in this way and knowledge 
interactions revolve around the employee. However, as previously mentioned, 
Mouritsen & Thorsgaard Larsen (2005) propose that the employee is not the sole 
source of valuable knowledge. Instead knowledge may be derived from the 
organisation itself from a series of knowledge resources. This in itself presents an 
interesting angle of introducing metrics to measure knowledge exchange and 
knowledge retention across multiple and non-homologous sources. The 
knowledge resources described by Mouritsen & Thorsgaard Larsen (2005) are 
believed to constitute: 
"A series of heterogonous knowledge resources such as employees, processes, 
customers and technologies, each of which is a possible object for decision- 
making". 
Unfortunately this view is generic in character and does little to accurately map 
and identify the knowledge within these resources. Sullivan (1998) on the other 
hand, calls for the codification and commercialisation of these knowledge sources, 
believing that this process allows the valuation of the intangibles that constitute 
organisational knowledge. Desouza (2003) contributes to the notion of 
quantifiable knowledge by identifying two further perspectives, he believes 
knowledge can either be classified as an object, which exists independently of 
humans and can be exchanged as a commodity. While the second perspective 
views knowledge as being entrenched within the human resource, where workers 
are motivated to seek and share their abilities with co-workcrs and thus expertise 
is transferred. Edvinsson (2000) proclaims that such interaction generates value 
for the organisation, a company rich in such interaction is said to hold a higher 
financial value. 
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The pharmaceutical industry is typical of such an area. Companies that invest in 
R&D generate substantially more revenue in the long term that is 
disproportionately above the value of the investment (Lev & Sougiannis, 1999). 
The discrepancy in apparent and realised value lies in the knowledge contained 
within the company. Knowledge which allows the organisation to lever a 
competitive advantage, fuel innovation and create a 'supernormal' economic 
return (Zucker et al. 1998). Alavi & Leidner (2001) believe that only individuals 
with a certain requisite of knowledge can exchange the knowledge that creates 
such value though. Establishing a means to measure the extent of this knowledge 
transfer is the precise realm that the field of intellectual capital and intangibles 
addresses. A role which equates to the measurement of the extent, and role, 
contextual metadata plays in the conveyance of understanding to the process of 
knowledge exchange (Lev 200 1). 
Nonaka et al. (2001) suggest that for individuals to transfer knowledge from tacit 
to tacit requires substantial cognitive and implicit reasoning. The transfer of 
knowledge from tacit to explicit such as during a meeting, requires a similar 
process. The assignment of measurable variables to the phases associated within 
this transference would allow a tentative value to be eluted and forms the basis of 
the measurement of knowledge within the innovative processes (Mascitelli, 2000). 
Yet in- order to achieve this, the metrics chosen would have to align with the drug 
development process of Figure 3.1, as how can we measure a process we don't 
understand? 
The processes, problem scenario and knowledge activities must firstly be defined 
and only then may the organisation define the metrics to measure the proposed 
knowledge system (Robertson, 2003). Unfortunately as many attempts at 
measurement fail to realise quantifiable or empirical data, this apparently simple 
statement is often complex. Metrics and the constituent parts of knowledge 
interaction comprise many facets and may also include additional financial 
constraints (Andriessen, 2004). The traditional Knowledge Management strategy 
of the introduction of a groupware system, implies that knowledge may be 
transferred within the collaborative medium of the system and also outside the 
system through contacts made within the system. 
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Wenger & Snyder (2000) note the individuals utilising the system may possess 
similar knowledge, but in order to teach and learn from each other the knowledge 
must be unknown to at least one party. Therefore capturing the information 
surrounding these processes, would in theory allows the management and 
quantification of the knowledge. As Mouritsen & Thorsgaard Larsen (2005) note, 
these are the principles that facilitate the translation of the 'three-dimensional' 
complex processes of knowledge interaction to be captured as 'two-dimensional 
inscriptions', which are akin to metrics. 
The review will now examine the components of intellectual capital and the 
methodologies that contribute to the evaluation of knowledge within the 
innovative processes of an organisation. 
3.5.3 INTELLECTUAL CAPITAL 
Firstly, it is advisable to cover the terminology surrounding intellectual capital 
and outline the common ground the Knowledge Management literature and the 
intellectual capital literature occupy. Stewart (1997) defines intellectual capital as 
the properties that allow an organisation to innovate, such as: 
"Knowledge, information, intellectual property, and experience that can be put to 
use to make wealth " 
The definition takes account of the many grey areas that may not be recognised by 
traditional fields of financial reporting using Capital Investment Appraisal 
Techniques, which tend to focus upon tangible assets (Augier & Teece 2005). 
Rather than the traditional tangible assets of financial reserves, stock and 
machinery, knowledge is placed at the forefront of the evaluation and it is this that 
allows a company with little visible assets to report a high turnover through the 
application of its intellectual capital (Aston, 2002). On this premise, it is 
important to note that intellectual capital is based upon knowledge and hence this 
knowledge is measurable and can be tracked and exploited within the company. 
Intellectual capital is not simply a measurement of the potential of the knowledge 
within a company it also reflects the actual use of the knowledge (Luthy 1998). 
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Thus there appears to be an irrevocable link between the areas of improving the 
use and exploitation of knowledge within the company, and the acknowledgement 
of intellectual capital as an important step in proving the worth of Knowledge 
Management. As Bukh et al. (2001) surmise: 
"Intellectual capital allows the reporting of the activities that management 
initiate and support in the name ofknowledge management 11 . 
However, it is evident that definitions surrounding intellectual capital are 
interchangeable and can be misconstrued. Bontis (2001) found companies and 
consultancies often define intellectual capital according to their specialist area. 
Yet most will include a reference to knowledge, organisational competence, their 
valued customer relations and the employees' professional skills. Edvinsson & 
Malone (1997) recommend that intellectual capital can be further defined within 
the three categories of human, customer and structural capital. These are defined 
as: 
1. Human capital is classified as the knowledge, skills, problem solving abilities 
and experience that can be lost when employees depart the company. Often this 
knowledge is generic, but depending on the role, a large extent of employee 
knowledge may be specialist. The loss of this may directly affect innovation, 
creativity and the fluidity of the company and has particularly consequences for 
R&D driven organisations. Losing a pivotal employee, knowledge champion or 
team within the new product development arena, can adversely affect the 
company's performance as staff adapt and fill the void in knowledge left by the 
individual or team. 
2. Customer or Relational capital refers to the links and resources that are external 
to the organisation - notably the customers, suppliers, or R&D partners. This area 
directly relates to the company's public image, customer satisfaction and the 
perceived value of the organisation by the customers and suppliers. 
72 
Chapter 3- Literature Review 
3. Structural capital provides the necessary supportive structures to define, to 
capture and retain knowledge within the company. The buildings, hardware, 
software, standard operating procedures, routines, business processes, knowledge 
stores and databases may all be classified as structural capital under the higher 
mantle of intellectual capital. This capital can be said to provide the supportive 
framework around which employees are able to generate knowledge within an 
organisation. 
Edvinsson & Malone (1997) further refline structural capital by including three 
further subsets in Table 3.5: 
Table 3.5: Structural Capital 
Type of Structural Capital Description 
Organisational Capital Organisation's philosophy and systems for 
leveraging the firm's knowledge capability. 
Process Capital The techniques, procedures and programs that 
allow the goods and services involved within 
knowledge creation to be delivered. 
Innovation Capital Intellectual property and intangible assets, which 
allows company growth and new product 
development. 
Marr & Starovic (2003) note there is often confusion as to the nomenclature to be 
used when discussing the types of capital, assets, intangibles and intellectual 
capital, as they are frequently classified as the same meaning. Marr & Starovic 
(2003) indicate that the assets of intellectual property should be identified as 
resources that can be legitimately recognised by an accountant and appear on the 
balance sheet of the company. Ifence they do not fall under the remit of 
intellectual capital. Conversely, Edvinsson & Malone (1997) and Luthy (1998) 
classify these assets as a form of structural capital, particularly when they support 
innovation. 
Mo & Zhou (2003) state that an intangible asset is a conglomerate of sources and 
confuse the terminology by including defined processes, intellectual property and 
tacit and explicit knowledge sources under the intangible asset boundary and not 
under the accepted definition of Human Capital as assigned by Edvinsson & 
Malone (1997). 
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Work by Brooking (1996) and Luthy (1998) adds further confusion to the 
definition of intellectual capital by describing four areas that overlap and differ 
from the definitions supplied by Edvinsson & Malone (1997). When describing 
innovation capital, Brooking (1996) and Luthy's (1998) define four areas: 
Market assets: these are the product brands, customers, distribution 
processes and business collaborations. 
0 Intellectual property assets: include the patents, copyrights, hidden 
innovations and the expertise to innovate in an area. 
* Human centred assets: include the education, skills and knowledge 
capacity of the employees. 
Infrastructure assets: look at the information system framework, the IT and 
financial systems in place and importantly the culture, management 
philosophy and management processes surrounding the knowledge. 
What is clear from reviewing the literature is that the term intellectual capital and 
the term "intangible" relates to a wide variety of the fuzzy knowledge components 
within an organisation and hence an accurate definition is rarely observed. 
Peppard (2005) is one of the few authors who attempts to look beyond the 
association of knowledge and information management activities with structural 
and organisational capital, by describing the processes that create value within the 
organisation. Edvinsson & Malone (1997) and Luthy's (1998) definitions cover 
similar ground yet use different categories and terminology. 
Peppard (2005) notes the terminology confusion and argues that the tacit 
knowledge of the employee falls within the boundaries of human capital. 
However, they also assert that structural capital can be an important component in 
supporting the human aspects of value creation. However, the overlap between the 
definitions offered by Edvinsson & Malone (1997), Brooking (1996) and Luthy 
(1998) are evident and on the whole, offer complementary views that are useful to 
an organisation seeking to define intangibles and discuss Knowledge Management 
processes. 
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Peppard (2005) states that intellectual capital may be represented as the 
management of the infrastructure that supports information and knowledge 
exchange. This then implies that intellectual capital may be used to measure the 
success and innovative behaviour of not only the IS/ Knowledge Management 
implementation, but also the subsequent generation of knowledge and information 
by the users. Although intellectual capital is based upon measurement and 
metrics, few authors commit these metrics to print. Brooking (1996) is one of the 
few to offer metrics to measure each stage of a process to provide an auditable 
outcome. However, the main proponents of intellectual capital, such as Edvinsson 
and Malone (1997), prefer to offer a generic view of intellectual capital which 
may be used to draw the attention of senior management to the organisation's 
intangibles. 
The aim of the generic metrics is to identify relevant subsets within the 
organisation, which relate to the definition of intellectual capital and relate to the 
structural capital, the cultural aspects, the management of the organisation and the 
knowledge potential of the employees (Edvinsson and Malone, 1997; Marr & 
Starovic, 2003; Peppard, 2005). Choo & Bontis (2002) describe intellectual 
capital as an organisational resource and note that no academic models provide 
sufficient rigour to explore these organisational resources accurately. They do 
however, list relational, human capital and structural capital as components and 
hence in keeping with the majority of published literature. This research will 
concentrate upon these aspects and the associated methodologies which may be 
used to assess these areas. 
Assigning a metric to these areas of intellectual capital suffers from similar 
confusion, as the definition of an intangible may be a component of a business 
process that is unique to that process. The potential interactions this sole process 
may have within the realms of human, relational and structural capitals are many. 
Hence an analysis of the environment and the interactions of the studied process 
are required, in order to assign a tangible value to an individual processes (Marr & 
Starovic, 2003). As the high level drug development diagram in Figure 3.1 
illustrates, this process is extremely complex and as yet little published work 
exists on these processes. 
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Although a new technique labelled 'Strategic Performance Management' by Marr 
(2006) shows promise in this field and will be addressed as a potential 
methodology in Chapter 4. One reason for the lack of published metrics, is that 
each metric found within an assessment of the process is unique to that process. A 
concrete example of an intangible metric is Moerman & Der Laan's (article in 
press) research into drug costs. Here they regard phan-naceutical intangibles as the 
investment in information and knowledge that are required to determine a drug's 
safety characteristics and effectiveness. These intangibles then determine the costs 
of the R&D work that will eventually lead to the generation of a patent and justify 
the steep costs associated with drug development. 
The review will now analyse the strategies and methodologies which are 
commonly implemented to measure intellectual capital and assess the value of a 
Knowledge Management strategy within an organisation. 
3.5.4 REPORTING INTELLECTUAL CAPITAL 
The following section aims to provide an overview of the methodologies that are 
commonly employed to measure organisational knowledge and attempts to 
provide justification for the use of intellectual capital assessment within drug 
development. It is important to note that the review serves to highlight 
methodologies that may be used within Objective 3, seeking to outline points that 
should be considered, rather than attempt to advance the field of intellectual 
capital research. To date little published work has been conducted on intangibles 
and intellectual capital within pharmaceutical R&D. Therefore the results of the 
research are expected to provide valuable insight into assessing innovative 
knowledge and Knowledge Management strategies within this area. 
Many in-depth studies on the development and measurement of intellectual capital 
are available (e. g. Andriesscri, 2004; Marr, 2006; Bontis, 2001; Wilkins et al. 
1997) and each offer insight into measuring intangibles. However, what is 
apparent is that the popular models of assessing tangible capital such as the 
Payback Period, the Return on Investment (ROI) and the Net Present Value as 
suggested by Milis & Mercken (2004) and Fairchild (2002) are far from suitable 
for measuring Knowledge Management activities. 
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The Payback Period defines the time required for a business project to generate a 
return on the initial investment. Milis & Mercken (2004) suggest that this is the 
least suitable for measuring the return on Knowledge Management as such 
schemes are generally long term projects. In the case of Knowledge Management, 
there is often no quick win or rapid strategy to generate a measurable return. As 
was witnessed in the earlier stages of the review, Knowledge Management 
success is often dependent on cultural change or at the very least progressive 
adoption (Darroch & McNaughton, 2002). This inevitably requires a larger time 
scale. Companies who adopt the Payback Period as their evaluation model may 
find they needlessly plump for short projects in order to show a tangible return. At 
worst, they may fail to acknowledge the benefits from the implementation (Milis 
& Mercken, 2004). The Payback Period also fails to take account of the risk from 
a failed or rehashed project. Within industry, KM implementations are notorious 
for continual reworks once operational (Ifung et al. 2005), with little excess 
budget to accommodate reworking, schemes will almost certainly fail in 
accordance with a Payback Period evaluation. The Return On Investment is 
considered to be a worthier technique, as there is the facility to evaluate the total 
lifecycle of the project. Thus the calculated return represents a more accurate 
picture of the schemes true financial value and can be used to track the long term 
performance of a project (Milis & Mercken, 2004). 
Although each financial assessment model provides valuable short-term feedback 
to senior management on their investments (Waterhouse & Svendsen, 1998), what 
they lack is recognition of the long-term human and social capital that may be 
generated from the inception of a Knowledge Management system or strategy 
(Scarbrough & Carter, 2001). The financial assessment models lack the concept of 
"intellectual agility" that are derived from social and human capital and are said 
to be the drivers of innovation (Roos et al. 1998). These include the invention, 
reuse, adaptation and exploitation of knowledge and as such are vital to 
innovative processes. The following section will now address measurement 
methodologies that address this shortfall and cover their usefulness to the research 
aim. 
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3.5.5 USING METRICS TO MEASURE KM 
Although there are many theoretical and practical techniques available for use 
when determining Knowledge Management strategies, most are regarded as 
flawed and inaccurate (Andriessen, 2004; Bontis, 2001). When viewed from the 
perspective of biotechnology and pharmaceutical innovation, each strategy should 
aim to assess the intellectual capital required to create intellectual property and 
reach the end result of a marketable patents (Augier & Teece, 2005). The number 
of filed patents may not be used as a measure on its own however. Augier & 
Teece (2005) note that although patents are a measurable and visible means of 
assessing intellectual capital, it is only when a patent has proven market 
application that it possesses a tangible value. The majority of patents within the 
Pharma industry are filed at very early stages of drug development. Often as a 
means to prevent competitors exploiting a particular compound family or drug 
group, hence the valuation of pharmaceutical innovation cannot solely be judged 
upon the production of patents (Hine & Kapeleris, 2006). A patent offers a 25 
year protection period on a new drug and a typical drug may take up to 15 years to 
reach the market. Hence the pharmaceutical companies have a short time to 
recoup their investment and the financial measurement of a marketable patent is 
easily visible through drug sales results (Hine & Kapeleris, 2006). What is less 
apparent though is the cumulative intellectual capital that has contributed to the 
successful marketable patent and the market release of a drug. SubbaNarasimh et 
at. (2003) conclude that a firm capable of not only retaining and owning a diverse 
technological knowledge base, but also knowing how to effectively apply this 
knowledge to achieve a marketable patent, ultimately allows a company to 
perform significantly better than its rivals. 
Yet how is intellectual capital measured? Luthy (1998) believes intellectual 
capital may be measured on a component-by-componcnt basis which is 
supplemented by the measurement of intellectual assets (e. g. patcnts) and is akin 
to a resource based view of the firm (Barney, 1991). Directly associating the 
measurement of intellectual assets with the financial aspects of the company, 
allow the company's intellectual capital to be related to the share price. 
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This is believed to reflect the effectiveness of the company in managing and 
utilising its assets and intellectual capital to create further value from a given 
situation (Luthy, 1998). At present, many component-by-component models exist, 
which attempt to assess the use of knowledge within intellectual capital. Of these 
the standard is the Balanced Scorecard or BSC, penned by Kaplan, & Norton 
(2001) which accounts for the majority of KM related metric surveys and as such 
will be covered in detail within this review. 
The component-by-component models share the common processes of assessing 
and assigning a metric to each component of the knowledge processes located 
within the area to be studied. As will be seen in later sections, they rely upon 
compartmentalising intellectual capital within constituent blocks that may be 
analysed in turn. However, a common failing suggested by Leitner & Warden 
(2004), is that the methods divulge little information regarding the relationships 
between the intellectual capital entities. Instead Leitner & Warden (2004) suggest 
a methodology that analyses the interactions within intellectual capital that 
contribute to the value chain and will ultimately reveal which processes drives 
innovation. However, their methodology falls short of visualising these links and 
instead provides indicators on how to assess the knowledge within these 
relationships within an R&D process. As in the intellectual assets model, the 
associated metrics may be quantitative and reflect higher level organisational 
traits. These traits may be the financial results or detailed unit metrics, such as the 
number of scientific researchers required (i. e. Full Time Employees), when 
quantifying units of work at a process level. A key characteristic of the technique 
is the assignment of accurate units of measurement to each component level and 
its inputs and outputs. It is thought that failure to do this may result in a poor 
evaluation of the target scenario (Leitner & Warden, 2004). 
It became evident while covering the literature, that the component-by component 
models are consistently popular, although many other methods are available. 
Svieby (2004) and Andriessen (2004) provide an excellent overview of 
assessment techniques and currently list twenty six methods between them. 
Although many are applicable to the research, to review all would be beyond the 
scope of this report. 
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Instead the review concentrates upon the models which may be used to identify 
the drivers of Knowledge Management that are termed by Du Plessis (2005) as 
the "catalysts that allow an organisation to achieve a competitive advantage". 
The following section will outline the various intellectual capital assessment 
models and provide details on their strengths and weaknesses, before concluding 
with a section analysing the use of these models. 
3.5.5.1 COXIPONENT-BY-COMPONENT EVALUATION 
3.5.5.1.1 THE BALANCED SCORECARD 
When discussing metrics to ascertain the worth of a Knowledge Management 
schema and intellectual capital it is rare that the work of Kaplan & Norton (1996) 
is not mentioned. They penned the use of the Balanced Scorecard (BSC) which 
was initially used to provide a measure of a company's intellectual capital, the 
potential future return and analyse how these factors stand in regards to the 
financial measure of the business. The scorecard has evolved however, to provide 
indicators that explain an organisations strategy with regard to intellectual capital 
(Kaplan &Norton, 2001). 
The balanced scorecard may be used to define metrics, indicators and Key 
Success Factors (KSF) for individual projects and overall goals and is widely used 
within Knowledge Management (Robertson, 2003). Marr et al. (2003) suggest the 
balanced scorecard may be used to assess the learning and growth potential of the 
organisation, through the elucidation of 'leading' and 'lagging' indicators that 
indicate areas of potential or concern respectively. The balanced scorecard 
framework uses a framework of four groups to offer a perspective of four 
measurable items, which individually equate to four scorecards. These are 
explained by Milis & Mercken (2004) and Spender & Marr (2005) as: 
1. Financial Perspective 
A financial scorecard that contains the traditional financial perfonmance measures 
such as Return on Investment or Payback Period. Sets of financial targets are 
assigned to projects and then assessed against management criteria. 
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2. Customer Perspective 
The customer scorecard is provided in order to obtain an objective view of how 
customers, whether internal or external, respond to, and rate the company or 
business department under scrutiny. 
3. Intemal Processes 
An internal business scorecard provides goals, measures and indicators to be used 
in measuring the internal value chain of the company. 
4. Learning and growth 
The final scorecard addresses innovation and the organisational learning ability of 
the company, analysing how knowledge and value can be created and improved 
alongside the growth of the company. 
The model determines a cause-and-effect relationship, where the evaluation of the 
results then leads to the formulation of a future strategy, rather than a tool with 
which to provide a definitive analysis of intangible assets (Marr & Starovic, 
2003). Bontis et al. (1999) suggests the technique offers managers a method of 
visualising the cause and effect relationships that occur within a given strategy. 
This is in addition to relatihg any financial failures to relationships that occur 
within the chain. Bontis et al. (1999) outline how the tool may be used by an 
organisation's management within Table 3.6: 
Table 3.6: Uses of the Balanced Scorecard 
Area Outputs 
Communication and linking Achieving a strategic alignment of the 
objectives of the whole organisation. 
Business planning Managing targets, co-ordinating 
initiatives and planning the budget. 
Translating the company's vision Clarifying the mission and long-term 
company strategy to all constituencies 
inside the organisation. 
Feedback and leaming Update plans, strategies and the BSC. 
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It is clear from the outputs in Table 3.6, that the adoption of non-financial 
measurements provides strategic benefit to the model and the reasons behind this 
lie with the engagement of top-level management to decree the measurement 
criteria (Kaplan & Norton, 2001). As Bukh et al. (2001) note traditional 
accounting techniques rely upon financial experts, while the involvement of 
management in deciding the areas to be assessed, allows the BSC to supplement 
the traditional accounting approach with additional strategic value. Milis & 
Mercken (2004) argue that due to this, the balanced scorecard may be used to 
force company management to take on a broader view of a Knowledge 
Management strategy. Fairchild (2002) supports this view, though stresses that in 
parallel to the evolution of a Knowledge Management strategy there must be 
supporting realignments of business practice and the organisation to reflect these 
facets. Kaplan & Norton (2001) suggest the BSC tool may be used to create 
strategy maps that visualise a cause and effect relationship or value chain. These 
maps start from the Learning and Growth Perspective, to the Internal Perspective, 
to the Customer Perspective and then on to the Financial Perspective. The four 
cards of the strategy are then assigned between 20 to 25 measures that allow the 
strategy map to be followed and assessed as a series of measured outputs 
(Andriessen, 2004). 
Although the technique is widely used, it is the actual application of the 
scorecards, the accurate mapping of the strategy and the identification of the 
measures to a given scenario that is deemed difficult. Marr & Starovic, (2003) 
found companies attempting to classify the cause-and-effect relationships between 
the various drivers of value creation often falter. Their study showed a single 
process can be isolated sufficiently. However, when viewed as a whole, the 
intricacies of linking such processes in order to elute a value-based matrix can be 
difficult. Bontis (2001) suggests that the framework of the BSC is too rigid and 
provides little scope for expansion outside of the four areas. Attempts by 
organisations to identify Key Success Factors (KSF) within the cause-and-effect 
relationships, often blinkers the participants to the interactions of the KSFs. 
Bontis (2001) also acknowledge that the relationship between these KSFs may not 
be recognised or mapped accurately. 
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A KSF may appear in multiple areas of the framework and in multiple processes, 
but only be reported and categorised within one area. In the case of the 
measurement of a Knowledge Management schema crossing multiple scorecards, 
this problem is perplexing and perhaps shows the downfall of the technique as 
few authors even venture an opinion on this area. Fairchild (2002) places 
Knowledge Management within the realm of the Learning and Growth card. 
Spender & Marr (2005) although in agreement, stress the perspective is unclear as 
the human factors are bundled with the technology aspects, which suggest 
knowledge is simply another physical asset. Evidently, such a view is against the 
popular definition of Knowledge Management which is seen as the exploitation of 
knowledge as an intangible and employee based asset (e. g. Newman & Conrad, 
1999). Due to this, many authors regard the BSC as a tool to outline rather than 
implement knowledge led learning processes (Choo & Bontis, 2002). 
Despite problems such as these, the scorecard remains a popular methodology to 
evaluate intellectual capital. Although as Marr & Starovic (2003) note, the main 
difficulty is in establishing tangible links between the value drivers, value creation 
and the future financial results. The four cards are logically linked but the model 
washes over the processes involved in defining the causal links behind these 
relationships and hence its usefulness is truly defining cause and effect 
relationships may be limited (Spender & Marr, 2005). 
Du Plessis (2005) concludes by stating that although the BSC technique is 
important in defining leading and lagging indicators, the use to assess the 
underlying relationships and reality of intellectual capital is lacking. The reasons 
relating to this shortfall are that the Leaming and Growth perspective only 
measures the improvement in specific areas, such as competencies, technology 
and corporate climate, and does not measure the size and value of the intangible 
assets as they flow within the organisation (Andriessen, 2004). 
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3.5.5.1.2THE SKANDIA NAVIGATOR 
The Skandia Navigator was initially developed in-house by the Swedish company 
Skandia to assess and promote the use of' intellectual capital within the 
organisation. The model is depicted in Figure 3.2 and has lound I`avour with other 
f inns and is based upon the work of Edvinsson & Malone (1997): 
HMORY Financial Focus 
TODAY 9L I 
Figure 3.2: The Skandia Navigator 
(Image from: http: //www. ]2manage. com/methods-skaiidiiinivigitor. htiiii) 
The model is based upon a framework that allows the user to navigate through a 
series of'criteria and hence recognise and introduce the principle of managing and 
assessing intellectual capital against the resources, capabilities and future 
ambitions of the company (Luthy, 1998). Central to the model is the human focus 
that denotes the intelligent driver of the process and, in turn, influences and drives 
the respective outer parts of' the model that contribute to file development of' 
structural capital that can be owned and traded (Edvinsson & Malone, 1997, 
Andriessen, 2004). 
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The model is similar in use to the balanced scorecard and as such may explain the 
successes and popularity of the technique (Svieby, 2004). 
The model is underpinned by the focus upon renewal and development, through 
which innovation is encouraged by manager's promoting interactions with the 
respective components of the model (Choo & Bontis, 2002). Intellectual capital is 
viewed as a sum of the navigator components (Edvinsson, 2002). Where the 
deduction of a market value that includes intangibles, allows the measurement of 
the company's investment in R&D and training, and provides a measure of the 
organisation readiness to adapt to the future market (Bontis, 2001). Positive 
metrics are employed to measure the rate of new product design, acquirement of 
new market places and the rate of introduction of new management techniques to 
exploit these areas (Edvinsson & Malone, 1997). Edvinsson & Malone (1997) 
ascertain that the financial focus concentrates upon monetary values, such as share 
price, past trends and historic financial data and reflects the general financial 
health of the company. The customer focus assesses the value of the customer 
capital to the organisation, making use of both financial and non-financial 
measurements. VAlile, the final process focus is based upon the business processes 
occurring taking account of measures such as computers per employee. 
All in all, the model aims to measure intellectual capital through the use of the 
five focuses, to which a total of 164 metric measures are applied, with 91 
intellectually based and 73 traditional metrics. The metrics are then analysed and 
reduced to 21 indices, which combine to give a rounded intellectual capital 
centred picture of the firm (Edvinsson & Malone, 1997; Bontis, 2001). 
Unfortunately each focus requires the development of its own personal metrics. 
Edvinsson & Malone (1997) do provide III generic metrics based upon their 
work within Skandia. Yet it is recommended that the critical success factors 
associated with individual processes, are highlighted and then assigned to one of 
the five focuses for each individual organisation (Andriessen, 2004). 
The process of actually elucidating these metrics and achieving this, is complex 
however, and unlike the BSC model, the navigator fails as a strategy mapping 
tool. 
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Andriessen (2004) ascertains that the navigator only provides information on what 
is happening within the organisation at that time and provides little notion of the 
cause and effect relationships that exist between the five focuses. The intellectual 
capital indices and metrics themselves are also arbitrary and consist of direct 
counts and percentages rather than monetary values. However, the financial 
capital aspect does provide monetary value, so is a useful measure with which to 
persuade management to invest and promote Knowledge Management and 
intellectual capital measurement (Mouritsen et al. 200 1). 
3.5.5.1.3 THE INTELLECTUAL CAPITAL STATEMENT 
A further aspect of intellectual capital study is the generation of an Intellectual 
Capital Statement. Mouritsen & Thorsgaard Larscn (2005) suggests this will 
allow an organisation to visualisc and manage its intellectual capital. The model 
does not intend to quantify intellectual capital, but rather attempts to track 
management activities that are employed to organise the knowledge resources of 
the firm (Andriessen, 2004). Of all the methodologies reviewed, this method is 
most clearly aligned with Knowledge Management activities and practice. 
Mouritsen et al. (2005) note there is a second wave of Knowledge Management 
that recognises and includes the remit of intellectual capital. The second wave of 
Knowledge Management is said to: 
"Address how the management control of knowledge resources allows concerns 
about economising (how much to invest in knowledge resources), organising 
(where to locate knowledge resources) and modularising (how to standardise 
knowledge resources). " 
In practice the method relies upon three elements to visualise Knowledge 
Management activities within an organisation, these are derived from Andricssen 
(2004) and Mouritsen et al. (2001) as: 
1. The knowledge narrative details how the company helps its customers, 
organises its resources and describes the ambition of a Knowledge 
Management schema. 
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2. The second element describes the challenges an organisation must 
overcome to implement the Knowledge Management strategy, these relate 
to the management of resources which include the employees, customers, 
processes and technology. 
3. The third element comprises the indicators that describe the resource itself, 
the indicators required to qualify an activity and indicators to describe the 
effects of an activity. 
Mouritsen et al. (2001) focus upon the visualisation of these knowledge activities 
through the use of narratives. In effect these are stories that link together the 
resources and networks that are required to understand the knowledge of the firm. 
The model seeks to analyse where the locus of knowledge creation occurs, 
whether this lies with the employees or as a result of management activities. So 
this is highly relevant to the R&D environment where there is a demand for 
transparency within knowledge activities (Mouritsen et al. 2001). The 
methodology is intended to provide an overview of the firm's knowledge 
activities and provides information on where intellectual capital may help the 
organisation. In this aspect it serves as both a management tool and as a 
communication aid (Mouritsen et al. 2005). These facets indicate the method may 
be of interest in advancing the research of Knowledge Management and 
pharmaceutical innovation and supporting Objective 3. 
3.5.5.2 ALTERNATIVE MODELS 
The Balanced Score Card and Skandia Navigator are established models, yet there 
are many models that are based upon, or bear similarities to these works. Research 
by Hendry & Brown (2005), Spender & Marr (2005), Petty & Guthrie (2003) and 
Andriessen (2004) outline many of these. 
These methods include the Intangible Asset Monitor by Sveiby (1997), which is 
based upon similar principles to the Skandia Navigator but specifically focused 
upon the measurement of knowledge. Sveiby (1997) and Andriessen (2004) 
advocate the measurement of intangible assets or 'invisible assets'. These do not 
derive from an accounting sense but instead are denoted by three areas. 
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Namely: 
1. Employee competences such as employee expertise and knowledge 
2. Internal structures such as computer systems, patents and models 
3. The external structure which includes the relationships with customers and 
suppliers 
Although the technique bears similarity to the Skandia Navigator, the matrix 
based framework, offers a comprehensive solution that allows the publication of 
intangible assets both internally and externally. However, it is important to note 
that the metrics used within the system are not monetary and are unique to an 
organisation. Hence an organisation can only be benchmarked and compared 
against further successive audits. 
Another model discussed by Hendry & Brown (2005) and Andriessen (2004) is 
the Value Chain Scoreboard (Lev, 2001), which is a method used to analyse the 
value of the knowledge required to drive innovation. Again the methodology is 
based upon a matrix arrangement, but has reportedly proven valuable, when 
analysing the knowledge assets' of large pharmaceutical companies. The method 
utilises publicly available data that is used to calculate the value of intangible 
earnings by subtracting the tangible and financial capital from the total earnings of 
an organisation. The evaluation is obtained when these figures are aligned with a 
series of lower level matrices that assign metrics to a specific process. 
Lev (2001) specifically concentrates upon measuring the value chain within 
innovative work, suggesting intangibles may only be generated from a new 
discovery. Hendry & Brown (2005) note these intangibles arise as a direct result 
of organisational practice or human resources. Andriessen (2004) notes the Value 
Chain Scoreboard can allow a company to speculatively calculate a return on 
investment from their R&D practices. In effect, by calculating the potential 
benefits in intangible capital, a previously impossible task in accountancy based 
R&D. 
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In addition to the reviewed models there are a growing number of methods that 
attempt to visualise intellectual capital, Of note is the Value Creation Map (Marr 
et al. 2004) and Strategic Performance Management (Marr, 2006) that both map 
the direct dependencies and relationships of knowledge assets. Also of note is a 
second Navigator model developed by Neely et al. (2003), which also seeks to 
depict the relevance and location of knowledge assets with relation to the 
organisation's strategic aims. 
3.5.6 SUMMARY 
There are evidently a wide variety of tools, methodologies and theories on how to 
measure the value of intellectual capital and to review all would be beyond the 
scope of the review. From the review of the literature, many of the approaches 
would appear to have merit to the research. Spender & Marr (2005) muse that 
there are three approaches to measuring intellectual capital, these are broadly 
classified as an economic valuation, a strategy map (a cause and effect scorecard) 
and a map of the dependencies, relationships and narratives that describe 
intellectual capital within an organisation. From a pharmaceutical viewpoint, few 
studies have been conducted. Hine & Kapeleris (2006) acknowledge the 
importance of intellectual capital within innovation, yet gloss over its 
measurement. As such, this research is well placed to advance this field and 
conduct further research into the use of measurement methodologies. 
As Marr et at. (2004) postulate, when the interaction between knowledge 
resources is known, a firm's knowledge strategy is clear. This section has partially 
achieved Objective 4 by discussing the evaluation of Knowledge Management, 
while Chapter 12 continues and discusses Knowledge Management evaluation in 
practice. 
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3.6 PHARMACEUTICAL KNOWLEDGE MANAGEMENT 
3.6.1 INTRODUCTION 
This review has shown that Knowledge Management is seen to be reliant upon the 
management of a company's intellectual capital (Guthrie, 2000). As the previous 
section on intellectual capital measurement discussed, there are many ways 
intellectual capital may be expressed and measured. Innovation is the main focus 
of the research and Knowledge Management should be a worthy supporting tool 
to enhance innovation within the pharmaceutical field (Davenport & Peitsch, 
2005). Metaxiotis & Psarras (2005) state: 
"Productive organisations have the ability to create an environment where the 
specialised knowledge, skills and abilities of all employees are leveraged to 
achieve advancements ". 
However, the practical means to achieve this is disconcertingly unclear. 
Metaxiotis & Psarras (2005) suggest the use of groupware, intranets, collaborative 
tools, portals and taxonomies as a means to support innovative Knowledge 
Management activities. However, the authors also suggest that tools such as data 
mining and information visualisation could also be employed. Although these 
tools are common components of a Knowledge Management strategy, it is unclear 
whether their use can support innovation across an organisation as a whole. 
Furthermore, does the practitioner employ all of them in a 'scatter gun' approach 
or are there certain Knowledge Management tools that are more suited to R&D 
bascd innovation? 
When the literature was researched to reveal the actual reality of Knowledge 
Management within pharmaceutical companies, very little empirical or 
practitioner based evidence emerged. In their support of Knowledge Management 
within innovative processes, Metaxiotis & Psarras (2005) list the Novo Nordisk 
Knowledge Management project as a positive success story. A story where 
collaborative dialog with disease sufferers and the company (e. g. the 
stakeholders), has enhanced the company's innovative efforts. 
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However, when one delves deeper into the cited article by Skovlund (2004), the 
actual Knowledge Management implementation is shown to rely upon "an 
exclusive dialogue tool" of unknown specification or nature. This tool facilitates 
collaboration between the stakeholders, yet the exact nature of the tool, or how the 
knowledge exchanged is used to directly influence the R&D process, is unclear. 
Such vagueness is common within the pharmaceutical Knowledge Management 
literature, indeed Davenport & Preitsh (2005) conclude: 
"There is much more that we do not know about knowledge management in drug 
discovery than what we do know. The subject has only rarely been studied in the 
context ofphannaceuticalfirnis and we can only extrapolate a limited number of 
findings from other industries. Yet, drug discovery is one of the most knowledge- 
intensive processes, and the ability to create, share and apply knowledge is 
crucial to its success. " 
So it is evident that Knowledge Management has a place within pharmaceutical 
drug innovation (Davenport & Preitsh, 2005; Sundgren & Styhre, 2004) and firms 
that have taken note of Knowledge Management, have been successful within 
other areas (e. g. Sher & Lee, 2004; Corso et al. 2001). Yet what academic 
evidence is available, that specifically links Knowledge Management and 
pharmaceutical innovation in the academic and practitioner based literature? 
As in the Knowledge Management literature, there are two streams of research 
that often overlap and these are: 
* Studies that concentrate upon the use of Knowledge Management 
technology 
9 Studies that concentrate upon the human or cultural aspects of Knowledge 
Management 
The review will now attempt to give the reader a clearer picture of how these two 
areas intertwine, within pharmaceutical Knowledge Management and how the 
various practical approaches are employed by the pharmaceutical companies. 
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3.6.2 NETWORKS OF KNOWLEDGE 
Pharmaceutical innovation is widely reported to be derived from knowledge 
networks. These may encompass both internal and external knowledge assets as 
drug companies' move from an in-house research model, to one of innovation 
acquisition (Kneller, 2003). Capturing the information concerning these networks 
has recently taken the limelight of Knowledge Management research, 
Pharmaceutical companies are now trying to store this information within 
corporate knowledge directories that capture the nature of information and 
knowledge assets used, and the employees who take part in the innovative 
processes (Wakefield, 2005). 
Research by Wakefield (2005) continues to hypothesise that there are two types of 
corporate repositories available. The first is concerned with the creation, storage 
and retrieval of knowledge within the drug development processes in a repository 
that allows knowledge transfer between users and the repository. While the 
second repository functions on a social level, serving simply to facilitate 
communication and collaboration on a social level or across communicative 
channels. Davenport (2002) ascertains that such collaborative work requires the 
workers to co-ordinate their activities and utilise tools on a selective basis as and 
when they see fit. As attempts to emulate and push knowledge from the employee 
using automated tools has often failed. Wakefield (2005) on the other hand 
suggests that a pharmaceutical Knowledge Management System should: 
1. Identify the members who actively share knowledge 
2. Show the degree of knowledge sharing that occurs in the organization 
3. Reveal where the most knowledge sharing occurs 
4. Identify high level knowledge sources 
S. Determine where each member exerts the most influence in the 
organisation 
6. Indicate the extent to which members seek knowledge. 
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Wakefield (2005) goes onto suggest a series of 'structural indexes' that facilitate 
the labelled processes, where the information is captured within a repository and 
then provides the organisation with a clearer picture of knowledge sharing. 
Recent research by Furukawa & Goto (2006) within the Japanese pharmaceutical 
industry supports the notion that networks of scientists are collaborating to obtain 
tacit knowledge and actively inducing innovation. Interestingly these appear to be 
centred upon core scientists or champions, who act as a central point of contact. 
The work of Roth (2003) within AstraZeneca Clinical R&D runs within a similar 
theme and suggests that the use of knowledge facilitators encourages cross project 
knowledge sharing. The premise is that the knowledge facilitator is in effect a 
knowledge broker and is responsible for matching employees to other relevant 
employees from their own personal network of colleagues. Once potential project 
teams and employees are united from across the R&D domains, one or many 
brainstorming face-to-face sessions occur that are focused upon a specific 
problem and directed by the facilitator. The results of the sessions are then 
disseminated through the organisation via seminars chaired by the facilitator. 
Roth's (2003) methodology relies upon the experience and wisdom of the 
facilitator to link and direct the debate and, intriguingly, relies purely upon social 
interaction rather than technology mediated interactions. In this manner Roth 
(2003) bypasses the failings of Knowledge Management systems associated with 
lack of use and the complexities of capturing relevant contextual information 
(Ilayes & Walsham, 2000). 
However, it is questionable as to the longevity of a Knowledge Management 
scheme that relies upon employees being granted time to work on projects outside 
of their specific role. Indeed McKinlay (2002) notes that knowledge interactions 
within a pharmaceutical environment is limited by the lack of diffusion across 
project teams and the tightening of timescales that is accompanying the rapid 
growth experienced within the pharmaceutical companies. Such pressures are 
coupled with the knowledge intensive nature of pharmaceutical innovation, as an 
inherently complex series of processes, where employees rely upon and require 
access to cross functional and distributed knowledge and information (Zack, 
1999). 
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By far the commonest means to achieve this internally is via a centralised portal 
system (e. g. GSK and Johnson & Johnson) which is intended to act as a network 
hub for information dissemination (Wang, 2006; Leavitt, 2003; Korctz & Lee, 
1998). 
McKinlay (2002) conducted a case study within a large US pharmaceutical 
company and noted Knowledge Management schemes principally took three 
forms: 
1. The enhancement of established social processes 
2. The development of further technical capability 
3. Experiments with virtual teams. 
On a practical note, the first strategy was associated with a best practice system 
that aimed to debrief drug project teams once a project was complete, in an 
attempt to address and capture the. lessons learned. The study concluded that after 
three years, the lessons captured were inadequate and scattered in point and 
nature. Furthermore the lessons that did exist, on the whole related to problems 
associated with Standard Operating Procedures not 'critical reflection' on the 
development processes, as was hoped. McKinlay (2002) found that the intended 
results were to encourage incremental innovation, where employees could refer to 
past work and subsequently build upon this base. However, such work rarely 
occurred, with the lessons on the whole serving to reinforce established 
organisational practices, rather than spark innovative decisions. 
The lessons learrit or best practice system holds substantial weight with many 
authors. Literature within the engineering field by Wong & Aspinwall (2006) 
describes a best practice system and work by Park & Kim (2005) also suggest 
such a system as an ideal Knowledge Management vehicle for innovative work 
within pharmaceutical R&D. Liebowitz's (2000) quantitative study of Knowledge 
Management within a large pharmaceutical company, also revealed that there is a 
definite employee based demand for systems that capture lessons leamt and best 
practices associated with drug development. 
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However, the results of McKinlay's (2002) studies, point to a subtle balance 
between a system, either being a hindrance or playing an effective role as a 
knowledge asset in the innovative processes. Evidently further research is 
required in order to elucidate the potential of such systems. This would include an 
investigation of how companies are successfully converting their intellectual 
capital and tacit knowledge into codified knowledge, in the form of drug 
submission data and results. Zucker et al. (2002) propose that as tacit knowledge 
is codified then the dissemination of the knowledge becomes easier. Although the 
notion of Furukawa & Goto (2006) that knowledge networks drives innovation, 
appears to negate the value of the vast amounts of codified knowledge captured 
within regul4tory drug submission systems in late phase development work. 
3.6.3 VIEWPOINTS ON PHARMACEUTICAL KNOWLEDGE 
MANAGEMENT 
Attempts to address the issues of information and knowledge extraction within the 
initial discovery stages of drug development have met with mixed results. The 
wealth of information generated from the human genome study and molecular 
biology is being subjected to automated techniques such as information retrieval, 
information discovery and clustering, although the majority of scientific research 
is still conducted upon the analysis of unstructured text (Fluck et al. 2005). This 
process requires scientists and R&D employees to intuitively link a molecular 
pathway with interacting proteins and a disease state, A task that at present is 
beyond automated procedures (Fluck et al. 2005). As the research is concerned 
with the application of knowledge within the drug development processes, such 
techniques and areas are beyond the scope of the review and on the whole relate 
to the founding stages of drug development within R&D laboratories. 
As Davenport & Preitsh (2005) conclude it is the human factors within drug 
development that are of interest to Knowledge Management, they classify these 
human factors as: 
* Social networks and communities of practice 
* The roles of professional knowledge managers 
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e The behaviours and processes of knowledge workers 
* Management strategies and tactics 
* The role of the extemal work envirom-nent. 
This research project was well under way at the release of this paper and as will 
be seen in the later stages of this thesis, the ideas of Davenport & Preitsh (2005) 
reflect the findings of the research. Interestingly their observations support the 
notion that the cultural aspects are of most importance to Knowledge 
Management within the phannaceutical environment, mirroring the observations 
of WiUmott (2000) and Currie & Kerrin (2003). This idea denotes that Knowledge 
Management practitioners should address the reasoning behind knowledge sharing 
and ensure knowledge sharing is aligned with an organisational learning 
perspective. This approach seeks to address both the means to, and the context of, 
knowledge sharing within the organisation rather than the technology (Currie & 
Kerrin, 2003). Although this premise appears worthy, few studies address its 
implementation. An eminent keynote speaker at a conference on Organisational 
Learning (OLKC Warwick, UK, 2006), concluded that the current models of 
organisational learning and Knowledge Management simply do not fit the 
pharmaceutical R&D environment (Dougherty, 2006). Put in context, the state of 
knowledge flux required to develop a new drug dictates that little reusable 
knowledge is generated and hence employees are unlikely to turn to information 
and Knowledge Management systems as a source of knowledge (Dougherty, 
2006). So what Knowledge Management measures are pharmaceutical companies 
employing to address these issues? And is Knowledge Management a lost cause? 
T'he following literature does suggest Knowledge Management can play an 
important role. 
Leavitt's (2003) research within Bristol Myers Squibb reveals the company has 
recognised the "knowledge network" model. The company has formed teams of 
'Knowledge Integrators' who act as central points of contact for drug project 
teams who require information and knowledge. 
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They also fulfil an alerting role by notifying their teams of relevant information 
and knowledge that is being published, crucially, they are said to have achieved a 
5-10% reduction on time spent per day by scientists researching material. 
Leavitt's (2003) research also points out that the Knowledge Integrators are 
highly skilled scientists in their own right and have input into project teams. 
Suggesting that the role requires valuable and senior experience which may prove 
troublesome in terms of recruitment, as the employee is expected to cover a broad 
range of issues such as competitor's patent application, and the dissemination of 
current and relevant scientific and business information (Leavitt, 2003). 
On reviewing the literature it was noted that the viewpoint on the issue of 
capturing the knowledge and information exchange associated with R&D and 
innovation buy in from biotechnology firms was lacking. Scarce Knowledge 
Management based literature exists on the subject. Indeed Schweizer (2005) 
questions the ability of the acquiring pharmaceutical company to 'absorb' the 
knowledge of the biotech company. Concluding that in many cases, the 
pharmaceutical company may prefer to outsource its R&D activities to these 
companies and instead concentrate upon its core competencies of late stage 
clinical trials, regulatory affairs and marketing activities. Schweizer's (2005) 
research suggests that the modem pharmaceutical company is essentially acting as 
a broker. Investing the resource to progress a novel compound to a drug but 
leaving the biotechnology R&D to external organisations, a situation reversed in 
Japan where in-house R&D is still largely prominent (Kneller, 2003). 
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3.6.4 SUMMARY 
An interview with Peter Goodfellow the Senior Vice President, Discovery 
Researcb of GlaxoSmithKline (Owens, 2003) quotes: 
"I think we're on the edge of being able to make drugs more easily, it will take us 
a couple ofyears to be certain that is the case, but I'm optimistic ". 
Contrast this optimism with the current state of knowledge surrounding the 
knowledge exchange and innovative practices within the industry as portrayed by 
Dougherty (2006) and Davenport & Preitsh (2005) and a very different story 
emerges. Yes, drug companies are beginning to adapt to the enormous growth in 
information from projects such as the human genome mapping through dedicated 
information management (e. g. Donelly, 2003) and companies now have the ability 
to rapidly screen chemical compounds through technology such as High 
Throughput Screening (Owens, 2003), yet just how far have pharmaceutical 
companies come to embracing the wealth of academic practices covered within 
the review? 
On first glance, work by Hung et al. (2005) suggests Knowledge Management 
may play a central role within drug development. Although in practice, further 
research by Wang (2006) within Taiwanese pharmaceutical companies concludes 
that pharmaceutical companies have been slow to adopt Knowledge Management, 
even though they believe there are benefits. As Peter Goodfellow (Owens, 2003) 
notes, companies are investing and targeting the problem areas of drug discovery, 
but there remain many areas that require further work and the benefits are not 
immediately noticeable due to the time scales of pharmaceutical development. 
Undeniably the stumbling blocks revolve around knowledge intensive processes. 
Early studies by Koretz & Lee (1998) suggest that the captured knowledge must 
remain available to relevant employees in order to promote reliable decision 
making. These so called "stop/ go" factors determine whether a drug is a failure or 
viable and marketable. Hence every effort is made to identify the characteristics 
of the compound in order to cease or accelerate development at the earliest 
possible stages. 
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Yet managing the process of knowledge acquisition is at the root of the 
development process and is essentially a Knowledge Management problem 
(Koretz & Lee, 1998; Dougherty, 2006). However, unfortunately one that has 
largely escaped an answer from both the pharmaceutical companies themselves 
and the academic literature. A fact that is understandable when the sources of 
knowledge driving pharmaceutical drug development and innovation may be 
internal, but are just as likely to be from an external and oflen unknown source 
(Powell et al. 2005). 
The review will now conclude with a synopsis of the research aim and objectives, 
in order to be certain that the research is addressing the issue of enhancing 
pharmaceutical innovation through the use of Knowledge Management. 
3.7 REVIEW OF THE AINI AND OBJECTIVES 
The literature review has uncovered many interesting facets of pharmaceutical 
innovation and Knowledge Management, what is clear is that there is little 
published empirical and qualitative work that links the two areas. Certainly 
Knowledge Management literature is widespread and abundant over many areas, 
but the specific area of pharmaceutical innovation is lightly researched. 
Furthermore the main research aim of creating a Knowledge Management tool set 
to enhance pharmaceutical innovation covers new ground. 
The objectives and tasks associated with measuring the success of a Knowledge 
Management strategy also appear to be well founded. Combining Knowledge 
Management strategy, measurement and innovation offers a unique research 
perspective and will help to inspire confidence in the research. As such, the 
research is expected to make a valuable contribution to both the public knowledge 
and the processes of pharmaceutical innovation within AstraZeneca. 
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3.8 CONCLUSION 
Chapter 3 has covered a great deal of ground that supports and argues a case for 
conducting the research. The chapter started with the topic of innovation and 
creativity where the terminology and research scope was clarified, before moving 
on to address pharmaceutical innovation so as to provide context for the reader to 
understand the research aim and objectives within AstraZeneca. 
The review then covered the fuzzy science of Knowledge Management strategy 
and tools. This stage provided an outline of the areas and concepts that are 
important to address when studying innovation. It must be noted that throughout 
the review, the author has witnessed confused ideas that require further 
investigation and believe at the minimum, an output of the proposed research will 
be a clarification of Knowledge Management within an R&D setting. The chapter 
then progressed to assess the methodologies for measuring Knowledge 
Management Strategy performance. Before suggesting some of the means with 
which the developed Knowledge Management tool set of Objective 4, may be 
assessed at a later date by AstraZeneca. 
Finally, the literature review then concluded with a study of the current published 
Knowledge Management strategies in place across a variety of pharmaceutical 
companies. Encouragingly, the author witnessed a lack of material which clearly 
outlined what Knowledge Management tools are required to drive pharmaceutical 
innovation and as such the research is well placed and novel. 
The following Chapter 4, details the research methodology that will be used to 
achieve the research's aim and objectives and answer the gaps within the existing 
literature. 
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CHAPTER4 
RESEARCH METHODOLOGY 
4.0 INTRODUCTION 
The literature review has shown that the management of knowledge and 
innovative processes plays a crucial role in the development of innovative 
behaviour and products. As the use of knowledge and Knowledge Management 
techniques within the innovative processes of AstraZeneca forms the basis of this 
research, it is important to choose a research methodology that supports the aim 
and objectives outlined within Chapter 2. Although the research is unique within 
the pharmaceutical environment, the methods used to collect and analyse the 
research data have a number of commonalities with published literature on 
Knowledge Management, innovation and academic research. The following 
chapter covers the research methodologies that may be used to conduct the 
research and explain the rationale behind the final chosen path. 
4.1 RESEARCH PHILOSOPHIES 
The term research has already been used within the thesis, but what does research 
imply? Taking the definition of Oates (2006) as a starting point, academic 
research is described as: 
"The creation of new knowledge using an appropriate process, to the satisfaction 
of the users of the research ". 
When this definition is placed in terms of AstraZeneca's phannaceutical R&D 
processes, the end result is the development of a new drug to combat disease; 
while in the context of the research within this thesis it is the clearer 
understanding of the processes and knowledge required to develop the new drug. 
Oates' (2006) definition also suggests that good research results in the end users 
of the research being content with the outputs, in this case both AstraZeneca and 
the academic community will benefit from the study. 
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However achieving a successful outcome relies upon the researcher successfully 
communicating why the research is being carried out and what the results may be 
used for. In the words of Nightingale (1984) this is the successful communication 
of the 'big idea' of the thesis, an idea that is stated in the early chapters as the 
principle aim and then rationalised and solved in the following chapters. Oates 
(2006) hypothesises that in order to achieve this goal, academic research requires 
a number of stages that should be addressed in turn, these are: 
9 The identification of a problem, 
o The gathering of data, 
9 The analysis of the data, 
9 The interpretation of the data, 
* The gathering of more data, 
9 The analysis of the new data, 
* The interpretation of the data as a whole, 
* Draw conclusions from the data as a whole. 
This approach implies that once the context of the research in the real world is 
known, a problem may be identified and the aim and accompanying objectives to 
solve and observe the problem, developed in a form of reiteration. Emory (1985) 
describes this series of steps as the 'research paradigm' which is said to consist of 
the research question, the research methodology and the output of the research. 
Hirschheim (1992) refers to the assumptions that underlie the research question 
and methodology as the epistemology that serves to guide the researcher and the 
research to a valid conclusion. However, research should be conducted without 
prejudice and be objective, that is to say preconceived notions of solutions to a 
problem should be avoided, as good research develops well-founded conclusions 
that are based on the data collected alone (Oates, 2006). 
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Furthermore research cannot be conducted without a purpose that is evident from 
the start (Lindsay, 1995); yet starting a research project is a daunting task and 
returning to the issue of how this research is conducted yields a bewildering array 
of approaches. However, there exists common ground, with the positivist, 
interpretative and critical research approaches well lauded and exercised within 
both IS and Knowledge Management academic research. These approaches are 
now examined alongside the views of Miles & Huberman (1994), Myers (1997) 
and Oates (2006) in the following sections and their suitability to be used as the 
philosophical basis, weighed up against the research aim and objectives detailed 
in Chapter 2. 
4.1.1 POSITIVISM 
Positivism is known as the scientific approach and adopts two principle 
assumptions; these are that the world is ordered and that we can investigate the 
world objectively. The first law implies regularity and is associated with assessing 
the validity of a theory or hypothesis that may be proven or disproved via the 
formal means of measuring and assessing phenomena. Positivism suggests 
repetition, in that a phenomena associated with the research environment will 
occur as a recognisable constant and this phenomena once identified, may be 
measured through experimentation. The second assumption of positivist research 
relies upon the phenomena occurring outside of the researcher's cognition, i. e. the 
phenomena will occur regardless of whether the researcher is present or not. 
Studies based upon positivism tend to align a theory with prediction and 
experimentation in an attempt to learn more about why an outcome occurs and to 
ultimately prove or disprove a hypothesis. An established positivist hypothesis or 
theory may be read as fact, but the researcher should be aware that the positivist 
or scientific approaches provides an indication of what is known at that moment. 
Hence a positivist theory or hypothesis is under constant test by researchers, 
where theories may be broken down into smaller constituent parts as more 
knowledge and theories on the subject emerge (reductionism), or tested repeatedly 
in an effort to elute problems with the researchers objectivity or environmental 
error (repeatability), or simply refuted where researchers who attempt to repeat 
the experiment cannot obtain the same result. 
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Scientific theories and hypotheses are based upon the objectivity and reliability of 
the research approach and the stronger a theory is, the longer it will withstand 
scientific scrutiny, yet as this research is based upon the social processes and 
wiles of knowledge interactions, the use of positivism as a research philosophy is 
questionable. Indeed, Hirschheirn (1992) questions whether social research is 
truly governed by scientific laws and whether objective measures with which to 
assess a theory or hypothesis can even be obtained using positivist research. 
4.1.2. INTERPRETIVE RE, SEARCH 
Interpretive research is a more open concept, being primarily associated with 
understanding the social context of a phenomena, a researcher may assume that 
the means to judge and analyse a scenario may be made through the use of social 
constructs. These constructs include language, consciousness and shared 
meanings and divulge a contextual based view of the studied process, due to this it 
is a popular choice to conduct Knowledge Management and IS research (Myers, 
1997). Walsham's (1993) view states that: 
"Interpretive studies are aimed at producing an understanding of the context of 
the information system, and the process whereby the information system 
influences and is influenced by the conlext'ý 
The interpretive approach seeks to identify, explore and explain how the social 
factors of the problem are interrelated and interdependent. Checkland & Holwell 
(1998) were early advocates of interprefivist research. Their work on the Soft 
System Methodology describes how the interpretive approach can be used to yield 
a valuable understanding on how the humans within a problem context, interact 
and perceive their environment. 
In light of this, the interpretive approach would appear well suited to Knowledge 
Managemcnt research as it lacks the preconceived variables of the positivist 
approach, relying instead on the elution of the sense that a human makes of their 
environment. This sense is derived from the social meanings and view that there is 
no single version of the truth; instead an interpretivist relies upon multiple 
subjective viewpoints that are taken into consideration and not immediately 
dismissed as erroneous events. 
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In this light, a single conclusive theory or hypothesis is rarely reached and, as 
such, interpretive research is often focused upon real world study outside of the 
regulated laboratory environrnent 
4.1.3 CRITICAL RESEARCH 
Critical research centres upon the relationships of the subjects and in many ways 
harks to the notion of a subject's social and economic status. The critical 
researcher aims to identify the conflicts, contradictions and the power held within 
the relationships between people, in order to bring these issues to the forefront 
where they can be addressed and ultimately eliminated. Therefore a critical 
researcher may be viewed as a challenger to the established organisational 
structures by using their research in an altruistic manner to realign the balance of 
power within an organisation. The critical researcher considers technology as an 
agent that may be shaped via employees, rather than technology being the agent 
with which to shape the role of the employee, a mantra in common with recent 
literature on Knowledge Management and innovative practice (e. g. Darroch, 
2005). 
4.2 THE RESEARCH PHILOSOPHY 
It is clear from the literature in Chapter 3 that Knowledge Management carries 
both a social and a technological construct. Assigning and uncovering measurable 
and reliable variables to construct a set positivist hypothesis appears ill founded, 
as the principle research aim is itself founded within a social context, e. g. the 
creation of a Knowledge Management tool kit that is useful to employees. 
Therefore aligning the research with a defined hypothesis and a positivist 
philosophy could be made to be suitable. However, compelling research by 
O'Neil (2002) concerning Communities of Practice, suggests that the positivist 
approach is flawed, when research intends to examine the values, ideologies, 
political interests and intangibles of a social environment. 
As the research within this thesis focuses upon the social contcxt, the rich 
exploratory data that could be obtained through the use of an interpretive or 
critical research path, represents a more beneficial and viable route. 
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Miles & Iluberman (1994) stress that it is important for a researcher to make their 
methodological intentions clear, particularly when conducting human centred 
research into social phenomena, where the research scope is governed by 
language, decisions, conflicts and hierarchies. These social factors essentially 
describe how an employee will think and act within an organisation. Taking these 
factors into account implies that the use of critical research may be suitable, 
however, as the research only seeks to analyse and not challenge the power 
relationships between the employees, the remaining interpretive philosophy is 
ultimately deemed most suitable. It must be mentioned that choosing an 
underlying physical framework for Knowledge Management research poses an 
interesting quandary, as the literature review of Chapter 3 revealed that the 
majority of published work is either positivist or interpretative. Authors such as 
Kaplan & Duchon (1988) and Oates (2006) suggest that both are worthy 
philosophies and even a combination of two philosophical strategies is feasible, 
but for the sake of objectivity and reliability, the interpretive pMosophy is chosen 
as the underlying framework on which to conduct this research. 
4.3 RESEARCH METHODS 
Although the underlying research philosophies chosen by Knowledge 
Management researchers may differ, the means to capture the data to drive the 
research is often based upon similar means. It is here that the notion of 
quantitative and qualitative study is introduced. Yin (1994) suggests quantitative 
research focuses upon data derived from surveys and archives, while qualitative 
research commonly uses interviews and observation. It must be made clear that 
the approaches are not mutually exclusive; indeed research may benefit from 
combining both qualitative and quantitative data collection and is termed 
triangulation (Mingers, 2001). 
Qualitative data may also be codified and hence rendered as quantitative data 
(Miles & Huberman, 1994), yet it is important to stress that quantitative and 
qualitative data is the end result of the research methodology and not the 
methodology itself 
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Choo & Bontis (2002) suggest that due to the difficulties of studying 
organisational knowledge, qualitative data collection is a worthy approach. 
However, when choosing a methodology that may yield qualitative data, it is 
important to bear in mind Shaffer's (2000) description of the methodology as: 
"A framework within which raw data is placed so that a meaning may be seen 
more clearly; where the methodology is the transformation of data into 
information ". 
Within this research, the desired result is the collection of useful data that has 
been collected by applying a research framework to study Knowledge 
Management and innovation within an R&D organisation. The suggestion of 
acquiring data in an organisation or field is also an accurate description of 
empirical research, where empirical research is a broad label that is not a 
philosophy or a method, but is an assumption that research has been carried out in 
the real world and is based upon evidence derived from experimentation, 
observation or assessment. Therefore empirical research implies the study of an IT 
or Knowledge Management system in the field (Oates 2006) and regardless of the 
final chosen research philosophy or method, may therefore be used to describe the 
research within this thesis. Indeed, Swan & Scarbrough (200 1) state that empirical 
research provides the means to make sense of the processes and objects that 
comprise a studied area; particularly advocating the use of empirical research to 
challenge the common misconception that labels knowledge as a commodity that 
can be captured and managed with an information management tool. 
Although the research may be labelled as interpretive and empirical in character 
this does little to explain how or what data should be collected, fortunately there 
are a wide range of methodologies with which to acquire data and answer the 
research aim within this thesis. 
Yin (1994) and Oates (2006) are key figures within qualitative research practice 
and Table 4.1 details some of the more common research methodologies 
suggested by the authors to collect qualitative data: 
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Table 4.1: Common Research Methodologies 
Methods Form of Requires control Focuses upon 
Research of behavioural contemporary 
events? events? 
Action Research Who, what, why, Yes and No Yes 
how many, and 
how much? 
Ethnography Who, what, why, No Yes 
where, how many 
and how much? 
Observation Who, what, why, No Yes 
where, how many 
and how much? 
Archival Analysis Who, what, why, No Yes and No 
where, how many 
and how much? 
Modelling How and why? No Yes and No 
H'st -0 How and why? No No ; 
Ej Experiment 
[ý 
x How and why? Yes Yes= =C ase Study I How and why? No Yes I 
As Table 4.1 reveals there are a considerable variety of methodologies to choose 
from, some require a rigid and controlled environment, while others, such as 
historical research, focus on past events. However, as the research requires a 
contemporary angle, the use of the historical approach may be excluded at an 
early stage, though the other methods mentioned in Table 4.1 all hold potential 
merit and application. In order to address this, the following sections now briefly 
cover the identified research areas and link their use or potential use to the main 
research aim and objectives outlined in Chapter 2. 
4.3.1 ACTION RESEARCH 
Action research requires that the researcher both observes and actively contributes 
to the results of the study. Greenwood & Levin (1998) state that action research is 
predominantly a social methodology, where the researcher actively sets out to 
improve the situation for the research stakeholders. In this way the organisation 
being studied benefits from the elucidation and examination of problem areas that 
are related to the research aim. 
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The action researcher is expected to take positive steps to rectify the problems 
identified and carry out and communicate remedial action. Kock (1997) describes 
action research as: 
"Research methodologies and projects where the researcher tries to direct y I 
improve the participating organisation and at the some time generate new 
scientific knowledge. " 
Action research is commonly used by researchers who wish to improve their own 
situation, or by academics: 
"Who initially present as experts to analyse, diagnose and suggest change and 
then progress to become thefacilitators ofchange. " Oates (2006). 
Despite its applicability to Knowledge Management research, the approach has 
largely enjoyed success within the social sciences (Myers, 1997). However, 
authors such as Checkland (1981) and Vigden (2002) have successfully used 
action research within their IS based methodologies. The use of action research 
within Knowledge Management is largely under explored, but does present 
considerable opportunity as it directly utilises the knowledge of the researcher and 
the employees in order to rationalise a problem area (Avison et al. 2001). Yet this 
process is also a shortcoming as the results may only be applicable to the studied 
organisation and attempts to replicate the results of the research will almost 
certainly differ. 
On consideration, action research is certainly a worthy approach and would 
provide value to both this research and to AstraZeneca. A benefit of action 
research is that the researcher is immersed within the research environment and 
actively collaborates with the employees, thus allowing the researcher to view 
whether the results of this study and the Knowledge Management toolkit is 
ultimately useful to support pharmaceutical innovation. However, to be conducted 
properly, active research would require direct participation within the drug 
development processes in order to assess the Knowledge Management tools that 
are currently used and may be used. 
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Although the researcher's Biochemistry background provides an excellent 
understanding of the drug development processes, the utilisation of the proposed 
and current Knowledge Management tool kit would require detailed biomedical 
knowledge, resource and authority, and although promising, the action research 
approach was on the whole deemed unsuitable. 
4.3.2 ETHNOGRAPHY 
Ethnography is derived from social and cultural anthropology, where the 
researcher studies the social and cultural implications in order to elute an accurate 
description of the people and cultures (Myers, 1997; Oates, 2006). Fetterman 
(1998) describes ethnography as research of the mundane, where the researcher 
seeks to analyse the routines of the organisation through extensive fieldwork. 
Ethnography intends to preserve the natural setting of the study and does not seek 
to disturb the subject's organisational behaviour, a stance that differs wildly from 
action research. Instead ethnography utilises multiple data collection tools such as 
the interview, documents and observations in order to produce a holistic picture of 
the organisation (Oates, 2006). As this suggests, ethnographers adopt the 
interpretive approach, relying upon the collation of views and observations across 
the whole organisation in order to reach valid conclusions. However, this 
approach is rarely formal and has provoked criticism from the more rigid research 
proponents (Myers, 1997). 
Evidently ethnography may be applicable to the research as throughout the project 
the researcher was immersed within the organisation and its operating procedures, 
and hence was in the position to make extensive field notes on which to base an 
analysis upon at a later stage. 
4.3.3 GROUNDED THEORY 
Grounded theory is an interesting concept, as it may be used to make sense of the 
data collected from field research and induce a theory or theories from the data 
(Strauss & Corbin, 1998). Due to the lack of prerequisites or hypothesises it may 
be viewed as an ideal tool with which to approach the study of an organisation, 
particularly from a Knowledge Management point of view. 
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However, the researcher must be careful, as grounded theory requires the 
elucidation and generation of theories from the research data and simply 
describing what was found within the data does not constitute grounded theory 
(Oates, 2006). The technique relies upon a process of discovery, whereby the 
researcher has an initial idea of what may be found but is unsure, a initial survey 
or exploratory study would then be carried out which then leads to further studies 
and refinement and eventually the elucidation of a validated theory (Oates, 2006). 
This process of refinement promotes reiteration and the development of firm 
concepts from an initial notion or a surmise (Denscombe, 2002); in the case of 
this research, this would be that Knowledge Management does indeed aid 
pharmaceutical innovation. 
Myers (1997) suggests the benefits of grounded theory lies within the continuous 
interplay between the data and analysis, whereby the data effectively steers the 
direction of the research. Due to grounded theories loose fitting nature, it has 
proven a popular research methodology within the IS and Knowledge 
Management fields alike (Myers, 1997), hence grounded theory represents a 
worthy avenue in which to progress the research aim and objectives. 
Grounded theory does however have its drawbacks, the primary one being that the 
initial investigations are often vague and lack a clear definition of what or why a 
s=ple is being studied. Due to this the researcher may find themselves repeatedly 
carrying out data collection in a vain attempt to define a theory or reach the fabled 
point of theoretical saturation, where additional data no longer develops further 
research but instead allows a theory to be developed (Strauss, 1987). Tlius the 
researcher must be able to collect and analyse useful data that can ultimately be 
used to derive a theory, the key problem here being that it is difficult to know 
what exactly useful data is at the early stages of data acquisition. 
Problems such as these, compel a grounded theory researcher to codify data in the 
hope that a theory that has practical relevance to the people involved may be 
uncovered. The initial stage of codification is termed open coding and requires 
that the researcher code data according to what is found within the data and not 
based upon the terms and concepts found within the existing literature, a task that 
is certainly easier to describe than carry out (Oates, 2006). 
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4.4 THE RESEARCH APPROACH 
The chosen research strategy must firstly address the vagaries of the 
pharmaceutical domain and from the review of the literature it is clear that few, if 
any studies, have specifically attempted to create a Knowledge Management tool 
kit to drive pharmaceutical innovation. Hence the research is a step into the 
unknown, techniques such as ethnography and grounded theory would therefore 
represent viable approaches. However, the research is also highly unique in that 
the researcher has unprecedented access to the employees and AstraZeneca as a 
whole, and it would be in the interest of both the organisation and academia, to 
conduct a study that spanned the organisation. Grounded theory would allow a 
researcher with no previous experience of the domain to conduct studies, yet the 
researcher's experience of the drug development processes and empathy with the 
knowledge to be studied, suggests that a more structured methodology will yield 
greater reliability and understanding. 
Ethnography is a serious contender as the EPSRC funded researcher is based full 
time within AstraZeneca; however, ethnographers must assess and report their 
prejudices and personal experiences when observing and reporting data, in a 
process named as reflexivity (Oates, 2006). Reflexivity and the documentation of 
the personal experiences of the researcher are a necessary part of a valid 
ethnography study. However, the extra work involved in providing a narrative of 
the researcher's time within the organisation is deemed to be an unnecessary 
burden, therefore the chosen research path focuses upon the use of the interpretive 
case study. 
A key advantage of the case study is that the initial investigational stages may be 
based upon existing literature and can be used to validate and shape existing 
theories (Oates, 2006). There is a great deal of literature on innovation and 
Knowledge Management, yet little upon pharmaceutical innovation and the use of 
Knowledge Management tools. Although the published literature largely applies 
to other fields, it would be foolish to ignore the existing generic literature on 
Knowledge Management and innovation. 
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The case study approach is valuable as it allows the development of an initial 
conceptual framework, with which to assess the organisation's Knowledge 
Management and innovation strategy in light of published Knowledge 
Management and innovation models. Hence the initial stages of this research may 
be viewed as a bridge, to link the existing literature and AstraZeneca's 
Knowledge Management strategy. Prior to moving on to develop new frameworks 
and theories that relate solely to the use of Knowledge Management within 
AstraZeneca and the drug development processes. 
The following section examines the reasoning behind the choice of the case study 
and the value of adopting the case study approach. 
4.4.1 THE CASE STUDY 
Ile case study is used to provide a rich and detailed insight into the studied 
processes and explore the complex relationships and processes that exist within 
the study area (Oates, 2006). Yin (1994) is a proponent of the approach as it 
allows investigation of a real life scenario with loosely defined boundaries. When 
undertaking this doctoral research, it was deemed vital to adopt a methodology 
that can embrace the indistinct scope of Knowledge Management, innovation and 
intellectual capital research. Methods to achieve this are rarely documented, yet 
the case study is commonly employed within Knowledge Management and IS 
research as the principle means of data collection (e. g. Carrillo, 2003; Myers, 
1997). Bcnbasat et al. (1987) state that the case study is useful when research is at 
its formative stages, this is certainly the case within this research project as the 
literature implies Knowledge Management will aid drug development, but little 
supporting empirical evidence corroborates this. 
Case study research is useful when looking at the 'how's and 'why's (Yin, 1994) 
and is valuable when the mechanics of a process are unknown, in this case it is the 
processes and nuances surrounding the use of knowledge within drug innovation 
which represents the archetypal 'black box' to be explored. Thus an advantage of 
the case study is that it provides focus and may be used to define the area to be 
studied. 
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However, Miles & Huberman (1994) describe this as a loose fitting 'focus' that is 
largely based upon what will definitely not be researched, rather than what will 
definitely be covered. In this way the case study is useful to serve as an 
exploratory tool to define and lead further study (Yin, 2003); however, the case 
study is also a powerful research strategy where the principle aim is to extract as 
much detail as possible from the case area in its natural setting. Consequently case 
studies may take either an interpretive or positivist approach (Yin, 1994), 
although the interpretive approach offers a subjective dimension where the beliefs 
and value of the studied system may be constructed and interpreted (Darke et al. 
1998). This subjective dimension is a valuable commodity and would both 
support and develop the primary research aim, by taking account of the views of 
the employees who utilise knowledge to drive drug development. Walsham's 
(1995) work supports this notion by highlighting that the interpretivist case study 
is able to provide an explanation as to what is occurring within the studied 
processes and the organisation as a whole, which may then be relayed back to the 
subjects by describing their role within these holistic processes. A further 
advantage is that the case study develops understanding by obtaining data from 
multiple sources across an organisation or field, utilising diverse sources such as 
interviews, field notes, documents and archival analysis in order to make sense of 
the study as a whole (Darke et al. 1998). Therefore the case study appears to be an 
ideal approach, but how can the case study help to achieve the main research aim? 
This question is partly answered by the ability of the case study to utilise multiple 
data sources, in conjunction with advice taken from Oates (2006) and Yin (1994), 
the following qualitative data collection techniques are utilised within the study: 
* Interviews 
4, Direct and participant observation 
* Process modelfing 
9 Document analysis 
0 Field notes 
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1n this fashion, the case study creates a descriptive and exploratory study, 
identifying and trying to explain why events happen, either by identifying them as 
unique events or by relating these findings and events to existing literature on the 
subject (Yin, 2003). How these factors then interrelate allows 'cause and effect' 
relationships to be uncovered, Oates (2006) also suggests that the case study 
should target more than one area and, if possible, spread across organisations in 
order to establish differences and trends within these 'cause and effect' 
relationships. 
In light of the findings of the literature review is it apparent that this research 
would indeed benefit from cross organisational research, as this would allow the 
assessment of the impact of Knowledge Management tools within similar 
innovative organisations and directly support Objective 4 in the process. Darke et 
A (1998) cite the use of dialectical hermeneutics as a theoretical framework on 
which to conduct a case study of the organisational impact of introduced IS 
systems. What is valuable within this approach is that the study relies upon 
reaching a consensus of value from the subjects studied, focusing not upon the 
'hard' aspects of measurement but on deriving value from the 'soft' social side. In 
many ways this research follows a similar fashion, as the objectives laid out in 
Chapter 2 initially seeks to identify and explore the organisational processes of 
innovative work from the perspective of the employee, showing how and why 
group interactions and the organisational structure influences innovative 
behaviour. 
As the research process was expected to be conducted over a number of years the 
case study is of the longitudinal variety. The research seeks to analyse R&D and 
innovative cases over time, noting and analysing the processes and relationships 
that are stable and those that exWbit a state of flux (Oates, 2006). However, case 
studies are not without their critics, in particular they are criticised for their abject 
specificity as researchers such as Oates (2006) and Yin (1994) suggest it is largely 
up to the researcher to assess how relevant the results are to other areas. This 
research was expected to allow generalisations to be made, as a case study 
regarding pharmaceutical innovation should have application to other knowledge 
intensive R&D processes. 
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This is a primary aspect of the research and an achievable aim, as Walsham 
(1995) suggests the findings of case study research often results in a series of 
practical implications or the development of a conceptual framework that has 
wider-application outside of the initial research domain. 
In order to commence the study, the research is conducted and analysed in 
accordance with the criteria detailed by Lincoln & Guba (1985) and Oates (2006), 
who ascertain that for the reader to have confidence in the findings of the 
research, the issues of internal and external validity, reliability and objectivity 
should be addressed: 
1. Internal validity relates to effectively ensuring that the concepts 
developed from the researcher's musing may be validated with the 
subjects themselves and possesses recognisable application. 
2. External validity applies to the environment outside of the studied area 
and emphasises that the research finding should convince an external 
organisation or subject, that the models eluted by the research will find 
merit within another context. 
3. The reliability or consistency of the research stems from the research 
results ability to be replicable, where the researcher must be able to 
convince the reader that the results are repeatable. 
4. The final criteria relates to objectivity, which proclaims that the results 
of the study are obtained from the data alone and not from the 
researcher's personal bias. Seeking to prove that the researcher did not 
unduly influence the case subjects or report their own preconceived 
notions as data (Walsharn 1995). 
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4.5 THE RESEARCH FRAMEWORK 
As previously mentioned, the research takes the form of a longitudinal case study 
coupled with an interpretivist approach, the methods of data collection used are 
now analysed and their use discussed in relation to the research aim and 
objectives of Chapter 2. 
4.5.1 CASE SELECTION 
The selection of the cases or units on which to conduct research is an important 
point to outline. Oates (2006) describes five criteria which influence what and 
where can be investigated within a case study and these are: 
1. The typical instance displays typical qualities that are representative of 
a class, the findings from one instance may be generalised to cover a 
class as a whole. 
2. The extreme instance is a sharp contrast to the established norm. 
3. A test bed for theory is a case that allows a particular theory or strategy 
to be examined and then modified, accepted or challenged. 
4. The convenience of a case also influences its choice, as restricted 
access or time related issues may hamper the quality of research that 
can be obtained. 
5. A unique opportunity is one that presents itself while the research is 
being carried out and may not reoccur, such events often represent the 
elusive 'holy grail' of research. 
In order to satisfy these five criteria the research undertakes multiple case studies 
across AstraZeneca R&D and two additional R&D intensive industries. 
Classifying the research as separate case studies recognises that innovation and 
Knowledge Management is a diverse environment to study. 
As the research will commence with an exploratory nature it was envisaged that 
the case study carried out for Objective I would target examples of typical 
instances of innovation. 
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A brief outline of the case studies researched, are presented in Chapter 5. Here the 
reader will note that these case studies represent the extent of what may be 
conceived of an 'innovation', from the development of an innovative new drug or 
dosing device, to the development of a new innovative process to introduce a KM 
system. Innovation and the processes of innovation possesses a wide guise; it was 
expected that eventually trends would appear that would allow some of these 
instances to be described as typical, but some cases would remain as extreme 
instances, while others that specifically relate to the use of Knowledge 
Management within an organisation would serve as a test bed for theory. 
In order to ensure that bias from the author's personal experiences can be 
minimised, the research utilises multiple sources of data to allow for triangulation, 
thereby bolstering the case study findings with evidence from similar but distinct 
areas (Yin, 1994). The results of the studied areas are clearly defined in Chapter 5 
in light of the research aim and objectives. Here the analysis will weave a 
narrative of the findings of the study and provide further validation of the research 
approach, in line with recommendations by Darke et al. (1998) and Walsharn 
(1995). The following sections cover the steps that were taken to collect the data 
from each of these diverse areas. 
4.5.2 INTERVIEWS 
Semi-structured interviews are the primary means of data acquisition and form the 
mainstay of the research; hence the development of a series of questions to study 
the relationship between innovation and Knowledge Management was required. 
The interview is commonly associated with the case study methodology and is an 
overt approach, where the participants are aware of the rationale behind the 
conversation and permit the researcher to conduct the study (Oates, 2006). 
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In all there were four stages of interviews conducted over a two year period, the 
stages are briefly outlined below: 
1. Preliminary Information Gathering 
Stage I was conducted with five known innovators working within 
AstraZeneca R&D and was used to assess the validity of the research aim, 
objectives and the conceptual framework upon which the interview 
questions were based. 
2. Secondary Information Gathering 
Stage 2 built upon the preliminary findings and was conducted with thirty 
two key personnel who are directly involved in innovative behaviour 
within the R&D wing of AstraZeneca. A further two case studies were 
conducted within Rolls Royce (Derby) and Johnson Controls (Derby) to 
assess the value of Knowledge Management within similar innovative 
organisations. 
3. Knowledge Management Tool Kit Design 
Stage 3 was conducted with ten innovators who were identified as 
proponents, expert users and sceptics of Knowledge Management 
technology in order to provide a holistic view of Knowledge Management 
within an R&D setting. 
4. Knowledge Management Tool Kit Validation 
Stage 4 was the final interview stage and required the validation of the 
research findings with 10 key innovative personnel across AstraZeneca 
R&D. A series of conference papers and presentations were also used to 
air and validate the research findings, as and when the study findings were 
released to AstraZeneca and the academic community. 
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The knowledge audit work of Coombs et al. (1998) was used as a provisional 
basis for the questionnaire, while the findings of Stage I and the literature 
findings from Chapter 3 completed the conceptual framework on which to base 
the semi-structured interview questions. The following components of the 
conceptual framework are based upon an expanded view of pharmaceutical 
innovation and Knowledge Management, derived from Cooper (2003), Tether 
(2003), Scarborough et aL (1999) and Dorabjee et al. (1998): 
* Innovation and risk management 
9 Knowledge Management within AstraZeneca 
o Knowledge and informafion sources 
* Knowledge culture, collaboration and knowledge networks 
* Knowledge Management/ Information Systems 
* Process management 
* R&D legal and regulatory influence 
The pilot study of five preliminary interviews (Stage 1) was required to align the 
semi-structured questionnaire with the AstraZeneca operating principles and 
internal company processes and the final interview structure and questions are 
detailed within Chapter 5. The framework concentrates on the notion of 
innovation as both a process and a new product, seeking to elaborate upon 
existing theory and ascertain the role of Knowledge Management within 
pharmaceutical drug development. 
All interviews were recorded directly into MP3 format using a laptop where 
possible, when interviews were conducted without recording, at the request of the 
intcrviewee, extensive field notes were taken. All interviews were transcribed 
within 24 hours of completion using Microsoft Word, after transcription the 
interview transcripts were reviewed with the participant in order to ensure 
accuracy. 
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4.5.3 PROCESS MODELLING 
Stewart (1997) hypothesises that Knowledge Management will be fundamental to 
a company's success, yet as the review in Chapter 3 concluded, strategies to 
achieve this elusive return are rare. 
Knowledge Management success stories are driven by companies that integrate 
the knowledge of the organisation and the business processes with that of the 
employees (e. g. Dilnutt 2002). Process modelling can be used to benchmark and 
visualise the existing business processes of the organisation for use with a 
Knowledge Management system. Nissen et al. (2000) state that before introducing 
a Knowledge Management strategy it is important to recognise and discuss what 
exactly Knowledge Management is intended to support and achieve. From the 
perspective of knowledge as a resource, the models employed to map a process 
are derived from intellectual capital models and differ from the more traditional 
Business Process Re-engineering models. Here the Value Creation Map (Marr et 
al. 2004) and Strategic Performance Management (Marr, 2006) methodologies 
may be used to visualise a business process in terms of the work flow, the 
organisational environment, the knowledge interactions and the value of the 
knowledge used. 
Due to the ambiguity of the chosen case study units, process modelling was an 
integral part of the work, the derivation of an accurate picture of how knowledge 
contributes to the drug development processes and how Knowledge Management 
tools may give support was deemed paramount. While conducting the semi- 
structured interviews of Stage 2, the participants were asked to describe an 
example of innovative work they had been involved in. These scenarios were then 
analysed and a map of the knowledge entities and work flow was drawn up 
utilising the technique of Strategic Performance Management (SPM) (Marr, 
2006). Focus groups and further discussions were also held with the participants 
to ensure that the models accurately reflected the true nature of the knowledge and 
workilows occurring within the innovative processes. The SPM technique was 
chosen as it allows the definition of strategy that encompasses the views of 
multiple stakeholders and allows the definition of how innovation is actually 
being driven to be uncovered. 
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Marr (2006) describes SPM as "an organisational approach to define, assess, 
implement and continuously refine organisational strategy", importantly the 
method may be used to refine and develop measurement indicators that can be 
used to reflect the success of a strategy. 
Tying AstraZeneca's innovative drug development strategy with a Knowledge 
Management strategy is seen as an important output of the research (Objective 4) 
and the application of the SPM technique allowed this goal to be reached. The 
SPM technique was chosen not only on merit, but also due to the researcher's 
familiarity with the technique and its application. The researcher was involved in 
a consultancy project conducted by Cranfield University's Bernard Marr. 
Following discussions with Bernard Marr, AstraZeneca and the research 
supervisors, it was viewed that this research would benefit from the benclimarking 
and mapping of the existing workflows, by specifically employing SPM to map 
the value creation processes involved in the innovative processes. 
4.5.4 OBSERVATION 
Observation played a key role in the acquisition of the research data; due to the 
researcher being based full time within AstraZeneca the opportunities to observe 
innovative work were widespread. Observation implies that the researcher has a 
choice on what type of data to collect and when utilising a case study the observer 
commonly utilises two types, namely direct and participant observation. Both 
types of observation were heavily utilised, but direct observation played a greater 
role in the research, as an autonomous observer, the researcher attended numerous 
departmental meetings, cross functional meetings, AstraZeneca seminars, drug 
development seminars and strategy meetings over the three year period at the site. 
Having been granted the status of an employee, the author had wide access to the 
organisation and interacted frequently with managers, directors* and scientific 
researchers. These informal conversations provided a rich tapestry of data 
concerning innovation and Knowledge Management. 
Participant observation requires a more direct role, rather than passive acquisition 
of data the researcher possesses the ability to actively participate and instigate 
data gathering events (Yin, 1994). 
122 
Chapter 4- Method 
Although the author's role within AstraZeneca was largely that of the direct 
observer, numerous meetings related to Knowledge Management and innovation 
were conducted over the three years and the author's role shifted from one of 
observer to participant on many occasions. However, participant observation 
requires focus as, when participating within meetings and discussions, it is 
important to remain objective and refrain from bias. 
In addition, the role of a participant observer often interferes with the collection of 
data and, as such, the author found a 'balancing act' between the demands of the 
organisation and the research was required at times. Over all though, the 
participant observer approach offered unique benefits to the research by allowing 
the researcher to empathise with employees, gain an insider viewpoint and 
highlight areas that were pertinent to the research as and when they arose. 
4.5.5 DOCUMENT AND ARCHIVAL ANALYSIS 
AstraZeneca is reliant upon the storage and retrieval of documents to support its 
drug development activities and as the research is 'focused upon Knowledge 
Management, it was deemed prudent to utilise the systems currently employed 
and analyse the documents that are used by employees during their work. The 
author had access to a number of these systems, including eRoom, GEL and PKT, 
during the three year project and key documents relating to the drug development 
work were identified and discussed during the interview processes. Participants 
were asked to gauge the effectiveness of AstraZeneca's current information and 
knowledge strategy and comment on areas of strength and weakness. In this 
fashion the interviews supplied important contextual elements, allowing the 
meaning and value of the documents held within the innovative R&D processes to 
be appraised. This allowed the author to judge the effectiveness of the Knowledge 
Management strategy and accurately model how employee's typically utilise 
Knowledge Management and information management systems on a daily basis. 
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4.5.6 CASE NOTES 
During the research, extensive case notes were taken in both notebooks and 
electronic form (Microsoft Word), these notes were largely derived from the 
interviews, observations and archival analysis and served to provide a 'mental 
note' of pertinent points that were relevant to the research. Electronic records of 
the case study were assigned to a Termeneutic Unit' within the ATLAS. ti 
software in order to map relationships between the collected data and highlight 
best and worst practice examples. 
4.5.7 DATA ANALYSIS 
The methods of analysing the data are covered at the beginning of each section in 
Chapter 5, but on the whole, relied upon utilising the matrix method described by 
Miles & Huberman (1994) to collate and analyse data with which to support the 
research aim and objectives of Chapter 2. The research concentrates upon the use 
of qualitative data to provide context within the fuzziness of the problem area and 
it is proven that the undefined processes and the importance of social interactions 
lend themselves well to quýlitative analysis (Daft & Lewin, 1993). However, it 
was expected that after the initial qualitative data collection, subsequent 
codification of the data would be carried out as suggested by Yin (1994). Preece 
(2001) and Hague (1994) note, the collection of qualitative data provides insight 
into the subjective feelings and social interactions of a given environment, and it 
is believed that insight of this type will be of highest value to AstraZeneca and 
innovative R&D in general. 
4.6 CONCLUSION 
This chapter has explained how the research study relies upon the collection and 
analysis of qualitative data through a series of serni-structurcd interviews, 
observations and archival analysis. These steps are designed to uncover the trends, 
strengths and weaknesses of the current innovative practice within AstraZeneca 
R&D. 
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After a review of potential research methodologies and philosophies, the final 
research approach is based upon the longitudinal case study and the interpretive 
philosophy, a strategy that is eminently capable of meeting the research aim of 
creating and evaluating a Knowledge Management tool kit to drive 
pharmaceutical innovation. 
Evidently approaching the tricky subject of innovation and Knowledge 
Management requires a focused research effort and the means to achieve this have 
been outlines. A more detailed explanation of the various research stages is 
provided in the next chapter and their contribution to the research aim is further 
clarified. 
This thesis now discusses the research data acquired from the case studies and 
explores the how, where and why's of innovative R&D within the case study 
organisations. 
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CHAPTER 5: 
SCOPING A KNOWLEDGE AND 
INNOVATION FRAMEWORK 
5.0 INTRODUCTION 
This chapter is aimed at setting the scene for the research and introducing the reader 
to AstraZeneca, innovation and drug development. The chapter forms the foundations 
from which the research is developed and is primarily concerned with establishing 
what innovation means to AstraZeneca, why innovative work is carried out and how 
employees are innovative. As the research is based within a real world organisation 
this stage also allowed the author to empathise with the organisation and made 
employees aware of what the research project would cover and what it intended to 
achieve. 
As the pharmaceutical industry is highly secretive, relatively few accounts are 
available that detail how the drug development processes are occurring within the big 
pharmaceutical companies. AstraZcneca kindly agreed to allow the author access to 
this environment, so as to benefit both AstraZeneca and the research contained within 
this thesis. From the review of the literature in Chapter 3 it is apparent that the 
published academic literature is generic in character. Rarely covering the depth of 
inquiry necessary to provide concrete guidelines to assist in the introduction and 
implementation of a Knowledge Management toolkit and strategy too specifically 
enhance drug development. 
In order to analyse innovative practice within AstraZeneca the primary means of data 
collection chosen was the semi-structured interview. Accordingly, this chapter 
discusses how a number of AstraZeneca employees were selected to be interviewed 
in line with the research interview tool outlined in section 4.4. 
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Hence this chapter is a pilot study, aiming to validate the research methodology and 
partly reveal the criteria that are central to analysing innovation and Knowledge 
Management within AstraZeneca. This chapter adopts an exploratory slant, seeking to 
develop the initial methodology and research framework so as to ultimately support 
the overall research aim and partly fulfil Objectives 1,2 and 3. 
5.1 THE RESEARCH PROCESS 
The overall research process map is displayed in Figure 5.1 and illustrates the sub 
processes that were followed in order to fulfil the main research aim of developing a 
Knowledge Management toolkit. 
Derine the Scope 
Group discussions 
Focus groups 
Interviews 
Interview plan 
Review 
Rescarch tool 
Research Process 
Research & Data Analyse Data 
Acquisition Codification 
Interviews Identify themes 
Process models Identify 
Document review 
Observation 
knowledge/ 
innovation criteria 
Case Notes 
Figure 5.1: The Research Process 
Derive metrics 
Discussion 
KM/ IS tools 
KM Strategy 
Culture 
Metrics 
Validation 
Innovation 
Ibis chapter deals primarily with the processes labelled as 'Define the Scope' and 
'Research & Data Acquisition', seeking not to collect extensive data, but instead to 
validate the research approach and create a preliminary tool with which to study 
innovative practice. Chapter 6 then follows on from this preliminary validation and 
applies the research tool across the organisation, obtaining a greater depth of data via 
multiple interviews, direct and participant observation, process modelling, archival 
analysis and the utilisation of case notes. 
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5.2 RESEARCH METHODOLOGY 
A selection of key AstraZeneca R&D personnel and a Knowledge Management focus 
group were chosen to question and ground the theory behind the innovation model 
detailed in Figure 5.3. The preliminary questions were derived from the innovation 
and Knowledge Management literature and a case study concerning the effectiveness 
of a Community of Practice within AstraZeneca. The results of the Community of 
Practice case study were presented at an academic conference to high acclaim. The 
paper received excellent reviewer's comments and generated a lively discussion with 
positive feedback from a number of noted audience members. The reference to the 
paper is included within the List of Publications. 
In all, six areas were identified as being pertinent to the use of Knowledge 
Management to drive pharmaceutical innovation within AstraZeneca. These are 
illustrated within the model outlined in Figure 5.3. Each step of the model is derived 
from the literature review of Chapter 3, and combines with the research tool to form 
the basis of an innovation framework that has been expanded in Chapter 10. Wiig et 
al. (1997) define a framework as a set of methods, techniques and tools that allow 
Knowledge Management to be performed in order. Hence the innovation framework 
developed by this stage of the research, consists of the initial innovation model of 
Figure 5.3 that is supported by a research tool or question set. Wiig et al. 's (1997) 
definition of a framework implies that fin-ther tools, methods and techniques are 
requirecL 
Hence this chapter contributes to the research by developing the first tool o; the 
framework that has allowed the author to uncover the subsequent Knowledge 
Management tools, methods and strategies that together form the innovative 
framework that is required by the innovators within AstraZeneca. Figure 5.2 outlines 
how the research tool may be applied to an organisation in order to uncover the 
specified outputs that may eventually drive innovation forward. 
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This pilot study concentrates upon the research tool primarily, but also serves to 
underline where the innovation model sits with respect to innovative practices within 
AstraZeneca. 
Innovation 
Process Knowledge 
Management Kni: iri, liledge---'ý Sources 
Management/ IS 
Regulato 
a Legal 
Case 
Organisation 
Apply the research tool 
Figure 5.2: Developing an Innovation Framework 
The American Heritage Dictionary of the English Language (4th Edition) describes a 
framework as: 
"A set of assumptions, concepts, vahies andpractices that constitute a way (? I'viewing 
reality. " 
Thus the assumptions and concepts are derived from the literature review of Chapter 
3 and form the Innovation Framework of Figure 5.2. While the values and practices 
within the innovation framework are themselves derived from the case study within 
AstraZeneca and uncovered by using the research tool. The use of the research tool 
has allowed the discovM of what an innovative organisation should look like with 
respect to processes, infon-nation, knowledge and Knowledge Management. 
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While the innovation framework may be viewed as a structure that allows the 
visualisation of the knowledge required for innovation and allows the user to examine 
the potential scope and application of Knowledge Management within AstraZeneca 
or the studied organisation. 
Innovation Ilk I Intangible 
Collaboration 
Knowledge Sources 
Knowledge Management/ IS 
Process Management 
Regulatory and Legal Compliance JIL I -rangible 
Figure 5.3: Drug Development Innovation Model 
'ro date the model within Figure 5.3 has been used to collect a set ofassuniptions that 
are derived from the literature review of Chapter 3 and can be tested by the research 
tool. Fach step of the model forms a component part of the organisational structure 
that is hypothesised to allow and influence pharmaceutical drug development and 
innovation. Innovation is visualised as the pinnacle ofthe triangle and in order for an 
innovation to succeed it must progress from the ground tip. This process is deenied to 
begin by progressing through the myriad of compliance issues, then only after the 
innovation has passed the internal processes and organisational structure of 
AstraZeneca, may an innovator consult Knowledge Management and IS systems to 
locate the knowledge required to continue. 
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Failing to find the knowledge there, may lead the innovation to fail or, alternatively, 
the innovator will consult alternative means of deriving the knowledge from sources 
such as collaboration. The published literature states that collaboration plays an 
integral role within innovation and, as such, is close to the peak of the model, 
indicating that collaboration may be a requisite of innovative activity. Although 
pharmaceutical development is quoted as a linear process within this model, in reality 
it is evident that the processes may take a more complex route and as such this model 
serves only to identify what factors and areas should be considered. It is intended to 
familiarise the reader with the scope of the research framework and is not intended to 
model how innovation is occurring within AstraZeneca. 
The model also draws reference to the notion that tangibles metrics are important at 
the inception of innovation while the intangibles aspects play a greater role the 
further an innovation is progressed through an organisation. At the base of the model, 
the tangible factors that a drug innovation is required to satisfy may be represented by 
explicit guidelines, legal regulations and business processes. Hence these are 
established and tangible measures that must be satisfied. However, as the innovation 
is progressed through the organisation the intangible aspect of intellectual capital is 
drawn into play. The nearer an idea is to fruition, then the greater the demand for 
human capital, customer capital and structural capital becomes. This aspect of the 
model is derived from the analysis of the literature and suggests that each of these 
areas of intellectual capital may be required in order to progress, although at this 
stage of the research it is difficult to draw valid conclusions. For example human 
capital relates to the knowledge and experience of the innovators, customer capital 
relates to the demand for the innovation, while structural capital refers to the 
supporting infrastructure required to realise the innovation. As of yet, no authors have 
attempted to encompass and explore the relevance of all of these areas in relation to 
pharmaceutical innovation. Although these factors are derived from an earlier case 
study and the literature review of Chapter 3, there is scant published material that 
identifies the intangible drivers and innovative criteria that supports these 
components. 
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This observation places this research in a unique position and it is envisaged that by 
fulfilling the research objectives a worthwhile contribution to the public domain of 
knowledge will be made. Therefore at this stage the framework possesses a model of 
innovation and a research tool or framework which will be expanded and developed 
within the latter chapters of this thesis. 
5.2.1 OBJECTIVITY 
When conducting interpretive research, it is wise to begin with a loose plan and 
structure (Oates, 2006), in this case the high level topics of the areas to be addressed 
by the interviews have been uncovered (e. g. Figure 5.3). However, structure can 
imply inflexibility and the author is well aware that the act of using a preconceived 
research tool creates a risk that research tool's specificity will cause a lack of 
objectivity. Thus it is important to avoid the situation where the researcher dictates 
both the question and the content of the response, whereby the interviewee elicits 
responses that they think are required rather than their true opinion (Oates, 2006). 
However, in order to address Objectives I and 2, a degree of specificity is required. 
Miles & Huberman (1994) believe that in order to conduct effective research you 
must ask how the research question can'be answered, stressing that: 
"Simply thinking of the methods of data collection will help clarify concepts and help 
set the prioritiesfor the actual data collection. " 
In this respect the innovation model has helped to establish the context that the 
research will cover, while helping to prioritise the areas that are to be addressed. 
Rather than serving as an inflexible approach, the innovation model merely seeks to 
guide the researcher and ensure that the data collected by applying the research tool is 
both relevant and reproducible. 
5.2.2 AN INTERPRETIVE ROUTE 
As this research takes an interpretive form, it was decided that the "open-ended" or 
semi-structured interview would allow the author to uncover new relationships and 
patterns within the innovation framework (Kvale, 1988). 
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This is an important point and the choice of the interview as the data collection 
method signified that this research would be covering new ground. Miles & 
flubennan (1994) believe that a single exploratory case study of this nature can 
benefit from a less formal approach. 
Yet, although this chapter seeks to explore what is occurring within innovative 
practice, it is also charged with creating a research tool that can be used to accurately 
identify the innovation criteria across multiple cases within the organisation. Hence a 
balance should be sought between the two opposing traits. A balance where the 
research tool allows the researcher to uncover the innovation criteria that are required 
to drive innovation across multiple case studies; but also allows the interpretive angle 
to sit alongside this and identify and assess the characteristics that are unusual within 
each study. Miles & Huberman (1994) describe the informal approach as little prior 
instrumentation and align this technique with "basic" research. Due to the nature of 
the case study, the author was at liberty to embrace both of the approaches (Yin 
1994), commencing informally at first and then aligning and strengthening the 
research tool over time. 
5.2.3 GOALS 
The goal of this chapter is to develop the research tool in order to study innovation 
accurately and allow the comparison of innovative practice across multiple 
organisations and partly satisfy Objectives 1,2 and 3. The very nature of 
pharmaceutical innovation is a fuzzy concept and Miles & Huberman (1994) 
emphasise that when faced with a complex organisational problem, a means to clarify 
and clute rich contextual data is through the collection and analysis of qualitative 
data. 
It was taken for granted by the author that the data collected would be contextually 
rich in nature and may be used to ground the research framework and literature, and 
may also be used on an iterative basis to further enhance and develop the research 
framework, so as to develop a research tool that AstraZeneca may employ in the 
future. 
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To ensure that the needs of the company were being met by the research, a series of 
discussions took place within AstraZeneca to highlight the areas of importance to the 
organisation at present. These were identified as: 
e The innovation strategy of AstraZeneca 
* The knowledge management strategy of AstraZeneca 
e The IT strategy of AstraZeneca 
e The present functionality of Knowledge Management/ IT systems 
e The required functionality of Knowledge Management/ rr systems 
Therefore, a secondary overall goal of the research was to provide AstraZeneca with 
a rich picture of what is occurring within their innovative processes, thus helping to 
justify the research and ensure that AstraZeneca employees are aware of where and 
how Knowledge Management practices can help. This pilot study also served to 
generate interest in Knowledge Management within AstraZeneca and helped to obtain 
the necessary resource required to tackle Knowledge Management issues. It was 
envisaged that the analysis and publication of the results surrounding these factors 
would gain the backing of AstraZeneca managerial staff, with the net result being that 
Knowledge Management is viewed not as a short term goal, but a long term strategy 
that can return tangible and financial benefits (see Roth 2003). 
The final goal of this pilot study was to build upon the author's current knowledge of 
the drug development environment and identify other innovative business processes 
that may be useful to the research. Examples of these innovative business processes 
may then be used as discussion points and analysed with subsequent interviewees in 
order to further clarify the research aims and objectives. 
5.2.4 LIMITATIONS 
As this was a pilot study targeting a small sample of interviewees, inevitably there 
were limitations. 
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Therefore this initial pilot study was used as a basis for understanding what is 
currently occurring and only after additional validation and refinement had been 
carried out in Chapters 6,7,8 &9 were the results used to model the Knowledge 
Management toolkit and fulfil Objective 4 in Chapter 11. 
5.2.5 ASSUMPTIONS 
As the components of the framework are largely derived from previously published 
studies on Knowledge Management identified within Chapter 3, it is assumed that 
these represent the key areas that cause the greatest difficulty to an organisation 
implementing Knowledge Management. Areas such as the organisational culture, 
working practices and availability of Knowledge Management and information 
systems are all noted to conspire to hinder the effective working practices of 
employees. Numerous examples of published studies supporting the basis for 
choosing these assumptions are provided within Chapter 3, Section 3.3 through to 
3.5. 
5.3 DEVELOPING THE RESEARCH TOOL 
The pilot study innovation model was used as a 'think-tank' and was intended to 
visualise these points made by the literature on pharmaceutical development. With 
the ultimate objective being to illustrate that the proposed research tool and 
innovation framework could answer the research aim. Hence practical application of 
the research tool was required to identify and address any areas of the research that 
was poorly conceived or lacking, in line with recommendations by Miles & 
Iluberman (1994). Although components of the research tool had been applied and 
discussed in a conference paper (see Appendix 1), this round of the research required 
a greater level of detail and investigation than had previously been employed, 
embracing not only the work of a single AstraZeneca department, but the knowledge- 
based work of the R&D wing of the organisation as a whole. In order to apply and 
refine the model, group discussions were planned and initiated. 
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During these the author presented and established the goals of this research and 
Knowledge Management as a whole, in order to draw comment from the delegates. 
At least 8 of these group discussion sessions were conducted with innovation experts, 
senior R&D staff, AstraZeneca IS staff and personnel involved with Knowledge 
Management research and strategy. The sessions ranged in size from 3 people to 10 
people and comprised of innovative personnel identified by the author from his time 
within the company. These sessions were conducted to ascertain the extent of 
Knowledge Management use within the company and relied upon promoting 
discussion under the headings suggested in the research model of Figure 5.3 and 
allowed the clarification of the more detailed interview questions of 5.3.1 through to 
5.3.6. The author's role within AstraZeneca focused upon the use of Knowledge 
Management and hence it was relatively simple to organise these sessions, which 
were conducted over a six month period and lasted from 2 hours to a full day. The 
author also undertook the role of a participant observer in at least II more meetings 
centred upon the development of Knowledge Management tools within AstraZeneca 
that were organised by AstraZeneca Information Systems Department and senior 
personnel from AstraZeneca Clinical and Discovery. 
After the research framework and questions had been devised a total of 15 semi- 
structured interviews were conducted with AstraZeneca staff over a period of a 
month, using the interview framework detailed in 5.3.1 to 5.3.6. These interviews 
were designed to 'set the scene' and identify where innovative practice was occurring 
and how Knowledge Management was perceived by employees. The interviews also 
served to identify employees who were involved in innovative practice, both at a 
managerial level and at a grass roots level in order to gain as wide a perspective as 
possible. All interviews were recorded into MP3 format and each interview lasted 
between 45 and 160 minutes, with the typical interview being 60 minutes in length. 
After the interview, the audio was transcribed and checked with the interviewee to 
ensure accuracy. 
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In keeping with guidelines recommended by Oates (2006), when transcribing the 
interviews the author made a point of utilising italics for emphasis and exclamations 
marks for heavily emphasised points, laughter or emotions were also recorded as 
encountered. The criteria by which innovative personnel were chosen throughout the 
pilot stage discussions and interviews, centred upon the employees involvement 
within innovative business processes or innovative drug development work. 
AstraZeneca is keen to highlight outstanding innovation by means of a public award; 
therefore employees could be easily identified by searching the in-house literature 
and archives relating to these awards. Additional personnel were chosen and 
identified via nomination by their peers for their contribution to innovative work. 
Innovations assessed included, a novel clinical trial, a novel dosing technology, a 
novel Knowledge Management system and a novel R&D project, amongst others. 
It must be noted that this stage does not intend to reach "theoretical saturation" as 
suggested by Glaser & Strauss (1967), rather it merely seeks to set the scene and 
familiarise the reader with the case study organisation and ensure the research 
framework can accurately answer the aims and objectives in Chapter 2. These 
sessions, the interviews, the Conununity of Practice conference paper (see 
Publication List) and the corresponding literature review of Chapter 3, were all used 
to create the series of questions detailed in 5.3.1 to 5.3.6 and ensure they covered the 
areas of interest within each component of the research framework. 
The questions were also designed to address the goals that AstraZcneca have 
demanded from the research, as detailed in 5.2.3. The interview structure and scope 
that forms the question set of the research tool will now be presented and discussed. 
5.3.1 INTERVIEW INTRODUCTION 
Firstly the author introduced himself to the interviewee and provided a rationale of 
the project aims, objectives and potential benefits in order to set the scene and 
address any ethical concerns the interviewees may have had. 
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A series of initial questions were designed to provide a brief overview of the 
interviewee's role and background, and provided a rationale as to why they have been 
chosen as an innovator within Astra. Zeneca. These questions were: 
I. Please give a brief description of your role and job responsibilities within 
AstraZeneca. 
2. What do you believe AstraZeneca's strengths are? 
3. Where do you see your role within AstraZeneca? 
4. How long have you occupied your role? 
As previously mentioned it was envisaged that the interviews conducted in the later 
stages of the research may focus upon investigating a single innovative business 
process. Therefore this first series of questions could be used to introduce an 
innovative work or business process that the interviewee and the author would focus 
upon throughout the interview. 
5.3.2 INNOVATION AND RISK MANAGEMENT 
After the introductory stage the research framework seeks to address Objectives I and 
2, by visualising how innovation is occurring within the interviewee's respective 
roles, the questions are derived in part from work by Tether (2003), Nieto (2004) and 
Dorabjee et al. (1998). Throughout the main interview process the author was 
interested in both the innovative nature of the work and how the knowledge and 
information was acquired to complete the task or tasks. On providing information 
regarding the knowledge processes involved within innovative work, the interviewer 
would draw a rough outline of these processes which were then validated at the end 
of the interview with the interviewee. The questions used to examine these areas 
wcre: 
5. What does innovation mean to you? 
6. Does your role encourage you to be innovative? 
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7. Can you describe an innovative process or project you have been involved in? 
8. How innovative do you believe your innovation was? 
9. Was the end result from momentary inspiration or steady development? 
10. How long did it take to realise the idea, from conception to realisation? 
11. What barriers did you encounter during the formative era of your work? 
12. Was the idea the result of a team or individual effort? 
13. What size was the team used? 
14. Were you reliant upon previous AZ innovations to achieve your innovative 
work? 
15. Do you believe that innovation within your area occurs through a methodical 
scientific approach or luck? 
16. Do you always build upon previous experience or is it more chance that the 
right people are there at the right time? 
17. In your view, does Astra. Zeneca build upon previous work or have to reinvent 
knowledge? 
18. Does your work mainly focus upon providing project solutions using existing 
processes or does it aim to provide an entirely novel solution via "out of the 
box" thinking? 
19. Do you believe that innovation requires risk taking? 
20. How do you weigh up the risks involved? 
2 1. Can you mention any positives and negatives associated with these processes? 
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22. Do you have adequate support from the organisation when undertaking 
innovative behaviour? 
23. Are there any ways that are available so you can publicise and disseminate 
your work? 
24. How easy was it to make the company aware of your work, gain backing and 
investment? 
25. Do you believe you are more innovative in the initial stages of a role or in a 
long-term position? Please elaborate upon your answer with regards to 
accrued knowledge, time in the job, fresh outlook, etc 
5.33 KNOWLEDGE MANAGEMENT WITHIN ASTRAZENECA 
KM literature implores that a knowledge culture is essential in order for innovation to 
succeed within a company (e. g. Darroch, 2005). Specifically this section of the 
interview was used to fulfil Objectives 2,3 and 4 by examining the roles Knowledge 
Management and Information Communication Technology (ICT) play in supporting 
innovation. As an example, AstraZeneca employees commonly utilise two systems 
labelled the Global Electronic Library (GEL -a large regulatory document 
repository) and Product Knowledge Transfer (PKT -a global information repository 
for drug and project related information across AstraZeneca) to locate information. 
The concept of intellectual capital is also raised by the questions and seeks to 
ascertain what this term means to the employee. Collectively these questions draw 
upon works by Alavi & Leidner (1999), Scarborough et al. (1999) and Robertson et 
al. (2000) and pay particular regard to the community and collaborative model of 
knowledge exchange suggested by Wenger et al. (2002). 
26. What does Knowledge Management mean to you? 
27. What role did Knowledge Management tools such as forums, information 
systems, PKT and GEL, etc. play in providing knowledge and support? 
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28. What are your favoured methods that you use to communicate at a cross- 
project/ functional level? Examples include: email, phone, intranet, e-room 
and discussion forum. 
29. Are there any particular technologies you've seen or used before, maybe 
within AstraZeneca or externally, which you believe could be useful? 
Examples include: databases, discussion forums, blogs or Web Logs and 
MSN Messenger. 
30. Do you have access to a specific budget for IS projects and support? 
31. Are your project information and knowledge needs analysed by AstraZeneca 
IS employees as the project is undertaken? 
32. Have you had any IS/ KM projects developed for you? 
33. Were you involved within the design and specification of it? 
34. Can you elaborate as to the need and success of these schemas? 
35. If not, are you aware of how to apply for funding and the potential use? 
36. Does the global IS strategy align with your needs? 
37. Have you and your department/ team/ organisation received help and training 
when using new software? 
38. Do you take part in IS surveys? 
39. As a key innovator, have you been contacted to analyse your needs? If so, has 
the information you have given been used to provide a solution? 
40. Was there a budget assigned to support your case? 
41. Are you aware of metrics or measurements used to assess the impact of 
Knowledge Management within AstraZeneca? 
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42. What do you understand by the term 'Intellectual Capital'? 
5.3.4 KNOWLEDGE AND INFORMATION SOURCES 
The following questions were intended to analyse the resource and knowledge bases 
that are available to AstraZeneca employees and discover whether they meet the 
needs of the innovators. Although the framework has touched upon these sources 
previously, this section was used to discover whether the chosen research strategy can 
accurately answer Objectives 3,4 and 5. 
The questions are derived, in part, from a Knowledge Management survey tool 
suggested by Coombs et al. (1998) and work by Tijssen (2004). 
43. What sources of information do you utilise? Please discuss the sources you 
concentrated on to develop your innovation, these may include: online j oumal 
sources, peer reviewed work, internal data and external data, AZ information 
and knowledge sources. 
44. Within your work, do you believe that AZ offers sufficient specialist 
knowledge to achieve the task assigned to you? 
45. Does everyone who needs it have access to "the right" information sources in 
order to imovate? 
46. Do you value particular sources over other areas? 
47. Do you find it easy to disseminate information and knowledge? 
48. Do you regularly use external, technology-based knowledge sources? 
49. Can you comment as to why you use them, what makes them useful? Is it the 
content? The layout? Familiarity? 
50. Do you utilise similar or the same infon-nation systems as your previous 
role(s)? 
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51. Do you utilise the information searching capability of the librarian service? 
Can you discuss your use? Do you value the service? 
5.3.5 KNOWLEDGE CULTURE, COLLABORATION AND KNOWLEDGE 
NETWORKS 
This set of questions was designed to explore the collaborative culture that appears to 
drive the innovation processes within AstraZeneca and addresses Objectives 1,2,3 
and 4. Zeller's (2002) work indicates that a trusting working relationship is important 
within an R&D organisation and the following questions were used to ascertain the 
importance of trust and collaboration within the pharmaceutical R&D framework. 
The following questions are intended to address these issues and discuss the 
importance of knowledge that is derived from external collaborations, in line with 
work by Kneller (2003): 
52. What part does collaboration play within the daily processes of your work? 
This may be related to cross-project teams or cross therapeutic area or 
research area collaborations. 
53. Are there specific tools, which you can use to facilitate this work? These may 
be net-meetings, email, discussion forums, eRooms, etc. 
54. Do you believe that AstraZeneca provides the systems to encourage 
innovation and collaborative behaviour? 
55. Are there specific processes to encourage collaboration within your work? 
56. Do you utilise cross-functional teams to enhance innovation? These may be 
from different project areas within AstraZeneca, i. e. therapeutic areas or 
research areas. 
57. Do you collaborate internationally with R&D colleagues from Sweden, the 
UK, the US or Japan? 
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58. Does spatial proximity to your colleagues influence your sources of 
knowledge? 
59. Is there a review panel, which oversees these collaborations? Le. review 
boards or steering committee. If so, please discuss the level of information 
capture; was it thorough or a high level overview? What is the scope of the 
data captured? (Key players and the key decisions, etc. ) 
60. What is the accuracy, usefulness, applicability and value of data gained from 
such collaborations? Can you (or do yd'u) use the data? 
61. Do you or your project team use external collaborations with outside firms, 
such as biotechnology companies to pursue innovative ideas? 
62. Can you describe examples of these where such work has led to innovative 
behaviour? 
63. What value does your work derive from such collaboration to drive 
innovation? Please discuss your opinions on the value and benefit of deriving 
innovative ideas from external sources; these may be collaborations, journals, 
seminars and conferences, etc. 
64. Can you recount favourable collaborative projects and were there any 
common processes throughout them? 
65. Were you reliant upon any particular method of communication, examples 
include: meetings, phone, teleconferences, net meetings, etc. 
66. Do you have a review panel for external collaborations? If so, please discuss 
the level of information capture, was it thorough or a high level overview? 
67. What is the scope of the information captured? (Key players and the key 
decisions, etc. ) 
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68. What are the accuracy, usefulness, applicability and value of data gained from 
such collaborations? Can you (or do you) use the infonnation? 
69. Social identity is often perceived as a key facet of a working and innovative 
environment, can you comment on your working environment? 
70. How much prior knowledge and background credibility do you require to 
conduct a formative working relationship? 
71. Do you strive to make yourself heard? 
72. Do you believe that a project success is dependent upon who implements it? 
73. Do you map the skills and knowledge of the people and departments within 
your innovative activities? Is this information used in subsequent projects? 
Examples include: skills used, FTEs, resources, products, costs and the 
knowledge base used. 
74. Is this information published to external departments? Do other AstraZeneca 
departments know about these maps? 
75. Have you undertaken work in other departments or other roles while working 
for AstraZeneca? 
76. Are you encouraged to take positions in different areas or adopt multi- 
disciplinary roles? Did you find this a valuable experience 
77. Within these roles, did you note any working practices that favoured 
innovation? 
78. Did they use tools or systems which would be of use to you? Please elaborate 
upon these. 
79. Can you envisage a Knowledge Management tool to span these areas, or link 
personnel from these different disciplines? 
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53.6 PROCESS MANAGEMENT 
It may be assumed that the drug development processes within AstraZeneca R&D are 
designed to drive innovation and further research, yet no empirical evidence exists 
that supports this assumption. The following questions were designed to fulfil 
Objectives 1 through to 4 and ascertain the knowledge sharing behaviour of the 
process teams at the forefront of the drug development processes. Concentrating upon 
the key points raised by McKinlay (2002) and Hayes & Walsham (2000): 
80. Do you believe AstraZeneca's drug development processes support 
innovation? 
8 1. Are your department's/ team/ organisation's objectives clearly defined? 
82. Do you map innovative processes and compare them against other similar 
areas? Do your employees get involved in this process? 
83. Do you believe that the information and knowledge gathered at project 
milestones and reviews is useful and is it available? 
84. Have you used such information/ knowledge before? 
85. Can you envisage using previous project data when starting a newer project? 
86. Do you measure the intangible aspects of project work? 
87. Do you believe that Astra. Zeneca offers a structured review of innovative drug 
projects after completion, including areas such as: process modelling, 
information and knowledge flow, intangible metrics, personnel review and 
appraisal, successes and failures, new skills leamt, task competence on an 
individual/team level, problems and redundant processes? 
88. Do you model processes or review innovative cross-project work? 
89. How simple is the process of accessing relevant information/ knowledge on 
cross-project work? Are there formal guidelines to achieve this? 
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90. Do you believe the knowledge gained from these processes is valuable? Can 
you give examples to support your views? 
91. Do you believe that a formal process for capturing best-practice decisions 
exists? Have you ever used best practice software to monitor process or 
innovation quality? Have you reflected on work that could have been done 
better? 
92. flow do you record the risks involved in innovative work? 
5.3.7 R&D LEGAL AND REGULATORY INFLUENCE 
The pharmaceutical R&D drug development process is a highly regulated and 
ordered affair. Intemal and extemal guidelines and regulations exert a strong 
influence upon the various processes. The following questions will analyse the extent 
to which these pressures contribute to, aid or hinder innovation within the 
development processes. They are based, in part, upon intemal AstraZeneca 
documents and work by Koretz & Lee (1998) and Dougherty (2006). 
93. To what extent do regulation and guidelines impact on your work? Please 
discuss those that directly impact innovation and are relevant to your area. 
Examples include the FDA (Food and Drug Administration - American 
government regulatory agency http: //www, fda. gov , AZ internal guides and 
external regulations. 
94. flow important are internal AZ procedures to your work? 
95. Do you conduct your work within the guidelines or try to justify a change in 
approach? 
96. Are the guidelines and regulations easily accessible during your work? Do 
you consult any particular reference sources? Are these sources accurate and 
clear? Do they include case study information? 
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97. Do the AstraZeneca Knowledge Management and Information tools you use 
take account of these regulations? 
98. To what extent are they taken into account? 
99. Are you aware of any regulatory guideline governing the use of the systems - 
do people tend to store knowledge and use the tools in the same way? 
100. Are you aware of specialist help, services or guidance in tenns of 
Intellectual Property searches, patent rights, internal/ external collaborations, 
etc. Can you perform these searches without specialist help? Please describe 
the available tools to search Intellectual Property and the failings of these 
tools. 
5.3.8 INTERVIEW CLOSE 
The interview research tool was designed to address the research aim and objectives 
and, above all, provoke thought and discussion with the innovators targeted. As the 
interview questions are semi-structured, each topic is intended to allow the 
interviewee to discuss multiple issues and areas that are successful within 
AstraZeneca. Time constraints meant that each interview was expected to last up to 2 
hours, it was also clear that the interviewee could not be expected to answer all of the 
questions. Throughout the interview the author used the questions as prompts and, in 
this way, covered all the aspects of the innovation model (Figure 5.3). 
As the question set deliberately employed overlap within the questions, it was 
expected that the interviewee would 'wander' across multiple topics and such 
behaviour was encouraged at this preliminary stage, in line with recommendations by 
Miles & Huberman (1994). The interviewee was also encouraged to highlight areas 
that they believe affect the innovation processes and raise ideas for process 
improvements. The interviewees were also expected to voice questions that they 
believed are important for the research to address. Questions outside of the initial 
research framework were noted and discussed with the interviewee as they arose. 
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5.4 PRELIMINARY RESULTS OF THE RESEARCH FRAMEWORK 
Cross sections of innovative AstraZeneca employees were initially chosen with which 
to conduct the preliminary interviews. In order to provide a representative sample, 15 
personnel were chosen in total. These consisted of senior managers from AstraZeneca 
Clinical and Discovery, research employees within AstraZeneca Clinical, and 
employees from AstraZeneca IS. On completion of the interviews, the transcripts 
were studied to ascertain if the research tool was viable and if further refinement of 
the question set in line with the interview findings was required. The results of the 
preliminary interviews are presented in the next section in line with the innovation 
model outlined in Figure 5.3. 
5.4.1 RESULTS: INTERVIEW INTRODUCTION 
The introduction of the research aims and objectives were well received by all 
interviewees. All interviewees unanimously agreed that Knowledge Management 
should be a key component of AstraZeneca's innovation strategy. As an initial sign, 
this is encouraging to discover that, firstly, employees are aware of Knowledge 
Management, and secondly, they appear to be keen to embrace Knowledge 
Management within the organisation. 
5.4.2 RESULTS: INNOVATION AND RISK MANAGEMENT 
The literature review of Chapter 3 discovered that the definition of innovation is 
rarely typical; instead the definition of innovation is open to interpretation. 
From these initial findings AstraZeneca appears to be viewed by its employees as an 
innovative organisation. However, when interviewees were pressed as to what they 
believed constituted innovation the majority viewed innovation as a process. This is 
evidently an encouraging finding as the research aim of linking Knowledge 
Management with innovative processes would appear to be feasible. This is further 
reinforced by the notion that an innovative culture appears to exist. A senior figure 
cormnented: 
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"Personnel want to share bestpractices and learnfrom others within the company. " 
Yet, although the outward perspective appears to indicate an innovative environment, 
many interviewees agreed that while in principle AstraZeneca was innovative, 
implementing innovation in practice was difficult. An interviewee commented: 
"Innovation to me is how we can think outside of the restrictive processes associated 
with drug projects and use other ways to add value. " 
Another interviewee viewed innovation as a 'hidden' entity that required considerable 
groundwork to allow an innovator to 'fit' their innovation within AstraZeneca's 
existing operating procedures. 
This raises the observation that it is the visibility of AstraZeneca's innovators, their 
innovations and the potential application of their innovation that is most important to 
study. This is coupled with evidence that AstraZeneca's own internal processes are 
restricting innovation. These findings provide this research with a sound rationale 
with which to proceed and address how these issues may be overcome with a 
Knowledge Management toolset. A factor that requires further investigation suggests 
that innovation stems from an individual response and that employees are having to 
operate outside of the guidelines and timelines imposed by AstraZeneca projects. 
This observation was supported by the finding that the innovators interviewed 
possessed a degree of autonomy, a senior clinician commented: 
"I'm lucky that I don't work on a lot of drug projects, I only work on a few which 
means I can make them good. " 
These initial comments indicate that although ideas are stemming from the individual, 
in order to get an idea up and running, innovators require further guidance and 
strategic advice when attempting to take a creative idea from conception to 
implementation. Some of the more senior interviewees had the flexibility, influence 
and resource that allowed them to evaluate, discuss and implement innovative 
solutions on their own when conducting drug project work. 
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Another less senior interviewee suggested that the effort taken to convince senior 
management to make a financial investment was often far too resource intensive. One 
interviewee had, however, stuck with their convictions and an innovative clinical 
study had been introduced as a result. The disparity, observed at this early stage of 
data gathering, indicated that an employee's seniority directly influences their 
innovative behaviour; however, this point required further clarification and analysis 
in order to assess its importance. Overall though, the initial data points to the lack of 
guidance when innovators are attempting to introduce innovative solutions or work 
around the established processes of AstraZeneca. However, the process that caused 
most concern to innovators was the process of evaluating the risks involved in 
undertaking innovative work. When asked how they assessed the risks an interviewee 
comniented: 
"When you see an opportunity you must be able to assess the potential of it, a high 
potential innovation would be taken and a low potential innovation would be 
avoided, it comes down to a ratio. " 
However, there does not appear to be software tools or a documented procedure in 
place to achieve this, let alone capture or publicise this decision making process. 
Instead, interviewees felt that it was largely their own responsibility to weigh up the 
potential benefits and risks. Discussing issues of risk brought the interviewees to 
begin exploring the provision of knowledge and information sources within 
AstraZeneca, a topic that is addressed in the second component of the framework. 
5.4.3 RESULTS: KNOWLEDGE MANAGEMENT WITHIN ASTRAZENECA 
The interviewees were asked to comment upon the potential of Knowledge 
Management to aid innovation within AstraZeneca and all interviewees agreed that 
Knowledge Management can play an important role, However, although the concept 
of Knowledge Management was recognised by all interviewees, the practical means 
associated with what Knowledge Management entails were unclear. An intcrviewee 
conimented that: 
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"I would like to see AstraZeneca making people more aware of what knowledge and 
information is available to me. " 
Similar views were upheld by other interviewees, who often questioned the visibility 
of AstraZeneca's Knowledge Management/ IT strategy. This suggests that this 
research will provide important insights into how AstraZeneca can address innovators 
knowledge and information need more accurately. One senior interviewee summed 
up the feelings of many: 
"Science based research generates a lot of knowledge and information that sits in 
many differentforms, and what doesn't happen is the integration - there is no ability 
to cross these sources ofknowledge and information. " 
Evidently employees feel under-served by the AstraZeneca Knowledge Management 
policy. However, given the potential scope and role of Knowledge Management 
within a pharmaceutical environment, this is hardly a surprising finding and ftirther 
research is required to generate constructive solutions to these issues. 
5.4.4 RESULTS: KNOWLEDGE AND INFORMATION SOURCES 
The interviewees widely agreed that knowledge and information may be obtained 
from a disparate range of sources, yet interviewees hinted that the preferred means of 
information and knowledge acquisition centres upon personal contact. A senior 
interviewee noted: 
"Within the biomedical literature there is a huge amount ofslicing and dicing - so to 
get to the bottom line talking to someone is often much quicker. " 
Yet one interviewee did favour online databases such as Ovid and PubMed as the 
primary means of acquiring data and information when conducting innovative work. 
Hence, there is a variety of knowledge and information sources open to 
AstraZeneca's employees, yet the use of colleagues and online databases were 
consistently mentioned and the use of specific Knowledge Management and IS tools 
provided by AstraZeneca were largely omitted. 
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A senior interviewee commented on the large amount of disparate information and 
knowledge sources that is available within the AstraZeneca intranet: 
"What we don't do is bring this together. Sometimes we are not aware of the 
information for months or years even and then suddenly it strikes you that there is a 
correlation, and some value is made, and the connections are made, and maybe new 
knowledge comesfrom this. So what I think is that we have a realproblem! " 
What is clear is that R&D personnel are required to keep abreast of large amounts of 
data, information and knowledge and draw valid conclusions from these sources. One 
interviewee commented: 
"This certainly isn't an easy task, if we startfrom some Discovery effort, there are 
many project based problems which we try and address and generate scientific 
knowledge on as we go along; and there are many independent, additional things 
happening in the world, literature, competitors and within other parts of 
AstraZeneca ... which we must address and 
keep up to date with. " 
This was a common theme throughout the interviews and an intervicwee suggested 
that it was not only the breadth and complexity of internal and external knowledge 
sources on offer that troubled them; it was also the process of weighing up the 
relevance of sources once acquired and understood. 
To overcome this, intcrviewees often relied upon external consultants to provide them 
with detailed knowledge regarding a drug's toxicology or pharmacokinctics. 
Interestingly the interne was also listed as a primary source of information: 
"Yeah, I would say I use external experts on a consultancy basis ... occasionally ifFm 
struggling Id do a general search on the internet to get a basic understanding. " 
This finding was replicated across the sample population and hints that AstraZeneca's 
own internal intranet and information sources lack the necessary depth of infori-nation 
and knowlcdge for innovators to procecd. 
153 
Chapter 5- Scoping a KM & Innovation Framework 
At times staff are being forced to look to the internet, yet by the admission of the 
interviewees, the reliability of information and knowledge on the intemet is 
questionable hence the information gleamed is treated with greater suspicion. 
5.4.5 RESULTS: KNOWLEDGE CULTURE, COLLABORATION AND 
KNOWLEDGE NETWORKS 
The research framework then moved on to facilitate discussion on the issues of 
collaborative working and innovation from the perspective of the employees. A 
senior interviewee summed up the feeling of the sample, when they explained the 
notion that innovation was concerned with the process of acquiring knowledge from 
colleagues or personal networks of external contacts: 
"Two of the main knowledge assets are internalpeople and externalpeople. " 
This component of the research framework and associated questions appeared to be 
well placed to address the issues identified by the staff so far. 
Having uncovered a level of dissatisfaction with the current Knowledge Management 
and information strategy previously employed by AstraZeneca, it was expected that, 
as the research scope and sample was broadened, trends and high priority items 
would appear as the data was subsequently analysed and codified in line with 
recornmendations by Miles & Huberman (1994). 
The reliance upon collaborative working patterns and Communities of Practice is an 
area that Knowledge Management is well positioned to address and lends further 
confidence to the main research aim and objectives. The following section briefly 
addresses the findings relating to the identification of the drug development processes 
that are driving, and in some cases hindering, innovative work within AstraZeneca. 
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5.4.6 RESULTS: PROCESS MANAGEMENT 
AstraZeneca appears to be typical of large organisations striving to balance the 
demands of efficient and manageable processes with the elusive knowledge 
requirements of innovative work (e. g. Dilnutt 2002). An interviewee who had 
recently joined the company highlighted the potential of AstraZeneca to innovate: 
"So I knew AstraZeneca quite wellfrom an external view, but I was a bit surprised to 
see they had a good early [drug developmentj pipeline but a poor ability to do 
anything with it " 
Although few interviewees were not overly pressed with regard to identifying 
specific processes, one interviewee mentioned that introducing a new clinical study 
design was a lengthy process that required a resource intensive development period of 
18 months: 
"You know, because it was a learning process as well, it was a new process and we 
had to write this into study protocols. Consent forms and our ideas about what we 
needed to look at were evolving as we went along, and this was a result of literature 
searches as we went along. " 
The notion of the intensive requirement for resource appears as a central trend to 
innovative work, interviewees were also unanimous in the belief that AstraZeneca's 
processes were inhibiting innovative practice: 
"I actually think our processes are very inhihilive in some respect Because we have 
a complex organisational model, the matrix is complex, levels of accountahility are 
odd and strange and decision resides at multiple levels instead at one clear level ... I 
think having a model like that will always make things harder and slower. " 
Data such as this suggests that problems do exist within the core innovative ability of 
the company. From this initial research with senior management and R&D scientists 
involved in both managing and implementing innovation, the majority appear to 
suffcr hindrance or barriers to innovation of some form. 
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Although this observation reflects poorly on the existing business processes it also 
offers this research great scope, with the potential to highlight areas of concern and 
instigate process improvement activities. 
5.4.7 RESULTS: R&D LEGAL AND RE, GULATORY INFLUENCE 
The area of legal requirements and regulations were addressed by questions 31-34. Of 
the employees contacted all agreed that regulation was crucial to their job. An 
interviewee noted: 
"Regulations dictate what we can and can't do " 
Ile added that the only way of getting work done is to operate and apply knowledge 
within the framework: 
"The driver within this framework is the knowledge that allows us to get things 
done. " 
Most interviewees felt that regulations played such a large part in their work that it 
was 'part and parcel' of the role. Although the established processes allow 
AstraZeneca to develop and ultimately submit successful drugs, it appears to be the 
innovative work that is falling foul. An employee noted: 
"It is hugely difficult for people who have ideas to imProve existing drugs to enter 
into this system ofprocesses and regulations. " 
On this basis it appears that regulation will indeed hinder innovation, but it is still 
unclear whether the guidelines of AstraZeneca are contributing to these phenomena. 
An R&D Discovery scientist voiced the opinion that adaptation was the key: 
"What we're doing now in the early stages of lead optimisation is working within the 
guidelines for future regulatory submission, in the past we only worked with lab 
notebooks and now we're entering that data into a system that is already in theform 
ofa regulatory submission. " 
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However, promoting the change from lab notebooks to electronic data systems has 
been a slow process. In the long term, adopting this change should allow the faster 
submission of a compound in the later stages of development. Yet, as the literature 
review revealed, few drugs will ever progress to regulatory submission and 
demanding that personnel use their stretched resources to prepare data that may never 
be used is a sensitive area in itself. Employees were often exasperated at the 
proliferation of what they perceived as misguided internal regulation. An example of 
this concerned the use of the AstraZeneca GEL system to retrieve project 
information. In short, GEL is a regulatory document store for data and information 
that supports drugs that have been submitted for approval. However, employees also 
view it as a valuable store for project and drug information. A senior Clinical 
manager was asked to provide advice to a colleague concerning one of their drug 
projects: 
"So I said why don't you just get the document from GEL? He replied 7 don't have 
access to GEL, well ok fell me the study numbers and Ifound that I don't even have 
access to them and I wrote the bloody things! " 
While this may be an atypical scenario, further research is required to establish 
whether this is a common finding. This finding raises two important questions. 
Firstly, to what extent are the established AstraZeneca processes hampering 
innovation? Secondly, if employees are relying upon information systems such as 
GEL to conduct innovative drug projects, can Knowledge Management provide a 
better solution? 
5.4.8 RESULTS: INTERVIEW CLOSE 
Employees were thanked for their time and comments and invited to contact the 
author to discuss the issues raised and any further observations. During the interviews 
the author asked the interviewees to identify further experts and employees who 
would be beneficial to contact and interview. At least 35 more potential candidates 
were identified across AstraZeneca Discovery and Clinical. 
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These additional employees were then contacted through email and face-to-face 
meetings, to invite them to the main study carried out within Chapters 6,7,8 & 9. A 
total of 32 employees out of those contacted, agreed to take part in the research. 
Overall it is fair to say that this pilot study allowed the main research to be conducted 
by unveiling areas of innovative activity within AstraZeneca that were unknown to 
the author prior to this pilot study. 
5.5 PILOT STUDY DISCUSSION 
The objective of this pilot study was to address whether the research framework can 
address the research aim and whether the data collected by the author appears to 
supports this notion. The framework will support Objectives 1,2,3 and 4 and allow 
the identification of the drivers and criteria for innovation and analyse how 
Knowledge Management may be utilised. It is believed that the interview question set 
may be used as a research tool to assess innovation across a variety of industries. 
Furthermore, data collected from future studies within other innovative organisations, 
may also be compared to the findings derived from AstraZeneca. 
However, during the interview process the area of intellectual capital was lightly 
covered. When asked to discuss their knowledge of the topic, no employee ventured 
an opinion. This area requires further study in order to clarify the intangible drivers, 
with one interviewee commenting it would be useful for this area to be addressed by 
this research. However, although no intangible assets and drivers were implicitly 
mentioned in this preliminary research, it is an area that should be addressed in order 
to satisfy Objective 3. 
5.5.1 PRELIMINARY INNOVATION CRITERIA 
Innovative practice within AstraZeneca appears to be a complex process, one where 
employees have the individual incentive but require the organisational resource to 
progress their ideas. Without the backing of senior management, innovative ideas 
may fall foul at a number of milestones with resource appearing as a critical factor 
within each component of the framework. 
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However, the area of the perceived risks and benefits of an innovative approach and 
its ability to comply with legislation also weigh heavily. There are areas of 
AstraZeneca's innovation policy that are successful and others that are less so and 
determining what factors are crucial in driving these processes is a prerequisite before 
undertaking any further action. 
The innovations studied at this stage included two innovative clinical trial protocols 
and a novel process to overcome a process development problem within the early 
stages of Discovery R&D. Table 5.0 lists the commonalities found across these 
processes, yet many themes were unique to the individual processes. Further research 
and a greater reach of data collection were required to clarify these trends but the 
research model and research tool appeared well founded to achieve this task. Table 
5.0 details the areas within the research framework that were deemed to be the 
preliminary Critical Innovative Factors at this early stage of the research. 
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Table 5.1: The Research Model and Critical Innovative Factors 
Area of Model Critical Innovative Factors 
Innovation & Risk Management Knowledge 
Information 
Data 
Resource 
Collaboration 
Experts 
Perseverance 
Perceived Risks/ Benefits 
Autonomy 
Knowledge Management Access to Knowledge, Information and Data 
Collation of Knowledge 
Capture of Knowledge 
Resource 
Knowledge and Information Sources Literature 
Colleagues 
Internal/ External Consultants 
Experts 
Internet 
AstraZeneca Intranet 
Resource 
Knowledge Culture, Collaboration and Communities of Practice 
Networks Internal and External Experts 
Resource 
Process Management Flexibility 
Resource 
Guidance 
Support 
Resources 
R&D Legal and Regulatory Influence Clear Guidelines 
Explicit Boundaries 
Guidance 
Receptive to Change 
Security and Access Rights 
Resources 
The Critical Innovative factors listed in Table 5.0 may also be used as a managerial 
checklist, serving as a high level guide to the identification of the pertinent areas 
within drug development. Although the author acknowledges that at present, these 
factors are limited by the amount of data collected. 
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Nonetheless they serve as important pointers or themes that may be used as the basis 
for the codification of the subsequent data collected within this research (Miles & 
fluberman 1994). As these factors underpin innovative behaviour within the 
innovation model of Figure 5.3, they were also used as a basis to develop the 
innovation framework which is subsequently revealed in Chapter 10. It was also 
noted by the author that these criteria form the basis of a research tool that may be 
used to assess how innovative a business process or project is, a fact which was 
discussed in greater detail within Chapters 10,11 & 12. 
5.6 CONCLUSION 
This chapter has partially fulfilled the first, second and third objectives and has 
primarily served to 'set the scene' by familiarising the reader with the environment 
that is being studied and the chosen research path. This chapter has also served to 
validate the research technique and methodology employed, providing a context to 
the research and exploring the real life constraints within pharmaceutical innovation. 
This section of the research has also met the secondary objective of promoting 
discussion and raising interest in Knowledge Management within AstraZeneca. The 
initial results are encouraging and a number of preliminary innovation factors raised 
within Table 5.0 present a checklist of areas that should be addressed when assessing 
innovative activity. The semi-structured questionnaire can now be considered to be a 
research tool with which to assess the ability of employees to innovate within an 
environment. The questions will also serve to highlight areas of the company's 
innovative strategy that are performing well or failing, in addition to revealing the 
nature of how employees are deriving their innovative knowledge. 
In conclusion, this chapter has laid the foundations on which to link the concepts 
inherent within innovative strategy and touches on the knowledge sources required to 
create a long term. Knowledge Management strategy for AstraZcneca. In order to 
address these areas further, the author began to collect data in earnest, focusing upon 
analysing the areas within the research model to ultimatelY fulfil Objectives 1,2 and 
3. 
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Chapters 6,7,8 &9 concentrate upon the results of a further 32 interviews conducted 
across the organisation with the key innovators identified within this pilot study. 
These interviews built upon this pilot study and question the nature of innovative 
behaviour, thus allowing the author to answer Objective 4 and a design a Knowledge 
Management tool set to drive innovation across AstraZeneca. 
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CHAPTER 6 
THE INNOVATION AND KNOWLEDGE CRITERIA 
The following results chapter utilises the observations of Chapter 5 as a starting point 
and seeks to expand upon this limited study by examining the interplay between 
innovation, Knowledge Management, risk, process management and regulation. 
6.0 INTRODUCTION 
This chapter examines innovation within drug development and plays an important 
role in analysing the differences between the innovative structures within 
AstraZeneca and those published in the literature. The chapter builds upon the 
framework published in Chapter 5 (see Figure 5.2) by seeking to conclusively define 
the innovation and knowledge criteria by drawing upon multiple case studies 
conducted across AstraZeneca. The aim of this chapter and the proceeding Chapters 
7,8 and 9 are to satisfy Objectives 1,2 and 3 and partly fulfil Objectives 4 and 5 by 
validating and elaborating upon the preliminary innovation criteria outlined in 
Chapter 5. In order to present the research coherently, the results are spread over four 
chapters in the following fashion: 
* Chapter 6 displays the generic innovation drivers that arc not specific to 
AstraZeneca 
* Chapter 7 covers the innovation drivers from an AstraZeneca. specific perspective 
and concentrates upon the culture of the organisation 
9 Chapter 8 examines Knowledge Management within AstraZencca 
* Chapter 9 details a case study conducted within AstraZeneca with regard to 
innovation and Knowledge Management 
The following section will briefly discuss the data collection and analysis method 
employed throughout the remainder of the results chapters. 
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6.1 DATA COLLECTION AND ANALYSIS 
6.1.1 COLLECTING QUALITATIVE DATA 
A critical part of fulfilling the objectives of Chapter 2 is to identify the innovative 
criteria that are essential for innovative drug development work to occur. The initial 
case study described in Chapter 5 has outlined that the research framework is a 
valuable research tool with which to study innovation; while Chapter 3 outlined that 
the available literature rarely tackles this area in the depth required by this study. In 
order to address this, the following chapters utilise the case study approach described 
in Chapter 5 over a greater number of innovative processes and with a greater number 
of employees. In all, 32 additional semi-structured interviews were conducted with 
renowned innovative employees across AstraZeneca R&D in line with the research 
tool framework detailed in Section 5.3. Each interview lasted between I hour and 21/2 
hours with the conversation and observation transcribed in full by the researcher after 
the interview. Although the initial case study of Chapter 5 served to define the 
boundaries and 'set the scene', the nature of innovation still requires a degree of 
flexibility and the case study approach was again chosen as the principle 
methodology to achieve this, in line with recommendations by Rowley (2002). In the 
interests of the ethical guidelines stipulated by Loughborough University, all 
employees and departments chosen will remain anonymous. So as to ensure the 
results and comments associated with this research cannot be identified with a single 
individual. 
The sample population of 32 innovators was derived from a large workforce of over 
10,000 personnel and was chosen to provide a broad representation of innovative 
practice within the organisation. The chosen interviewees consisted of senior 
managers, physicians and research scientists within the company and, as such, 
represented a broad cross section of the organisational culture. A primary criteria for 
inclusion within the study focused upon an annual recognition award for innovative 
behaviour, where the nominated candidates had performed work relating to the 
development process outside their remit to result in an outstanding contribution. 
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The study also included key innovators who were identified in the initial interviews 
of Chapter 5. Many of the chosen interviewees are people who are renowned for 
providing maverick answers to difficult problems. The interviews sought to elaborate 
and reveal the knowledge sharing behaviour of the staff, discussing their role within 
the development process, their use and sourcing of knowledge and information, and 
their use of KM based technology within such activities. Above all, the aim was to 
uncover the real life context of the actors within the social tapestry of the case 
research areas (Yin, 1994). 
Throughout the case studies, supplementary supporting data was derived from direct 
and participant observation as described in Section 4.5.4. Where possible, the author 
attended meetings and focus groups specifically concerning innovative development 
projects and acted primarily as an observer, but on occasions this role turned to one of 
a participant observer when the topic being discussed turned to a Knowledge 
Management nature. Attending these meetings has provided a valuable contribution 
to this research and provided a rich data source of detailed case notes. These 
principally relate to how the employees utilise and derived information and 
knowledge within their normal working environment. 
Due to the researcher's emersion within AstraZeneca, it was possible to access to a 
wide range of internal data and information sources with which to supplement the 
interview data and these are acknowledged when used. A process of analytical 
induction was employed in line with recommendations by Miles & Huberman (1994), 
to identify and discuss the key themes that ran within the research framework. The 
interpretive case study requires a constant process of refinement, in that the themes 
identified were constructed in line with the research framework in a process described 
by Klein & Myers (1999) as dialogical reasoning. This approach is based upon the 
work of Gallivan (2001), who successfully identifies a number of key themes from a 
similar qualitative research project, which centred upon innovative practice and, as 
such, provides a worthy example of how to conduct such research. 
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The researcher chose to group thernes in accordance with either an innovation- or a 
knowledge-centred slant. As this research concerned the use of Knowledge 
Management to enhance innovation it was a natural choice to utilise this methodology 
to explore the research data. This was grounded by the literature review of Chapter 3 
which shows that models of innovation often include innovation as a consequence of 
applying knowledge (e. g. Alavi & Leidner 2001); while flicks et al. (200.6) perceive 
innovation as the pinnacle of what can be achieved once knowledge has been applied. 
Chapter 5 identified that knowledge is required in order to innovate and as this 
research aims to develop a Knowledge Management toolkit to promote innovation, 
the researcher deemed it wise to suggest both an innovation and a knowledge 
grounded theme. These themes are based upon applying each of the following 
dcfinitions to the points raised. 
The definition of innovation chosen is: 
"A process of creating and developing new products or services through 
collaborative team processes and mechanisms that utilise and empower the skills and 
knowledge ofthe people" (Terziovski & Morgan, 2004) 
The definition of Knowledge Management chosen is: 
"A discipline that seeks to improve the peýjbrmance of individuals and organizations 
by maintaining and leveraging the present and future value* of knowledge assets" 
(Newman & Conrad, 1999) 
Each definition has been used to ground the themes generated during this analysis. 
Innovative themes will concentrate upon defining the drivers and criteria that utilise 
the knowledge and skills of the employees; while the Knowledge Management 
centred themes concern the utilisation of the knowledge within these innovative 
processes and highlight areas of success and concern for Knowledge Management 
discussion within the discussion chapters. Above all the rationale behind the 
following chapters is to: 
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Answer Objective 2: Identify the drivers, the criteria for innovation, the 
outputs of the innovation and the themes associated with innovation 
specifically within AstraZeneca. 
Answer Objective 3: Examine and evaluate the Knowledge Management 
strategy and existing tools in use across AstraZeneca R&D. 
Utilising this approach has provided sufficient data and discussion points to answer 
the research objectives within the discussion of Chapters 10,11 and 12. 
6.1.2 PRESENTING QUALITATIVE DATA 
Upon analysing the data obtained throughout the research project, it became clear that 
attempting to categorise findings into the distinct subsections of the research 
interview framework would result in a biased picture of what is truly happening. 
From the previous definitions of Knowledge Management it is evident that what may 
be construed as a Knowledge Management problem, may also be construed as an 
innovation problem. At this point of the research the researcher was faced with the 
decision to either mimic the results of Chapter 5 and elaborate upon these findings; or 
analyse the interplay and correlations between these areas. Rather than simply state a 
linear series of findings in strict categories, a conscious decision was taken to adopt 
the latter approach and weave the findings into a narrative concerning: 
* The innovations studied 
9 The use of Knowledge Management 
* The risks taken and the regulations that affect the process based stages of drug 
development studied. 
By adopting both innovation and Knowledge Management centred "themes" 
throughout the presentation of the research data, Objectives 2&3 were satisfied 
throughout these chapters and this negates the need to devote a chapter to each 
respective theme. 
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This approach is in line with recommendations by Maxwýell & Miller (1992) who 
state that qualitative data may be loosely categorised around a number of conceptual 
elements, in this case the innovation and Knowledge Management themes. 
This means that, examples of a particular event serve to ground the data within 
conceptual elements, while the qualitative data and accompanying narrative reinforce 
the resulting themes. In this case, the high level categories developed within Chapter 
5 serve merely as guides to ensure that the data can be selected, condensed, 
transformed and displayed coherently within the following chapters (Miles & 
Huberman, 1994). In addition to utilising themes, the research findings are presented 
in a conceptually clustered matrix which allows a number of important concepts to be 
clustered. In this case, matrices concentrate upon the type and location of the 
innovative aspect being assessed, the drivers behind the innovation, the criteria 
required to fulfil the innovation and the outputs of the innovative process. Clustering 
the individual concepts avoids the lengthy process of reanalysing the data over and 
over again to satisfy each individual research objective present within Objectives 2& 
3. Miles & Huberman (1994) recommend this technique when informants are 
presenting similar responses to similar questions or "tying together" concepts as a 
whole. 
In order to make the data coherent the following data presentation structure, 
suggested in part by Chenail (1995), is employed: 
* Section heading 
9 Present the finding 
Introduce the first data exemplar of this finding 
9 Display the first data exemplar of this finding 
e Comment further on the first data exemplar of this finding 
Make transition to the second data exemplar of this finding 
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* Display the second data exemplar of this finding 
ý Comment fin-ther on the second data exemplar of this finding 
Make the transition to the next data exemplar of this finding and repeat the 
pattern 
9 Present the corresponding innovation and Knowledge Management themes 
Present the conceptually clustered matrix: innovation, drivers, the criteria & 
outputs 
e Closing of the section and introduction to the next section 
In this way, the data is presented coherently and accurately and provides the reader 
with a narrative that can be used to ground the data in particular areas of innovation 
within AstraZeneca. Interviewees' comments are always represented in italics while 
observations are built into the narrative. It should be noted that due to the context of 
the data, the content of Chapters 6,7,8 and 9 are at times, largely worded for 
someone who has an understanding of the drug development processes. However, 
every effort has been made to make these sections understandable by a range of 
readers, so the level of detail expressed has been reduced somewhat and generic 
findings presented. The following sections commence the presentation of the results 
in this format and elaborate upon the findings so far. 
6.2 IDENTIFYING THE CRITERIA AND DRIVERS OF INNOVATION 
6.2.1 THE BEGINNINGS OF INNOVATION 
This section assesses how novel drug development and innovation commences within 
AstraZeneca. Earlier within this thesis, pharmaceutical innovation was defined as 
"the series of processes that yield a new medical drug", yet this definition does not 
consider the knowledge requirements that are critical within these processes. 
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It may be taken for granted that novel drug development requires innovation and a 
good deal of supporting knowledge, yet the knowledge processes within this model 
are poorly understood. Figure 6.1 outlines the high level drug development processes 
where the interviews took place: 
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Figure 6.1: Principle Milestones (MS) and Tollgates JG) ofthe AstraZeneca Drug 
Development Processes (the grey line in Figure 6.1 are reproduced by the Discovery, 
Clinical & GMBD led boxes beneath the main image to aid in clarity) 
The majority of innovations studied, covered the initial stages of Target Identification 
through to Proof of Concept. 
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It is important to note that although the majority of the researcher's time within 
AstraZeneca was within the Clinical wing, Discovery innovators were also 
interviewed extensively so as to provide a broad cross section of innovation. Due to 
the "snowballing" nature of the interview Process, a large number of interviewees 
also operated at the interchange between Discovery and Clinical and their views were 
highly valued. 
Due to the iterative and dynamic nature of drug development, an interviewee's role 
and innovative work often spanned multiple processes within Discovery and Clinical. 
Hence this diagram is only there to provide a guide to where the research data has 
been derived from and is not an accurate reflection of the processes themselves. 
Evidently knowledge is a requirement within these processes, yet there remain many 
unanswered questions, one of which is: how does knowledge and innovation fit into 
this generic process model? 
As discussed in Chapter 3, Dougherty's (2006) hypothesis is that none of the existing 
Knowledge Management and Organisational Learning models accurately fit 
pharmaceutical innovation. Instead, the models and the literature review of Chapter 3 
simply raise more questions such as: How does innovation happen? How important is 
knowledge and intellectual capital? What can be done to support innovation? ... and so 
on. 
The data shown in Table 5.0, Chapter 5 identified a number of concepts or critical 
innovation factors that were deemed important from the interview data. Yet these 
lack context and require ftirther elaboration before the research aim and objectives 
can be met. Figure 6.2 demonstrates the concepts this research has addressed. The 
various colours indicate the degree of uncertainty associated with each concept and 
the dashed arrows indicate a conceptual link may exist. A green box indicates that 
this information can be ascertained relatively easily through document analysis, while 
a yellow box indicates a higher level of complexity that will only be apparent after 
detailed analysis. The red boxes indicate the highest level of dynamic behaviour in 
that they are largely unknown at present. 
171 
Chapter 6- The Innovation and Knowledge Criteria 
Chapter 5 indicates these concepts are in a state of flux and essentially change in 
accordance with what innovation is being carried out. Detailing the concepts 
identified from Chapter 3 and Chapter 5 and identifying any unknown concepts 
(marked by the "Unknown" concept) is central to this research and occupies the bulk 
of this chapter. 
The green and yellow data and information concepts indicate that AstraZeneca is 
relatively content with their current strategies. The results from Chapter 5 indicated 
that this research should specifically address the knowledge required to enhance 
pharmaceutical innovation as the areas of data management are beyond the scope of 
this research. However, if promising data is divulged within this area that could better 
support an overall Knowledge Management strategy, then this will be noted for 
discussion in Chapters 10,11 and 12. 
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The aim of the following sections of this study is to address these concepts and 
analyse innovation and knowledge from the personal perspective of' the innovators 
themselves. The objective is not too identify specific problems but to highlight areas 
where applying a Knowledge Management toolkit may be beneficial. As such, the 
observations identify areas which the literature review of Chapter 3 would consider to 
be knowledge and information intensive areas. 
This chapter considers the concepts that are derived from the literature review of 
Chapter 3 in the context of innovation within an organisation. These concepts include 
technology, individual creativity, collaboration and regulation. 
Individual & 
Management 
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Each concept is strongly associated with innovation across diverse organisations and 
this chapter serves to identify the applicability of these concepts for pharmaceutical 
innovation. While the later Chapter 7, considers the AstraZeneca specific innovation 
concepts that are lightly, if at all, covered by the published literature. 
Figure 6.2 provides a loose model on which to base the research. Powever, where 
appropriate, the data will also be grounded in the drug development model of Figure 
6.1 so as to maintain continuity. The first area of the model to be addressed is the role 
of technology in driving innovation. This is followed by the role of the individual in 
driving innovation, the importance of collaboration and finally the influence of 
regulation upon innovation. 
6.2.2 WHAT IS REALLY DRIVING INNOVATION - TECHNICAL 
ACHIEVEMENT? 
Innovation itself is an interesting concept and Chapter 3 revealed there are many 
facets of innovation. Of these, an interesting observation by Tether (2003), raises the 
possibility that technological achievements may drive innovation. In Tether's (2003) 
hypothesis, innovation is said to arise as a direct result of introducing a new 
technology such as a new manufacturing process or, in this case, a drug development 
technology. Undeniably drug development technology is a huge area and beyond the 
scope of this research, yet when grounding the data within the initial stages of 
"Target, Hit and Lead Identification & Optimisation" (represented in Figure 6.3) 
there are specific technological advances that have had a significant impact: 
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Figure 6.3: The First Four Milestones of the AstraZeneca Drug Development Process 
Watson (2004) notes that, within the last few decades, technology, such as high 
throughput chemistry fflTS) and automated screening, can now assess potential 
compounds extremely rapidly. As the principle goal of the AstraZencca Discovery 
wing is to firstly identify promising biological targets and then supply compounds to 
assess, Discovery interviewccs quickly agreed that these technologies have made 
their roles easier. Discovery chemists can assess many hundreds of thousands of 
compounds per year, which is an unparalleled ability when compared to two decades 
ago, yet the hard truth is that almost all of these compounds will fail to make a 
marketable drug (Dodgson et al. 2005). 
One intcrviewee commented that although these technologies have made their work 
quicker, it is the development of the novel compounds to test against a biological 
target that has remained the sticking point. Hence, in this case, the technology is not 
directly driving innovative compound development; it is merely helping the process. 
The technology itself does not give rise to innovation; instead it is the knowledge that 
is required to supply the "right" compounds to assess using the technology, which is 
the overriding rate-limiting factor. 
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A senior Discovery interviewee commented that this study should be concerned not 
with the technology that drives this process, but with the knowledge behind the 
innovative ideas that leads to a novel compound that can be tested. They commented 
that chemistry is an established science so physically creating a new compound is not 
the bard part: 
"Chemistry is a mature discipline, if I want to find something out ... I can go to text 
books that are 40 years old and the knowledge is still relevant, but clinical knowledge 
is different " 
Another interviewee commented that the early stages of drug development were 
fairly traditional until Clinical knowledge was applied: 
"Once they (the chemists) have a structure then it's afairly defined area ... we've got 
70% that's conventional and then the other 30% isn't and that's the interesting bit. " 
Hence, even though computer aided drug technology has evolved rapidly (for fiifther 
details see Horrobin. (2001)), the interviewees stressed that it is not this which is 
holding back drug development. Interviewees explained that AstraZeneca possesses a 
library of many millions of compounds and the necessary reserve of Intellectual 
Capital to develop many more. Current technology can quickly screen whether these 
compounds are applicable, yet the chemists must have an idea of what type of 
compound can be applicable. HTS effectively allows many thousands of compounds 
to be assessed yet, without the application of knowledge; the whole process is akin to 
looking for a needle in a haystack. 
So is technology really aiding innovation? Although technology can aid drug 
development, it is the creativity and knowledge of the employees or "a result of the 
firm's dynamic capabilities" that results in the initial stages of innovative drug 
development. In light of the first stages of the drug development processes, these 
observations give rise to the first two themes: 
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Innovation Theme 1: Technological advances in drug development is not one of the 
main drivers of early stage drug innovation. On the whole it quickens the current 
"weight in numbers" approach but does not give rise to new compounds. 
Knowledge Management Theme 1: Phannaceutical innovation is heavily reliant 
upon applying technology and knowledge to develop a refined approach to 
discovering a viable compound at the early stages. 
An interview conducted with a Discovery research scientist ascertained that although, 
on the whole, technology was a positive and driving force of drug innovation, 
conversely, drug processes could become overly complicated through the 
introduction of new technology. 
Technology is a vague concept and may refer to a wide variety of concepts such as 
machinery, data mining, IT or even Knowledge Management systems yet, in this 
case, individuals associated early stage drug development technology specifically 
with HTS and screening technologies. As will be seen throughout the stages of this 
chapter, technology has many meanings, yet all do not directly result in innovation 
without the application of knowledge instead they aid innovation. A clear example of 
this related to the introduction of a novel method of dosing drugs in a First Time Into 
Man (FTIM) study: 
"A few years ago our head of department saw an advertfor a machine that weighs 
drugs into capsules, but we saw it and had no idea what we could use itfor, but he 
made us buy it! " 
The intcrviewce went on to explain the reasoning behind why they bought the 
machine: 
"There was an assumption that in the pharmacy business you couldn't just use a 
capsule to dose drugs, but this company had said you could - so we tried it andfor 
some compounds it worked really well andfor others it didn't " 
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Further comments by the interviewee explained that if the technology did work it 
could save a huge amount of resource: 
"Even though it's not a launch submission, it's three man months effort toformulate 
a tablet and this can do it in an hour. 
Therefore although this project ultimately failed, interviewees who were part of this 
work stressed that this allowed the capture of knowledge and information around a 
project that would have otherwise been disregarded: 
"Now as it turned out this compound didn't perform particularly well - but from my 
point of view the real innovation is we've enabled a project that otherwise would 
have become reprioritised down. " 
Therefore in this case technology was a driver of innovative work. It did not actually 
result in an innovative product; instead it enabled innovative work to happen and 
influenced the direction of innovation. However, in order to acquire this technology a 
considerable financial risk was taken by the head of department to acquire the 
technology without a specific project need, requiring an investment somewhere in the 
region of E100,000 on a "hunch". This case was a rarity and the majority of 
innovations studied had trouble acquiring any budget. These observations give rise to 
the following themes: 
Innovation Theme 2: Technology can drive innovation within the right environment, 
an environment that is open to change and welcomes innovative ideas which do not 
have a specific application. 
Knowledge Management Theme 2: AstraZeneca possesses sufficient knowledge 
and intellectual capital to adapt and exploit innovative technologies that have no 
specific need when purchased, although this is difficult to achieve, as the financial 
risks are increased by taking this approach. 
178 
Chapter 6- The Innovation and Knowledge Criteria 
The findings of these two innovative areas are captured in Table 6.1. The findings are 
certainly interesting as they compare two distinct poles: one where technology fulfils 
a definite need and one where technology results in an innovative process. Evidently 
there will be traits of both areas when a technology is applied within a highly 
innovative environment. Yet these findings do provide justification that technology 
can influence and act as a driver of innovation: 
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Table 6.1: Conceptually Clustered Matrix: Technology 
Area Studied Discovery Phase I- FrIM 
Innovative Aspect Technology - IITS, Technology - dosing 
automated screening etc technology 
Drivers 0 "Technology to speed 0 Potential innovation 
up the process" 0 Unmet and unknown 
" The need for need in the future - 
information quickly proactive approach 
" Commercial, strategic 0 To acquire 
and project necessity to supplementary 
discover viable knowledge 
compounds 0 Expand their R&D 
capabilities 
Required Criteria 0 Clinical and chemistry 0 Resource - both 
knowledge to refine financial and time 
the compound being 0 "An unknown use" 
studied *A risk embracing 
* Information and environment 
strategic direction 
0 Multiple potential 
compounds 
outputs 0A viable compound 0 Knowledge 
Information and data 0A greater 
Limited "new" understanding 
chemical knowledge 0 The potential to 
innovate 
Underlying themes Innovation at this stage 0 Availability of 
requires established technology does not 
"text book" knowledge directly drive 
and "unknown" innovative behaviour 
clinical knowledge but can influence the 
" Technology is not a direction of innovation 
key innovative driver Technology can create 
" Limited new chemical 66new or innovative 
knowledge will arise knowledge" by 
from these process utilising the untapped 
adaptive knowledge of 
the cmployees 
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This section's most significant conclusion is that technology is simply an enabler of 
innovation and does not result in an innovative product. 
Hence, if technology is simply an aid to innovation in the early stages of drug 
development, then how is innovative work started? The previous example 
demonstrated how one creative and farsighted manager eventually sparked an 
innovative drug dosing process. The following section will continue this along this 
theme and examine the role of the innovative individual within AstraZeneca. 
6.2.3 WHAT IS DRIVING INNOVATION - INDIVIDUAL CREATIVITY? 
Sundgren & Styhre's (2004) previous study of innovative practice within 
AstraZeneca, suggests intuition may play an important role within both Discovery 
and Clinical, but many interviewees were sceptical of this. Many voiced that 
"intuition is only developed by a scientist when they become a master of the 
knowledge within a particular drug domain". Knowledge Management literature 
describes such people as 'knowledge workers' whose main role is to use their own 
competencies to convert information to knowledge (Sveiby, 1997). 
Existing Knowledge Management research suggests that once an employee is a 
'knowledge worker' then the individual begins to play a key innovative role. Yet 
within pharmaceutical innovation (i. e. target identification and onwards), a team bias 
emerges, which is a rather different observation to the creative individual as the 
principle source of innovation. Interviewees suggested that it requires decades of 
experience to reach the level of a 'knowledge worker' and, due to the depth and 
breadth of knowledge within the pharmaceutical field, this was considered 
"impossible". All employees interviewed felt that an innovative drug rarely, if ever, 
stemmed from one creative individual: 
"Not nowadays - you can have the conceptual link, but nowadays no. There was a 
guy who was asthmatic and he'd test the drugs on himsey. 7 You can't do that 
an o YM 
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It is perhaps evident that one person cannot develop a compound alone, it is simply 
impossible within AstraZeneca, yet what of suggesting and moving an innovative 
idea forward? Comments by interviewees also stated that there had to be group 
backing and a consensus. This is a stark contrast to the early laxly regulated drug 
development environment of the 1970s, when interviewees noted that creative ideas 
were often taken forward by their creators alone. These comments and observations 
are captured in the following themes and matrix: 
Innovation Theme 3: Pharmaceutical innovation is reliant upon collaboration and 
teamwork. An individual may have the initial idea but without co-operation it will 
ultimatcly fail. 
Knowledge Management Theme 3: Pharmaceutical innovation relies upon 
assimilating the complimentary knowledge of the individuals. Specialist knowledge 
workers must act in synergy in order to innovate. 
Table 6.2: Conceptually Clustered Matrix: Discovery & Clinical 
Area Studied Representative findings across 
Discovery & Clinical 
Innovative Aspect Drug development through creativity 
Drivers A conceptual idea 
Scientific knowledge 
The combined efforts of knowledge 
workers 
Required Criteria Detailed clinical & chemistry 
knowledge 
"Consensus" 
Team backing 
Collaboration 
Outputs A group consensus 
Collaboration 
Underlying thernes Innovation via a creative individual 
requires collaboration 
Requires many specialist "knowledge 
workers" who work together 
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The idea of loosely formed communities of practice and collaboration resonates 
strongly throughout this section's themes. A notion underpinned by the need to obtain 
financial resource and identify the Human Capital resources, e. g. the crucial people 
within the organisation, who you must see to take the idea forward. Hcnce, there is 
little doubt that innovation stems from collaboration with the "right person", whether 
this is an individual or a team of employees who have sufficient influence. However, 
can AstraZeneca rely upon collaboration as the principle means to drive innovation? 
These results indicate that gaining acceptance of an innovation is a tricky affair, but 
nonetheless, AstraZeneca is a highly innovative company and the following section 
examines how AstraZeneca is promoting innovation through collaboration. 
63 NETWORKING AND COLLABORATION AS THE IDEAL MEANS TO 
DRIVE INNOVATION? 
Collaboration can cover a wide variety of formats, from face to face meetings to 
teleconferences to email conversations, and plays an important role within 
AstraZeneca and organisations across the board (Wenger et al. 2002). AstraZeneca 
has chosen to drive innovation by establishing networks of innovators and 
collaborators and at first glance this appears to be a valid business model: 
" We have strengthened our pipeline in 2005 and 2006 will see the continuation of 
our pipeline replenishment, whether the opportunities come from our own 
laboratories or from outside. The future security and success of our business 
demands that we are open to the vast array of opportunities for healthcare that exist 
now and in the coming decades. " (AstraZeneca Strategy Report 2006) 
The interviewees revealed that the typical means to promote collaboration, internally 
and externally to the organisation, rests in the medium of the face-to-face meeting, 
telephone and videoconferences (VCs). Overwhelmingly face-to-face meetings were 
considered to be the primary means to achieve this by the interviewees. 
A clinical employee expressed the view that the majority of their personal innovation 
stemmed from face-to-face meetings: 
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V have to say that most of the inspirational ideas come from meetings - they don't 
come out of things like teleconferences [TCs] and VCs [videoconferences]-they're 
quite restrictive and can misrepresent people's views; you can't see the body 
language behind that. Every time something good has come out, it's been ffrom] a 
jace-to-jace meeting. " 
However, in order to drive innovation, AstraZeneca is seeking to go beyond the 
simple sharing of information and share, capture and reuse knowledge within 
collaborations, which, in turn, is hoped, will drive innovation. Yet there are two sides 
to a debate and basing an innovation strategy upon face-to-face meetings creates a 
scenario where prior preparation of information is the key, which interviewees 
acknowledge is difficult when dealing with early stage drug development work. 
Forcing this explicit link between collaboration and innovation raises the issue of 
bias. As one interviewee commented: 
"The only problem about face-to-face is it doesn't give the protagonist a chance to 
think about it and come up with their counter arguments. " 
Interviewees mentioned that face-to-face meetings relied upon both parties being 
adequately prepared. The outcome of a meeting rests with how prepared both parties 
are. Just as AstraZeneca have a strategy designed to attract research within its 
principle disease areas, the research organisations and companies that it intends to 
collaborate with also have a set agenda to attract investment. As interviewees 
explained that balancing and recognising the bias between these two sides is a critical 
part of advancing innovation: 
"We may say we're [AstraZeneca] as open minded as possible but it's not the case. 
We all have a world view of what's possible and the way things work ... you Iblow 
there's nothing that's clean of bias- particularly data. There's bias in the way you 
generate it andpresent it. You know you ask the Paxman question - what is this lying 
b *stard lying to me about? That's the point of it, nothing is without strengths. " 
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The last point implies bias exists to persuade a potential stakeholder that an 
innovative idea is worth pursuing, both from the point of AstraZeneca attempting to 
drive research that complements its aims and from the point of the biotech company 
trying to "fit" their research into AstraZeneca's future portfolio. 
However, interviewees explained this type of bias will always exist and it is 
important to recognise this "world view" when "weighing up" the majority of 
scientific research. Hence, interviewees recommended that to counter this they had to 
use their own knowledge to assess the self-interests of both parties. Yet interviewecs 
expressed that this knowledge intensive aspect is often overlooked. Particularly 
within the stages of early drug development meetings where one point of view will be 
championed over another: 
"Usually you have two conflicting opinions that oppose each other and I don't see a 
conscious effort to consider the two. I think the word is triangulation - there is no 
deliberate attempt at the start of the presentation to say "right" this other way didn't 
work to 
Interviewees noted that presentations rarely covered both sides of an argument in 
sufficient depth and essentially noted that this was due to a lack of time within 
meetings. Others noted that in the context of innovative activity it is often in the 
protagonist's interest to place their point of view above others, even if it is to the 
detriment of scientific rigour. Interviewees also noted that in many cases it was their 
job to assess this bias and the act or ftirther discuss this accordingly. 
A further warning by a Clinical manager questions how easy it is to truly capture and 
discuss both sides of an argument within AstraZeneca, let alone between AstraZeneca 
and external organisations: 
"Networking and collaboration - on the outside it looks pretty straightforward as 
we're all working in a company and it should work seamlessly but it's not. It comes 
down to whereyou are sitting in the organisation and what's yourposition. " 
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Therefore, AstraZeneca's strategy to actively pull ideas from internal employees, 
academia, scientific literature, biotech's and licensing agreements requires innovation 
to be discovered and is reliant upon both employees and these organisations being 
able to put ideas forward. These case studies revealed that internally, collaboration is 
reliant upon overcoming a distinct hierarchy which can limit access to the employees 
able to progress innovation: 
"Ifyou are a manager, sitting at a group level, then you have a higher chance, but if 
you are actually doing the [innovative] work then it [access] is very poor -you may 
get one [person] in your department but beyond that, no. " 
While externally the element of cost and scientific bias may adversely affect the 
success of each innovative project, these findings are represented in the following 
themes: 
Innovation Theme 4: Collaboration both internally and externally are expected to 
play an important role within AstraZeneca future strategy and portfolio. However, 
there are difficulties carrying out collaboration across the organisation, let alone 
extemally. 
Knowledge Management Theme 4: AstraZeneca are seeking to drive their future 
strategy through collaboration and extended external Communities of Practice, yet, in 
order to progress beyond simple information exchange, a knowledge centred strategy 
that reduces the bias that exists within scientific research is also required. 
The Knowledge Management Theme 4 emphasises the need to address the 
knowledge aspect, yet how this will be achieved by AstraZcneca is unclear, other 
than the basic proposition that collaboration will play an important role. It has already 
been ascertained that collaboration takes a number of guises, and furthermore, it is 
implied that internally, an innovator must be able to effectively collaborate across the 
management and stakeholder hierarchy in order to succeed. 
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Therefore- interviewees stressed that it is "who you know" and how good your 
"political skills" are in convincing management and the associated stakeholders, that 
results in the financial backing of an innovative project. The comments of an 
innovator reveal the extent of the frustration caused by the need to convince and 
consider multiple stakeholders: 
"Say you've got an invention, well you can't really sell it, unless you sell it to a 
project manager, and I guess that's right, but you need to alter your communication 
style to suit someone who may not understand the science, because they come from 
lots of different backgrounds. " 
While there are an abundance of highly specialised and technical proficient people 
within AstraZcneca, finding the one person with the political and social influence and 
the necessary scientific background to understand the potential of an innovation was 
rare: 
"I mean, there are so many levels ofpeople that you have to influence, in order to 
play the influential game. You've got to understand the mesh and the grid, sadly - so 
that's a very importantpart ofthe learning process. " 
Innovators commented upon the existence of an unseen grid or matrix across the 
organisation that differed from the published organisational charts, implying that the 
apparent hierarchy can be circumvented by knowing the right people. Therefore, 
collaboration with these people can significantly improve the chances of developing 
an innovative project. Yet when asked if it was clear who these people were and what 
people could help them, many replied: 
"No it isn't, and that's because it's a3D grid. It's not even a grid it's a spiders web 
in three dimensions so you can be interacting with people all over it and that bit is a 
bloody nightmare. " 
While others gave more explanation of just how difficult it was to truly identify who 
could help them and where they operated within the organisation: 
187 
Chapter 6- The Innovation and Knowledge Criteria 
"Getting a feel for the entirety of the grid and where you lie in it is mind boggling 
and is a distractionfrom what you need to do - and it is pointless to learn because it's 
a moving structure because its not like it'll be fixed like this forever - the next 
reorganisation will move it again. " 
In this statement the sense of frustration is heightened by the sense of fluidity which 
arose from a recent reorganisation of the functions and departments within 
AstraZeneca. However, it appears that collaborating with these "innovation 
champions" is critical to maintain innovative activity. As one Clinical scientist 
explained, their social networks are vitally important: 
"For me there are two dimensions, one is protecting my innovation and the other is 
progressing it. Some collaborators I use just to keep my innovation alive and there 
are others who help to aid it. The smaller grotp who keep my innovation alive - 
they're quite hard tofind actually. " 
These observations give rise to the following themes and matrix, which are based 
upon the frustrations felt by innovators attempting to tackle the complexity and 
dynamic nature of AstraZeneca's collaborative structure: 
Innovation Theme 5: Innovation relies upon an unpublicised and unseen grid of 
"innovation champions" who hold the influence to drive innovation forward. 
Knowledge Management Theme 5: The unseen "innovation grid" implied by the 
employees is not publicly known and relies upon personal networks of collaboration 
to achieve results. The knowledge and information generated from this grid is rarely 
captured and shared. 
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Table 6.3: Conceptually Clustered Matrix: Collaboration and Innovation 
Area Studied Representative findings across 
Discovery & Clinical 
Innovative Aspect The acceptance of innovative ideas 
through collaboration 
Drivers 0 Networking - both internal and 
external 
0 Collaboration - primarily through 
face to face meetings 
* External organisations vying for 
funding 
0 Scientific bias to concentrate upon 
innovations that fit the portfolio 
* The "unseen grid" 
Required Criteria 0A promising idea or innovation 
0 The means to collaborate i. e. face to 
face, TC or VC 
0 Sufficient scientific knowledge and 
information to "weigh up" and 
recognise scientific bias 
0A "feel" for the organisational grid 
9A knowledge of who within the grid 
can help to drive innovation 
0 Knowledge of who can "keep an 
organisation alive" 
Outputs * Tacit knowledge and information 
(rarely if ever captured) 
0 Political influence 
0 Frustration felt by many if they failed 
in their bid for support 
Underlying themes 0 Difficulties in effective collaboration 
* Poor knowledge and information 
capture 
0 Organisational matrix underpinned by 
an unseen grid 
a Poor capture of the collaboration, 
knowledge and innovative potential 
within these grids and social 
networks 
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AstraZeneca is relying upon its ability to draw in knowledge and skills as it requires, 
yet to an extent, this model relies upon the location of the necessary internal resource 
and skills to drive an innovation once an idea appears promising. 
Interviewees noted that compound attrition is incredibly high within the 
pharmaceutical industry and higher still when new disease areas are being considered. 
Hence, being hampered by these internal factors related to innovation take up, only 
enhances this problem. As this research has discovered, adapting to factors, such as 
the changing "3D grid" requires considerable flexibility in terms of organisational 
intellectual capital. However, it also raises the question of what happens when a 
project is highly regulated and flexibility is difficult? In order to explore this area 
further, the following section considers the extent to which regulation drives 
AstraZcneca's innovative abilities. 
6.4 THE IMPACT OF REGULATION UPON INNOVATION 
6.4.1 INFORMATION AND REGULATIONS 
Throughout the series of interviews and the observation gathering phases of this 
research, employees' comments indicate how the regulation of drug development has 
progressed from the early days of relatively lax regulatory influence, to a state where 
regulation effectively controls how innovative a company and the eventual drug can 
be. All interviewees unanimously agreed that regulation was a key factor throughout 
innovative drug development, yet their own understanding of how regulations 
affected their own work was clouded by inadequate information. When asked about 
the influence of the regulatory bodies a Discovery director exclaimed: 
"Yes! That's another aspect which we have to look at, more a regulatory aspect ... So 
it's very complex in our organisation " 
The regulatory influence is so widespread as to be omnipresent, in that the 
interviewees commented that the complexity of regulatory influence is such that it 
affects almost everything that an employee will and can do within AstraZcneca. 
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Research by Moerman & Van Der Laan (2005) provides further information in 
relation to how regulatory agreements such as the Trade-Related Aspects of 
Intellectual Property Rights (TRIPS) effectively govern the global extent of 
innovative drug development. To further confound this problem, interviewees noted 
that accessing the relevant regulatory information that directly affected their work, 
could be difficult, with no clear guidance on which one to utilise: 
"Again this is something you'd want to access through the internet, not talking to the 
regulatory agencies directly. They obviously have websites, where you have access to 
the guidelines, documents, processes, the regulation and their interpretations and so 
on, which again are quite useful - but really [there are] so many different 
[regulatory] sources which aren't very intuitive to use. " 
These observations are summed up in the following themes: 
Innovation Theme 6: External regulatory bodies (i. e. the FDA) have a powerful and 
controlling influence on how innovative drug companies may be throughout the 
development processes. 
Knowledge Management Theme 6: The provision of external regulatory 
information is poorly handled; employees are unaware of where to find and how to 
interpret information that is applicable to their roles. 
The data suggested that even though regulation is omnipresent, it does have differing 
degrees of influence on each respective stage of the development process. One 
particular highly regulated area is Phase I clinical trials, where it effectively shapes 
how innovative an individual's role can be. 
6.4.2 REGULATIONS AS THE DRIVER OR THE BARRIER TO 
INNOVATION? 
Innovators within Clinical were particularly vocal on the affects of regulation, with 
one interviewee involved in Phase I Clinical Trials stating: "My role is a well defined 
role by legislation and regulation ". 
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Ile continued to explain that their job was a balancing act between carrying out a 
clinical trial in accordance with these regulations and acquiring new innovative 
knowledge. This observation implies that regulation can inhibit innovative work and, 
from the interviewee's comments, appears to impact at a highly crucial stage within 
the drug development processes. Interviewees stated that a higher throughput of 
successfW trials essentially equates to a greater potential profit, so it is easy to see 
why the balancing act between running a successful trial and acquiring 
supplementary innovative knowledge is tipped in the favour of profit and a low risk 
Phase I clinical trial. However, the interviewees always strived to include innovative 
work within the stages regardless of these barriers: 
"All the processes are one - strictly regulated and two - there are some ethical 
restraints and all the processes have to go through the process of informed consent. 
So the innovation is difficult, so it sometimes occurs in a different type of way, so 
maybefrom an observation in a study or experiment we learn something on how to 
improve things, so it's more evolution rather than innovation - it's incremental, " 
Ilerefore the highly regulated pharmaceutical environment means that employees 
treat their governance with differing degrees of interpretation, as one interviewee 
commented: 
"You can have a wide comprehensive knowledge of the regulations, but a lot of it 
isn't clear. So for many people, depending on where they work, they will have an 
extreme interpretation and this may be unreasonable in legal terms. But generally 
speaking, there will be a range of what is possible andpeople will be toward one end 
or the other, and that gives you an opportunity to negotiate " 
Stringent regulation certainly affects innovation but as one interviewee stated it gives 
rise to incremental innovation carried out within the bounds of what is legally 
feasible. Hence as one interviewee commented, permissible innovation is simply a 
case of knowing, how and which regulations govern your work: 
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"What I class as innovation is to make best use of what's already there [the 
regulations] and come at itfrom a different angle. " 
On a more pressing note little knowledge capture was noted to occur around these 
"incremental innovative processes" typically employed within clinical trials. This 
research suggests that within pharmaceutical innovation, the regulations impact an 
employee's ability to apply their knowledge to such a degree, that they are both 
simultaneously a driver and an inhibitor. These comments, observations and the 
previous comments give rise to the following important themes: 
Innovation Theme 7: Creativity and innovation arise as a result of negotiating the 
rules and regulations implied both externally and internally. Without this foundation 
of external regulation, some innovative practice would not occur. 
Knowledge Management Theme 7: External regulations govern the degree of 
additional knowledge that may be applied and acquired from conducting 
supplementary drug development processes, and in many cases the knowledge 
surrounding this process is poorly captured. 
These comments also raise the spectre of risk avoidance in taking a "straightforward 
and safe path", particularly in risky areas such as Phase I Clinical trials. Ilence 
innovators also stated that it is not only the external regulations that govern 
innovation but AstraZeneca's internal interpretation of these regulations that 
prescribe how innovative they may be. 
6.4.3 EXAMINING THE EFFECT OF EXTERNAL REGULATION AND 
INTERNAL PROCESSES 
A study by Schmid & Smith (2004) explains that the increase in regulatory pressure 
has caused R&D costs to rise steeply. This may explain why the safer option is the 
preferable option, from an economic sense at least. As regulatory bodies demand ever 
greater detail on a prospective drug's safety, efficacy and differentiation to other 
existing products, so the costs associated with meeting these demands rise. 
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Yet this research has revealed that there are differing levels of regulations and 
differing impacts associated with these regulations. 
Employees perceive that in many respects not only do external regulations set by the 
regulatory bodies, sway their innovative ability, but the internal regulations of 
AstraZeneca are unfairly hampering their innovative ability as well. A "tongue in 
cheek" comment by one interviewee was: 
"I've spent most of my life trying to avoid the procedures and processes that are 
already there in order to get on and do things. There's nothing particularly 
innovative about that, apartfrom how you can get away with it - Ijust ignore the 
rules and try to get away with them. " 
AstraZeneca's company mission statement (AstraZeneca, 2006) maintains that 
creativity is the key through the offering of 'an environment that allows employees to 
exercise and reward their creativity'. Yet the results of this study question whether 
employees are being allowed to exercise their creativity in the innovative stages of 
drug development. The interview data implies that AstraZeneca does possess a 
creative environment, although there are strong hints that creativity is being stifled 
across the organization: 
"I think it's about putting more emphasis on creativity and making sure it's 
rewarded, but in the same time you have to have tolerance if a democratic decision 
goes wrong. If they bang around when something goes wrong then people will not do 
it again. " 
Ifencc, employees are wary of a "blame culture" with regards to regulations, erring 
on the side of caution. Furthermore, this suggests that an employee's innovative 
ability is governed by their environment and the direct management associated with 
their role. Although the data collected by this research was comprehensive, it would 
be unfair to label AstraZeneca's management as directly stifling innovation. 
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However, this research concludes that there is evident disaffection and this arises 
from the difficulties in effectively balancing the need to innovate within regulations 
and the need to generate a profit. Interviewees commented that creativity and their 
innovations often arose from the need to circumvent an AstraZeneca management 
process: 
"Creativity comes out of needs, sometimes quite desperate needs, and you have to 
have an environment that gives you a certain degree offreedom, but ifyou have an 
environment [like AstraZeneca] that has very clear restraints, then you will become 
creative in solving the problems that arise. " 
So for some, innovation is born out of the necessity to adapt to ambiguous 
regulations, their innovation is simply adaptive and raises the interesting observation 
that internal regulations are also both a driver and an inhibitor of innovation. The 
issue of innovation always led the conversation to one of prohibitive regulation, a fact 
that is seemingly inescapable within modem drug development. 
When a senior research scientist was asked if they could obtain previous development 
work that had occurred within AstraZeneca, they commented: 
"Yes, I have access to some that has been done. Sometimes I get it through people 
who are good enough to show me whalpecpleý have done, andsomelimes I rely on the 
literature that covers those areas. " 
The interviewee continued to state that these two internal and external sources of 
knowledge and information are essentially the same: 
"To a large extent these are the same and the reason that these are the same, is 
[regulatory] bodies like the FDA don't want innovation, they want validatedproof of 
principle. " 
This comment implies that regulatory control is highly significant and controls how 
innovative personnel can be, as by their observation, the published literature and 
internal 
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AstraZcneca work is highly similar because it is subjected to the same regulation. The 
interviewee proceeded to explain that although their work was corralled, there was 
still scope: 
"But within that system there is room and scope to be innovative and to develop 
biomarkers [measures] that not only talk about the efficacy of the drug but the 
mechanism and mechanisms of classes of drugs as to why they are successful or not. 
So yes, we're getting information, but we're not getting all the information we should 
be. 
Many innovators were quick to point out that regulation was significant in 
influencing their behaviour: 
"Regulatory is an issue. For the innovative things I've tried to do, regulatory has 
been a hurdle rather than a help. " 
The regulatory environment may be construed as omnipresent within AstraZeneca. 
An innovative Knowledge Management tool the researcher was involved with in 
AstraZeneca was also subject to these constraints, as information or knowledge 
captured effectively created an audit trail. However, at a fundamental level, 
interviewees agreed that regulation will always hamper innovation. Yet, it is the view 
of many innovators that AstraZeneca's approach to regulating their drug development 
processes may be a farther unwarranted constraint: 
"There are people there [regulatory] now who are approachable, but I think that 
because we've possibly got such a poor track record with the guys like the FDA, 
there's a paranoia around regulatory which I have a hard time getting my head 
around, probably because I don't understand it " 
So far this research indicates that both internal and external regulations play an 
important role in driving innovation. These observations and comments form the final 
themes, before the section is concluded with a conceptual matrix of the main findings 
of this section: 
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Innovation Theme 8: Innovation can arise as a direct result of the need to 
circumvent existing AstraZeneca processes in order to fulfil their role yet this carries 
the potential of blame. 
Knowledge Management Theme 8: Knowledge Management may play an 
important role in addressing the issue of reluctance associated with trying an 
innovative approach by ensuring that employees are aware of how their innovation 
could fit in within the regulatory framework. 
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Table 6.4: Conceptually Clustered Matrix: Regulation and innovation 
Area Studied Findings across Discovery & Clinical 
Innovative Aspect The role of regulations in influencing 
innovative activity 
Drivers 0 Strong external regulatory pressure to 
conform to published guidelines 
0 Strong internal pressures to conform 
to the interpretation of external 
guidelines 
0 The need to be innovative within a 
regulatory boundary 
Required Criteria * Access to information and knowledge 
with regard to regulations 
0 An understanding of regulations that 
affect their role or innovation 
0 Patience to adopt an incremental 
approach to innovation within a 
regulatory framework 
0 An understanding of how to interpret 
a broad range of requirements and 
develop innovation from there 
Outputs * Innovation within the framework of 
regulation 
0A drug that will conform to legal 
requirements across many markets 
0 Potential capture of information and 
knowledge with regard to how 
innovation have succeeded 
0 The potential to succeed over the 
"blame culture" 
Underlying themes 0 Innovation is heavily influenced by 
internal and external regulations 
6A successful Knowledge 
Management schema needs to draw 
in the regulatory aspect alongside the 
need for information and knowledge 
As this section cmphasises, regulation is an omnipresent factor within pharmaceutical 
drug development and employees must be aware of how this area affccts; their 
innovative work. 
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A careful balance between innovation and regulation appears to exist and it may be 
wise to include this aspect within any Knowledge Management toolkit. 
The following section briefly concludes this chapter. 
6.5 CONCLUSION 
Throughout this chapter, interview comments have been used to provide an insight 
into how innovation is occurring within AstraZeneca. The key concepts studied 
within this chapter have largely been derived from the literature yet the extent of their 
influence has been surprising. For example, the notion of the individual 'knowledge 
worker' driving innovation alone does not apply to the pharmaceutical arena. Factors 
such as regulation and the need for collaboration all contrive to ensure that innovation 
is beyond the scope of the individual. In order to clarify these observations further the 
following chapter examined the innovative culture of AstraZeneca in greater detail, in 
order to ascertain how innovation is being driven and supported within AstraZeneca 
at present. 
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CHAPTER 7 
ASTRAZENECA AND AN INNOVATION CULTURE 
7.0 INTRODUCTION 
AstraZeneca are a highly innovative company and the third largest pharmaceutical 
company in Europe. In order to understand the complexities of innovation and the 
potential for Knowledge Management within AstraZeneca, this chapter examines the 
issues that are specific to AstraZeneca's organisational culture. It seeks to explore the 
findings of Chapter 6 in greater detail and uncover the innovation and knowledge criteria 
that are specific to AstraZeneca. The starting point of this chapter is thus the starting 
stage of pharmaceutical innovation within AstraZeneca and considers the R&D behind 
the identification of a biological target. 
7.1 THE PROCESS OF FINDING A BIOLOGICAL TARGET -A PROCESS OF 
STRATEGY OR INFLUENCE? 
In order to proceed down the drug development pathway a pharmaceutical company must 
have a biological target on which to develop a compound on which to act. Throughout 
this research AstraZeneca innovators were questioned as to the roots of pharmaceutical 
innovation and the extent to which they can influence how and which biological targets 
are being discovered. From the interviewees' answers to this question, it is apparent that 
not only do the innovators have scant personal influence on the processes of identifying 
biological targets, but AstraZeneca itself has little influence. A Discovery research 
scientist clarified this by commenting on the influence of AstraZeneca on external R&D 
activities: 
"Almost nothing, because that isn't the way it works. You [the research organisation] 
come up with targets not because AstraZeneca would want that. 
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You come up with targets because you are working in that area and subsequently you 
think "Oh yes, AstraZeneca would like thatl " So, in a way it's not even market led, it's 
interest led and academic. " 
71icrefore, when innovators were questioned over whether they could influence the initial 
identification of targets the majority reply was, unsurprisingly, "No I Other, more senior 
intcrviewees explained that they did possess a minor degree of influence: 
"There's the Respiratory Strategy Team which is meant to set broad ideas on what where 
we should be, they also set the disease target andproduct profiles which will be what we 
fit our drug to, and then there are dozens of other strategy teams - so you do have some 
influence in a vepy broad sense. " 
Yet in the majority of cases they were tasked with making a drug that "met predefined 
expectations ". Therefore, the degree of influence is dependent upon who is suggesting 
the idea. More worrying, however, was the opinion of the majority of interviewees that 
once a target had been identified and information was available (either in-house studies 
or peer reviewed publications) their influence on which of these promising targets should 
be brought into the AstraZeneca development portfolio, was again limited. When asked if 
they could influence this process within Discovery, a senior interviewee commented: 
"Nol Well sort of - the chemists have so many different groups, all doing slightly different 
things and quite often not liaising. There's a thing called the Science Group which meets 
about once a month, but they sit at a really early stage and brainstorm new targets. " 
The interviewee continued: 
"3-4 people will present, which will be based on really early knowledge and everyone 
will get chance to have their say. Then when it's a bit more developed, we vote on if to 
progress, so we do have some influence " 
7bis answer implies that there is an avenue for innovators to broach ideas on what targets 
should be examined within AstraZeneca but it is not open to all, other innovators were 
unaware of this group or were not privy: 
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"People do not have an equal chance of influencing the system and that, therefore, 
becomes orthodoxy ofopinions within the company, which is again against innovation! " 
Implying that innovation at the early fundamental stages is dependent on who you are and 
who you know, this edict was a corrunon finding throughout the research and typically 
rcflects this organisational-cultural issue plays a hand in influencing target selection. 
The other striking finding is the need for accurate knowledge at this early stage. When 
discussing the Science Group, the interviewee stated that without sufficient supporting 
information, a potentially promising innovation could be overlooked. It is the proponent's 
role to sufficiently research the proposed innovative approach and as this was often based 
upon early ground-breaking work. Presenting rigorous scientific evidence could prove 
difficult. 
This results in a requirement not only for accurate knowledge but also for an ability to 
present and pitch information at sufficient depth to gain interest and demonstrate the 
potential of an innovative idea. These areas are more important when a large conceptual 
leap is required, and interviewees who were members of the Science Group acknowledge 
that this generated intense competition between innovators for the limited resources 
available. 
Innovation Theme 9: Innovative ideas that could be of use within AstraZeneca's drug 
development portfolio are poorly received. It appears difficult for the majority of 
innovative employees to suggest potential innovative ideas and, therefore, influence the 
carly development work. 
Knowledge Management Theme 9: Early drug development innovation requires an 
entrepreneurial approach to develop interest from limited resource and organisational 
support, and is reliant upon sufficient knowledge to generate interest. 
Failing to provide innovative personnel with the opportunity to suggest innovative targets 
is indicative of both a cultural and a Knowledge Management problem. 
202 
/ 
Chapter 7- AstraZeneca and an Innovation Culture 
Although AstraZeneca does not appear to be able to directly request work on a specific 
area, there is still the question of using AstraZeneca's influence to fund work on 
biological targets that are in line with the company's future desired drug portfolio. 
Unfortunately, as a Discovery scientist explained, the way of influencing which targets 
were being discovered was also minimal. Pharmaceutical companies do fund scientists 
(i. e. biotechnology, post docs & PhDs) to conduct research into targets that might have 
application only once they have been identified. Furthermore the means of learning the 
nature of the work that was being carried out, both externally and intemally, within 
AstraZeneca was distinctly hazy. Many employees commented that they relied on direct 
communication with colleagues as the principle means of discovering past work and 
promising work: 
"I would ask around Id probably go to the head of the CPU, head of Discovery and 
Translational Science - all guys who have been around the block a couple of times and 
ask "Have you ever heard ofanyone actually trying this? "" 
Above all, there is a focus upon practicality, regardless of how promising or exciting 
innovative research appears, it must possess a place within AstraZeneca's strategy. As a 
senior director remarked, it is often relaying messages about the "right" innovations that 
enable innovative work to receive backing: 
"So the Global Product Teams (GPT) are very practical, they want something that they 
can use, and they ultimately can only get better the next time they do it. So they've been 
very good, but we've not been very good at explaining the messages " 
Although there is evidently an innovative culture that drives this initial research, to an 
extent, it is the act of "presenting a strong enough business case" to influence the early 
stages of innovation, which appears to be hampering the introduction of new ways of 
thinking and practice. 
Innovation Theme 10: Successful innovative practice requires the right information, 
organisational structure and team commitment at the very earliest of stages to gain 
momcntum. 
203 
Chapter 7- AstraZeneca and an Innovation Culture 
Knowledge Management Theme 10: Supporting innovation at an early stage can be 
aided by ensuring that sufficient information is available, presenting a strong business 
case and having access to the "right" influential strategy groups. 
Table 7.1: Conceptually Clustered Matrix: Influencing early phase drug development 
Area Studied Representative findings across 
Discovery & Clinical, but principally 
Discovery 
Innovative Aspect Identification of Biological Targets 
Drivers 0 Relevant targets from external 
work 
0 The need for innovative 
biological targets 
0 Strong employee drive to 
supplement the portfolio with 
promising areas 
Required Criteria 0 Clinical and chemistry 
knowledge to develop a strong 
business case 
0 Managerial influence and access 
to the groups that influence future 
strategy 
0 Promising scientific research - 
almost exclusively externally 
derived' 
Outputs *A promising biological target 
0 Hitherto unknown data, 
information and knowledge 
0 Potential lucrative returns if the 
research is unique 
Underlying themes 0 Innovation at this stage is reliant 
upon a structured business case 
0 How innovative the idea is, can 
be outweighed by the availability 
of supporting information and 
data 
0 How innovative the idea is, can 
be outweighed by the lack of 
managerial influence 
0 Sufficient support at this stage is 
essential for innovation 
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The following section examines the means AstraZcneca as an organisation, is employing 
to enhance innovative practice. 
In order to gain an overview of how AstraZeneca is tackling the problem of broadening 
its drug portfolio and discovering new biological targets, after recent setbacks (BBC 
2006a), the researcher analysed documents across the AstraZeneca intranet and learned 
that a specific team, named the 'New Opportunities Group', has been set up to promote 
innovation outside of the normal therapeutic areas. A key remit is to develop innovative 
drugs that have traditionally been outside of AstraZeneca main disease areas and hence 
expand the market potential of AstraZeneca's portfolio. An interview conducted with a 
New Opportunities Group member, sourced from an AstraZeneca internal newsletter, 
stated: 
"Until now, it has been difficult to develop projects falling outside our traditional 
therapeutic areas of expertise. The New Opportunities Group will address that by 
providing a homefor the ideas thatpreviously had nowhere to go. " (Charnwords 2005) 
Hence, it appears that AstraZeneca has rccognised the need to embrace innovation on a 
greater scale than it currently does, the interview finishes with a request: 
"We really want to hear about creative thoughts and ideas that may not have had the 
opportunity to surface before. " (Charnwords 2005) 
An email address is provided where employees may email suggestions and ideas for 
consideration. The team appears to have senior management backing but at the time of 
this research, no employees interviewed had submitted an idea, some were aware of the 
group but others were not. The majority of employees interviewed gave the opinion that 
unless the proposed group possessed considerable managerial backing, it was likely to 
fail: 
'There seems to be very little interest in innovation in this company, at the bottom line - 
its all very "be innovative "- but as long as it doesn't worry us and as long as it doesn't 
interfere with the nominal timelines you can be innovative - but that doesn't work. " 
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Hence, buy-in from all hierarchical levels is required. In essence, innovators surmised 
that an idea must be targeted professionally, scientifically and financially and, if an 
innovation fell within the remit of the New Opportunities Group or a Global Product 
Team (GPI), then it could be well received. Yet interviewees noted that this constrains 
the extent of innovative work possible, whether this is a new biological target or a 
potential new compound. A Discovery research scientist commented that this relies upon 
being able to access the groups that decide upon funding: 
"It depends on who you have to see. Ifyou come up with an idea that you think is going 
to add value and help, you need to get funding. If it's going to help a project then you 
need to approach the global product teams (GPT) or within your team. In my case, I 
know most of the people to speak to. I know for a lot of other people that certainly isn't 
the case. " 
These fmclings give rise to the following themes: 
Innovation Theme 11: AstraZeneca have taken positive steps to embrace innovations 
that occur outside of their traditional therapeutic areas, but further steps need to be taken 
to ensure this resource meets the needs of the employees and is as receptive as it 
proclaims. 
Knowledge Management Theme 11: Knowledge Management may play an important 
role in publicising and defining the innovations that AstraZeneca will specifically fund 
and manage. As the concept of innovation is perceived to differ according to who is 
proposing an idea, a common understanding to develop a symbiotic relationship would be 
beneficial. 
The previous section implied that, although AstraZeneca is trying to be a receptive 
company to innovation within both Discovery and Clinical, the interface between 
Discovery and Clinical was commonly cited as poor: 
"It is better than a lot ofp1aces I've worked in... I think here it is very much more open, 
they may not take any notice ofyou but at least they're polite! " 
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This observation is worrying yet confirmed by the majority of employees interviewed, it 
implies that people are open to suggestion and will listen but then fail to take the 
suggestions on board, particularly if the suggestion arises from a Clinical employee and 
concerns a Discovery focused area. As such it is again an area where Knowledge 
Management could play an important role by ensuring that employees have the 
opportunity to raise suggestions across the organisation. The findings of this section are 
represented in the following themes: 
Innovation Theme 12: Innovation is hampered by the interchange between Discovery 
and Clinical resulting in the potential loss of valuable ideas. 
Knowledge Management Theme 12: Information and knowledge exchange and reuse 
between Clinical and Discovery are felt to be poor and can lead to a sense of frustration. 
Knowledge Management techniques could help to improve this area. 
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Table 7.2: Conceptually Clustered Matrix: Innovation Acceptance 
Area Studied Representative findings across 
Discovery & Clinical 
Innovative Aspect The acceptance of innovative ideas 
Drivers 0 Innovation (and therefore financial 
reward) may lie outside its 
traditional portfolio 
0 Employees may drive this process 
0 Market drivers and competition 
from rival pharmaceutical 
companies forcing AstraZeneca to 
utilise its internal knowledize 
Required Criteria 0 Detailed clinical & chemistry 
knowledge 
0A valid idea or innovation 
0 Scientific knowledge and 
information 
0 New Opportunities Group backing 
Outputs 0 Financial backing and 
management support 
0 Potential diversification of the 
existing portfolio 
Underlying themes 0 Few innovators implied that the 
group would be as receptive as it 
proclaimed 
0 Knowledge Management could 
help to form the "link" between 
this group and innovators and 
ensure mutual benefit 
0 Innovation can be hampered when 
Discovery and Clinical are 
involved 
0 Information/ knowledge exchange 
was felt to be poor across 
Discovery/ Clinical 
Ibis section has examined the acceptance of innovative ideas from the employee's 
perspective. On the outside there appears to be avenues for employees to broach their 
innovative ideas, yet this is rather more difficult than AstraZeneca would suggest. 
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A key factor in this is that recently innovation has largely stemmed from external 
organisations through a process of acquisition. This paradigm shift from in-house R&D 
to external acquisition is examined in greater detail in the following section. 
7.2 ACQUIRING INNOVATION RATHER THAN GENERATING INTERNAL 
INNOVATION: A FACT OF LIFE? 
7be last 20 years has witnessed the large pharmaceutical companies switching to the 
scenario, where they outsource increasing amounts of the initial R&D work. The majority 
of innovators questioned, agreed that AstraZeneca was reliant upon acquiring the initial 
innovative work from external organisations. In the case of Knowledge Management 
systems, this research certainly detected antagonism to developing complete systems in- 
house. Although the internal functions were highly welcoming to Knowledge 
Management ideas that arose "in-house", there is a definite reluctance to progress them: 
"Lets take the ontology backed discussion forum, it would be relatively easy to go to a 
company like IBMand buy it infor say f250,000 " 
In many ways this is a similar model to how AstraZeneca operates in terms of early phase 
drug development, it is simply easier to acquire an idea that shows promise and then 
tailor it to a situation. AstraZeneca appears to be content to encourage innovation, yet 
relatively reluctant to exploit these creative ideas, with the principle reason behind this 
being assigned to cost. While this may be counter productive in a Knowledge 
Management setting, within the early drug development stages it is an absolute necessity. 
As one interviewee commented: 
"It's cheaper to buy infor a huge number of reasons. First ofall a lot of the research you 
do is pointless, you know it happens in academia. It happens in a big project and that bit 
[of research] is swept under the carpet or it is part of a bigger project and that dies and 
thepeople die andyou never hear about it! " 
In many respects these observations suggest that a dichotomy of innovation exists. 
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With respect to early phase drug development the preferred model is to acquire novel 
work, while, outside of that, innovative ideas are widely applauded, yet poorly acted 
upon. Large scale funding exists to acquire promising pharma-relatcd work but, outside 
of this, funding is limited to supporting what innovators termed AstraZeneca's "core 
competencies" which, in this case, is drug development. Knowledge Management 
appears to be very much on the periphery. 
However, from a pharmaceutical point of view, is it simply cheaper to acquire the rights 
to research a biological target or molecule rather than conduct in-house research to 
discover it? When questioned from a Human Capital perspective, innovators indicated 
that AstraZeneca no longer requires the ability to innovate at these early stages and 
instead acquisition and collaboration are the preferential means. 
On ftirther investigation of this point many interviewees pointed out that academia 
fuelled the majority of innovative pharmaceutical related work, although innovators 
acknowledge that, due to the complexities of biological systems, a percentage of this 
academic research is essentially useless: 
"That's the thing about academia, you don't hear about thefailures because you cannot 
publish - so it's impossible to assess those costs but that is huge - and, in a way, it's why 
drug companies aren't doing it" 
Ile interviewee continued to say that the capability of the system meant that a huge 
amount of work was never published, even though it could have potential: 
"There's enough redundancy /R&D capability] in the system [AstraZeneca R&D] once 
you've got a target and made a drug. Imagine what there is when you come up with the 
target - and because of that, a lot ofpeople will come up with some incredible stuff that 
has amazzing commercialpotential and never realise it! " 
These findings concerning redundancy are important for a number of reasons, not least 
because it implies that promising innovation can be overlooked. These findings are 
represented in the following themes: 
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Innovation Theme 13: Pharmaceutical innovation relies upon a plentiful supply of 
innovation stemming from external organisations. This effectively reduces the risk 
associated with innovation by the costs of the innovation being absorbed lower down the 
chain. 
Knowledge Management Theme 13: The degree of knowledge and information 
disregarded within these early stages is prolific, as only research that can be published 
will be shared publicly. 
Ilerefore, as long as there are still viable innovations stemming from academia, 
interviewees noted that AstraZeneca and the other pharmaceutical/ biotech companies are 
at liberty to pick and chose what innovations suit their current portfolio and strategy. 
However, due to this, competition will arise and inevitably the more potential an 
innovation appears to have, the higher the price tag will have to be paid. Interviewees 
explained that it is, therefore, a careful balance between the perceived risk and the 
perceived potential benefits of the research being acquired. Interviewees expressed 
dismay at the number of promising areas of research being heralded as the next big 
breakthrough and the interviewees mentioned that the popular media is often awash with 
such claims. Yet the innovators' agreed that optimistic and published research, stands a 
higher chance of being taken into a company overall. 
A senior manager commented: 
"Biotech 's are fascinating because there's always a perception that it's [their research 
is] easier to develop, you listen to people [in AstraZeneca] and they say "you get this" 
and they say "This is wonderful! It'll be on the market in two years "- but it's complete 
bollocks! " 
It has been interesting for the researcher to reveal the innovator's opinions on 
biotechnology companies and their role within AstraZeneca's innovative future drug 
pipeline. A senior employee provided a memorable comment when discussing how 
AstraZeneca sometimes drives itself to acquire research, rather than accept "in house" 
innovation: 
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"It's like playing Chelsea by sitting in the stands and trying to poke the ball away from 
them with a broom. You are definitely handicapping yourself before you start, so in that 
respect it's dijricult to be ever truly innovative. " 
Ibis point referred to the strategy employed by AstraZeneca to largely focus upon 
compounds that are capable of being dosed by mouth. Recognising that in order to have 
an affect at the site of the disease the compound must fulfil a greater number of criteria in 
order to eventually arrive at the disease site. This was labelled by a senior physician as 
the "scatter gun" approach to drug development and was perceived to be relying upon 
stumbling across a compound that would act on the disease and be administered orally. 
However, aside from the difficulties of finding a compound that is biologically active 
against the identified target, many interviewees raised the spectre that the politics 
associated with what is perceived to be a successful drug, effectively governs how 
innovative they can be: 
"The key decision is what's trendy and can we raise small molecules to it? And there are 
things that might be trendy but we don't think we can raise small molecules to it, so we 
don't bother. " 
While others confirmed that because external organisations were researching the targets 
that required small molecules, AstraZeneca were more likely to look to this research and 
ultimately take these onboard. A research scientist of considerable experience indicated 
that the obvious problem of how knowledge and intellectual property was exchanged was 
relatively minor: 
"Yes, well I'm involved with Cambridge Antibody Technology, but its different - JP 
[Intellectual Property] doesn't seem to be a problem, there's always some little 
reservation about doing things. " 
Many interviewccs noted that the difficulties lay in quantifying the benefits obtained 
from the collaboration. 
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Yet as a recent news article detailing AstraZeneca's recent acquisition of Cambridge 
Antibody Technology in May 2006 suggests, if such collaborations do yield a promising 
drug then the potential benefits are worth the effort and cost (BBC 2006b). Yet when 
discussing the acquisition by Discovery of the licence to research a promising antibody 
from a biotech, another interviewee commented: 
"There are things that you cut corners on, but there are other things that take longer, so 
often it's not much quicker to get them [the drug7 on the market " 
Iley continued to say that acquiring biotech antibodies was far from a commercially safe 
way of obtaining a marketable drug: 
"You can patent your specific antibody usually, but not always... then someone can come 
along with a slightly different antibody and put it on the market and there's nothing you 
can do about it - but it's interesting" 
7be bemused comment at the end stems from the intcrviewee's experience of a 
competitor releasing a drug based upon a similar antibody a considerable time before 
their own project could be released. Within this lies a clear message, speed is of the 
essence and the failure to reach market first results in valuable revenue being lost. 
However, the desire to recoup the substantial R&D investment required to develop a 
drug, may lead to haste. Innovators noted that the desire to embrace promising 
compounds, novel target data and licence antibodies from biotech should be carefully 
weighed up against the risks and costs involved. A process which, at present, is reliant 
upon sufficient information and knowledge being made available to aid the decision, a 
situation that interviewees noted was not always the case. The following themes and 
matrix summarise this section: 
Innovation Theme 14: The process of acquiring innovation was perceived to be 
AstraZeneca's preferential means of driving innovative drug development. However, the 
benefits from acquiring this research rather than developing it in-house are not always 
clear. 
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Knowledge Management Theme 14: Acquiring innovation does not always mean that 
the knowledge and information is also acquired. In certain cases the desire to acquire 
cutting edge molecules may mean this supporting information/ knowledge is scarce. 
Table 7.3: Conceptually Clustered Matrix: Acquiring innovation 
Area Studied Findings across Discovery & Clinical 
Innovative Aspect Acquiring innovation from external 
organisations and academia 
Drivers A promising compound or the 
identification of a biological 
system 
Promising academic research 
Strict criteria of what a drug "can 
be" that effectively limits 
innovation 
0 The perception that external 
innovation is "better" because it 
meets the criteria of what a drug is 
supposed to be i. e. orally dosed 
and a small molecule 
Required Criteria 0 Sufficient published information 
to drive AstraZeneca's interest 
A collaborator within AstraZeneca 
to drive the relationship 
Plentiful academic research 
Research that shows promise but 
is not sufficiently developed to 
attract a competitor's interest 
outputs 0 An innovation that could result in 
a new drug 
0A collaboration and funding for an 
external organisations or academia 
Underlying themes 0 There is a huge degree of 
redundancy within the system 
from both an R&D and a 
knowledge perspective 
a Acquiring innovation does not 
always demonstrate an evident 
return on investment 
0 Knowledge and information 
generated via an acquisition may 
be lost or disregarded 
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71iroughout the discussions on external organisations, interviewees repeatedly mentioned 
that biomarkcrs are a highly innovative area. Furthermore it is an area that is heavily 
reliant upon acquired innovative research from academia and biotechnology firms. The 
following section details a series of case studies which examined biomarkers in greater 
depth with regard to innovation and Knowledge Management. 
7.3 BIONIARKERS AND THEIR ROLE IN DRIVING INNOVATIVE R&D 
In order to examine the innovative nature of work concerning biomarkers, a detailed case 
study was conducted around this area and the results from this are presented in this 
section. Although this section presents the results of this research, an introduction is 
required at the start that draws upon prior research. This part of the research also draws 
upon published work within this area by an AstraZeneca employee who provided 
valuable guidance to the researcher (Gaughan, 2006). 
When a drug is applied to a biological system, various biological cycles and pathways are 
invoked or altered and the identification and measurement of these changes is the role of 
the biomarker. Although exploring the mechanisms of biomarkers is beyond the scope of 
this research, for the interested reader a review by Seo & Ginsburg (2005) provides a 
thorough overview of the role of biomarkers. Importantly, within pharmaceutical drug 
development, biomarkers are amongst the primary means of predicting and measuring the 
response and efficacy of a drug. Unravelling the clinical and biological characteristics 
that are present, once a drug is dosed, is the key to planning an effective clinical trial and 
developing therapies that are targeted to a particular disease area (Gaughan, 2006). 
Due to the complexity of the drug development processes, biomarkers fall under a 
number of categories (Seo & Ginsburg, 2005) and range from a simple clinical marker 
such as the blood glucose level, to more complex molecules that may be used to profile a 
patient in order to provide personalised medicine (Gaughan, 2006). The categories 
suggested by Seo & Ginsburg (2005) include: 
*A pharmacogenetic biomarker measures the effect of a drug on a single gene. 
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*A pharmacogenomic biomarker refers to the effects of all the genes that impact on 
the behaviour of a drug. 
*A pharmacodynamic biomarker assesses, through biochemical measures, whether 
a drug has reached its intended target 
9A disease marker may be used to assess the efficacy of a drug (e. g. how well the 
drug is performing by modifying a disease state). 
However, what appears to be happening with regard to biomarkers is complex, all 
interviewee agreed the role of biomarkers is crucial, yet their opinion on how 
AstraZeneca deals with the knowledge and information surrounding biomarkers was far 
from positive. One interviewee who was partly responsible for the development of viable 
biomarkers with which to assess the pharmacogenomic properties of a compound, 
believed that although biomarkers represented a crucial stage in the development Process, 
one where the compound becomes a potential drug, the time and resource devoted to 
these processes was nonsensical. 
This case study followed the work on an innovative drug, which had been assigned a 
month by the project management team to develop biomarkers. When questioned about 
the risk involved in not finding a biornarker in this time, an interviewee replied: 
"It's animmense risk ... The chances of us finding any biomarker that we can use in the 
month is negligible, about 2-3% - in 3 months we've got maybe a 25% shot, in 6 months 
It's maybe a 50% shot - but if we ace it it's a big deal, we get a drug for an unmet 
medical need which is veryfuyilling in its own right, it's not a blockbuster - but it'll be 
financially rewardingfor the company. " 
Many interviewees also suggested that although the identification of biomarkers is a key 
component of developing a successful drug it is rarely assigned the time it requires. 
In many respects biomarkers are a "pinch point" or a "double edged sword" that can be 
used to both drive a drug and also effectively end research if biomarker work is 
unfavourable. 
216 
Chapter 7- AstraZeneca and an Innovation Culture 
flence by identifying biomarkers that are likely to highlight rogue characteristics sooner 
or complimentary characteristics sooner, the likelihood of compound attrition within 
clinical trials is likely to be reduced. Innovators explained that to overlook the former 
may result in attrition further down the development line, and to overlook the latter may 
result in attrition at this stage if the drugs mechanism of action is poorly understood. One 
interviewee described their role was to both "nurture" and "cull" drugs at this stage: 
"Ifeel as ifI'm a gamekeeper here, whereby I try and slaughter as many new drugs as I 
possibly can. " 
Another interviewce summed up the complex task of balancing the risk between the two 
sides, which was present at all times: 
"My understanding is - ifyou kill a bad drug early then you've got more money to spend 
on the other drugs, so I'm always aware when I approach a problem of what hasn't been 
done [innovative biomarker work], that may have relevance to the compound and other 
compounds like it" 
Here the notion of risk and resource is paramount, whereby there is an implication that 
freeing resource on one project by ending the project earlier, will allow this resource to 
be channelled into other drug projects. Innovators, who mentioned this, effectively used 
their innovative talents to develop innovative biomarkers in order to stifle drug 
innovation. Although this appears to be juxtaposition, it is symptomatic of the drug 
development process. Great lengths are taken to develop novel compounds that meet a 
defined criteria prescribed by Discovery and Clinical yet, as many innovators voiced, 
little notice appears to be taken of what happens outside of the defined framework of 
mcasurcment: 
"AII those drugs thatfail, we throw them away asfailures. What we should think of them 
as is test beds of the system not of the drug, so we ask "if we do this to the system why 
doesn 'I it do this? "" 
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To put a perspective on this, an interviewee explained that clinical studies take a variety 
of guises, yet early studies are primarily to assess the risk in taking an innovative 
compound forward and look at specific biomarkers that can prove a drug's potential to 
both the company and to also withstand regulatory scrutiny: 
"Basically to give the company confidence and see if it can be progressed to a larger 
study - or stop the whole thing. " 
At this stage interviewees explained that it is usual for only certain characteristics of the 
compound to be assessed and interviewees were unanimous in their observation that it 
was difficult to build innovation into standard biomarker chemical assays. However, the 
more innovative the compound was the more innovative work was possible when 
biornarkers outside of the "norm " were required. 
Innovative compounds require biomarkers that interviewees noted could potentially shed 
greater light on the expected and unexpected mechanism of action of an innovative 
compound. For example, a "routine " Phase I clinical trial will concentrate upon a defined 
number of biomarkers and little consideration will be taken of biomarkers or physiology 
that lay outside of these markers. Even though many innovators voiced the opinion that 
little extra effort would be required to acquire this greater knowledge and understanding 
it was rarely instigated. An interviewee commented that this related to the promise of the 
project and who was managing the work: 
"This is when it becomes subjective rather than objective. It depends on who you're 
working with and who you are trying to convince and what level ofrisk they are prepared 
to accept and on the disease itself " 
For example, numerous innovators stated that there is a higher degree of flexibility 
concerning biomarkers, when working upon a drug that challenged an unmet medical 
need. 
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However, interviewees noted that drugs that are attempting to challenge brand leaders are 
set "higher hurdles" simply because there appears to be a degree of restrictive thinking 
that drives colleagues to match and better an existing drug, using "existing and 
established mechanisms and measures" which, in other words, may be construed as a 
"standard". The findings on this aspect are presented in the following section and 
examine how the standardisation of biomarker work has Iýd to the standardisation of 
innovative compound development. 
The findings of this section lead to the following observations and themes: 
Innovation Theme 15: Biomarkers represent a highly innovative and time sensitive area 
that requires innovative work to both stop and drive further R&D. It is also an area that 
has the potential to divert resources to other more promising projects earlier within the 
processes. 
Knowledge Management Theme 15: Innovation at the biomarker stage relies upon 
sufficient knowledge and information to understand the mechanism of action of the drug. 
Without this, the risk of attrition finther down the development pathway increases 
substantially. 
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Table 7.4: Conceptually Clustered Matrix: Biomarkers and Innovation 
Area Studied Findings across Discovery & Clinical 
Innovative Aspect Developing innovative biomarkers to 
highlight innovative drug R&D 
Drivers 0 Strategic drivers to prove that a 
drug is viable 
0 Existing and known biomarkers - 
a drug should conform to these 
(within strict limits) 
0 Promising R&D that requires 
biomarkers that exist outside of 
the norin 
Required Criteria 0 Sufficient time and resource to 
develop biomarkers that fully 
capture a drugs potential 
0 An acceptance that novel drugs 
require greater resource but the 
rewards are potentially greater 
Outputs 0A biomarker that allows a drug to 
progress 
0 Confidence in the safety and 
efficacy of the drug 
0 Greater resource availability if a 
drug can be "killed" earlier 
9 Knowledge and information that 
may provide a greater 
understanding of the drug's action 
- if innovation is allowed 
Underlying themes 0 Biomarkers are an area of intense 
innovative activity 
9 Without sufficient resource the 
risks associated with each 
compound increases, i. e. with 
inaccurate biomarkers a poor 
compound may progress, yet on 
the other hand a compound may 
be disregarded if its expected 
actions are not confirmed 
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7le potential of Knowledge Management within biomarker work is evident, but these 
findings also revealed that there is a push towards large pharmaceutical organisations to 
develop a standard drug. The following section examines this aspect of AstraZeneca's 
innovative strategy in greater detail. 
7.4 DEVELOPING A "STANDARD" DRUG? 
Intcrviewees pointed out that a drug development project typically falls under three 
strategies; these are 'first in class", 'fast follower" or "me too". "First in class" 
represents highly innovative work and requires a drug to be radically different to any 
other on the market. A "fast follower" aims to seize market share by the introduction of a 
drug which out performs a recently released drug, whether it be from AstraZeneca or 
from a competitor. "Me too" drugs exploit commercially available knowledge to create a 
drug that offers advantage over currently available similar drugs. When questioned over 
the strategy adopted by AstraZeneca, a Discovery employee commented that each type 
required a different' approach, however, each suffered from the same blinkered and 
process driven view: 
"We don't care how a drug works, just if it does and that's our data. All these drugs that 
make it [a disease] go slower are as much use as the ones that make it gofaster - it'sjust 
we've got tofind a way ofmeasuring that. " 
An employee from Clinical noted that the AstraZeneca strategy appeared to gear its drug 
development work towards "first in class" whereby the drug meets an unmet medical 
need or approaches a disease from an innovative angle. Although the precise data 
concerning the extent of AstraZeneca's drug strategy is unavailable, innovators were of 
the opinion that it was significantly easier to work within the boundaries of a "first in 
class" product. However, a "first in class" drug places heavy demands upon resource and 
many employees again voiced the opinion that this could be futile. A researcher 
commented that, although AstraZeneca devoted great resource to its projects in order to 
be "first in class", in effect the end result was a "me too" as it's competitors were all 
drawing from popular research and hence working upon similar areas: 
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"20 years ago companies seemed to be a lot more secretive because they were doing the 
same sort of stuff, but nowadays everybody is doing a 'me too' as they're all using the 
same sources, and so we have a lot ofX antagonists, so we're all competingfor the same 
market. In effect, we're making a 'me too'rightfrom the wordgo. " 
Although Astra. Zeneca may be developing drugs that are 'first in class', interviewees 
noted that the competition is also highly likely to be developing compounds along similar 
lines. Therefore, when the drug is released it is likely to face stiff competition from rival 
drugs and become a 'me too', perhaps inadvertently. Employees raised concerns that not 
only were there competitors working on similar biological targets, but other AstraZeneca 
departments could be, and in some cases were, working on the same area and target. A 
senior physician raised this as an unavoidable scenario of the 'scatter gun' approach 
adopted by AstraZeneca: 
"The other thing we're in danger of doing is because we're not being so specific 
anymore, there's a risk of duplicating effort - You may find out that the GI [Gastro 
Intestinal] people are working on the same target and you don't know about it - and 
that's a difficult thing to know what's going on. " 
This is an alarming comment when the expense and resource of developing a drug are 
taken into account. However, all interviewees commented that this situation can exist due 
to the closed project mentality adopted by AstraZeneca. When interviewees were 
questioned over the extent of how collaborative working patterns have been introduced to 
stop this, an interviewee noted: 
"Well we try to [collaborate], we were tasked with looking at X [established AstraZeneca 
drug on the markeljfor broncho inhalation and we thought we'd ring up the guy at X and 
look to see if there was any hint that it had an action on COPD - and theyjust wouldn't 
give us the data. " 
The interviewee continued: 
"It was a sort of "it's ours, its proprietary "- they've only just agreed to send the data 
and that's 6 months later - it's crazy! " 
222 
Chapter 7- AstraZencca and an Innovation Culture 
This outcome resulted in a tangible 6 month delay in the process of accessing project data 
that, by the accounts of the interviewees, should be available to all (or most) employees 
within AstraZeneca. Yet all innovators were certain that delays of this kind were rarely 
reported or more importantly acted upon, they fell under the banner of "the way we do 
things round here. "A fundamental reason why this may be was proposed by an 
interviewee: 
"77ie way we do research around here is what we call hypothesis driven, so we have a 
hypothesis that we test. " 
The interviewee continued to comment that hypothesis driven research was at the root of 
why compounds or even drugs were steadfastly applied to one disease area alone. Rarely, 
if ever, would a compound be investigated across Therapeutic Areas (TAs). This is 
certainly a common finding and essentially arises due to the hypothesis being 
"restricted" to a certain area. Other interviewees commented that other potential ways of 
research could be effective in driving innovative work across TAs: 
"There's another complete way ofdoing research which is the engineering approach and 
the way we do it is to tweak something to see if it goesfaster or slower. " 
Yet interviewees stressed that the current situation can and does result in the people and 
tearns working on the project becoming disinclined to accept research outside of the 
hypothesis: 
"Team processes are very discrete groupings. Because we're working with some people 
who are very innovative in their thought processes - working with them is a no-brainer. 
Others are starting to come round but in the same department some are so 
mechanistically entrenched that it's beggar's belief. " 
When referring to "discrete groupings", the intervicwcc clarified that, within tearns, a 
distinction of innovative behaviour existed, however the extent of entrenched behaviour 
exhibited, varied in accordance with the risk associated with being innovative. This 
juxtaposition in behaviour by employees may be explained by the proposition of risk and 
the management of risk. 
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Once a compound has been identified as a potential drug, then AstraZeneca must have 
confidence in the safety and efficacy of the drug which involves weighing up the 
perceived benefits and the known facts. An interviewee explained that promising drugs 
could-generate unrealistic expectation, particularly if it was highly innovative, a factor 
that certainly causes a change in people's reactions to sharing information and 
knowledge: 
"If it's an unmet medical need then the hurdles are lower. Even in my own thought 
processes, working for the unmet medical need project, the processes are completely 
different, not easier but different. The only thing that gets to me in terms of ability to do 
things - is unrealistic expectations. " 
The following themes and matrix condense the findings of this section: 
Innovation Theme 16: Hypothesis driven research restricts the extent of innovative 
activity possible by narrowing the viewpoint of the employees involved. As a result, 
innovative research and data is poorly shared across AstraZeneca. 
Knowledge Management Theme 16: The hypothesis driven approach results in 
duplication that may or may not be uncovered. Adopting a "systems engineering" 
approach may avoid duplication of effort and wasted resource. 
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Table 7.5: Conceptually Clustered Matrix: Standardisation and hypothesis driven 
research 
Area Studied Findings across Discovery & Clinical 
Innovative Aspect Developing innovative drugs that are 
differentiated from the competitors 
Drivers 0 Strategic drivers - the drive to be 
"first in class" 
0 Competitors' drugs 
Financial drivers 
Promising external research that 
could lead to a competitive 
advantage and a less 'WsW' 
product development route 
Required Criteria 0 External research that promises 
differentiation 
0A hypothesis that is flexible and 
allows innovative thought within 
its bounds 
0 The innovative vision and 
freedom to drive a differentiated 
product 
0 Access to work across TAs within 
AstraZeneca 
*A lack of competition within 
AstraZeneca - or at least co- 
operation concerning compound 
data 
Outputs 0A potentially innovative drug that 
is first in class 
0A drug that adopts a "me too" or 
"fast follower" stance - either 
should provide a degree of 
financial return 
Underlying themes 0 Hypothesis driven research may 
result in a standardisation of the 
developed drugs which results in 
"similar " drugs being developed 
0 Hypothesis driven research results 
in a duplication of evidence as it 
fails to take into account areas 
outside of the boundary of the 
hypothesis i. e. other disease areas 
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While this section has examined how hypothesis driven research can adversely affect 
pharmaceutical drug development, the following section continues to explore the criteria 
and drivers that allow innovation within AstraZeneca. 
7.5 CONSIDERING THE CRITERIA THAT DRIVE INNOVATION 
7.5.1 INNOVATION OUT OF NECESSITY OR LUCK? 
As this research has shown, innovation arises out of a number of areas including 
collaboration and acquisition amongst others. However, of the innovations studied, all 
were driven by a need to either solve a specific process related problem or improve the 
way a process was carried out. For example, one interviewee, who developed an 
innovative way of running a clinical trial, had the opinion that unless you had a solution 
to a known problem within a current project, then you were unlikely to receive funding: 
"He [the project manager] had a real problem in that he didn't have the resource to run 
the study and so called upon us to fix it - and only then was he interested in it [the 
innovation], but maybe ifyou tried to sell him that technology generally then he'd be like 
"I'll see you later " ". 
Although this comment is tongue-in-cheek, it sums up the feeling of many in that their 
problem solving abilities and skills are often overlooked and only needed when projects 
hit a dead end. Others said that a way they could bring their own innovative behaviour to 
bear would be by analysing their current ways of working, and processes, and 
highlighting the areas that caused the most problems: 
"So the innovation is in doing a proper gap analysis and then actually working with all 
those projects that are coming through to work with these new methodologies. So every 
time we have a new project we bring it onto the radar of the Global Product Team 
[GP77. " 
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In this manner innovation stands a higher chance of being accepted as it meets a defined 
need and will be highlighted to the senior strategists, which in this case is the GPT. These 
observations are represented in the following themes: 
Innovation Theme 17: Innovation typically arises as a result of a defined need by a 
project. Innovation that lacks specific and immediate application outside a project is 
highly likely to be disregarded. 
Knowledge Management Theme 17: There is a lack of appreciation of the knowledge 
capabilities of the employees and this is manifest in the levels of discontentment felt by 
innovators who may struggle to progress their innovative work. 
The previous themes are relatively self evident but important, none the less. They 
indicate the importance of defining a problem to spur collaboration and to attempt to 
meet a previously unknown need. However, many innovators broached the interesting 
idea that serendipity or luck plays a major role in AstraZeneca's dynamic ability to cope 
with highly varied problems. As one interviewee commented: 
"Yes, serendipity, that's how you find most things in life. Most things in life happen by 
luck; it's all luck, and its being in the rightplace at the right time -you meet oneperson. " 
While another Discovery interviewee emphasised how at odds this reliance upon luck 
was within a scientific organisation: 
V believe this is very dangerous for an innovation led industry that the chance element 
plays such a big part and is so prevalent. It is dependent upon the right people making 
the right connections at the right time, and that's a problem. " 
The role played by luck within drug innovation is startling; with many innovators 
believing it is a necessary factor of drug innovation. Luck certainly plays a key role in the 
beginning cycles of drug development as innovators' suggested that this process appears 
to rely in part, upon employees stumbling across the work of others in journal papers or 
at conferences. Furthermore, the research data suggests that luck is apparent throughout 
the drug development stages. 
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A clinical scientist commented that their idea, which had won an AstraZeneca innovation 
award, initially stemmed from academia, but a passing comment had allowed it to 
progress: 
"I would say that the initial idea came from academia but then I took it forward and 
presented it to the project teamsfor agreement. So it wasjust a chance remark when they 
asked "have you considered doing an IV and an oral dose on the same day? " and I 
thought, yes, that's going to work. " 
While it is difficult to gauge the influence of luck within the daily work of the employees, 
it is evidently a valuable factor within many of the cases studied and has been responsible 
for driving the innovation itself on occasion. 
When coupled with a "slow and incremental" pace of innovation suggested by many 
interviewees, it provides a good indication of the amount of risk involved within 
AstraZcneca's innovative processes. Without a degree of luck, many of the innovations 
studied would not have been possible, yet of the innovations studied, almost all resulted 
from the innovator's personal network of acquaintances. While the degree of managerial 
influence that formed these connections cannot be measured at present, the research data 
gathered from managerial staff suggests that the innovators are placed in the right place at 
the right time through the structure of the organisation. 
A senior director explained: 
"It's not what I do, but how I do it that is the innovative aspect .... two of the main 
knowledge assets are internal people and external people. The people that work for me 
directly and I interact with offer me the most knowledge, and knowing who to interact 
with and what they do and don't know, is to me the most important aspect. " 
From a Knowledge Management perspective this firmly equates to the description of a 
Community of Practice facilitator, yet from an innovation perspective this managerial 
influence equates to a "guiding hand", but the extent and effectiveness of this guidance 
is rather unclear. This observation also contradicts the observation in chapter 6 that an 
employee's capabilities can be overlooked. 
228 
Cbapter 7- AstraZeneca and an Innovation Culture 
On one hand there is the innovative manager attempting to utilise people, while the 
reality for some innovators was markedly different. When interviewees were asked if the 
relationships in their personal network were ever written down or captured electronically, 
innovators resoundingly replied "no". This suggests that without an innovator's personal 
network the concept of luck would play an even greater role. 
Innovators also raised the point that employees who were new to the organisation lacked 
this network and in a large organisation, such as AstraZeneca this was essential to 
innovate. These observations give rise to the following emergent themes and matrix: 
Innovation Theme 18: Luck plays an essential role throughout the early stages of drug 
innovation, yet may be guided and created through effective management practices. 
Knowledge Management Theme 18: The community-of-practice model plays an 
integral part in bringing potential innovations to the forefront. However, this process may 
still be reliant upon an clement of luck to make'thesc initial connections. 
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Table 7.6: Conceptually Clustered Matrix: The drivers of innovation - necessity and luck 
Area Studied Representative findings across 
Discovery & Clinical 
Innovative Aspect The role of necessity and luck to drive 
innovation 
Drivers 0A specific and defined problem 
within a project 
0A problem that can prevent a 
milestone being reached, i. e. 
inadequate means of collecting 
clinical trials data 
0 An opportunity to introduce 
innovative work 
0A need for a greater awareness of 
what could be achieved 
Required Criteria 0A defined need and a vision of 
what could happen 
0A degree of luck 
0A personal social network of 
colleagues 
0 The knowledge required to form 
worthwhile social connections 
0 The initiative to challenge what is 
the "norm " 
Putputs Meeting a specific need through 
innovative behaviour 
Stronger bonds within the network 
- greater awareness of the 
capabilities of people within the 
organisation 
Underlying themes 0 People's capabilities can be 
overlooked unless a manager 
explicitly performs a "gap 
analysis " 
" Poor knowledge and information 
capture surrounding the personal 
networks 
" The Community-of-Practice 
model is widely employed to 
acquire innovative knowledge, yet 
relies upon an element of luck 
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The role of luck and innovation out of necessity brings an element of risk to the 
innovative ability of AstraZeneca. To explore this further the following section examines 
how innovations are either embraced or discarded dependent upon the perceived risk 
associated with the novel approach. 
7.5.2 INNOVATION AS A RESULT OF CONSERVATISM? 
A Discovery director proclaimed that effective innovative practice is dependent upon 
mitigating the risks involved within pharmaceutical development and making the 
connections between disparate "bits of information andpeople". However, the extent of 
how much this cautious interplay between risk and innovation should be managed was a 
contentious point. On one hand, interviewees were quick to point out the successes of 
AstraZeneca and describe the innovative drugs they had been involved in producing. Yet, 
on the other hand, the risk adverse organisational culture was described as a handicap by 
all on occasions: 
"There is reluctance in AstraZeneca to do these things, and it's interesting - again a very 
rich and innovative early portfolio with all sorts of new mechanisms, but a relatively 
conservative development organisation. " 
Other interviewees also suggested that the conservative approach to drug development 
arose through the need to innovate to avoid crises: 
"Not innovation in products or technology but more innovation in processes, so you 
know how to deal with specific issues - so you Io7ow that's how to avoid getting into 
problems or crises. " 
Hence, innovation was viewed not as a tangible end product, but as a response to avoid or 
side step a potential crisis. Yet, even when faced with considerable pressure to innovate, 
the existing status quo exerts a strong force with little capture of the reasons and decision 
as to why this would be so. A Clinical physician commented: 
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7found out that more recently there has been an initiative to shift certain hehaviours, 
hut even within a meeting of a short span, perhaps an hour, within the presentation, the 
questions and the conclusions -there's a kind of return to the status quo. " 
All innovators voiced this opinion and the majority remarked that rarely is the knowledge 
and information around these discussions captured -a situation which arises due to the 
pressure to work quickly and at times against their better judgements. Many innovators 
remarked that Phase I clinical trials was an area where this was greatly felt, because its 
aim is: 
"Basically to give the company confidence and see if it can be progressed to a larger 
study - or stop the whole thing". 
This is evidently a crucial point and can lead to a considerable pressure on the employees 
involved to take a calculated and innovative risk rather than the "safe route". As one 
manager remarked: 
"The ultimate aim is to get better by doing these technical studies in a more innovative 
way, so cheaper, quicker, better and not necessarily at the same time " 
Innovators voiced that the continual managerial pressure to quickly react and complete 
projects in the shortest possible time was an unrealistic means to develop products. In 
many ways, interviewees said that a cycle existed where innovative work was a necessity 
to overcome problems as they arose, yet on the whole it was difficult to gain acceptance 
even though it was necessary. This was a common finding across the interviews and the 
resulting themes and matrix from these findings are: 
Innovation Theme 19: Innovation is required to allow employees to overcome 
traditional working practices, yet the conservatism of AstraZeneca can prevent innovative 
work from succeeding. 
Knowledge Management Theme 19: The knowledge and information generated from 
the discussion of potential alternatives and innovative work is rarely captured and rarely 
disseminated organisation wide. 
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Table 7.7: Conceptually Clustered Matrix: A conservative approach to innovation 
Area Studied Representative findings across 
Discovery & Clinical 
Innovative Aspect Organisational culture and acceptance of 
innovation 
Drivers 0A specific and defined problem/ 
process that creates a demand for 
innovation 
0 Pressure to work ever quicker 
0 Pressure to be more productive 
Required Criteria 0A defined need or process to 
change 
0 An "open attitude " to accept that 
change could bring about benefit 
0A means of convincing people to 
take an innovative route - 
meetings, face to face discussions, 
etc. 
0 Convincing information to take 
the innovative route 
0 Determination to see an idea 
through 
outputs Meeting a specific need through 
innovative behaviour 
At present a return to the "status 
quo" on the majority of occasions 
Underlying themes 0 Conservatism is rife within 
AstraZeneca and may hamper 
innovation 
0 Poor knowledge and information 
capture concerning the decisions 
on whether to take the innovative 
or conservative route 
The reasons that are hampering innovation are many, and the discussion of these factors 
that are returning the organisation to the status quo, produccd some strong feelings 
amongst intcrviewees. In particular, a lack of resource and a lack of appreciation of an 
employee's skills are discussed in greater detail in the following section. 
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7.5.3 INNOVATION OUTSIDE OF AN EMPLOYEE'S SPECIFIC ROLE? 
As this research has already revealed, the lack of financial resource pushes innovative 
work aside and leads innovators to perceive that their skills are underutilised. Many 
interviewees voiced that "outsourcing" was the route drug companies such as 
AstraZeneca were using to save resource and "speed up the development processes" 
instead of utilising the employee's in-house skills. However, interviewees mentioned that 
outsourcing cannot solve AstraZeneca's internal problems; it merely results in a short 
term alleviation of the problem. Interviewees commented that outsourcing was seen as 
the panacea to solve the problems faced by AstraZeneca and the industry as a whole: 
"More and more and more people are "externalising funding" - because in effect, if 
you've got a good group of bright people, they could do more and cheaper than you 
could in-house. It's cheaper to buy a post doc than to work in AstraZeneca! " 
Ibis observation was also raised by other innovators who voiced that they felt their work 
was of little value to the organisation. Employees perceived that it was preferential, in 
terms of resource, to outsource innovative early development work, yet this often led to 
innovative work being carried out within the company being overlooked to the detriment 
of the innovators: 
"Its not really about where it [the innovation] has comefrom it's about who gets credit 
for that. For example, Xs [name of innovator omittedfor privacy] work - why should we 
develop it? U%y can't we just buy it from the company who is providing XYZ [name of 
Innovation omittedfor privacy]? And then that hurts - it doesn't hurt the company it 
hurts the innovator. " 
Iley continued to raise the interesting point, that the innovators themselves could be 
viewed as external collaborators in order to drive innovation: 
7 think we need a mechanism whereby you have an idea andyou know what you can do 
with it and you can suggest to the company or how you can push things forward. In that 
case you are treated as one of the [external] collaborators. " 
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As another intervicwce explained, employees have traditional roles which are the 
mainstay of the company. Within these roles the emphasis is upon performing tasks 
quicker and not necessarily in a more innovative fashion: 
"So it's about doing things in a narrow area and knowing exactly how to do things and 
how to do them better - but keeping a similar standard, but I think that innovation goes 
off when you deal with the professional element. " 
Few innovators felt their innovative ability was truly valued within their role, an 
interview explained that once their innovation had been funded their principle role in its 
inception was overlooked: 
"That's the thing that kills innovation .... You've got to be quick andprotect your idea, as 
once these things start happening it's very easy to get crushed under bigger things. " 
Another conunented that there were no clear benefits to being innovative, unless you had 
to specifically solve a problem: 
"Do you do it for research or for recognition from your peers? It comes down to 
protecting your Intellectual Property within the company. " 
Tberefore, interviewees also raised the traditional adage that handing over an innovative 
idea also handed over power, as it was their personal knowledge and tenacity that 
provided the ability to progress drug projects and generate a financial return for 
AstraZeneca: 
"There is an element of knowledge, but there is the element of the human dimension. The 
element ofpower, where certain people will share up to a certain point where that gives 
them power - if they completely release that to any given point, they relinquish that 
[power] - so in any Knowledge Management strategy that cannot be completely 
underestimated or ignored. " 
The interviews also focused upon exceptional innovations outside of the traditional arena 
of drug development and this raised some interesting responses. 
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A number of Knowledge Management systems were developed within AstraZeneca and 
achieved recognition, yet winning the support to continue this work was often hard: 
"It's dijfIcult to try andprove it's [the innovation is] worthwhile. Yes, it depends on your 
background - ifyou have a successful track record then it's easier, but ifyou have just 
come into the company, then I thinkpeople are a bit scared of the risk. " 
Others with the "successful track record" noted that although it is difficult to gain 
management backing, part of the problem with Knowledge Management also lies in 
ensuring the end users support the project: 
"It's quite dijfIcult in the company to get any kind of backing especially from 
management - so the real driver is not management it is the users. Men you approach 
an idea to the users and they say that this idea is good and then, yes, you get a team 
aroundyou " 
On the whole innovation within an individual's role is acceptable but when it lies outside 
of an employee's recognised expertise it becomes increasingly difficult. These 
observations give rise to the following themes and outline the dynamic nature of 
knowledge required to innovate within AstraZeneca. 
Innovation Theme 20: In many cases innovation occurs outside of the individual's 
traditional role, yet attempting to progress these innovations is particularly difficult as it 
rclies upon both management and the end user (i. e. project team or-software user) 
accepting the innovation. 
Knowledge Management Theme 20: Innovation requires an exchange of knowledge 
where the innovator feels valued and rewarded for knowledge outside of their job remit. 
Sadly, in AstraZeneca, this sometimes is not the case. 
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Table 7.8: Conceptually Clustered Matrix: Driving innovation outside of an employee's 
role 
Area Studied Representative findings across 
Discovery & Clinical 
Innovative Aspect The acceptance of innovative 
employee behaviour 
Drivers 0A specific and defined problem 
that requires an innovative angle 
9 The availability of "oulsourced" 
knowledge and information 
0 The perception that external 
innovation is "heifer" 
Required Criteria 0A defined need 
0A persistent innovator who does 
not "give up " when external 
innovation is sought over their 
ideas 
0 The ability for the employee to 
broaden their role beyond their 
normal duties 
0A means of convincing people to 
take an innovative route - 
primarily management, but also 
users for Knowledge Management 
innovations 
0 The ability to make yourself heard 
in the organisation 
0 The people to accept internal 
innovation over external 
innovation 
Outputs 0 The Intellectual Property 
associated with the innovation 
Recognition as an innovator 
An innovation that meets a 
defined need - developed by 
people who are part of the process 
Underlying themes 0 Innovations often lie outside of an 
employees role or expertise 
0 Innovative behaviour demands 
appreciation, which is not always 
forthcoming 
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71c previous findings illustrate how innovation may stem from areas outside of an 
employee's role. The role of the highly talented individual within AstraZeneca is, in 
many ways, restricted and this leads to innovative ideas outside of their role, as has been 
witnessed within this study. Yet if such innovations are poorly accepted, how is 
AstraZeneca trying to encourage innovative ideas? As the previous findings suggested, 
the answer appears to lie in providing the employees with the ability to innovate, through 
organisational change. 
7.6 INNOVATION THROUGH A PROCESS OF CHANGE 
7"he research has revealed that AstraZeneca is largely reliant upon acquiring innovative 
research that has reached a certain stage, e. g. one where there is confidence that a new 
drug can be eventually marketed. The research has also shown a tendency for these drugs 
to essentially be a "me too", which is evidently less risky and less expensive to develop 
than a "first in class". The reasons behind this are largely financial. As an example of the 
expense associated with "first in class" drugs, the industry giant Pfizer recently acquired 
a biotech company that was developing a HDL-raising (good cholesterol) drug for $1.3 
billion (Barrett, 2005). Such expenditure is becoming commonplace amongst drug 
companies, but acquiring creativity at this stage where there is good supporting scientific 
knowledge that a viable "first in class" drug can be marketed is exceedingly pricey, but it 
does remove an element of risk, as does the development of a "me too". As mentioned 
previously in sections 7.4, the traditional model of in-house drug development is now 
largely redundant, and in many ways the AstraZeneca strategy to diversify its pipeline 
outside of its standard therapeutic areas is an approach that is not an option but a 
necessity. When interviewees were questioned as to how innovative drug development 
can continue and how AstraZeneca can diversify with the financial costs associated with 
acquiring "first in class" research, many interviewees recognised that fundamental 
organisational change was required. 
While the researcher was working within the organisation, a whole-scale change in the 
R&D Clinical organisational structure occurred, which was designed to improve 
efficiency and innovative activity. 
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As expected, the results of this change met with varied opinions, some in favour while 
others distinctly less so. The majority response ventured by innovators within Clinical 
was that the change had resulted in a lack of resource, with personnel expected to cover 
more work than they had previously with less human resources available to them. All 
interviewees who ventured this opinion had experienced the need to change their working 
structure and felt an increased pressure. As one commented: 
"Having people in positions where they are so stretched is also a waste, you know 
someone of that standard [a consultant physician] should be given something that 
deserves theirfull attention ... 
but to be brutally honest, the new Clinical operating model 
stifles innovation full stop. It's a thoroughly biased objective opinion but I truly believe 
itl PP 
The interviewee was a senior researcher within AstraZeneca Clinical and they continued 
to give the reasons behind their views: 
"By trying to rush things and doing things without adequate and appropriate resource, 
you make mistakes and that is very hadfor the profile of the company. Its one thing to 
take risks but it's another thing to make mistakes. 
They continued to blame this upon the differences in how scientific and non-scientific 
personnel across AstraZeneca perceived the risk/ benefit model: 
"Now You can say by stripping down available resource and available expertise, that is 
an acceptable risk, but it's something that I don't see at all. The process people will 
probably see that as an acceptable risk but I don't - the logical, scientific mindjust sees it 
as stupidity! " 
Again, the majority of interviewees focused upon insufficient resource - failing to 
provide employee's adequate time to complete their new work were the most cited 
reason. Others felt uncomfortable because after the reorganisation their role was less 
defined, effectively being told to learn new skills in order to maintain their position and 
hence, to an extent, loosing their specialist knowledge of one critical step within the drug 
development phases. As one key innovator within AstraZencca broached: 
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"When I think of my drug development experience, when I give advice and expertise to 
leams - I'm mainly relying upon my experience in previous drug development" 
However, they continued to mention that adopting a "generalist" model could extend 
AstraZeneca's innovative abilities: 
"I'm more relying on lateral thinking - I've got very broad interests. I wouldn't say I've 
got all science knowledge to a certain depth but I'm very broad, more a generalist. I 
think I can take my creative energy out of the breadth rather than the depth of a certain 
thing. " 
Hence, there is a clear disparity between drug development knowledge which is specific 
and a valuable subjective resource, against innovative knowledge that occurs from 
applying unrelated knowledge to a problem. The tail of the previous comment explains 
that if innovators are generalists, it raises the question to what extent can drug 
development specialists entrenched in one part of the organisational process, ever be truly 
innovative? When interviewees were questioned as to the extent of their background 
research prior to joining a drug project, a research scientist commented: 
"I believe that you should read as little as possible, because you cannot help but be 
influenced by what's been written. So, if you want to be truly innovative, you take the 
biological system you've got and think about it tofind out where it is leading. " 
However, the interviewee noted that this went against Knowledge Management 
principals and could result in the duplication of work: 
"It's a bad way of doing something, as you can then find "Oh yes, someone has already 
done that! "... But if you go down papers [academic literature] as the first route you 
become seduced into ways of looking and thinking about things - that may or may not be 
true. OK, so ifyou have to be truly innovative then you have to be without inj7uence. " 
Thus a characteristically complex scenario emerges, one where the purported benefits of 
Knowledge Management, e. g. knowledge capture and reuse, may inhibit innovation! 
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A subtle balance is therefore required between avoiding the reinvention of knowledge 
and retaining a basic level of knowledge that may prompt innovation. Yet, as Section 7.5 
noted, personnel simply do not know what is occurring within AstraZeneca, both with 
regard to international colleagues and to drug projects that fall outside of their immediate 
project work. The new Clinical operating model places employees within multiple 
projects and, therefore, multiple teams that span the organisation, in an attempt to 
promote collaborative behaviour in this respect. It would appear that the reorganisation 
attempted to address the entrenched culture, but through the introduction of more work 
and less resource, innovation has been inadvertently stifled. Furthermore, the majority of 
innovators noted that organisational change occurred whether they wanted it or not, 
prompting employees to question whether another round of organisational restructuring 
could ever bring about the result of increased productivity required by senior 
management: 
"They almost see organisational change as a way ofgaining more productivity - and that 
may be true in some artificial way - in terms of management metrics where we measure 
the productivity. However, if we measure it in terms of innovation then I'm not sure that 
this happens in a clear way. I don't think the connection between an organisational 
change and innovation is clear. " 
Undoubtedly Knowledge Management and intellectual capital can play a role here. 
However, even though the restructure has "streamlined" the resource available to the 
project teams, many interviewees were still expressing that this new model would still 
lead to an ever greater waste of the available resource within these restructured project 
teams: 
"You'd have tofire halfthe people in AstraZeneca to make it more efficient! I mean I've 
been working here for three years and I don't know who two thirds of the people in this 
building are and I certainly don't know what they do - are they actually doing anything 
useful? " 
Another interviewee commented on the convoluted processes being made worse by the 
number of "hoops" that employees had to pass though to proceed. 
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Again, it was a question of "too many goodpeople " working in the wrong organisational 
structure that did not utilise their key skills: 
"The more people you have the more it generates more people and more waste of time. I 
workedfor a small American biotechfor a while... We had time off to go to the pub, gofor 
lunch and we did it because there were only six of us, so we didn't have any meetings, 
you know you couldJust go on and do thejob. " 
The interviewee ended this comment by adding: 
"To befair life was a bit easier as this was 15 years ago andyou didn't have to comply 
with so many things, but I think the same model would hold true here to an extent. " 
Evidently there are issues that are causing concern to the employees interviewed for this 
research and within a large and highly regulated organisation these views would be 
expected. However, even after a reorganisation there are still concerns within project 
teams, most notably the perceived waste of resource of skill and expertise of the 
employees. These key observations and the qualitative findings of this section are 
captured and represented in the following themes and conceptual matrix: 
Innovation Theme 21: Organisational restructuring is intended to increase productivity 
and drive innovation. However, in certain cases, the increased responsibility and 
realignment of the employee's roles leads to a decrease in potential innovative ability. 
Knowledge Management Theme 21: Organisational change causes a distinct change in 
the relative information and knowledge needs of the employees as they learn new skills 
and take on a different role. 
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Table 7.9: Conceptually Clustered Matrix: Organisational change and innovation 
Area Studied Findings across Clinical 
Innovative Aspect Examining the affect of organisational 
change upon innovation 
Drivers 0 Organisational change as a 
perceived means of driving 
innovation 
* Redefinition of roles to cover a 
broader remit 
0 Strategic drivers - development 
of a "first in class" 
0 Financial considerations 
Required Criteria 0 Employees capable of adapting to 
their new roles quickly 
0 Sufficient knowledge and 
information to make the transition 
0 Sufficient resource (financial and 
time) to encourage innovation 
within their new role 
Outputs 0 Potential increased productivity 
0A leaner organisation that utilises 
less resource 
The potential development of 
drugs that are "first in class" 
Underlying themes 0 Organisational restructuring is 
difficult to achieve correctly 
without stifling innovation 
0 Information and knowledge 
requirements for innovation may 
be hampered by an ineffective 
reorganisation strategy 
It was apparent throughout these interviews, that a clear dissatisfaction with the 
organisational structure existed and in many ways interviewees mentioned that the 
management drives to increase efficiency and productivity can act against innovation. 
The following section discusses this relationship in greater detail and examines the means 
employed to measure innovation and productivity within AstraZeneca. 
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7.7 MEASURING INNOVATION 
7.7.1 MEASURING THE SUCCESS OF INNOVATION THROUGH 
PRODUCTIVITY 
As the last section revealed, organisational change does not necessarily lead to 
innovation. In this case, the transitional stage posed considerable problems for the 
interviewees as they adapted to their new roles and, on occasions, a lack of resource. A 
number of interviewees concluded that this could be a result of how innovation was 
perceived and acknowledged by the relative parties. One interviewee explained that the 
strategic vision of managemýnt differed from theirs: 
"That's the difference in the definitions of innovation. For some [management] it's doing 
things quicker. For me it'sjust about creating and doing something new! " 
Others noticed that reorganisation and management in general, firmly linked measuring 
innovative activity with the speed a project or development progressed, regardless of the 
difficulties associated with carrying out a project, whether it is innovative or not: 
"You know whether it's an easy or a hardprocess ... I mean people say "be innovative, be 
fiaster ", but it's often "be innovative, take your thne "" 
Certainly all AstraZeneca employees strive to be productive, yet the research findings 
question whether productivity and innovation are linked to the extent that is perceived by 
management organisational strategies. The views of innovators varied but the majority 
viewed innovation as a separate entity: 
"Although I think organisations can facilitate innovation and we [. 4straZeneca] should 
do - though this would be very difficult to quantify and demonstrate that this particular 
organisational change has done that, is not so easy, but there might be a productivity 
ratio you can measure - but these are not necessarily the same things and they are not 
equivalent [productivity and innovation] " 
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Of the innovators interviewed, only one interviewee commented that "innovation and 
productivity go hand in hand", but continued to state that they viewed innovation as 
"designing the best solution "- in effect, the most productive solution. 
However, the majority of interviewees felt that pharmaceutical innovation sat aside from 
productivity, and stated that increased productivity rarely meant increased innovation. 
However, all interviewees agreed that innovation often results in a tangible outcome that 
is distinct from creativity: 
"I see it differentlyfrom creativity. Innovation is really the proof of concept, you take the 
Idea andprototype it. Innovation is notjust about being creative, you have to show that it 
might work andfor me that is important. So that has implications - the company really 
has to allow prototyping ifyou foster creativity, ifyou don't allow the next stage - then 
you're stuck with your innovation process. " 
What was also apparent was the apparent disconnect between the measurement of 
innovation and productivity through Key Performance Indicators (KPIs). Although 
innovation can result in a tangible end product, interviewees noted that the metrics 
associated with this are different to those used to measure productivity. All interviewees 
stated that AstraZeneca's KPIs simply did not cover innovative activity and, worse still, 
they are often unrealistic, with many expressing the opinion of the following employee: 
"We have our KPIs and we have no role in setting these up - on the record, these are 
people who don't have a clue! I would like to say that the company is looking at realistic 
planning - but it doesn't. It's the same for everything, you put forward a realistic plan 
and it's cut in half- It's stupid! " 
11is study certainly generated emotional answers concerning this subject and although 
there is a divergence between measuring innovative activity and productivity, the data 
suggests this leads to a worrying difference between what is planned and measured and 
what can actually be achieved. 
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This was a consistent observation throughout the interviews and appeared to stem from 
the fact that staff at the "shopfloor" lacked the "voice" to assist in setting realistic KPIs 
that reflect their true working environment. As an example, this illustrates this point: 
"When you are told [by project managers] that there's no reason why you can't write a 
protocol [Clinical Trial protocol] in the afternoon and in fact it takes 6 weeks - when 
you've got that level of disconnect then it's very, very difficult - it's just totally 
pathetically unrealistic. The reality [of what is possible] versus the mission statement 
[measures and metrics] - there's a huge difference. " 
Interviewees frequently mentioned this type of unrealistic expectations and mentioned 
that it was, therefore, difficult to measure innovation effectively. The reliance upon 
standard KPIs to assess productivity and therefore act as a measure of innovation is at 
odds with the review of Chapter 3 which covered intellectual capital methods. When 
innovators were quizzed concerning the use of intellectual capital assessment methods 
almost all were unaware of the available methods. A number of senior directors had, 
however, heard of the term, yet expressed that the current measures did not address this 
issue: 
"No there isn't and that is a worry, there is no way or formal audit process to capture 
this information. " 
Of the methods suggested to the interviewees the Balanced Scorecard was recognised 
though its application and use was confined to one Clinical department. Overall however, 
the innovators recognised the need to concentrate upon this area further to link 
innovation, productivity, the people and the knowledge required by drug development 
projects. Yet due to the unforeseen needs associated with a project as it progresses, this 
approach was viewed as difficult. A comment by a director summed this up: 
"Yes, interesting. That would always be the best way, and have all the people operating 
in the sameframework - but sometimes the looseness of the requests, we don't work out 
what is thejob of the person on that team, with no definition of what the project requires, 
prevents thatfrom happening. " 
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They continued to note that this difficulty stemmed from a tendency to improperly plan 
projects: 
"So people don't always spend the time to work out what is being requested, and work 
out what really is thejob of theperson on that team, and identify thepeople with the right 
skills, background, knowledge, experience. It's more that there's a team here that needs 
this resource and this person's available - if it's at that level, then itfails to address the 
realfundamental aspects of theproject work. " 
This section gave rise to the following themes which centre upon the measurement of 
innovation within AstraZeneca. 
Innovation Theme 22: Innovation and productivity are markedly different in the scope 
of drug development. The current measures and KPIs employed within AstraZeneca often 
fail to take account of the breadth of innovation occurring throughout a project and focus 
upon reducing the time required to complete a task. 
Knowledge Management Theme 22: There is a need to employ intellectual capital 
assessment to measure the innovative activity occurring within AstraZeneca; yet also a 
need to develop a framework that accurately supports innovation within the organisation 
so as to encourage further innovative behaviour., 
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Table 7.10: Conceptually Clustered Matrix: Measuring innovation within AstraZeneca 
Area Studied Findings across Discovery & Clinical 
Innovative Aspect Measuring innovation within AstraZeneca 
Drivers 0 The need to develop drugs faster and 
more efficiently 
0 Intense commercial pressure to reduce 
development costs 
0 Management and reporting metrics to 
show progress through development 
Required Criteria 0A sound recognition of the processes 
employed within the organisation 
0 An appreciation of where innovation 
has helped to drive these processes 
0 Separate measures that accurately 
reflect both innovation and 
productivity as separate entities 
0A framework that both supports 
employees and allows measurement 
0 Sufficient resource to meet 
expectations 
0 The resource to allow prototyping - 
whether it succeeds or not 
Outputs 0 Currently metrics (KPIs) that measure 
the cost, resource and outputs of a 
project based on tangible milestones or 
tollgates alone 
0 Potentially a greater understanding of 
the processes with intellectual capital 
measurements and the ability to 
identify and aid innovation 
Underlying themes 0 Innovation is rarely measured within 
AstraZeneca, instead the measure of 
success of a project is based upon 
productivity and efficiency 
0A framework that provides measures 
to support innovation is required 
The following section questions the role of the patent as one of the few common tangible 
methods employed to measure pharmaceutical success (Furukawa & Goto, 2006). 
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7.7.2 THE INFLUENCE OF PATENTS ON THE PROCESSES OF INNOVATION 
Measuring productivity occurs at many levels, but a tangible measure that is reported for 
financial analysis is the number of patents or patent applications submitted by a company. 
To the pharmaceutical industry patents are the means to protect the considerable 
investment a new drug requires. As a measure of success they are relatively easy to 
assess, yet the process of acquiring a patent is far from easy and requires innovation. A 
Discovery physician explained that: 
"The key thing that gives you your patent, is that it has to be something that isn't a 
logical conclusion of other things, so it's got to have popped out of the woodwork and, of 
course, you've got to be the person who supplied the principle intellectual and how's 
yourfather - otherwise, ifyou're not, the other person has the rights to the patent. " 
Therefore, the balance between creating an innovative drug or discarding it, lies not only 
with whether it is possible to patent the research or final molecule, but also with who the 
instigator of the research was. As the previous sections have noted, developing R&D that 
is unique is increasingly difficult when so many companies are drawing their work from 
the same sources. 
Intcrviewees also explained that once a patent is granted it can be a telling signal of what 
disease areas and biological mechanisms a company is researching. From there the need 
to generate a marketable product is driven by strong commercial pressures to "make 
good" on the promise of the patent: 
"You can imagine how long the gap is between a patent being granted and you actually 
having a product, a huge, huge, huge amount of time. But it doesn't stop you of being 
aware of other molecules - so you could do [patent] searches and it will fell you the way 
other people are thinking and it may be applicable to you. " 
In many ways the use of an external research organisation is an attempt to again minimise 
risk. A Discovery employee, who had spent considerable time within academia 
researching novel targets before joining AstraZeneca, noted that he had approached his 
research based upon patent and literature analysis. 
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lie concluded by saying that this method was commonly employed, but is expensive and 
"constitutes a huge gamble" in that it may not yield a viable and unique research project. 
In addition, there is no clear cut way to assign a cost to this process and measure its 
success, other than a patent. Yet interviewees explained that the act of striving to develop 
a patent narrowed the innovation possible. 
The interviewee explained that developing a number of compounds that acted upon a 
specific target derived from the literature was a vastly expensive process, one that by 
their accounts could be approached. from a different angle. Other interviewees summed 
this up by questioning the drug development model employed by AstraZeneca, stressing 
that rather than looking to raise a compound that specifically acts upon a target, 
pharmaceutical companies should instead be seeking to understand the disease in greater 
detail: 
"If we do that this way and the other, we'll actually come up with key components of this 
disease and these components and their related chain of activities. This is where we 
should be going and, to me, that is the next huge intellectual challenge that drug 
companies should be addressing. " 
The viewpoints of the innovators stems from the way disease is viewed, to clarify this, a 
senior physician explained: 
"The way disease works ifyou think about it - is how many ways can it be manifested? 
Because "it does this", doesn't mean it's this type of disease, and that really is doing 
yourset(a huge injustice. Until we think beyond that complex, then we're never going to 
go anyfurther because we're constraining ourselves by things we don't need to. " 
Tlierefore, the act of 'pigeonholing' a disease along with the target that is believed to 
affect this disease was viewed by many innovators as flawed, certainly in terms of 
innovative activity. When interviewees were questioned as to the major hurdles that 
affected the generation of patents from innovative work, one replied: 
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"So when we're talking about the whole areas of innovation they're huge. "ere we give 
drugs to, when and how we give drugs, how we decide which drugs to give, how we 
monitor those drugs properly, how we make best use of the compounds we throw away 
because they have huge amount of utility to befed back into the processes - all of this is 
missed out on asfar as I can see. " 
Unfortunately swaying the processes of AstraZeneca away from producing compounds to 
target a specific biological target and focusing upon the wider picture is, by the admission 
of the interviewees, exceedingly difficult. Due to the complexities surrounding drug 
development and the biology of a disease, it is often taken for granted that a drug that 
works on X disease will not work on Y disease. On the whole this was deemed a fair 
assumption, yet innovators complained bitterly that this knowledge as to why this was so 
was considered irrelevant and largely worthless when a patent application was sought: 
"Well its not that they [compounds] have other application, it's what they tell us about 
that disease. " 
Innovators frequently called for the means to review past work and in particular any 
failures associated with trying new compounds within multiple disease areas. 
As one innovative Clinical physician commented, innovation that generates a patent is 
generally reliant upon prior yet elusive work: 
"Yes, ifyou look in terms of innovation and work [R&D patents] that has been previously 
done, there is never actually, let's say .... an easy connection, between something you 
do 
now andsomething that's truly ground breaking concept tomorrow. 
Iley continued to say that patent data, previous R&D and the employees within the 
organisation provide the basis for innovation: 
"There is often a good ground base of information, knowledge and experience which you 
need, and then to make the right connections at the right time and make that big leap 
always has a very big part to play, indeed, as innovation can't occur without them - so 
we need these things to exist " 
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Hence, it appears a fine line between relying upon prior information and generating a 
novel idea which is patentable. As prior data has suggested a fine line also exists between 
having too narrow a scope to be truly innovative and developing patentable research. 
Additional knowledge and information that has been generated from R&D that lies 
outside of the patent may also be useful, but may be disregarded as employees are too 
constrained by the need to register a tangible and measurable patent as an output. The 
following themes and conceptual matrix summarise this section: 
Innovation Theme 23: Patents are a tangible means of measuring pharmaceutical R&D - 
but may not recognise the amount of innovation required to reach that stage. 
Furthermore, the process of patenting research may constrain innovation. 
Knowledge Management Theme 23: Conducting patentable R&D results in additional 
knowledge and information than is not required to submit a patent and consequently may 
not be captured effectively. Measuring and using the information and knowledge 
generated outside of the patent may be more valuable than the patent itself in some cases. 
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Table 7.11: Conceptually Clustered Matrix: Assessing thý influence of patents upon 
innovation 
Area Studied Findings across Discovery & Clinical 
Innovative Aspect Patents as a means of measuring 
innovation 
Drivers 0 Commercial pressures to develop 
patents from stakeholders etc 
Required Criteria 0 Access to patent databases and 
business intelligence 
0 Research that is novel enough to 
warrant a patent 
0 The ability, the knowledge and the 
information to generate a patent 
Outputs 0A patent which is a measure of 
. R&D "potential not success" 
0 Detailed chemical or clinical 
information and knowledge that 
siippdrts a patent and the 
associated research 
0 Supplementary innovative 
knowledge and information that 
has driven the process, but is 
rarely recorded 
0 In some cases a limited 
understanding of the disease itself, 
due to the constraints associated 
with filing a patent 
Information to competitors on 
your R&D strategies 
Underlying themes 0 Patents can both protect 
innovative R&D yet constrain the 
innovative activity possible 
0 Supplementary information and 
knowledge that lies outside of the 
formal patent application, may in 
some cases, be more valuable than 
the patent itself 
As these previous sections have noted, measuring and assessing innovation is a tricky, yet 
important part of the development process. 
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Interviewees stated that an organisation will evidently be reluctant to invest financial 
resource into an innovation that does not guarantee a tangible return. This chapter now 
ends with a brief set of concluding remarks with regards to the observations within this 
part of the research. 
7.8 CONCLUSION 
7bis chapter has explored a wide range of criteria and drivers that are critical to 
innovative activity within AstraZeneca. The findings analyse an area that is poorly 
represented by the literature and clarify the extent to which innovation is driven by 
external influence across the pharmaceutical industry. Overall the concepts within the 
innovation model suggested in Chapter 6 have been expanded to specifically address the 
effect of the organisational culture upon the reuse of knowledge to drive further 
innovation. In particular, the findings relating to the success of organisational change, the 
acquisition of innovation, the role of luck and the perceived strategy by AstraZeneca to 
develop a "me too" drug and avoid excessive risk were notable findings. 
Throughout this chapter the interviewees placed a strong emphasis upon the generation of 
information and knowledge that was rarely captured. Noting that although AstraZeneca 
was highly innovative, aspects could be changed to capture the innovative nature of the 
individual employees and fundamentally change the current means of developing 
innovative drugs by avoiding a hypothesis driven approach. It is the researcher's view 
that the observations within this chapter will form the cornerstone of a successful 
Knowledge Management tool set, as required by the research aim and objective. In order 
to discuss the development of the tool set further, the following chapter now turns to 
examine the present role of Knowledge Management within AstraZeneca. 
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CHAPTER8 
KNOWLEDGE MANAGEMENT AND INNOVATION 
8.0 INTRODUCTION 
Throughout the presentation of the results a number of themes that have detailed the 
requirements for knowledge and information that drives innovation have been 
outlined. This series of Knowledge Management themes has focused specifically 
upon the innovative processes knowledge requirements. Yet AstraZeneca's current 
Knowledge Management strategy that supports these aspects has been lightly 
explored. This section explores this aspect and details observations and qualitative 
data derived fr6m the research results, seeking to examine the role of the current 
Knowledge Management tools within AstraZeneca as an aid to innovation. 
A conscious decision was made by the researcher to avoid a consultancy type report 
which simply listed AstraZeneca's Knowledge Management strategy and the tools 
used. Instead the focus was upon how innovation occurred using the Knowledge 
Management tools, which then allowed the development of an innovation centred 
Knowledge Management tool kit described in chapter 10. 
During the researcher's time within the organisation, the Knowledge Management 
strategy was evolving and therefore the issues raised here may have been addressed. 
Nonetheless, the results presented here are not intended as a criticism of 
AstraZeneca's current strategy, but merely highlight areas that could be addressed 
from an innovation perspective. 
8.1 KNOWLEDGE MANAGEMENT TOOLS 
AstraZeneca is typical of a large multinational organisation, having many repositories 
of information that fall under a combined KM/ IS strategy. Of these, the more 
commonly used tools include: 
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* PKT: an information library for project based documents and information 
GEL: a regulatory information store that is designed for the submission of 
regulatory information and supporting documentation 
9 eRooms: a recently introduced collaborative and document management tool 
designed to facilitate project based collaboration 
e Our Discovery: an information and document store 
e An email service utilising Outlook 
eA number of departmental, independent discussion boards 
9 The Autonomy search engine system 
e An expert location service 
* Numerous databases associated with departments throughout Clinical and 
Discovery - many are in proprietary format 
e E-learning tools for staff training and education - topics range from medical 
to ethics 
Numerous other proprietary Knowledge Management websitcs, departmental 
websites and document/ information stores, examples include Process R&D 
and Global Safety Assessment 
During the three years this research was undertaken, AstraZeneca IS launched a 
strategy to pull in all the disparate intranet sites and Our Discovery under the 
umbrella of a single portal, namely the R&D Portal. While the researcher was 
conducting this research, interviewees were asked on their opinion of the strategy 
after the portal had been running for a period of approximately six months. 
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The results were surprising as it showed that innovators and employees are more 
reliant upon external information sources, than internal sources such as the R&D 
portal and intranet. The combination of resources needed to innovate was wide and 
innovators noted that it was beyond the scope of one particular Knowledge 
Management based tool: 
"We have multiple sources that we use, medical scientific literature, multiple internal 
repositories holding different information and knowledge in many diff forms ... we 
have the Global Electronic Library or GEL, PKT, Our Discovery, R&D portal, 
eRooms and shared drives - an oldfashioned way ofsaving information. " 
The interviewee continued to note the complexity of the currently available systems: 
"So we have all of that existing at the same time - and that makes it not very useful 
because you can't bring it together in a clear way! " 
What was apparent is that the R&D portal cannot link the broad array of potential 
sources of information and knowledge, there are simply too many that have a 
"potential" use. An interviewee noted their reliance upon external patent databases as 
a basis for innovation: 
"I use these databases, because these sources are not widely available through the 
company. .. these are databases like Pharma Projects, Scrip, R&D 
Insight, R&D 
Focus, Global Project Database and a few others - so these are commercial 
databases which capture things which aren't in the medicaliournals. " 
The interviewee continued to explain that these external sources were so important 
because they aggregated diverse information sources: 
"They use various sources such as companies, conference proceedings, abstracts, 
external stuff which you don't necessarilyfind in the normal literature. " 
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A number of interviewees stated that because of the bewildering array of sources, 
their first choice source of information when beginning innovative work would be 
external literature sources such as PubMed. Many innovators expressed regret that the 
R&D Portal model had (at the point this data was gathered) missed what was 
perceived as its key goal of bringing these disparate sources of information together. 
One senior interviewee noted: 
"So the intention is to bring quite a bit [information sources] together - but not all, 
as PKT and GEL will still remain independent. Our Discovery will sort of stop and 
be transferred to the Portal KM systems of the portal project and eRooms - so that 
will be transported, but there are many, many systems and things which will remain 
outside. " 
Hence many interviewees believe that AstraZeneca have missed an opportunity to 
collate these diverse sources under a common access portal: 
'7 think at a strategic high level, the company has created a relational hierarchical 
system for linking all of these things [with the R&D portal]. However, what happens 
within the company is that there are many independent things going on and they're 
generating specific solutions for specific groups, yet there is no direct link to this 
relational hierarchy that exists. " 
Other interviewees were rather more complimentary, but again described the R&D 
portal as a strategic information repository rather than a store of drug development 
information and knowledge. On the whole most utilised internal sources such as the 
R&D portal, along with a combination of sources: 
"One of the key sources would bejournal searches to get background info. The other 
searches we would do would be internal, because often they are centred around 
projects, project and compound information, background information and then 
people, using one-to-ones [meetings or telephone] - going to people who have got 
that bit of expertise. " 
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It is important to note that the key reason behind employees failing to consult internal 
IS and Knowledge Management sources is due to the difficulty in finding any 
relevant information. 
All employees, including those who could be considered highly skilled in the use of 
computers e. g. programmers, complained that locating infon-nation across the 
AstraZeneca intranet was far too laborious: 
"From a pure Knowledge Management point of view it would he ahsolutely 
wonderful if, for each of our drugs, there was one place you could go to and you 
couldfind everything- in one place. That's not exactly innovative; you would have 
though it was common sense. " 
Interviewees were particularly vocal upon this point and viewed that, although the 
goal of Knowledge Management and AstraZeneca IS were positive, very little help 
had been given to them with regards to their knowledge needs: 
"We've been harping on about Knowledge Management and how it can help and 
very little has been actually executed " 
However, many were realistic as to what a Knowledge Management strategy could 
achieve. Of particular concern was that a system or tool should make the process of 
keeping up to date with the inordinate amount of current pharmaceutical related 
research easier than it was now: 
"Certain types of information we must keep up to date with, in this industry it is very 
important to keep up to date with on a day to day basis, particularly the scientific 
Medical literature andjournals. These discuss new mechanisms, new clusters, new 
compounds and ideas, so you have to be on top of this on an almost day-to-day 
basis. " 
Hence, there is reliance upon external sources that, as the previous sections have 
explained, will always remain: 
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"Well in reality a lot of ideas come from many different sources ... no one source 
provides the single idea ... I would say, over my career, the main innovations, from 
which we've produced valuable blockbuster drugs - they've comefrom many different 
sources. Sometimes we've read literature and distilled ideasfrOm there. " 
Unfortunately, as one interviewee noted, without detailed background knowledge and 
the ability to compare the proposed research with "what is already out there", the 
prospect of reinvention is very real: 
"Well, you have to have a reasonable amount of knowledge to thake sure you don't 
invent something that's already been invented afew years ago -I would say that hau, 
an hour in the library would save you, say, three months in the laboratory. " 
Another interviewee noted the need to keep abreast of all the various sources 
throughout the life cycle of a project in order to avoid duplication of effort, although 
some sources were more valued than others in this respect: 
"I guess you see we use all of them, some at certain times depending what stage of 
the project we are in... I guess if I have had to put a value to each one of them, I 
would say sources like PKT [and] Our Discovery. Our Discovery is really quite 
useful and then recently the emergence of the eRooms which are very useful when 
they're actually populated " 
While others preferred to consult favoured journals for innovative ideas yet found 
that setting aside time to achieve this was difficult: 
"The external scientific and medical journals provide information and knowledge 
that are very valuable when you access it. " 
Yet intervicwees noted that although it is vital for them to read specific journals to 
gain broad understanding, they often have to focus upon a particular target due to 
time constraints: 
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"There's ajournal, but I don't have time to search or reviewjournals, which is what 
I'd like to be doing. I tend to look at them and go after a specific target or you could 
take in some news and reviews in specificjournals. " 
Once the information on the target was discovered then rapid progress could be 
made: 
"It'sfairly easy and mostly obvious, so ifyou identify a target you can either make a 
molecule, or an antibody or whatever and so you decide on various reasons to do 
what ever you can. " 
This comment explains that, with the correct information and in sufficient detail, 
invoking the early stages of drug development was relatively straightforward. Others 
noted that a Knowledge Management system that could provide a link to the 
underlying research data derived from both Discovery and Clinical and the published 
literature, could provide a valuable insight and potentially drive innovation. When 
asked what a Knowledge Management system should provide, an interviewee 
commented: 
"Things we've done ... there are times we've pursued experimental work to obtain new 
novel data, and this new novel data has been pursued and this had led to a product at 
some stage down the line, yet this is a long protractedprocess, but that's often where 
ideas comefrom. " 
Another interviewee noted that with the ability to link data, information and 
knowledge, potential problems could be foreseen earlier: 
"It was preclinical data that indicated there would be non-functionality with a 
particular genotype for the receptor, emerging biomark-er data from the clinical 
studies and potential genotype data in the literature which indicated there could be 
issues with the metabolism of the drug, absorption, distribution -a combination of 
sources " 
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Therefore, in many respects innovators concluded that access to sufficient 
information and knowledge is critical, whether it be from academic journals or 
pharmaceutical databases. However, on a more social note, interviewees noted that 
collaboration between colleagues and externally was just as likely, if not more likely 
to provide them with the information or knowledge they required easier and quicker, 
These observations are captured in the following themes: 
Innovation Theme 24: Knowledge Management can play an important role in 
driving innovation by providing the means to access cutting edge research, both 
internally and externally to AstraZeneca. 
Knowledge Management Theme 24: Innovation requires multiple and disparate 
sources of information and knowledge. Many are available within AstraZeneca but 
keeping abreast of the important sources is paramount to promote innovation and 
avoid reinvention. 
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Table 8.1: Conceptually Clustered Matrix: Assessing the role of Knowledge 
Management upon innovation 
Area Studied Findings across Discovery & Clinical 
Innovative Aspect Knowledge Management Systems and their role 
within innovation 
Drivers 0 Knowledge Management/ IS Strategy to 
provide relevant information and 
knowledge 
0 Acknowledgement that pharmaceutical 
R&D requires multiple cutting edge 
sources of knowledge and information 
Acknowledgement that a range of 
Knowledge Management tools are 
required 
Required Criteria 0 Access to information and knowledge as 
and when required 
0 The infrastructure to support the systems 
0 Knowledge Management tools that 
provide sufficient information and 
knowledge to drive information 
0 Sufficient knowledge of the individual to 
know when and how to use research 
information and knowledge 
0 The ability to locate and make sense of 
the multitude of sources required to 
innovate 
0 Access to scientific data to support 
rationale and hypothesises 
Outputs 0 Innovation if the "correct" information 
and knowledge can be located 
0 The capture and dissemination of 
information and knowledge - to a limited 
extent 
0 The identification of which sources are 
key to innovation 
Underlying themes 0 Knowledge Management could play a 
greater role in providing innovative 
knowledge 
" Innovators require to keep abreast of 
multiple sources and as such a 
Knowledge Management schema should 
take this into account 
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8.2 KNOWLEDGE MANAGEMENT AND COLLABORATION 
Throughout this research, the aspect of collaborative knowledge has been strongly 
evident. Without internal and external collaboration innovation would certainly falter, 
if not entirely fail (Section 6.3). Interviewees regarded fellow employees and 
collaboration as an important aspect of innovation that could be overlooked by the 
current Knowledge Management tools. While others noted that it would be highly 
useful to review the knowledge sources used within a project, both as contributions 
from colleagues and information sourced from the various Knowledge Management/ 
IS systems within AstraZeneca: 
"A review of the people involved and the knowledge [used] then yes, it comes back to 
the idea of one store. I'djust like something really logical - so if we had the invitro 
pharmacology, the animal pharmacology - and you couldjust type in [a search for 
information or knowledge across all sources] and get back something that you 
wanted. " 
Ilence innovators are requiring a Knowledge Management system that can supply 
information, knowledge and the means to instigate and record collaborations as they 
occur. As one interviewee noted, their personal network of collaborators is essential 
to drive the initial processes of innovation: 
"Obviously there are a lot of interactions with the guys in Discovery and Clinica4 
trawling the literature trying to see the knowledge around the target and looking at 
what people have measured previously which is related to the disease process or 
related to the mechanism of the target we're looking at. " 
Other interviewees believed that, prior to the lead optimisation phase, drug 
development is essentially an established and documented process reliant upon 
chemistry that may be obtained from any textbook. However, the managerial 
interviewee noted that the further down the development phases a compound passed, 
the greater the need for clinical knowledge and information became. 
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They noted that this may be the arena that Knowledge Management could posses the 
highest impact, when a compound has proven its worth but clinical knowledge is 
required. A Discovery manager explained that their innovative role stemmed from 
applying clinical knowledge to early stage development work through the 
development of a Discovery Medicine department: 
"Discovery medicine is a concept not an actual reality. It's all about bringing the lab 
closer to the clinics, physicians and vice versa - both directions are important. We 
bring a lot of clinical disease knowledge into the process of target identification, how 
patients manage and cope with the disease, the clinical need, disease knowledge ... so 
it's mainly about bringing this aspect to the hardcore, vernacular geneticists and 
molecular biologists with more disease background. " 
In effect, this type of work, where R&D laboratory data is reinforced with Clinical 
knowledge, requires collaboration and was hailed as a potential Knowledge 
Management arena. Other employees working in this area noted, however, just how 
difficult this area was to bridge successfully. Even though promising data could be 
generated, the further stages of actually using this data to drive innovation were often 
held back: 
"Ifinallyfound some of the data and the individuals behind the data. It was obvious 
that it hadn't been analysedproperly, sometimes property but not thoroughly enough. 
On the clinical side I think they had been analysedproperly but they [the resultsfrom 
the data] hadn't been used. " 
Therefore, acting upon the data derived from collaboration is imperative. Yet, as 
previously discussed, it appears that the favoured mediums of face-to-face meeting, 
the telephone and the videoconference (VC) are given preference by almost all of the 
innovators interviewed, even though the majority of innovators felt these were poor 
channels with which to publicise innovation in relation to "knowledge and 
information discussion and capture". Yet it is the employees, who at times strive to 
hold meetings with limited time, who are undoubtedly essential for the day-to-day 
workings of AstraZeneca innovators: 
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"There are good people, mainly we communicate through face-lo-face, email or 
telephone... but again it's difficult to get the key players in place. " 
They continued to note that a lack of the "right" people meant that people's skills 
were not utilised effectively, with one of the key skills recognised by the interviewees 
being the ability to network effectively in order to drive innovation: 
"In key positions there is a shortage ofpeople, so having the director working on a 
project is probably not the most convenient thing ... but he's the guy who's meant to be 
pressing theflesh and meeting the key people. " 
Yet the face-to-face meeting consistently rated highly as the preferable means of 
sharing knowledge and information, over the available Knowledge Management tools 
in most cases: 
"One of the best ways information gets passed around is when we have meetings. 
Something that's happened a few times is when we discuss our current views and 
knowledge, then out of that come suggestions for new ideas and the suggestion that 
could he done to meet everybody's requirements. " 
The reasons behind this stemmed from the fact that interviewees often found it is 
easier to explain vocally than to attempt to write down a complex idea for 
dissemination within a Knowledge Management system: 
"Maybe it's me but I don't write as well as I speak and that's why [I prefer 
meetings)" 
Other interviewees mentioned that attending a meeting or looking over a meeting 
presentation was often the easiest way to quickly get the "gist" of a project: 
"Well I'm extremely lazy. I always try and do things in the easiest way possible. If I 
get a new project and I'm taking it over, then I hope that someone would send me a 
slide set and then Id go into Google and get some more papers and some review 
articles. " 
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During the researcher's time within the organisation a discussion forum was used 
within Clinical as a primer for meetings, this met with widespread success and an 
exponent explained that a variety of techniques are generally required to ensure 
clarity and consensus. Many stem from a Knowledge Management perspective, but 
others stem from the field of psychology: 
"The discussion forum, I'm keen on online mind mapping, two things which I think 
are really valuable - these are using online mind mapping within meetings, the other 
is talking about problems. If you want to find a solution to the problem you must 
spend two thirds ofyour time talking about the problem. " 
The interviewee continued to explain that there are practical means available to 
facilitate complex discussions: 
"At my last place a psychologist got everyone to write what the people thought the 
problem was on a card - he then found that no two people had the same 
understanding of the problem. So how can you even begin to solve a problem when 
thepeople haven't got a common understanding of the problem? " 
What is evident from interviewees' comments is that no one solution can fit all. Such 
is the range of sources and scenarios encountered within pharmaceutical R&D that a 
diverse range of tools are needed to ensure that employees are fully aware of the 
information and knowledge available to them. Further care is also needed to ensure 
that each person has a good understanding of what innovative problem is being 
attempted to be solved, as misunderstanding rarely allows innovative ideas to 
progress, let alone when outside the scope of an employee's role: 
"If you want to collaborate you need to communicate the message then you must 
make sure it doesn't step on anyone's feet. Let's say I'm in Clinical and I do 
something regularly that's innovative for Discovery, it won't matter because I'm 
sitting in the wrongplace. " 
Hence strong social ties certainly drive innovation, with the idea of "water cooler 
innovation" being mentioned a number of times: 
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"The time when you come up with good ideas is when you're sitting down with two 
otherpeople over apint of beer or a coffee andyoujust brainstorm. " 
The move to an open plan environment within Clinical to increase "water cooler" 
interactions, had met with mixed views, primarily due to the lack of privacy 
associated with an open plan environment. When raising this point, the issue of 
discussing confidential project material in an open plan office was raised. A curious 
scenario is thus raised between allowing enough information and knowledge transfer 
to innovate, and restricting access to only allow certain people. 
During the researcher's time a similar observation regarding confidentiality was made 
I surrounding the introduction of a Knowledge Management system named eRoom 
This system was introduced to encourage collaboration and lessen duplication of 
project documents. Even though the tool is not designed to replace all the information 
tools available to employees, it is designed to link the ad hoc departmental and drug 
project websites that previously dominated the R&D intranet. The strategy of 
AstraZeneca appears to view eRoorn as an informal collaborative environment, where 
discussion across project work could occur prior to making a "stop/ go decision" on a 
drug project. However, again interviewees complained of the closed project mentality 
existing within this virtual world: 
"We do have eRooms for some of projects which have been quite useful, but in a 
sense it's duplicating them [the physical closed project environment], I think it's the 
wrong way ofaddressing the problem. " 
The interviewee continued to comment that eRooms appeared as the proposed 
solution to address the usability issues associated with tools such as GEL, in 
particular: 
"The reason why we have eRooms is that the other things are difficult to use and 
that's not really the right way of addressing the problem - we end up duplicating and 
then don't know where to lookfor something. " 
I blM-, #software. emc. com/microsites/eRooin/index. i52 
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Others commented that although the tools that were available to them had changed, 
their ways of producing documents to populate these tools had essentially remained 
the same: 
"No I'm producing documents, but I don't know if I'm doing it right ... but I'm 
circulating bits I've donejust by email to my collaborators and various teams but I'm 
not sure if that's right. I'm showing it to them and [sayingl if you're the wrong 
person then please show it to the right person. " 
Overall the reliance upon emailing documents to fellow employees followed by a 
physical meeting was still very apparent, a situation eRoom in particular is meant to 
stop to an extent: 
Yd Raise with the Discovery people and get them to send [email] me the relevant 
stuff-I'd ring up the guy in Discovery who would cut and paste the bit of the MS3 
document, but you know there's no logical way ofdoing ifl. " 
The utilisation of virtual eRooms also possesses a tangible cost benefit. As one 
interviewee noted, the costs associated with not using a Knowledge Management 
system and holding a meeting instead, are high: 
'7 can sit in a2 hour VC with haýf a dozen people this end and half a dozen at the 
other end, with a couple in the States and Sweden - so ifyou actually cost out how 
much these meeting cost, then it's a ridiculous process - probably costing about 
2a 000 dollars or something per meeting, a ridiculous waste! " 
Another interviewee indicated that the cultural differences associated with Sweden 
and the M was demonstrated by the preference for meetings over email: 
"Again, our Swedish colleagues, you often find they've put a meeting in my calendar 
and you ask them "why are they having it? " And they say they just needed the 
information, so we're thinking well why didn't you just email and I could send it to 
you? But they like talking about it! " 
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Other interviewees noted that a Knowledge Management system could be used to cut 
down upon the time taken to reach a decision: 
'I find a lot of the meetings are just about information ... you'd have a 3-4 hour 
meeting scheduled and a lot of it was just going over the ground of the previous 
meetings and the actual decision time was about halfan hour. " 
Others commented that although holding a meeting such as this was often the easiest 
way, but sometimes it was not the most innovative way. Instead, possessing the 
ability to search across a drug information or knowledge domain with a Knowledge 
Management system, could offer a different viewpoint other than the "acknowledged 
AstraZeneca expert": 
"I'm involved in a side effect project and I spoke to X who said, " Well, why don't you 
just ring up all these people in Sweden who have been do ing th is for years and they 
would give you all that straight off the back? " And, in a way, I know exactly what 
he's saying, it would save me time, but its back to never thinking about it yoursetrand 
just taking on hoard whatpeople have done. " 
Hence interviewees noted that the danger of not using a Knowledge Management 
system could lessen the extent of free innovative thinking. However, a number of 
innovators mentioned the importance of capturing innovative ideas generated across 
the company in order to enhance the existing Knowledge Management systems 
available within AstraZeneca. Many interviewees particularly noted that innovative 
ideas, usually in a verbal form, stem from a wide variety of environments: 
"Sometimes it's just conferences, meetings, and literature, speaking to people- that 
always lead to good ideas, speeches and stuff like that. " 
Again the notion of effectively capturing what was said was mentioned, in addition to 
the need to capture innovative thoughts that attending events generated. An 
interviewee had developed a PowerPoint template to aid the capture of information 
while at events, yet when user-led solutions such as these, are suggested they often 
fall upon deaf ears: 
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'771 give you an example, when I started working on X-I went around to all the IS 
groups askingfor help because I wanted some kind of input, but there was no helpfor 
two Years and then they somehow get feedback from users who started saying that 
this thing is important. " 
Evidently, if there is sufficient demand for Knowledge Management systems to 
become common place within the processes mentioned within this section it will have 
to be led by the end users to an extent. However, without sufficient management 
backing, this again will fail, which is a situation akin to the findings on innovation 
throughout this chapter. Unfortunately there are difficulties associated with 
developing a Knowledge Management system that details the thoughts and decision 
processes involved in producing a drug. Recording such events not only provides the 
means for employees to visualise what has occurred but also the regulatory 
authorities, a factor that many interviewees acknowledge has a significant impact on 
what can and should be recorded: 
"I think to be fair, the whole process has got much more complicated mainly due to 
the regulatory environment, so there are a lot of things we have to do, keep now, and 
file and do things, but I think there's no reason why we should make it more 
complicated than it has to be. " 
Hence, even though the process of managing information and knowledge is complex, 
the interviewees noted that the provided systems are also overly complex, with the 
regulatory information system, GEL, in particular being mentioned. 
Throughout this section the emphasis has been upon capturing the discussion and 
ideas that stem from collaboration that are driving innovation. Yet the research data 
suggests that due to their complexity, Knowledge Management systems play a 
relatively minor role within the collaborative processes. These observations and 
comments captured within this section are represented in the following themes and 
conceptual matrix. 
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Innovation Theme 25: Innovation is reliant upon discovering diverse knowledge and 
information sources and generating an idea, but the collaborative culture within 
AstraZcneca sometimes fails to provide the opportunity to grasp the understanding 
and as such, a great deal of time is wasted within meetings. 
Knowledge Management Theme 25: Collaboration occurs primarily via meetings, 
yet collaborative Knowledge Management tools exist throughout AstraZeneca. There 
is a greater need to either exploit or develop these tools to provide the collaborative 
medium required by innovation. 
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Table 8.2: Conceptually Clustered Matrix: The role of Knowledge Management as 
an aid to collaboration and innovation 
Area Studied Findings across Discovery & Clinical 
Innovative Aspect Knowledge Management tools and collaboration 
Drivers Knowledge Management/ IS Strategy to 
provide collaborative environments 
An acute need for information and 
knowledge 
The need to discuss complex topics 
The need to cut down on the "meetings 
culture" within AstraZeneca 
Required Criteria 0A medium to invoke collaboration and 
discussion i. e. a meeting, TC, VC, 
discussion forum or an eRoom 
0 The time and resource to conduct 
meetings on a regular basis in an 
environment that is conducive to 
innovation 
0 Employees who have the ability to 
understand diverse information and 
knowledge and reach a consensus 
0 Cornmitment to act upon information/ 
knowledge derived from collaboration 
0 Usable Knowledge Management tools 
that fit the requirements of the innovators 
Outputs 0 Innovation from collaboration 
0 The potential capture and dissemination 
of information and knowledge within a 
Knowledge Management tool 
0 Potential saved time with a greater 
reliance upon Knowledge Management 
tools instead of meetings 
Underlying themes 0 Knowledge Management could play a 
greater role in stopping wasted time 
within meetings 
0 Knowledge Management systems are not 
utilised to their full potential and end- 
user driven development could lead the 
way 
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8.3 CONCLUSION 
This chapter has explored the relationship between innovation and Knowledge 
Management within AstraZeneca Discovery and Clinical. A number of key areas 
relating to the acceptance of innovation have been examined along with the 
associated knowledge and infon-nation drivers required to conduct innovation within 
pharmaceutical drug development. 
The observations and findings within this chapter form a powerful and compelling 
argument to introduce Knowledge Management tools that link disparate information 
and knowledge sources and provide the means to promote discussion and 
collaboration. Furthermore, the aspect of information overload has been apparent as 
an undercurrent throughout this chapter. 
The key findings of this study largely relate to a sense of disappointment with the 
Knowledge Management systems on offer. While many of the systems were 
relatively new and rolled out while the researcher was within the organisation, there 
remains scope for introducing a tool kit that specifically addresses all the 
observations of this research. It is also highly apparent that innovations stem from a 
large number of disparate external and internal sources. So any Knowledge 
Management system should bridge and refine these information and knowledge 
sources into a manageable environrnent. 
The following chapter concentrates upon results of a case study conducted within 
AstraZeneca relating to a Knowledge Management based decision mapping exercise 
carried out within AstraZeneca, and provides an 'employees eye view' of innovation 
and its place within the organisation. 
This chapter concludes with the innovation and Knowledge Management themes 
elicited from the data of chapters 6,7 and 8, presented in Tables 8.3 & 8.4. 
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Table 8.3: Innovation Themes 
Innovation Themes 
Innovation Theme 1: Technological advances in drug development is not one of the 
main drivers of early stage drug innovation. On the whole it quickens the current 
"weight in numbers" approach but does not give rise to new compounds. 
Innovation Theme 2: Technology can drive innovation within the right environment, 
an environment that is open to change and welcomes innovative ideas which do not 
have a specific application. 
Innovation Theme 3: Pharmaceutical innovation is reliant upon collaboration and 
teamwork. An individual may have the initial idea but without co-operation it will 
ultimately fail. 
Innovation Theme 4: Collaboration both internally and externally are expected to 
play an important role within AstraZeneca future strategy and portfolio. However, 
there are difficulties carrying out collaboration across the organisation, let alone 
externally. 
Innovation Theme 5: Innovation relies upon an unpublicised and unseen grid of 
"innovation champions" who hold the influence to drive innovation forward. 
Innovation Theme 6: External regulatory bodies (i. e. the FDA) have a powerful anT 
controlling influence on how innovative drug companies may be throughout the 
development processes. 
Innovation Theme 7: Creativity and innovation arise as a result of negotiating the 
rules and regulations implied both externally and internally. Without this foundation 
of external regulation, some innovative practice would not occur. 
Innovation Theme 8: Innovation can arise as a direct result of the need to 
circumvent existing AstraZeneca processes in order to fulfil their role yet this carries 
the potential 2f blame. 
Innovation Theme 9: Innovative ideas that could be of use within AstraZeneca's 
drug development Oortfolio are poorly received. It appears difficult for the majority 
of innovative employees to suggest potential innovative ideas and, therefore, 
influence the early development work. 
Innovation Theme 10: Successful innovative practice requires the right inforination, 
organisational structure and team commitment at the very earliest of stages to gain 
momentum. 
Innovation Theme 11: AstraZeneca have taken positive steps to embrace 
innovations that occur outside of their traditional therapeutic areas, but further steps 
need to be taken to ensure this resource meets the needs of the employees and is as 
receptive as it proclaims. 
Innovation Theme 12: Innovation is hampered by the interchange between 
Discovery and Clinical resulting in the potential loss of valuable ideas. 
Innovation Theme 13: Pharmaceutical innovation relies upon a plentiful supply of 
innovation stemming from external organisations. This effectively reduces the risk 
associated with innovation by the costs of the innovation being absorbed lower down 
the chain. 
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Innovation Theme 14: The process of acquiring innovation was perceived to be 
AstraZeneca's preferential means of driving innovative drug development. However, 
the benefits from acquiring this research rather than developing it in-house are not 
always clear. 
Innovation Theme 15: Biomarkers represent a highly innovative and time sensitive 
area that requires innovative work to both stop and drive further R&D. It is also an 
area that has the potential to divert resources to other more promising projects earlier 
within the processes. 
Innovation Theme 16: Hypothesis driven research restricts the extent of innovative 
activity possible by narrowing the viewpoint of the employees involved. As a result, 
innovative research and data is poorly shared across AstraZeneca. 
Innovation Theme 17: Innovation typically arises as a result of a defined need by a 
project. Innovation that lacks specific and immediate application outside a project is 
highly likely to be disregarded. 
Innovation Theme 18: Luck plays an essential role throughout the early stages of 
drug innovation, yet may be guided and created through effective management 
practices. 
Innovation Theme 19: Innovation is required to allow employees to overcome 
traditional working practices, yet the conservatism of AstraZeneca can prevent 
innovative work from succeeding. 
Innovation Theme 20: In many cases innovation occurs outside of the individual's 
traditional role, yet attempting to progress these innovations is particularly difficult as 
it relies upon both management and the end user (i. e. project team or software user) 
accepting the innovation. 
Innovation Theme 21: Organisational restructuring is intended to increase 
productivity and drive innovation. However, in certain cases, the increased 
responsibility and realignment of the employee's roles leads to a decrease in potential 
innovative ability. 
Innovation Theme 22: Innovation and productivity are markedly different in the 
scope of drug development. The current measures and KPIs employed within 
AstraZeneca often fail to take account of the breadth of innovation occurring 
throughout a project and focus upon reducing the time required to complete a task. 
Innovation Theme 23: Patents are a tangible means of measuring pharmaceutical 
R&D but may not recognise the amount of innovation required to reach that stage. 
Furthermore, the process of patenting research may constrain innovation. 
Innovation Theme 24: Knowledge Management can play an important role in 
driving innovation by providing the means to access cutting edge research, both 
internally and externally to AstraZeneca. 
Innovation Theme 25: Innovation is reliant upon discovering diverse knowledge and 
information sources and generating an idea, but the collaborative culture within 
AstraZeneca sometimes fails to provide the opportunity to grasp the understanding 
and as such, a great deal of time is wasted within meetings. 
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Table 8.4: Knowledge Management Themes 
Knowledge Management Themes 
Knowledge Management Theme 1: Pharmaceutical innovation is heavily reliant 
upon applying technology and knowledge to develop a refined approach to 
discovering a viable compound at the early stages. 
Knowledge Management Theme 2: AstraZeneca possesses sufficient knowledge 
and intellectual capital to adapt and exploit innovative technologies that have no 
specific need when purchased, although this is difficult to achieve, as the financial 
risks arc increased by taking this approach. 
Knowledge Management Theme 3: Pharmaceutical innovation relics upon 
assimilating the complimentary knowledge of the individuals. Specialist knowledge 
workers must act in synergy in order to innovate. 
Knowledge Management Theme 4: AstraZeneca are seeking to drive their future 
strategy through collaboration and extended external Communities of Practice, yet in 
order to progress beyond simple information exchange, a knowledge centred strategy 
that reduces the bias that exists within scientific research is also required. 
Knowledge Management Theme 5: The unseen "innovation grid" implied by the 
employees is not publicly known and relies upon personal networks of collaboration 
to achieve results. The knowledge and information generated from this grid is rarely 
captured and shared. 
Knowledge Management Theme 6: The provision of external regulatory 
information is poorly handled; employees are unaware of where to find and how to 
interpret information that is aP21icable to their roles. 
Knowledge Management Theme 7: External regulations govern the degree of 
additional knowledge that may be applied and acquired from conducting 
supplementary drug development processes, and in many cases the knowledge 
surrounding this process is poorly captured. 
Knowledge Management Theme 8: Knowledge Management may play an 
important role in addressing the issue of reluctance associated with trying an 
innovative approach by ensuring that employees are aware of how their innovation 
could fit in within the regulatory framework. 
Knowledge Management Theme 9: Early drug development innovation requires an 
entrepreneurial approach to develop interest from limited resource and organisational 
support, and is reliant upon sufficient knowledge to generate interest. 
Knowledge Management Theme 10: Supporting innovation at an early stage can be 
aided by ensuring that sufficient information is available, presenting a strong business 
case and having access to the "right" influential strategy groups. 
Knowledge Management Theme 11: Knowledge Management may play an 
important role in publicising and defining the innovations that AstraZcneca will 
specifically fund and manage. As the concept of innovation is perceived to differ 
according to who is proposing an idea, a common understanding to develop a 
symbiotic relationship would be beneficial. 
Knowledge Management Theme 12: Information and knowledge exchange and 
reuse between Clinical and Discovery are felt to be poor and can lead to a sense of 
frustration. Knowledge Management techniques could help to improve this area. 
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Knowledge Management Theme 13: The degree of knowledge and information 
disregarded within these early stages is prolific, as only research that can be 
published will be shared publicly. 
Knowledge Management Theme 14: Acquiring innovation does not always mean 
that the knowledge and information is also acquired. In certain cases the desire to 
acquire cutting edge molecules may mean this supporting information/ knowledge is 
scarce. 
Knowledge Management Theme 15: Innovation at the biomarker stage relies upon 
sufficient knowledge and information to understand the mechanism of action of the 
drug. Without this, the risk of attrition further down the development pathway 
increases substantially. 
Knowledge Management Theme 16: The hypothesis driven approach results in 
duplication that may or may not be uncovered. Adopting a "systems engineering" 
approach may avoid duplication of effort and wasted resource. 
Knowledge Management Theme 17: There is a lack of appreciation of the 
knowledge capabilities of the employees and this is manifest in the levels of 
discontentment felt by innovators who may strugýle to progress their innovative 
work. 
Knowledge Management Theme 18: The community-of-practice model plays an 
integral part in bringing potential innovations to the forefront. However, this process 
may still be reliant upon an element of luck to make these initial connections. 
Knowledge Management Theme 19: The knowledge and information generated 
from the discussion of potential alternatives and innovative work is rarely captured 
and rarely disseminated organisation wide. 
Knowledge Management Theme 20: Innovation requires an exchange of knowledge 
where the innovator feels valued and rewarded for knowledge outside of theirjob 
remit. Sadly, in AstraZeneca, this sometimes is not the case. 
Knowledge Management Theme 21: Organisational change causes a distinct change 
in the relative information and knowledge needs of the employees as they learn new 
skills and take on a different role. 
Knowledge Management Theme 22: There is a need to employ intellectual capital 
assessment to measure the innovative activity occurring within AstraZeneca; yet also 
a need to develop a framework that accurately supports innovation within the 
organisation so as to encourage further innovative behaviour. 
Knowledge Management Theme 23: Conducting patentable R&D results in 
additional knowledge and information than is not required to submit a patent and 
consequently may not be captured effectively. Measuring and using the information 
and knowledge generated outside of the patent may be more valuable than the patent 
itself in some cases. 
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Knowledge Management Theme 24: Innovation requires multiple and disparate 
sources of information and knowledge. Many are available within AstraZeneca but 
keeping abreast of the important sources is paramount to promote innovation and 
avoid reinvention. 
Knowledge Management Theme 25: Collaboration occurs primarily via meetings, 
yet collaborative Knowledge Management tools exist throughout AstraZeneca. There 
is a greater need to either exploit or develop these tools to provide the collaborative 
medium for innovation. 
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CHAPTER9 
AN INNOVATION CASE STUDY 
9.0 INTRODUCTION 
While the researcher was in AstraZeneca, an opportunity to conduct a detailed case- 
based study of an innovative project arose. The case study concerned the use of a 
promising compound that had application across two diseases within the Clinical 
wing of the company. The decision making processes were examined and captured 
with the help of a novel Knowledge Management based too] (Adelmann & Jashapara, 
2003). This chapter presents elements of the decisions captured and the results of a 
series of extensive interviews. 
9.1 CASE STUDY: MANAGING RISK -A CAUTIONARY TALE 
This particular drug project was investigated by the researcher over a period of six 
months and was highlighted by a number of interviewees across AstraZeneca 
Discovery and Clinical as an interesting example of AstraZeneca's policy on 
innovative behaviour. The family of compounds in question, showed a potentially 
useful indication in both Rheumatoid Arthritis (RA) and Chronic Obstructive 
Pulmonary Disease COPD. A compound that can act on two types of diseases is rare 
and it is possible to run the initial series of clinical trials in parallel. This is an 
innovative way of conducting drug trials and holds the potential to save a 
considerable amount of financial resource. This study demonstrates that while the 
initial idea was innovative and scientifically sound, the project was hindered in a 
number of areas. The reasons behind this are discussed within this section, but overall 
the findings graphically illustrate the observations and themes stated within this 
chapter as a whole. Namely that driving innovation (even a scientifically viable one) 
is a decidedly risky and complex process, requiring the support from a diverse range 
of areas from organisational structure, to Knowledge Management systems, to 
regulation. 
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As this section discusses an example of innovative practice within AstraZencca, no 
themes or conceptual matrix will be generated. Its purpose is merely to illustrate the 
drivers for and the requirements of, ir1novation within AstraZeneca at present. The 
compound in question was recognised by senior management to be potentially 
effective in two disease areas: 
"That [the idea for the project] came about as a result of a joint [across disease 
areas] TA [Therapeutic Area] discussion as they were thinking how they could best 
optimise the current poqfolio and it wasn't a bad idea. " 
In this case the interviewees agreed that although the project was innovative and it 
appeared outwardly acceptable to all, the employees who worked upon this project 
were unsure who ultimately gave permission to proceed. One senior research scientist 
commented: 
'7 really don't know where the idea came from, but the Portfolio Management 
Committee and the heads of the T, 4s all agreed. Certainly it's nothing new under the 
sun hut it was something that was worth trying at the time. " 
This indicates that responsibility for the project rested loosely with senior 
management. Yet those involved with the day to day physical co-ordination and 
interaction between the two Therapeutic Areas (TAs), were poorly informed and 
knew little of who would provide them with the managerial backing needed to drive 
the project forward. Another research scientist from the COPD side commented: 
"Unfortunately the decision makers never got down to my level and consulted with 
us ... When you're working on the shop floor it's very difficult to get an idea 
recognised - you'll hear something fantastic like the guys in logistics who came up 
with a recycling idea - you get those examples and that is an innovative idea that has 
comefrom the shopfloor, but it's much harder in this part of the world. " 
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Hence, interviewees felt that innovation was certainly possible within other functions 
of AstraZeneca, yet within their own department they were disappointed by the 
difficulties associated with obtaining support for a scientifically and financially sound 
schema. In an attitude typical of innovators consulted across AstraZeneca this lack of 
support rarely discouraged employees. One interviewee, who was the Project 
Manager for the RA side, commented: 
"I was happy to take it [the drug project] on but there was a lot of pushback 
[resistance to change] and it was this pushback that won in the end. " 
Such was the extent of the resistance to change, that the end result was that the drug 
was forced through a rigid set of defined procedures and processes within the scope 
of the disease area that had showed the least promise. The term "pushback" indicated 
that although there was support to proceed with the innovative piggybacking study, 
the end result was that procedures designed to support running a single clinical trial 
had to be employed. The project manager continued: 
"The main pitfall was that several of the processes that were in place are huge 
hurdles, investigators' brochures being one - but one of the big things that tripped us 
up was looking at compounds going into Xý [disease 1]. For the XY [disease 2] 
aspect to work we would have needed to go into XYpatients before Xxpatients and 
that wasjust too muchforpeople to get their head around. " 
Therefore, there were clear procedural and cultural hurdles to overcome, yet both 
were surmountable in the opinion of the project employees. Particularly if the senior 
managerial backing that remained "hands off', had stepped forward and approved the 
work required to ensure the project ran successfully. A senior research scientist 
commented that, although the project failed to run concurrently and could have 
shared resource and knowledge at many stages across TAs, it was now being run as 
two distinct projects that required greater resources: 
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"It would have saved the company an absolute fortune - in fact the study we should 
have started in 2003 is going to start in 2006. So this has now been taken on by 
process and started by process and we're now at the point where the study we wanted 
to do - is actually starting in 2006! " 
From these comments the interviewee went on to explain that : Process'simply meant 
that the study had been allocated a budget and was being project managed. However, 
a high ranking senior manager within this project was also interviewed and they 
expressed dismay at how the innovative aspect of the project was sidelined and 
effectively shunned. Another managerial employee summed up the linear and 
enclosed attitude to drug development work that, due to strict project structures, could 
essentially mean ignoring a compound that had application outside of the project's 
immediate remit: 
"So now they've gone through AX and now they're thinking let's try XY and it's the 
same with one of the other key compounds I've been working on - there was a total 
unwillingness to take the risk andput this drug into a XYpatient on a variety of levels 
from safety to political. " 
They continued to say this went against the compelling scientific evidence that was 
available: 
"Yet probably, from a clinical and a scientific perspective, it is the most likely drug to 
succeed in the arena, but one of its sisters will eventually get into patients, but again 
the study could have been done in 2005 but won't get done until 2007.1 mean, losing 
2 years ofmarketing to the competition, it beggars belief " 
The majority of employees explained that once a compound has exhausted its 
promise in one disease area it is either disregarded or applied to another disease area. 
However, this is very much dependent on who was working on it and their influence, 
and as previously mentioned (see 7.5), the knowledge and infon-nation captured 
rarely leaves the immediate drug project environment. 
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From a scientific rationale this is clearly at odds with AstraZeneca's mission 
statement and does little to create an environment conducive to innovation and 
knowledge sharing. The ground-level and senior employees involved within this 
project expressed considerable dismay that the reasons behind the cessation of the 
project and their work falling behind by 2 years, was not aired within the company. A 
research scientist noted: 
"We have no appreciation of the pressure higher up the chain, and what structures 
are forced higher up, but I really don't think it would be too difficult to send some 
clearer messages. It's sad when you see documents and statements that are cobblers. 
I mean, its not lies by any means but it is cobblers! " 
Therefore, poor communication and a tendency to enclave the decision making 
processes are a key characteristic of this project. However, similar innovative projects 
also suffer from a similar ethos. As part of the case study approach, the researcher 
targeted a number of other innovative projects outside of the drug development arena. 
Although not directly involved in producing innovative drugs they centred upon the 
development of innovative software or business processes to aid drug development in 
the long term. Amongst those employees interviewed, was a physician who worked 
on an innovative IT software tool. They expressed similar concern that although their 
idea had been taken on by senior management, the end result was a diluted version of 
the prototype software: 
"When something gets into IS you initially have control, but as it gets deeper then 
you don't have any control on what gets delivered - but it still gets delivered, but 
concealed in all the mumbojumbo of announcements and newsletters, hiding the real 
work [ofcoming up with the software and the idea]. " 
The sense that AstraZeneca's innovation strategy is designed to encompass 
innovation and outwardly encourages innovation is widespread. Ilowcvcr, when the 
process of introducing innovation is examined in greater detail, there is an undeniable 
consensus that support for innovative work is lacking across diverse environments 
from AstraZeneca IS to Discovery to Clinical. 
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Furthermore, a prototype innovative project may become changed and diluted by the 
time it is instigated. What is more apparent is that. the classical principles of 
Knowledge Management, explored in Chapter 3, that may be used to support 
innovation are also noticeably absent or lacking in functionality. Providing the 
employees the opportunity to reuse, capture and exploit knowledge is fundamental to 
innovation within AstraZeneca, yet the practice is rather different. The following 
section concludes this chapter and briefly discusses the key findings in relation to the 
overall research aim. 
9.2 CONCLUSION 
This chapter has examined a highly innovative project within AstraZeneca from the 
perspective of the employee. By taking this stance a number of interesting 
observations and findings have been made, not least the notion that projects are 
driven by the need to avoid risk. In this case taking the safer option and trialling the 
drug within X disease did not yield a successful outcome. Throughout the process the 
employees tasked with trialling the compounds, expressed dismay that the compound 
was not also trialled in disease Y simultaneously. This point appears to be down to 
simply not knowing, who could provide support to the project. As the interviewees 
noted, to have achieved the project would have saved a considerable amount of time 
and resource. The data suggests a number of factors caused this, but the principle 
factor appears to be the difficulty in presenting a strong business case to try an 
innovative approach first. As noted in 7.1, managerial support is required to gain 
initial support to progress from an innovative concept, yet in this case the 
groundwork appears to have succeeded. It is the subsequent and continued support 
that appears to have been withdrawn at some point, most likely due to the resource 
demands from other, existing and less risky projects. Undoubtedly Knowledge 
Management can play a role in this area by providing the knowledge and information 
required to support all phases of innovation. 
285 
Chapter 9- An Innovation Case Study 
The following chapter utilises the findings of chapters 5,6,7,8 and 9 to develop a 
Knowledge Management tool set that can aid the innovator overcome these and other 
difficulties faced by innovators within the pharmaceutical industry. 
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CHAPTERIO 
DEFINING A KNOWLEDGE MANAGEMENT & 
INNOVATION FRAMEWORK 
10.0 INTRODUCTION 
This chapter marks the start of the discussion phase of the thesis. Throughout the 
chapters so far there has been a strong emphasis upon the interplay between 
knowledge and innovation. Innovation cannot proceed without adequate knowledge 
and information and it is undeniably a crucial factor within pharmaceutical drug 
development. Chapter 6 expanded upon the results of Chapter 5 and provided a 
valuable insight into the generic factors that affects innovation within AstraZeneca. 
While Chapter 7 examined those factors that were specific to AstraZeneca, Chapter 8 
continued to explore the current Knowledge Management strategy employed by 
AstraZeneca and finally Chapter 9 provided details of a case study that utilised a 
Knowledge Management tool for analysis of the key decision making points. This 
chapter examines the link between innovation and knowledge management in greater 
detail, concluding with a novel Innovation/ Knowledge Management framework 
based upon the results of this research and subsequent work by the author (Parsons et 
al. 2005a). 
10.1 DEVELOPING A KNOWLEDGE MANAGEMENT & INNOVATION 
FRAMEWORK 
Throughout the previous chapters, innovation and Knowledge Management was 
analysed within the processes of AstraZeneca, specifically with regard to the 
knowledge and infonnation required to drive those processes. To recap the definition 
of innovation chosen as the basis for this research was: 
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"A process of creating and developing new products or services through 
collaborative team processes and mechanisms that utilise and empower the skills and 
knowledge of the people" (Terziovski & Morgan, 2004) 
The definition of Knowledge Management chosen was: 
"A discipline that seeks to improve the performance of individuals and organizations 
by maintaining and leveraging the present and future value of knowledge assets 
(Newman & Conrad, 1999) 
These definitions are markedly similar as each suggests that the output, i. e. 
innovation or knowledge, derives from improving the relationships between 
employees within an organisation. The following discussion seeks to ground the 
results from this research within the pharmaceutical environment of AstraZeneca and 
shed light upon future developments for innovation and Knowledge Management. 
To an extent the results of the previous chapters were to a degree expected from the 
literature review of Chapter 3, yet surprising in the insight that they give into the 
complex field of pharmaceutical innovation. Throughout the results, the notion that 
the organisational. structure plays as important a role in driving innovation as the 
access to knowledge and information, counters the idea that providing an employee 
with sufficient knowledge and information will drive innovation. Nonaka & Takeuchi 
(1995) emphasise this finding in their archetypal work upon knowledge management 
by stating that simply providing an individual with a search capability across a 
knowledge repository is not the answer. The results of Section 8.1 imply that 
innovators will assunie that repositories of this type within AstraZeneca, such as the 
R&D Portal will not contain the correct information requirca. Instead they appear to 
prefer to find their information and knowledge elsewhere, principally via 
collaboration or external sources. 
The majority of technology focused Knowledge Management research espouses the 
use of a repository system, and in many ways, this reflects the strategy of 
AstraZeneca with the R&D portal and eRooms. 
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Yet the user still has the difficult task of converting this knowledge (or, in many 
cases, information) into a usable form that can then be applied to a problem, a process 
Nonaka & Takeuchi (1995) refer to as combination. The results of Chapter 7 
demonstrated that the act of interpreting and then applying this information to 
generate knowledge and then to perform innovative work is the stumbling block. An 
employee may have a potentially lucrative idea, yet gathering in the necessary 
information, knowledge, political support and avenue for exploitation of the 
innovative concept remains an area that requires facilitating. 
10.1.1 INNOVATION, KNOWLEDGE AND COLLABOPATION 
During this research a Discovery director proclaimed that effective innovative 
practice is dependent upon mitigating the risks involved within pharmaceutical 
development and making the connections between disparate "bits of information and 
people". This finding supports the work of Dodgson (1993) who also observes that 
effective management style is an essential part of managing collaborative work. 
Unfortunately this research found that, although the management style could be 
effective, in terms of innovative work this was often followed by a lack of time and 
resource in terms of budget and manpower to follow up an innovative concept, a 
finding also in line with earlier research by Davenport & Prusak (1998). 
This research also covered the role of biotechnology firms and university research as 
the precursor to innovation. On the whole many of the innovative concepts within 
AstraZeneca have their roots within an external organisation or contact and this may 
be considered as the archetypal notion of Customer Capital. The acceptance of 
externally derived innovation over internal innovation was also an interesting finding. 
This is a finding that bodes well for the future of the biotech industry, but perhaps 
less well for in-house pharmaceutical R&D. Hence there is considerable opportunity 
for external innovative ideas to progress within AstraZeneca. Yet, in order for an idea 
to stand out, Tcrziovski & Morgan (2004) suggest that the managers of these firms 
must be more aggressive in marketing their firm's potential for collaborative work. 
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Particularly as the majority of biotech firms rely upon pharmaceutical companies 
taking on their ideas and investing resource at some stage (Canongia 2007). 
It is fitting that since the results gathering stage was conducted in 2005, the 
collaboration between Cambridge Antibody Technology and AstraZeneca, mentioned 
in Section 7.3, resulted in AstraZeneca purchasing the company outright (BBC News, 
2006b). Therefore to have the highest chance of an innovation succeeding, the results 
and Dornblaser et al. (2003) found that optimistic and advanced research stands a 
higher chance of being taken into a company. Hence, it would appear that if an 
external innovative concept is sufficiently well advanced, then AstraZeneca will 
certainly take interest in it. This is largely because the financial risks associated with 
the early stages of compound development have been minimised. 
Relying upon acquiring established research lessens the danger associated with 
innovation but can mean that compounds become a "me too" as Section 7.5 
demonstrated. Conversely the level of risk must be balanced against the competition. 
If a competitor decides that the risk to progress an innovation is acceptable then they 
could gain a competitive advantage, particularly if the drug is a "first in class" and 
outperforms the available "me too" drugs. 
This research emphasises that although the majority of innovation is externally 
derived, it is the individual who usually finds the source of the concept of innovation 
by assimilating multiple knowledge and information sources. In this case, these 
concepts are external ideas provided by a biotech, these are then required to be 
acknowledged and "bought in" to the company at a strategic level in order to have 
sufficient momentum. The results of Section 7.1 indicate this aspect from the point of 
early phase drug development, while the results of Section 7.2 acknowledge that 
"broadcasting" or "advertising" an innovative idea to the organisation can encourage 
innovation through the use of groups such as the Science Group and the New 
Opportunities Group. These findings are represented in Figure 10.1 and show two 
important aspects: 
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1. Creating the initial concept of innovation lies with the individual. The results 
of Chapter 7 indicate that while innovation can be acquired, the responsibility 
to develop and highlight an innovative concept essentially lies with the 
individual. 
2. An innovative concept can only be progressed to a prototype once it has 
received the employee support (a critical mass) and backing of the 
organisation. Progression from a concept to an innovation rarely occurs 
without substantial organisational backing, e. g. managerial support, project 
management backing and project team backing. This aspect is indicated by the 
transition over the boundary between the "Individual Level" and the 
"Organisation & Project Team Level" (indicated by the dashed line). 
I Individual Level I 
Collaboration & 
Assimilation of Knowledge 
& Information Sources 
I Concept I 
Organisational & 
Project Team Level 
I Prototype I 
Innovation 
Figure 10.1: Modelling the employee as the initial driver of the concept of 
innovation and the organisation as the means to achieve innovation. 
This research acknowledges that collaboration and networks of innovators primarily 
drive the assimilation of relevant ideas and innovative concepts. Of the innovations 
studied within this research almost all relied upon an external idea, whether this was 
derived from a colleague, a conference or a journal paper. Therefore this research 
dismisses the idea that the individual can be the sole creator and implementer of 
innovation. 
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This finding dismisses the idea of the 'skunk works' model associated with software 
organisations, where creative individuals are allowed the time and resource to 
progress innovations themselves (Kohn, 1995). This appears to be due to the extent 
that regulation and the regulatory bodies (e. g. the FDA) curtail and shape innovation 
within the pharmaceutical industry as shown by S ection 6.4. Therefore, although the 
individual was responsible for the majority of the innovations studied, collaboration 
played a key role in gaining the knowledge and information required to develop the 
innovation. This is represented in Figure 10.1 by the reliance upon collaboration by 
the individual and the notion of teams supporting the development of a prototype. 
These findings that the individual cannot largely drive innovation alone are in stark 
contrast to the majority of the Knowledge Management literature. The literature 
frequently proposes that innovation is derived from free (and creative) individual 
thought and the application of the tacit knowledge of the individual (e. g. Lemon & 
Sahota, 2004; Mascitelli, 2000). Although the initial idea may be derived from the 
individual the act of progressing it clearly falls outside of one person within the 
pharmaceutical industry. 
Hence, if Knowledge Management is to play a part, the main focus of the Knowledge 
Management toolset should be upon the creation and mimicking of social networks to 
drive innovation, thereby reflecting the current situation within AstraZeneca. 
Although AstraZeneca possesses an active Knowledge Management strategy the 
results of Section 8.2, has demonstrated that the emphasis remains firmly upon face- 
to-face communication. The literature also confirms that this is still regarded as the 
key communications channel in terms of innovation, in the majority of organisations 
(Rogers 2003). 
The foundation of external social networks is an interesting area, as in some cases the 
external relationship was viewed as short term and transient, such as the case of 
innovation stemming from a small university grant for a novel dosing method. Hence, 
little physical knowledge capture occurred at the early stages due to the expected 
short term nature of the project. 
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Yet, if as in that case, the working relationship developed ftirther and showed greater 
potential then it makes strong business sense to capture the knowledge exchanged. 
Interviewees noted that this would have made the case of the CAT collaboration 
easier and could potentially have helped to make this relationship more productive. 
Pittaway et al. (2004) imply that these relationships are dependent upon the type of 
innovation occurring, namely either incremental or radical. This research also 
confirms this finding, yet stresses that what may begin as radical innovation may 
quickly progress to incremental innovation once an innovative concept has been 
taken into the organisation. The acquisition and the development of the dosing 
hardware discussed in Section 6.2.2 is an example of this type of evolution of an 
innovation from relatively radical to evolutionary. 
It is interesting that a number of the innovations studied, like the dosing technology, 
started off as solutions for a problem that did not exist or was ill defined. Developing 
radical innovation is the realm of the creative scientist and Astrazeneca possesses 
many of these types of people. Sometimes it appears that these ideas are ahead of 
their time, as in the case of a novel Knowledge Management system, yet other times 
they are applicable to current processes. Hence it is important to store these ideas for 
future use, as what may be dismissed today by their peers, may be highly applicable 
in the future. Above all, this research has demonstrated that there is a focus upon 
"knowledge networks" and collaboration as a driver for innovation, whether this is a 
positive or a negative influence. 
The results of Section 7.3 suggest that the link between the type of innovation and the 
success of the innovation are important, and hence emphasises the importance of 
capturing innovative practice however radical it may be. The following section 
examines this in greater detail and seeks to develop the model denoted in Figure 10.1. 
293 
Chapter 10 - KM & Innovation Framework 
10.1.2 CHANGE, INNOVATION, SCIENTIFIC BIAS AND MANAGEMENT 
Section 7.3 noted that regardless of how promising or exciting innovative research 
appears, it must possess a practical place within AstraZeneca's overall strategy. There 
is evidently an innovative culture within AstraZeneca that drives this initial 
conceptual innovative research. Yet to an extent it is the act of presenting the results, 
which appears to be hampering the introduction of new ways of thinking, practice and 
innovation. Newman & Conrad's (1999) definition of Knowledge Management 
emphasises that Knowledge Management is concerned with leveraging the 
knowledge and information of the organisation. In many respects it is the aspect of 
leveraging the knowledge of the organisation that appears to be extremely difficult 
within phannaceutical innovation. 
As Chapter 7 illustrated, the key factor behind the difficulties in levering existing 
knowledge is that innovation on the whole creates change, whether to AstraZeneca's 
existing processes or to the role of the employee. This change can tangibly affect or 
reduce the amount of resource available to the employee to conduct their project 
based role. Hence an employee must make their own time to be innovative or simply 
try to be innovative within what interviewees regarded as inhibitive management 
structures or 'ýprocess" (see Section 9.1 with respect to the "piggybacking" drug 
innovation). Findings by Hotek & White (1999) also surmise that when introducing 
change such as this, employees must be made aware of what resources will be offered 
and how such a change can help them. In the case of innovation within AstraZeneca, 
the benefits to the employee are unclear, particularly when their innovative idea may 
or may not be progressed beyond a concept or prototype (e. g. a novel Clinical Trial 
methodology). Hence the "piggybacking" example illustrates that the more radical 
the innovation is, then the greater the resistance to change is, regardless of the 
potential benefits. 
The results of Section 6.3 illustrated that the reasons behind this resistance stem from 
scientific bias which will effectively act against novel ideas that lie outside of the 
accepted inethodologies and structures of AstraZeneca. 
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So tackling this bias against innovation felt by employees is an important aspect of 
any potential Knowledge Management toolset. However, many authors state that bias 
will always exist within scientific research (Starbuck 1992) and this research suggests 
that a blinkered "world view" along with self belief in the idea, is sometimes 
necessary to initially drive an innovation. This aspect requires further research to 
clarify this point and may, in many respects, be countered by the creation of the New 
Opportunities Group who will try to reduce scientific bias through collaboration and 
the exploitation of Customer Capital. This research has shown that this group has 
chosen to drive innovation by establishing networks of innovators and collaborators 
in a classical Community of Practice (see Wenger & Snyder, 2000) and is an ideal 
team to be supported by Knowledge Management systems. 
However, there is evidently a fine line between excessive management of innovation, 
which Section 6.4.3 noted can stifle innovation and supportive management. While 
Section 7.6 suggests that from an innovation perspective managerial direction should 
equate to a 'guiding hand', whereby innovation is not forced but helped. In addition, 
the overall research data suggests that innovators can be placed in the right place at 
the right time through the structure of the organisation and the actions of management 
(e. g. the purchase of the FTIM dosing technology). In essence an exploitation of the 
existing employee based Human Capital. However, Section 7.6 also demonstrated 
how difficult it is to exploit the various skills of the employees already within 
AstraZeneca, with the preferred model being the acquisition of external innovation 
and knowledge. The ability of an organisation to draw in innovation, knowledge and 
skills as it requires, is well documented (see Thonike et al. 1998) and more recently 
has been named absorptive capacity (see Fosfuri & Tribo 2006). Yet this absorptive 
model relies upon the location of the necessary resource and skills to overcome a 
problem as it is posed. Relying upon this type of reactive model to drive innovation 
in this fashion, introduces risk into the equation and hence financial consequences if 
an innovation fails to solve the problem. This is particularly potent when viewed 
within the concept of long term compound development time scales and high attrition 
rates as revealed by Section 3.1.4. 
4 
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Hence this also explains AstraZeneca's reliance upon external organisations such as 
biotechnology firms and universities to fund this early stage development work. The 
early literature findings of this research found that compound attrition is incredibly 
high within the pharmaceutical industry and higher still when new disease areas are 
being considered (Alanine, 2003). However, AstraZeneca has an enviable record in 
later phase compound attrition and this is due to caution, a strategy of risk aversion 
and an organisational culture that promotes collaboration. This results, in part, 
through achieving a consensus before work is progressed, albeit primarily at a 
managerial level. Tbis, in turn, reduces attrition but also makes "shop floor " drug 
related innovation difficult as Section 6.2.3 illustrated. Hence, many interviewees 
stressed that driving innovation relies upon "who you know" and how good your 
influencing skills are in convincing management and the associated stakeholders to 
back an innovative project. This finding is also confirmed by Bovey & flede (2001) 
and is conceptually indicative of the supportive Structural Capital of AstraZeneca. 
Overall this research and the Knowledge Management literature suggest an 
employee's innovative ability is governed by their environment and the direct 
management associated with their role, a finding confirmed by Probst et al. (2000). 
The findings over the last sections have made a number of important points that aid 
the development of the model in Figure 10.1. Primarily they introduce the role that 
Intellectual Capital plays in relation to innovation, the individual and the 
organisation. Therefore, in terms of Intellectual Capital at an organisational level, the 
influence on innovation, based upon the findings from this research, can be described 
in a number of ways: 
The Human Capital (employees) of the organisation can drive innovation and 
help to lessen the reliance upon absorptive capacity. 
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Customer Capital relates to the formation of collaborative networks with 
external and internal customers. In particular, this should exploit the 
relationship with external research organisations, such as biotechnology 
companies and universities, that effectively drive compound innovation 
within AstraZeneca at present. 
Structural capital (e. g. the organisation's knowledge, processes, and 
organisational structure) can only support innovation once the concept has 
been approved at the organisational level. 
These findings are represented in Figure 10.2 and illustrate how the levels of 
Intellectual Capital within AstraZeneca influence innovation. 
Of particular interest is that although the individual, whether this is an employee (i. e. 
Human Capital) or external contact (e. g. Customer Capital) provides the innovative 
concept, it is only when the concept can be progressed to a prototype will the 
Structural Capital of the organisation play a role in supporting the innovation: 
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I Individual Level I 
Collaboration & 
Assimilation of Knowledge 
& Information Sources 
Concept 
Organisational & 
Project Team Level 
I Intellectual Capital I 
I Human Capital I 
I Customer Capital (Biotechs) I 
I Structural Capital I 
I Prototype I 
Innovation 
Figure 10.2: Modelling the drivers of innovation and the Intellectual Capital of the 
organisation as the means to achieve innovation. 
The arrow linking the individual and the Customer Capital is two way. This indicates 
a collaborative and strategic relationship, in that knowledge & information exchange 
is a two-way process in order to drive innovation. Section 8.2 indicates that this 
relationship may be transient and under exploited from a Knowledge Management 
point of view (e. g. little information and knowledge capture), but having a strong 
external collaborator (e. g. a respected biotech or renowned university)'does appear to 
lessen the risk associated with innovation. 
The collaborative aspect appears to protect the innovative employee from risk, and 
the potential to be blamed for failure as it can encourage sponsorship at a project 
level, thus taking the onus off the individual. 
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Yet the data in Section 6.4.3 indicates that employees perceived that a "blame 
culture" does exist within AstraZeneca, which can affect the ability of the employees 
to be innovative. 
Prior findings by Sundgren & Styhre (2003) within AstraZeneca R&D, Lund, also 
concluded that there is disaffection with regards to innovation and the management 
culture. Yet this is a finding that appears typical within large organisations in general 
and typically arises within project focused teams (Argote et al. 2003). Section 7.4 
found that "discrete groupings" within R&D project teams causes a distinction of 
innovative behaviour between employees. In that certain groups of employees arc 
more likely to accept responsibility for any failure and hence would be more likely to 
adopt innovative practice. This factor was shown by this research to be a key driver 
of innovative drug development work and this view is supported by literature from 
Mahesh & Suresh (2004) and Gunnlaugsdottir (2003). 
This dichotomy between employees, and in certain cases, project teams, appears to 
largely arise from the difficulties in effectively balancing the need to innovate and the 
need to generate a profit. Interviewees commented that creativity and their 
innovations often arose from the need to circumvent an AstraZeneca management 
process. Interestingly, Knowledge Management literature is particularly emphatic that 
a "blame culture" can do nothing but hinder innovation (e. g. Corso et al. 2001). Yet 
this work and a study by Waring (2005) suggest that a "blame culture" is thought of 
by physicians as a natural part of a medical culture. Many of the interviewecs have a 
medical background and it is interesting to perceive similar perceptions with regards 
to innovation, risk and blame. 
A ftirther important point is that the support of AstraZeneca processes and Structural 
Capital is dependent upon an innovative concept meeting the needs of the 
organisation. Section 7.5.3 revealed that innovation which lies outside of the defined 
strategy may be disregarded, regardless of its potential. This is largely due to the use 
of measures and metrics that measure efficiency and productivity, not innovation. 
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Furthermore teams such as the Science Group and the various Therapeutic Areas 
Global Product Teams will assess a potential innovation on these measures. This 
inevitably leads to the lack of support unless there is a specific business need. Hence 
an innovation must: 
1. "Get on the radar" of these teams 
2. Overcome scientific bias 
3. Meet a defined business need 
4. Overcome resistance to change 
5. Create sponsorship 
6. Meet the existing metrics 
The first point is interesting as currently these teams meet at most on a monthly basis 
and interviewees noted that making time to discuss ideas outside of existing projects 
could be sidelined. In addition to this, many different groups at each stage must 
approve the process. Examples of these groups include the Commercial Review 
Board (CRB), Product Review Board (PRB), Senior Executive Team (SET)'and 
Therapy Area Portfolio Team (TAPT). This obviously takes time and for some 
groups a meeting may only occur annually, hence the focus and resource is firmly 
upon compounds that are currently in the development pipeline and not innovation. 
Therefore, it is not hard to see the affect that process can have upon innovation, 
particularly if it is unclear which of these controlling groups can help to sustain an 
innovative concept. It is clear that these tollgates will favour external work and not 
the in-house individiial, as external work will generally have progressed beyond the 
concept phase. These observations are represented in Figure 10.3 by the addition of 
tollgates, which are based upon productivity metrics, within the organisational 
supportive processes: 
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Individual Level Organisational & 
Project Team Level 
Intellectual Capital 
Human Capital 
Customer Capital (Biotechs) 
Structural Capital 
Collaboration & Tollgates 
Assimilation of Knowledge 
& Information Sources 
F Prototype 
Concept Tollgates 
Innovation 
Figure 10.3: Modelling the drivers of innovation and the Intellectual Capital of the 
organisation as the means to achieve innovation. 
10.13 THE ROLE OF REGULATION, SAFETY AND LUCK 
This research found that patient safety and regulatory compliance is the topmost 
priority with regards to AstraZeneca's overall role in innovative drug development. 
The research data also noted that due to the stringent regulations and the exemplary 
standards set by the employees, it was highly unlikely that a dangerous drug would 
ever make it to Phase I clinical trials. Yet, as the ill fated trial run by Parcxel (BBC 
News, 2006c) demonstrated, due to the degree of unknowns involved in innovative 
drug development, relying upon the regulatory process alone is not enough. 
AstraZeneca possesses an exemplary safety record and this is largely due to the 
scientific expertise and peer review culture within AstraZeneca. 
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The recent release of the lung cancer drug Iressa was highlighted by a number of 
interviewees as an example of how the efficacy of a drug is hard to predict. During 
the clinical trials the number of patients that positively responded to the Iressa 
treatment was statistically significant, yet on release of the drug it became apparent 
that only 10% of patients responded to the drug and this was later found out to be due 
to a mutation in a patient's EGFR gene (Ruder, 2004). Interviewees stressed that their 
early opinion was that the drug was a potential blockbuster product, but went on to 
say that you can only be fully certain of a drugs chemistry and efficacy when a drug 
is released after Phase III clinical trials. The following quote concerning Iressa, taken 
from an article by Ruder (2004), explains that even though Iressa may never be a 
blockbuster product, AstraZeneca and its employees are still fundamentally driven to 
save lives and release promising compounds as quickly as possible: 
"Iressa camefrom the lab to the clinic before the mechanism of the drug was truly 
understood because it so dramatically extended some patients' lives, which is a 
positive thing. " 
Hence the drive to release promising drugs and balance the risk is a contentious area 
and one that Knowledge Management could undoubtedly aid, primarily by linking 
like-minded innovative employees together. This research found that an unusual, and 
welcome, side effect of gathering innovative people together was the generation of 
luck. Indeed the results of Chapter 7 suggested that luck plays an important role in 
initial innovative work. Research by Schmid & Smith (2004) also suggests that luck 
has an important role in pharmaceutical innovation and this largely stems from 
collaboration with other employees (e. g. the Human Capital of the organisation). 
Yet it is the extent of luck'. s involvement which is startling, particularly when the 
slow and "incremental" pace of pharmaceutical innovation is taken into account. 
These findings relating to luck and the slow innovative pa: ce also emphasise the 
amount of risk involved within these processes, mirroring findings of research by 
Schmid & Smith (2004). These findings are represented in the model of Figure 10A 
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Figure 10.4: Modelling the drivers of innovation and the role of luck and safety as a 
means to achieve innovation. 
The acknowledgement by the majority of interviewees, that luck plays an important 
role emphasises the role that Knowledge Management could play in reducing this 
reliance. The following section utilises the previous discussion and expands the 
model within Figure 10.4, to develop a theoretical Innovation and Knowledge 
Management centred framework. This framework illustrates the scope of a potential 
Knowledge Management toolset within AstraZcneca as a means to drive innovation. 
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10.2 DEFINING THE KNOWLEDGE MANAGEMENT & INNOVATION 
FRAMEWORK 
Innovation has been shown to rely primarily upon assimilating information and 
knowledge at the individual level. Although luck plays an important role it is the 
individual who locates the necessary sources of knowledge and information. 
However, Chapter 8 implies that Knowledge Management must offer more than the 
act of retaining information and knowledge, a finding also implied by 
Wickramasinghe's (2003) research. The view resulting from this research is that the 
goal of information and knowledge exchange and capture is not enough of a driver to 
ensure a system's use in terms of innovation. 
The results of Chapter 8 indicate that from a technology perspective, information is 
primarily acquired rather than contributed. However, at a social level both acquisition 
and contribution occur through collaboration and social networking (see Section 8.2). 
This is largely because employees stated that in order to contribute to a KM system 
they must have specialist knowledge of both the system and their scientific domain, a 
finding also implied by Grant (2002). It would appear that this also holds true if the 
employee is to adequately contribute knowledge or information, to a Knowledge 
Management system. Effectively the employee must be able to capture their 
specialised domain knowledge in a form that represents the tacit knowledge within 
their role. A feat that Chapter 3 noted has been the 'bug bear' of the majority of 
Knowledge Management systems to date and appears to be independent of the 
training received. 
As the results of Section 8.1 demonstrated the broad range of Knowledge 
Management and IS systems within, and external to AstraZcneca, also means that 
users become accustomed to finding information in a particular system, be this 
internal (Product Knowledge Transfer) or external (Scrip). 
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The results show that users prefer to utilise Knowledge Management systems 
passively and therefore not contribute information or knowledge, such as using the 
R&D portal search functionality. Therefore the results of Section 8.1 indicate that 
from a technology perspective, the information is acquired rather than contributed. 
Providing a system that allows the employee to capture their knowledge and then 
allows another employee to understand and apply this information is tricky, 
particularly when the diverse range of information and knowledge sources that an 
innovator must take into account whenever they attempt pharmaceutical based 
innovation, is recognised. Hence, this research recognises that within AstraZeneca, 
the renowned knowledge push/ pull model suggested by Williams & Gibson (1990), 
firmly rests with the "pull" of information & knowledge at present. While the results 
imply that providing a Knowledge Management based system for innovators to 
64 push" their ideas and knowledge across AstraZeneca should, if the employee can 
master the system, theoretically enhance innovation. 
Therefore, a major finding of this research is that Knowledge Management's apparent 
obsession with explicitly capturing the information and knowledge of the employees, 
may not offer the greatest return in terms of pharmaceutical innovation. Instead it 
would appear that this aspect should be. tertiary to the primary role of facilitating 
social networks and the secondary role of disseminating external and internal 
information. This research suggests that only 
* 
once the primary and secondary 
considerations have been addressed, can an employee hope to be able to capture 
knowledge in sufficient depth to be worthwhile to the organisation. In essence, an 
employee must have sufficient "worldview" of their domain before capture can take 
place, an analogy that is reminiscent of the German word "Weltanschauung". 
The main aim of this research as detailed in Chapter I was to develop a Knowledge 
Management tool set that could drive innovation. So far, the discussion suggests that 
a tool set should possess varying levels so as to drive innovation in line with the 
findings of Section 10.1. 
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The reluctance to embrace change implies that it would be wise to mimic the existing 
innovative drivers within AstraZeneca at present and seek'to aid, rather than induce 
change. To take account of these factors the proposed toolset features three levels: 
1. A Primary Level based upon social networking and collaboration both 
internally and externally, which is driving innovation within AstraZeneca at 
present 
2. A Secondary Level of internal and external information sources that are 
largely used to "pull" information from sources such as the R&D portal, 
internal AstraZeneca websites, GEL and PKT, and external sources such as 
MedLine, SCRIP etc 
3. A Tertiary Level Knowledge Management system that can be used to store 
innovative knowledge with the correct support e. g. Case Based Reasoning/ 
Decision Capture system. This "push/ pull" level is becoming more 
widespread within AstraZeneca with innovations such as Knowledge Objects 
(Adelmann & Jashapara 2003) and other Knowledge Management based 
systems. 
Therefore, a set of Knowledge Management systems should be able to play the 
important role of providing accurate current knowledge that allows an employee to 
collaborate and assimilate information and knowledge rapidly. The toolset is 
designed to be used by the individual and as such, sits with the individual as 
conceptually represented in Figure 10.5: 
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Individual Level 
Knowledge Management 
Primary Level - Social 
Networks (Push/ Pull) 
Secondary Level - Internal/ 
External Knowledge & 
Information (Pull) 
Tertiary Level - Knowledge 
& Information Capture 
(Push) 
Organisational & 
Project Team Level 
Figure 10.5: Modelling the levels of Knowledge Management tools required for 
innovation. 
Central to this idea is the notion that a set of Knowledge Management systems can 
perform three distinct roles, namely: , 
1. The foundation and facilitation of social/ knowledge networks 
2. The assimilation and dissemination of relevant up to date information and 
knowledge - both from within the organisation and from external sources 
3. The satisfactory capture of infon-nation and knowledge 
These roles are quite separate in character and require a different set of tools, yet 
must be introduced to meet the requirements of AstraZeneca's innovative employees. 
In reality the proposed Knowledge Management toolset is essentially a descriptive 
framework that can be used to suggest components to support and sustain innovation. 
Chapter 3, Section 3.3, illustrates the difference between a prescriptive framework 
and a descriptive framework in greater detail. 
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Primarily a prescriptive framework defines a set methodology that must be followed 
to provide benefit, while a descriptive framework merely suggests a structure and 
components (Rubenstein-Montano et al. 2001). 
Prior to carrying out this research the research aim was to develop a tool set, yet it has 
become clearer that upon observing the relationship between Knowledge 
Management and innovation this stage of the tool set development is in reality a 
framework. Simply because this stage of the research provides an indication of what 
is required and not how to specifically carry out a task Above all the framework's key 
role is to, channel information and knowledge to the individual in order for the 
individual to assimilate these sources and ultimately drive innovation. Figure 10.6 
demonstrates how the previous models of innovation have been aligned with the 
Knowledge Management framework: 
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Knowledge Management 
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Primary Level - Social 
Networks (Push/ Pull) 
Secondary Level - Internal/ 
External Knowledge & 
Information (Pull) 
Tertiary Level - Knowledge 
& Information Capture 
(Push/ Pull) 
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- Safety/ Regulatory etc 
Organisational & 
Project Team Level 
Intellectual Capital 
Human Capital 
Customer Capital (Biotechs) 
Structural Capital 
I Tollgates I 
I Prototype I 
I Tollgates I 
Concept 
Innovation 
Figure 10.6: Modelling the Knowledge Management Framework with regards to 
innovation. 
Figure 10.6 provides an insight into how the Knowledge Management toolset may be 
deployed within AstraZeneca. While illustrating the means for the employee to view 
as wide a range of information, knowledge and collaborative sources as possible. 
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While the two way relationship between the concept and the Knowledge 
Management toolset, indicates the means to channel a supported and peer-reviewed 
innovative concept back into the organisation, either through the social networks 
within the Knowledge Management system or through the capture of relevant 
knowledge. In this manner the Knowledge Management framework will allow the 
employee to access a wide range of potential sources and have the ability to publicise 
their work to their peers and potential strategic sponsors. 
However, Figure 10.6 does not demonstrate the link between the intellectual capital 
of the organisation and Knowledge Management. In order to fully develop the model 
it is important to model the role of Intellectual Capital within the system. In order to 
support the current activities, the role of Intellectual Capital is restricted to providing 
employees (e. g. Human Capital) and external contacts (e. g. Customer Capital) access 
to the Knowledge Management toolset. T1-e role of Structural Capital is to support the 
Knowledge Management framework and sustain the innovation. It is important to 
note that Structural Capital does not contribute to innovation; it is only used to 
support the Knowledge Management technology and sustain an innovation once an 
individual has developed a prototype. Figure 10.7 illustrates the interaction between 
the Knowledge Management toolset and the Intellectual Capital of the organisation: 
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Individual Level Organisational & 
Project Team Level 
Knowledge Management 
Primary Level - Social Intellectual Capital Networks (Push/ Pull) 
Secondary Level - Internal/ Human Capital 
External Knowledge & 
Information (Pull) Customer Capital (Biotechs) 
Tertiary Level - Knowledge Structural Capital 
& Information Capture 
(Push) 
Figure 10.7: Modelling the interactions between the Knowledge Management 
framework and Intellectual Capital 
Throughout this discussion the development of the framework's varying levels was 
driven by the results of the previous chapters. In this manner the framework or toolset 
attempts to support innovation by mimicking the existing innovative environment. 
Figure 10.8 brings together the entire models of this chapter to provide a descriptive 
framework of Innovation and Knowledge Management. 
Knowledge Management 
Primary Level - Social 
Networks (Push/ Pull) 
Secondary Level - Intemal/ 
External Knowledge & 
Information (Pull) 
Tertiary Level - Knowledge 
& Information Capture 
(Push) 
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Figure 10.8: An Innovation and Knowledge Management Framework for driving 
pharmaceutical innovation 
The framework in Figure 10.8 is a summation of this discussion and earlier research 
within a conference paper, written by the author on Collaboration and Organisational 
Learning (Parsons et al. 2005a). 
Knowledge Management 
Framework 
Primary Level - Social 
Networks (Pusb/ Pull) 
Secondary Level - Internal/ 
External Knowledge & 
Information (Pull) 
Tertiary Level - Knowledge 
& Information Capture 
(Push/ Pull) 
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It is intended that the framework's role is to graphically illustrate how Knowledge 
Management may be used to drive innovation within AstraZeneca. For example it is 
the author's view that concentrating upon offering collaborative tools to the 
employees will offer the greatest benefit. This facet is represented by the two way 
arrow between the Primary Knowledge Management toolset and the assimilation of 
ideas stage. It is envisaged that the framework could form a central role to support 
innovation within AstraZeneca. In essence it suggests the means to drive innovation 
at the individual level to an organisational level. The framework also describes how 
innovation may be sustained and suggests the starting point for developing a process 
that ties in all the elements that are required for innovation to firstly occur and 
secondly be sustainable. 
The elucidation of the various innovation models and the development of a 
Knowledge Management framework is a novel contribution to Knowledge 
Management research in the field of pharmaceutical innovation. The researcher 
acknowledges that there are many alternative models of innovation available (e. g. 
Jashapara (2004); Edvinsson et al. (2004); Tidd et al. (2001)) yet none consider the 
importance of Knowledge Management, Intellectual Capital and pharmaceutical 
innovation as a whole. For example Jashapara's (2004) model acknowledges that tacit 
knowledge is of greatest importance for the initial aspect of knowledge creation. This 
research confirms this with regards to the social networks within pharmaceutical 
innovation. Yet in all cases this research suggest that social networks are only fruitful 
if the scientific bias that stops an innovation being accepted is overcome. This is a 
process which takes considerable time and effort from the employee and can result in 
an innovative concept but little, if any, management backing or practical help. 
Evidently there are many viewpoints that may be considered as viable, particularly 
when conducting interpretivist research. However, from the perspective of 
technology it has been noticeable that current models of innovation rarely provide 
practical advice. They only provide an insight into what is currently perceived to be 
occurring within an organisation. 
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The following chapter addresses this gap in the research and discusses the Knowledge 
Management technology that is required to use the Knowledge Management/ 
Innovation framework and implement a Knowledge Management toolset. 
10.3 CONCLUSIONS 
This chapter has demonstrated the development of a series of models of 
pharmaceutical innovation and a descriptive framework for Innovation and 
Knowledge Management. The framework in Figure 10.8 forms a sound basis on 
which to develop the final Knowledge Management toolset and, as such, makes a 
novel contribution to Knowledge Management research. The research discussed in 
this chapter expands peer-reviewed work by the author (see Parsons et al. 2005a) and 
is intended to promote discussion with Knowledge Management practitioners and 
academics alike. 
A key finding of this research is that collaborative tools potentially offer the greatest 
impact and gain to an organisation. Furthermore this "social" level of Knowledge 
Management systems can be supported by a2 nd Level that allows effective 
knowledge and information retrieval across disparate domains, both internally and 
externally. A 3d Level of decision support and capture complements these two levels 
and ensures. that information and knowledge can be captured as required. The models 
developed within this chapter illustrate the role of the individual within innovation 
and counter established Knowledge Management literature that places value 
primarily upon capturing the knowledge of the organisation. 
The discussion within this chapter also raises a number of valid points that shed light 
upon the use of Knowledge Management within an organisation, while raising areas 
for further discussion and research as to how Knowledge Management can aid 
innovation, with regards to an organisation's overall strategy. 
The Knowledge Management toolset and its implementation are discussed in greater 
detail in the following chapter. 
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CHAPTER 11 
DEVELOPMENT OF THE 
KNOWLEDGE MANAGEMENT TOOLSET 
11.0 INTRODUCTION 
The interviews raised a number of points with regard to the Knowledge 
Management requirements of the employees. Such is the diversity of information 
and knowledge sources available to the innovator that an attempt to provide a 
44one system fits all" approach and corral the many sources within a single 
Knowledge Management system may be futile. Instead this chapter discusses the 
findings of the research and explores the notion that a modular approach to 
support the organisation's use of knowledge may be more beneficial. Hence this 
chapter aims to define how Knowledge Management can support innovation 
within the pharmaceutical industry and provide practical guidance to the 
Knowledge Management practitioner. This chapter is based upon the Framework 
(Figure 10.8), the discussion of the previous chapter, three conference papers 
presented by the researcher (Parsons et al. 2005c, 2006a & 2006b) and a book 
chapter which is currently in print (Parsons et al. 2007). 
11.1 DEVELOPING A SOCIO-TECIINICAL FRAMEWORK TO 
SUPPORT ASTRAZENECA'S INNOVATION STRATEGY 
The development of the framework in Figure 10.8 stems from the belief that it is 
essential to pass ownership of an innovation from the creative individual to the 
organisation. Only once this has occurred will an innovation succeed. Hence the 
role of a Knowledge Management system or toolset differs in this case from the 
established norm of a simple knowledge repository. There is a plethora of 
academic research and practitioner's guides advocating the value Knowledge 
Management systems of this type can provide (see Gunnlaugsdottir's (2003) 
review of current Knowledge Management technology). 
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Yet Walczak (2005) noted that few papers are actually linked to what is currently 
occurring within an organisation and fewer still seek to support an organisation's 
intellectual capital in order to specifically drive innovation. 
The work of the previous chapters have provided a detailed analysis of 
AstraZeneca's innovative work from a social employee perspective and so the 
researcher is well positioned to provide comment upon what technical Knowledge 
Management methods and tools could be used. Amalgamating the two areas of the 
social aspect and the technological aspect will yield a socio-technical solution that 
will support innovation within the company and this socio-technical, approach is 
in line with recommendations penned by Earl (1996). 
Hence, this chapter will elaborate upon the Innovation and Knowledge 
Management framework from Chapter 10 and suggest "best fit" technical systems 
to carry out innovation. Table 11.1 details a number of critical innovation factors 
for each component of the proposed socio-technical system and these are deemed 
the socially derived factors of the system. These high level factors are derived 
from the analysis of the research data to date and stem from the conceptual 
matrices of Chapters 6,7 and 8. These factors provide a description of what the 
overall Knowledge Management toolset should provide and this can be mapped to 
the Knowledge Management Framework of Figure 10.8. 
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Table 11.1: The Critical Innovative Factors 
Area of Framework Critical Innovative Factors 
Innovation to concept to prototype Knowledge 
Information 
Data 
Resource 
Collaboration and social 
networks 
Expert knowledge 
Perseverance 
Perceived risks/ benefits 
Autonomy 
Guidance with regards to 
46strategic" innovation 
Tollgates, milestones & metrics 
Knowledge Management Access to relevant knowledge, 
information and data 
Collation of knowledge 
Capture of knowledge 
Resources of external and 
internal information and data 
Communities of Practice 
Identification of internal and 
external experts 
Resource 
Knowledge and Information Sources Literature 
Colleagues 
Access to internal/ external 
consultants 
Biotechs, universities, etc. 
Internet access - RSS (Really 
Simple Syndication) 2.0 feeds 
" AstraZeneca Intranet - R&D 
Portal, GEL, PKT, etc. 
" Clear guidelines & explicit 
boundaries with regards to 
regulation 
Reception to change 
Security and access rights 
As the table demonstrates, these factors are diverse in nature. At present no one 
system could deliver all of these aspects. It is essential for the toolset to focus 
primarily upon the collaborative aspect as this currently reflects the means by 
which employees are currently working. 
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Furthermore, captured information and knowledge can quickly become outdated 
within pharmaceutical R&D; hence the reliance upon collaboration rather than 
capture becomes more apparent. Yet it is still vitally important to capture work 
that is occurring within AstraZeneca in order to avoid rehashing existing work. As 
an example, a decision capture system would be valuable to capture and 
disseminate the decisions of the Global Product Team in each Therapeutic Area. 
Section 10.1.3 suggests that the Knowledge Management toolset should also play 
an important role in attempting to mitigate the risk associated with drug 
development, particularly concerning early work for Phase I Clinical Trials. A 
recent article in Eye for Pharmaceutical (Hardy et al. 2005) demonstrates how 
Knowledge Management can be used for drug safety and provides a pQtential 
model for implementation within AstraZeneca. 
The results of Chapters 6,7 and 8 detail many areas where such tools may 
potentially be useful, but this chapter is primarily concerned with developing the 
technical aspect of the Knowledge Management Framework of Figure 10.8. The 
Ulowing sections develop a "state of the art" toolset that reflects the findings of 
the research and will support the framework of Figure 10.8 Where possible, 
examples of the technology being proposed are provided through links to 
commercial or open sources projects and software. However, before a Knowledge 
Management system can be implemented, it is wise to address the underlying 
technical framework that should be used to support the tool set. Rather than 
choose a proprietary information and knowledge storage forma% the research of 
Chapter 3 revealed that the semantic web and XML based technology appears to 
offer the greatest benefit. 
11.2 CREATING A SEMANTIC FRAMEWORK - USING Al ETADATA, 
ONTOLOGIES AND SEARCH ENGINES TO DRIVE INNOVATION 
In order to successfully implement a knowledge management toolset, it would be 
wise to introduce an underlying architecture and framework that supports 
knowledge capture, searching, and collaboration. 
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While the researcher was in AstraZeneca, work by Adelmann (2006) was actively 
examining the use of ontologies to "dynamically categorise" information and 
knowledge as it was presented to the user and this work offers great potential for 
overcoming the problems associated with disparate information sources. It is 
important to acknowledge that the semantic framework mentioned in this part of 
the research stems from, and builds upon the result of the author's collaboration 
with AstraZeneca's Dr Holger Adelmann and Andy Gaughan. 
The need to define the underlying architecture is clear. Currently several hundred 
different software systems exist within AstraZeneca and most of these will utilise 
a proprietary schema to store information and data. Attempting to integrate these 
is almost impossible, so in order to avoid this scenario and add another proprietary 
system schema to the mix, it is wise to adopt a data schema that is platform 
independent such as YML (Yu et al. 2003). 
Currently a wide variety of commercial knowledge management systems and 
existing AstraZeneca information systems such as GEL and eRooms have support 
for XML. XML access takes the form of a Simple Object Access Protocol 
(SOAP) request that includes user level security protocol as standard within 
eRooms (Connolly, 2002) while the proposed GEL architecture was unknown at 
this point. However, AstraZeneca possesses a large resource of talented software 
developers who are familiar with XML technologies and schernas so 
implementing a suitable schema should not prove overly difficult. Furthermore 
AstraZeneca's choice suppliers Microsoft (Microsoft, 2007a), Oracle (Oracle, 
2007), and other major software suppliers are championing XML within their 
latest releases. Hence the functionality to use XML may exist within AstraZeneca 
due to the process of software upgrades alone. This would allow a variety of 
information to be captured and be in line with recommendations for information 
capture by Anagnostakis et al. (2005). 
The Semantic Web on the other hand, is a concept that creates a framework 
around information and knowledge stores and is rapidly gaining acceptance as a 
credible knowledge and information retrieval approach (McGuiness, 2002). 
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The interest in this area is particularly apparent within the biotech field, as 
pharmaceutical based R&D is known to require more than simple web based 
information (Goble et al. 2005). It is also evident within Section 8.1 that the 
simple provision of information alone is insufficient to drive innovation. 
This research discovered that the sheer magnitude of sources meant innovators 
were unable to discover relevant information without taking considerable time out 
of their normal work. The Semantic Web attempts to bypass these problems by 
utilising a domain specific ontology to physically map interrelated concepts 
within the domain. The Semantic Web is reliant upon the use of ontologies to 
create this logical framework and this process can provide a backbone to a 
knowledge management system. Gardner (2005) provides an excellent illustration 
of the use of ontologies within Pfizer utilising the Spotfire DecisionSite software 
(Spotfire, 2007) to promote areas such as "blomarker discovery, alternate 
indications discovery, in-licensing opportunities, market differentiation and 
predictive toxicology ". 
Hence, the use of domain ontologies infers cognitive reasoning and structure 
between domain specific terminology and the elucidation of the relationships 
between these concepts. Ontologies may be tailored to capture the domain specific 
terminology within the various arenas of drug development across the company. 
The early results suggested that a degree of personalisation of information sources 
was preferable when attempting to aid innovative employees. This implies that the 
ontology should be tailored to the individual. Rather than conduct this time 
consuming task it may be possible to utilise an existing ontology such as MeSH 
(MeSH, 2007) and allow the user to modify this as they uncover relevant 
information. In effect, providing a system that allows the user to create links 
between knowledge and information sources for themselves, rather than rely upon 
specialist ontology developers or automated systems. 
During the researcher's time within AstraZeneca, the researcher was involved in a 
project utilising a domain ontology created using KAON (Adelmann, 2006). 
KAON (KAON, 2007) is an interactive and intuitive tool that creates ontologies 
with a proprietary data model. 
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However, other open source tools such as Protdg6 (Protdgd, 2007) offer export in 
OWL, XML or RDF schemas. OWL is now widely acknowledged as the current 
ontology standard by the W3C, so it makes commercial sense to develop the 
ontology in the format with greatest potential long-term support (Olavsrud, 2003). 
Alternatives to developing an in-house ontology include commercially developed 
ontologies and other accompanying tools that aim to specifically target a 
particular drug development domain. The BioWisdom software, Sofia 
(BioWisdom, 2007), is currently being trialled within AstraZeneca and it is this 
type of tool that employees believe could offer great benefit. 
Systems that can recognise synonyms, drug related terminology, company 
specific terms, and generic drug terms via a mapped ontology could solve the 
problem faced by innovators of attempting to amalgamate disparate information 
sources. With the ultimate aim of allowing the representation, retrieval, 
processing, and indexing of information and knowledge contained within 
AstraZeneca's systems and external systems. 
Further work by Lee & Sohn (2003) examines embedding rules within 
information sources using a rule based language that would automatically aid in 
ontology development. During this research innovators noted that the ideal system 
would be very much in the background and utilising rules to classify and derive 
ontologies automatically would offer this functionality. Furthermore it may be 
possible to explicitly model the rules that the innovators are utilising with further 
research. For example the research identified that external sources such as SCRIP 
and PubMed were highly important to innovators. Hard coding rules that exploit 
the ontology to filter and then present information sources, would enable this 
information to be automatically presented to other employee's researching the 
same area. Hence the RuleML language would offer AstraZencca the 
functionality to be reactive to received information depending upon the 
information content, rather than simply pull information (see Boley et al. 2001). A 
factor that this research suggests, would be invaluable to the overloaded 
innovators and could be perceived as capturing the tacit social networking side of 
the innovator's work into a hard coded form or "intelligent networking agent ". 
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Patel et al. (2005) also note that this concept has shown promise when used for 
collaborative tasks within the engineering domain. Furthermore, the use of rules 
to filter information has been explored by Eberhart (2003) in greater detail and it 
would appear possible that with the correct rules, information could be flagged up 
to areas of the organisation that effectively control innovation. 
For instance this research found that the therapeutic Global Product Teams are a 
controlling influence for innovative activity through the use of milestones and 
tollgates. Therefore, if relevant information and knowledge on innovative work 
was highlighted to them automatically with regards to these tollgates, then the 
chance of obtaining funding could be greater. In many respects a rule based 
system could be used to automatically "market" and highlight innovation that met 
AstraZeneca's strategy either automatically or as the individual uncovered it. 
Specialist Business Intelligence functions already exist within AstraZeneca to 
carry out this task, yet there is still a large disconnect between their work and the 
work of the innovative employee. Hence, providing the functionality for the 
individual to further their innovation from concept to prototype would aid these 
processes overall. 
From a search and retrieval perspective, AstraZeneca already possesses a 
powerful search engine called Autoriomy which also possesses the ability to act as 
a form of intelligent agent. This is a document retrieval system that attempts to 
"Intelligently " create inferences between documents (Autonomy, 2007a). At 
present employees commented that although the system holds promise, the 
information that was currently indexed and searched was not conducive to 
innovation. Yet such a system would be a powerful information and knowledge 
resource if it could be interlinked with domain ontologies to search both internal 
and external information and knowledge stores as suggested by the soilware 
suppliers (Autonomy 2007b). This would be similar to Bristol-Myers Squibb, who 
utilises the Autonomy IDOL K2 system to search internal information and collate 
newsfeeds form external sources to good effect: 
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Vlen a scientist looks for the latest clinical trial findings on a treatment for 
schizophrenia known to researchers as 'Aripiprazole, " IDOL K2 expands the 
term to include synonyms like "BMS-337039" and "Abilitat" and returns all 
documents relevant to this compound " Bristol-Myers Squibb Autonomy Case 
Study (Autonomy, 2007c) 
As the previous chapters indicated, AstraZeneca employees rely upon external 
sources such as SCRIP to obtain the latest relevant information. Hence employing 
an automated system to index this would automatically link relevant internal 
research to relevant external research. Although this may heighten the element of 
scientific bias and therefore encourage "me too" drugs, it would also make 
employees aware of other relevant information and provide the knowledge and 
information base to make the mental leap to develop an innovative concept. From 
a visualisation perspective Autonomy provides a powerful means to visualise 
clusters of results according to the content of the information. This process utilises 
an underlying technology labelled "KeyView", which can extract content 
information from over 300 file types, such as Word, PDF, XML, Excel etc 
(Autonomy, 2007d). As AstraZeneca already possesses this functionality, it would 
appear that utilising the KeyView system to extract a summary of relevant 
information in an XML form from documents would be a worthy premise. 
However, Autonomy is a proprietary system so developing and altering the code 
requires the purchase of licences, which would require capital resource. Lucene 
(Lucene 2007) is an open source Java search engine which offers the ability to 
extract content from many file types across platforms and has been used with 
good results by Adelmann (2006). 
A further notion to consider is that, at present, the structure of AstraZeneca's data, 
information and knowledge varies according to the author, the template used and 
the project. Attempting to standardise this process would appear be almost 
impossible, yet efforts by other companies with similar information requirements, 
such as BAE Systems, show considerable promise when linking structured 
information sources with Autonomy's search capability (Autonomy 2007e). 
Additional work by Eldridge (2006) examines visualisation tools currently used 
within AstraZeneca for the display of patent and chemical data sets. 
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Although these tools are based upon data, the article does illustrate the 
visualisation methods that could offer a means of linking in the higher levels of 
knowledge and information to low level data sets. This would be very helpful if 
the employee required further investigation or verification of the data that had 
generated the information and knowledge (e. g. Phase I Clinical Trials ECO data), 
as raised by the notion of scientific bias in Section 6.3. 
Utilising a semantic framework such as the one described, with the addition of 
metadata. tags in line with Claus & Underwood (2002) or the Dublin Core (Dublin 
Core, 2007), maximises the chance of relevant knowledge and information 
retrieval, which the research suggests could lead to innovation. However few 
validation studies exist with regard to semantic technology and the pharmaceutical 
domain. Earlier work by Feldman et al. (2003) supports this notion that the only 
means of tackling pharmaceutical information is to pre-process the source text to 
extract relevant information and then search across this simplified domain to 
make inferences. Employees in this research also noted that if they were to search 
across free text sources with a drug related keyword, then this would retrieve 
many thousands of results. 
A typical drug project report or regulatory submission document would contain 
numerous mentions of numerous drug related terminology, hence a mechanism to 
summarise and simpliky this within the context of a drug would be required. 
Software tools are available for extracting key points from text such as Copernic 
(Copernic, 2007) or Extractor (Extractor, 2007), but even after pre-processing this 
would still be reliant upon the semantic framework to make the links between 
relevant summarised documents accurately. 
This observation also raises the point that the sources searched should differ 
according to the task in hand. As the research data in Section 8.1 revealed, 
innovators already search for knowledge, information and data across multiple 
domains and then use their experience to assimilate these sources. Yet an 
employee tasked with producing a project management report may only require 
internal sources, which are very different to an innovative research scientist. 
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Hence it would be wise for a Knowledge Management system to include the 
element of context with regard to what type of innovative work is being 
undertaken. Context may be addressed by a number of means, from the 
technological based strategy of text mining or the use of ontologies (see Lin & 
Harding, 2007), to the social aspects of Communities of Practice and expert 
systems for example. The aspect of utilising the semantic framework and the 
Knowledge Management tool set will be examined further in greater detail in the 
following section with regards to driving pharmaceutical innovation. 
11.3 DEVELOPING THE KNOWLEDGE MANAGEMENT TOOL SET 
So far this chapter has confirmed that the use of semantic web technologies could 
be used to theoretically support a Knowledge Management toolset. Yet the 
framework of Figure 10.8 requires that three levels of Knowledge Management 
systems are put in place to perform these tasks, namely: 
1. The foundation and facilitation of social/ knowledge networks 
2. The assimilation and dissemination of relevant up to date information and 
knowledge - both from within the organisation and from external sources 
3. The satisfactory capture of information and knowledge 
Collaborative tools within the Knowledge Management tool set, could take many 
guises such as forum-based Communities of Practice, expert location systems, and 
knowledge mapping software. Section 10.2 notes that they would offer a high 
return on innovative performance above that of information/ retrieval and capture 
tools according to the literature review of Chapter 3 and the results of Chapters 
6,7 & 8. Furthermore the results of Chapters 6,7 &8 indicate that no one tool can 
fit the needs of pharmaceutical innovators. Instead an array of tools must be used 
depending upon the situation. If these tools use the functionality of a semantic 
framework and provide the means to visualise and link knowledge, whether this 
knowledge is a tangible asset such as a Knowledge Object or an example of 
human capital in the form of a knowledgeable employee, then this research 
indicates that innovation can be driven. 
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The literature review of Chapter 3 suggested that Knowledge Management within 
the pharmaceutical industry primarily focused upon social networking. However, 
Section 6.3 of this research has demonstrated that innovative networking is far 
from simple. Organisational structure, the need to negate bias, the impact of 
regulation and a host of other factors affect the ability of a Knowledge 
Management tool to drive innovation. 
Yet what tools should the Knowledge Management tool set comprise of? There 
are hundreds, if not thousands, of potential systems available and many would be 
suitable. To help this task, Chapter 3 (Section 3.3.3) named and classified a 
variety of Knowledge Management tools within Tables 3.2,3.3 & 3.4. This 
section of the research discusses their value to pharmaceutical innovation and 
their proposed role within the Knowledge Management framework of Figure 10.8. 
11.3.1 DEFINING THE KNOWLEDGE MANAGEMENT TOOL SET 
Tables 3.2,3.3 & 3.4 within Chapter 3 provided many potential tools that could be 
of use in developing the tool set. To reduce the tool set to a manageable level, 
each tool was assessed in line with its potential to fit the needs of the Knowledge 
Management framework of Figure 10.8. Each tool was awarded a theoretical 
value of "High", "Medium" or "Low" depending upon its potential value to 
innovation. The reasons for this are briefly denoted in Tables A. 2.1, A. 2.2 and 
A. 2.3 within Appendix 2. 
In short, each tool was assigned a subjective value based upon the potential of the 
tool to support the Knowledge Management Framework and hence innovation. 
This was either "Low", "Medium" or "High" and was assigned based upon how 
closely the tool could support a "Representative Ilieme". For example Innovation 
Theme 25 states: 
"Innovation is reliant upon discovering diverse knowledge and information 
sources and generating an idea, the collaborative culture within AstraZeneca 
sometimes fails to provide the opportunity to grasp the understanding and as 
such, a great deal of time is wasted within meetings. " 
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Therefore this theme is representative of the need to store accurate information, 
and hence this theme is directly associated with the need for information storage 
and hence a Knowledge Management "Storage" type tool. 
Of the "Storage" tools detailed in Table A. 2.1, the database is essential for 
accurate information storage and would support the needs detailed in this theme 
and hence is rated "High". 
Similarly collaborative files systems such as eRooms and potentially GEL, meet 
the needs of this theme, hence are rated "High". However, shared folders were 
highlighted in Section 8.1, as prone to errors and inaccurately classifying 
documents, hence their use within the tool set is limited and hence are rated 
"Medium". Therefore this stage produces a "best fie' type tool set that utilises 
both the Innovation and Knowledge Management Themes to support the tool's 
I selection. 
As this stage is subjective, it will require further validation, but as a star ting point 
it serves to identify what tools are categorically required and which are surplus to 
requirements. Due to the diverse issues identified within each theme, it is simply 
beyond the scope of this research to attempt to assign a tool to each theme in turn. 
Each theme covers quite a diverse range of findings and it is unlikely that each 
theme could be met by a specific tool in any case. Instead the "best fit" approach 
has been taken in order to make this stage feasible, while keeping the 
requirements of the innovators in mind. 
Validation of the choice of tool can unfortunately only occur once the tools are 
rolled out in practice, However, Chapter 12 details a potential means of evaluating 
the success of these tools in relation to an existing project. Chapter 12 also 
examines the likelihood that a Knowledge Management tool will be successful 
and hence provides theoretical support for these choices. 
Finally after each tool was chosen and assigned a "Representative Theme", the 
tools that scored a theoretical "High" value were collated and then assigned to 
either: 
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* The Semantic Framework: tools to support the Knowledge Management 
Framework 
Level I of the Knowledge Management & Innovative Framework: tools to 
found and facilitate social/ knowledge networks 
Level 2 of the Knowledge Management & Innovative Framework: tools to 
assimilate and disseminate relevant up to date information and knowledge 
- both from within the organisation and from external sources 
Level 3 of the Knowledge Management & Innovative Framework: tools to 
capture information and knowledge 
Table 11.2 illustrates the conceptual Knowledge Management semantic 
framework required to drive pharmaceutical innovation based upon the evaluation 
of the known Knowledge Management tools: 
Table 11.2: A conceptual underlying Semantic Framework to drive innovation 
Knowledge Management 
Semantic Framework 
Component 
Name of Tool Value and 
applicability to 
driving Innovation 
Organisational Ontology/ Taxonomy 
development 
Iligh 
Ontology/ Taxonomy 
acquisition 
Iligh 
Glossaries High 
Tliesauri Iligh 
Search Search engines Iligh 
Indexing High 
The Semantic Web Iligh 
Storaj! e Databases - XML Iligh 
Workflow Process modelling Iligh 
Text mining Semantic analysis Iligh 
Web mining Collaborative profiling High 
Visualization 2D and 3D navigation Iligh 
Knowledge/ geographic 
mapping I 
High 
Table 11.2 illustrates the toolset and various components that could be 
theoretically used to implement a Semantic Framework within AstraZeneca. 
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Employing these tools as a framework within AstraZeneca, would provide a basis 
for innovation that would then allow the additional levels of the Knowledge 
Management toolset to function effectively as denoted in Table 11.3. 
Table 11.3: A conceptual Knowledge Management Toolset to drive innovation 
Level of 
Knowledge 
Management 
System 
Type of 
Knowledge 
Management 
Tool 
Name of Tool Value and 
applicability 
to driving 
Innovation 
Primary 
Level 
Social Networks 
(Push/ Pull) 
Community Communities of 
Practice/ Forums inc 
facilitation and 
management 
Iligh 
Knowledge Mapping 
Social Network/ 
Analysis (SNA) 
High 
Idea generation High 
Collaboration Calendaring Iligh 
Meeting support - 
Decision capture 
Iligh 
Application sharing - 
Office Communicator 
Iligh 
Expert location systems Iligh 
Secondary 
Level 
Internal/ 
External 
Information/ 
Knowledge (Pull) 
Distribution Web/ Internet/ 
Extranets 
High 
Personalisation High 
Connectivity File sharing - cRoorn Iligh 
Wireless networking/ 
mobile computing 
Iligh 
Peer-to-peer (P2P) High 
Personalization Iligh 
Audio/video streaming High 
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Table 11.3: A conceptual Knowledge Management Toolset to drive innovation 
continued 
Tertiary 
Level 
Knowledge & 
Information 
(Push) 
Authoring Knowledge Objects/ 
Knowledge-bases 
High 
Office suites High 
Desktop Publishing Iligh 
Graphic suites & 
multimedia tools 
Iligh 
Groupware & decision 
support technolog 
High 
The reasons behind the deployment and selection of the various tools are denoted 
in Appendix 2 and are based upon prior findings of this research. The prior 
discussion within this thesis suggests that deploying the framework and toolset 
would meet the needs of AstraZeneca's innovators and allow the process of 
concept development and innovation to occur more readily than at present. Each 
level of the toolset is designed to leverage different aspects of AstraZeneca's 
intellectual capital, such as structural, human and customer capital by founding 
links between the organisation and innovative employees. 
Evidently this toolset could be expanded, but at a bare minimum it is theorised 
that the deployment of these tools, in line with the framework of Figure 10.8, 
would answer the problems currently felt by AstraZeneca's employees. The key is 
identifying and allowing people to collaborate across AstraZeneca by utilising the 
toolset. Unfortunately it is beyond the scope of this research to investigate in 
detail the potential application of each tool. However, the researcher analysed the 
use of a Community of Practice while in AstraZeneca (see Parsons et al. 2005b) 
and the following section examines this in greater detail. 
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11.3.2 COLLABORATION, THE COMMUNITY OF PRACTICE AND 
NETWORKS- A MODEL FOR INNOVATION 
Collaborative tools within the Knowledge Management tool set, could take many 
guises such as forum-based Communities of Practice, expert location systems, and 
knowledge mapping software. Section 10.2 notes that they would offer a high 
return on innovative performance above that of information/ retrieval tools 
according to the literature review of Chapter 3 and the results of Chapters 6,7 & 8. 
The model of the Community of Practice (CoP) was initially studied by the 
researcher within AstraZeneca and gave many promising results, within the 
closely knit Clinical Medical Science department (see Parsons et al. (2005b) 
presented by the researcher at IRMA 2005, San Diego). However the successful 
departmental CoP was disbanded when the intranet websites were replaced with 
the R&D portal, a step that eradicated the information and discussion that took 
place within the forum, but could be simply reinstated if needed. 
The research paper showed that the forum was a highly valued means of 
achieving valuable collaboration and formed a viable Community of Practice 
(CoP) of approximately 20 employees. This is an example of a CoP in its simplest 
guise and was based upon the provision of a proprietary software discussion 
forum or bulletin board. Topics and questions relating to drug project work were 
posted to a forum and fellow employees posted replies to discuss the questions 
posed. This approach is widely adopted (Wenger & Snyder, 2000) and basic 
forum software is freely available (e. g. PhPBB, 2007). 
Empirical research by the researcher in 2003, published as an in-house report for 
the specification of a new discussion forum (see Experimental Medicine 
Discussion Forum Specification, Appendix 3). Demonstrated that the community 
had a positive affect in terms of supporting project work, yet its use for driving 
innovation was unclear. However, what was apparent was that employees were 
beginning to utilise the forum as a media to promote and discuss innovative 
clinical trials work, rather than as a media to discuss existing techniques. This 
aspect suggests a network of forums across AstraZeneca that focus specifically 
upon innovation would be worthwhile. 
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AstraZeneca's R&D portal currently uses a software tool called eRoom (eRoom, 
2007) to replace the older defunct forums. This software is principally used to 
capture and display the documents and information surrounding drug projects. 
However, eRooms could be used to provide the organisation with Communities of 
Practice and a collaborative discussion environment. 
Employees may search for knowledge and information across all eRooms within 
the organisation and collaboration is encouraged through the interaction of 
employees over common topics. However, due to security constraints, the eRoom 
system is provided on a restricted access basis. The process of gaining access is 
complex and dependent upon a business need. This is made worse by the fact that 
an employee can still search across all eRooms within the company, and retrieve 
the titles of relevant files or discussions. However, due to file security constraints 
they may be unable to access the contents of these files or discussions. Therefore, 
the research data of Chapter 6 showed that innovators are more likely to turn to 
colleagues. 
However, eRooms could be specifically used to drive innovation by allowing 
open access to all employees who could discuss and contribute to issues outside of 
their immediate project teams. As one employee noted, this type of open access is 
largely against the culture of AstraZeneca, when they tried to access relevant data 
from a Global Product Team within the oncology therapeutic area they met with 
resistance: 
"It was a sort of "it's ours, it proprietary". You know, I don't have to sign a 
confidentiality agreement I've already done that and that was very bizarre. To he 
fair, it was right in the middle of the Iressa problem so they were very protective, 
but that held us back a lot. " 
Hence, an innovative elloorn based CoP must have management backing and must 
provide an area that is separate from the specifics of project, in effect, a sanctuary 
from the process orientated culture that dominates AstraZeneca at present. 
However, interviewees noted that although such an area would be welcome they 
must still be careful not to divulge sensitive project information. 
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The act of committing information to an online media essentially provides a 
permanent audit trail for regulatory authorities, hence this may explain 
AstraZeneca's reluctance to allow free form discussions across many topics. Yet 
if the balance between regulatory and innovation can be achieved, then employees 
could be directed to this resource for innovative work across AstraZeneca. 
The idea of using the domain ontology to support a discussion forum was 
discussed with Holger Adelmann of AstraZeneca, as a way around the security 
constraints imposed by eRoom. This led to the development of an in-house paper 
that described the benefits of linking the semantic framework to a discussion 
forum. This paper is included in Appendix 4 and makes a case for running 
multiple discussion forums. The majority of forums would be based within an 
eRoom for project support, while others would act on a global level and use a 
semantic Eramework to support innovation, link discussions and allow "dynamic 
categorisation" of discussion threads. The paper in Appendix 4 elaborates upon 
these concepts and is based upon the work and ideas of Dr Holger Adelmann. 
The semantic framework and search technology previously discussed would play 
a key role in driving innovation, principally, by exposing the forum to employees 
across the organisation through visualisation and the ontology backed search 
engines. eRooms currently does not offer the functionality to utilise an ontology- 
based search, instead they offer a simple Boolean-based search across multiple 
communities. Evidently this type of search is limited to correctly using keywords 
to return relevant results, but a semantic search utilising a domain-ontology would 
return all related concepts. However, it may be technically possible to invoke this 
type of system across the many eRooms. This advance would prove a powerful 
means of sharing information through discussion and collaboration. Another key 
tool that is worthy of further attention is an expert system which again would rely 
upon the semantic framework for its use. 
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11.3.3 COLLABORATIVE NETWORKS THROUGH EXPERT 
LOCATION 
An expert location system is deemed a "High" value component as they allow 
staff to discover colleagues across the organisation regardless of location. An 
expert location system or People Pages exists within AstraZeneca and consists of 
a simple web-based interface that records employee's contact details, skills, 
interests, role, and areas of interest. Evidently this system requires users to input 
their skills and expertise on a regular basis but the research data revealed that few 
innovators made use of the current system. 
Innovators noted that it is easy to forget to update the system and there is no 
mandatory requirement for them to update their skills. In order to exploit this 
technology it may be necessary to record the skills of personnel as they undertake 
and end a project. In this manner they would record that their activities are 
focused upon a particular compound and then record the relevant skills and 
knowledge they have acquired from the project. This would potentially allow 
collaboration to occur in near real time as each employee published the area they 
are working upon. This research found the information and knowledge 
requirements for innovation are immediate and an out of date system can not be 
used to drive cutting edge innovation. Chapter 6 notes that innovation requires 
scientific debate in order to gain credibility, reduce bias and obtain organisational 
backing. One way to encourage this would be to allow innovators to easily locate 
each other via this type of system, particularly if the employees who effectively 
drive innovation, such as project managers, were included. It is envisaged that the 
expertise locator system would also utilise the semantic framework to promote 
project based collaboration and ensure that staff that who are working on similar 
areas or have expert knowledge are identified and informed. 
An alternative to manually inputting skills would be to use an automated system 
that derives the relevant expertise data from e-mail and documents (AGUENCE 
Expertise Locator, 2007). However, the use of an automated system raises 
questions concerning privacy and trust and innovators voiced that this should be 
approached with caution. 
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During the interviews staff responded that an automatic system would be a useful 
addition, although some expressed an interest in remaining anonymous through 
fear of an increase in demand for their expertise and resources. Above all, if social 
networking tools are to be effective, the employees will require time to conduct 
these activities and answer queries. 
The researcher was present within many HR meetings and it is the goal of 
AstraZeneca for collaborative working to be built into a mandatory HR 
requirement, by assigning time into the processes surrounding implementation of 
a drug development project. However, how much of this time will actually be 
available is unclear. Nevertheless, if the system simply functions as a networking 
tool, on the level of software such as FaceBook (FaceBook, 2007) then it may 
help to strengthen existing networks and retain the critical mass of people required 
for innovation. 
The means to identify relevant personnel and visualise the results has also 
received significant academic and practitioner research. The following section 
discusses these developments in line with the Knowledge Management tool set 
and AstraZeneca's requirements. 
11.3.4 KNOWLEDGE MAPS 
A knowledge map is the means by which an organisation's knowledge and 
information may be visualised. It graphically illustrates the knowledge contained 
within the knowledge and information archives of an organisation and allows 
users to quickly track like minded colleagues and knowledge across the 
organisation (Dong & Li, 2004; Kang, et al. 2004). A system to provide 
Knowledge Mapping functionality to the R&D portal would be a welcome 
innovation, particularly when tied in with the semantic framework, Autonomy and 
an expert locator system. In essence, a user searching for a particular phrase or 
drug could invoke a system that returns the knowledge entities as visual 
references within the R&D portal. Employees would be able to search across all 
the information sources, discussion forums, and expert location systems within the 
R&D domain. 
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The results would then be retrieved in accordance with the ontology of' the 
semantic framework and visualisation could be provided by a systern akin to the 
Kartoo search engine (see Kartoo (2007) & Figure 11.1) and Spotfire (Spotfire, 
2007). 
Figure 11.11: The Kartoo Search Engine showing results from a search flor 
"pharmaceutical innovation" 
AstraZeneca currently utilises Spottire for data display and tile researcher 
demonstrated the Kartoo software within AstraZeneca to positive interest. In- 
depth research by Hellstrom & Ilusted (2004) also suggests that providing a visual 
interactive map of the knowledge retrieved by a search engine is a powerful 
medium and would allow staff to rapidly locate valuable information and 
knowledge and forge collaborations within the organisation. 
Kartoo software is noted to be effective at linking poorly categorised documents 
and any proposed search system would require this ability. 
36 
Chapter II- Development of the KM Tool Set 
Chapter 8 noted that project documents are archived at a project level and not at a 
global level which would be more conducive to searching. 
Efforts being made to make GEL easier to search and locate documents would 
benefit from the inclusion of a visual element such as Kartoo. A similar system 
exists within Pfizer who use a semantic framework and metadata to provide 
clustering and retrieval, thereby allowing the user to navigate through the 
available information and knowledge in a clear manner (Goble, Stevens, & 
Bechhofer, 2005). 
In short the key to the collaborative aspect of the Knowledge Management toolset 
is to found and mimic the existing internal and external knowledge networks that 
are fundamental to innovation within AstraZeneca. With the advent of 
collaborative elements appearing in commonplace software such as Microsoft 
Office (Microsoft, 2007a), the choice of potential tools is widespread. It may 
simply be a question of highlighting the potential use of software that already 
exists within AstraZeneca. The following section briefly examines additional 
"cutting edge" tools that may be added to the toolset if required. 
11.3.5 SOCIAL MEDIA 
While this research was carried out, collaborative and social tools such as the blog 
or Weblog and Wiki became more prominent. Karger & Quan (2006) advocate 
the use of the blog as a powerful knowledge creation and capture tool when used 
in conjunction with a semantic framework. Blogging software such as WordPress 
(WordPress, 2007) is common place and theoretically allows the rapid creation 
and communication of semantically rich information, which may aid the retrieval 
and capture of organisational knowledge. While the use of Wikis within industry 
is poorly understood at present, the growth of internet based Wikis such as 
Wikipedia (Wikipedia, 2007) is undeniable. In short a Wiki allows web based text 
to be edited and altered by other users, while the blog allows comments and 
suggestions to be posted regarding a piece of text or an article, see Ramos & Piper 
(2006) for further information. 
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It would appear that the blog is certainly a popular and established medium for the 
communication of news over the Internet, but to date little research has been 
conducted into their use within the pharmaceutical industry. 
Todoroki et al. (2006) have conducted a promising study into the use of a blog to 
capture the information regarding laboratory experiments that would usually be 
captured within notebooks. An example of another pharmaceutical related blog is 
"In the Pipeline" (Lowe, 2007). This is an established public access blog that 
focuses on drug development within the pharmaceutical industry and illustrates 
the potential of the medium as a Knowledge Management tool set component. 
"In the Pipeline" is run by one man, David Lowe and illustrates how articles and 
comments on drug development promote discussion within an online Community 
of Practice. These discussions attract responses from a wide range of people who 
are primarily employed within the pharmaceutical industry and the use of a blog 
to generate discussion surrounding innovative concepts could prove worthwhile 
within AstraZeneca. 
The researcher presented a paper at the OLKC, 2006 conference in Warwick, UK 
(see Parsons et al. 2006b) and this generated discussion suggesting that the blog 
could prove worthwhile if used to drive innovation. In particular, the audience 
agreed with the researcher's observations that a blog could provide a worthwhile 
record of a drug project as it was carried out. In this way the blog would capture 
an overview of the information that was generated by the project as it occurred 
and, to some extent, form a "ready made" network of semantically rich 
information if each innovative drug project captured key decisions as they 
occurred using a blog. Unfortunately whether the idea of open access information 
that can be edited and discussed online, such as that provided by blogs and wikis, 
would be welcomed by all is debateable. As Section 6.3 and 6.4 suggest, the 
issues of security, regulation and Intellectual Property make publishing emerging 
project information a risky venture, as essentially all the thoughts and debate 
could potentially be audited by regulatory authorities. Furthermore the web based 
use of social media tools such as blogs and wikis, are founded upon the principle 
of freedom of information and if such issues constrained the discussion, then their 
value in an internal site would require further research. 
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However, what a social tool would achieve is to link employees principally within 
project teams but also externally to that team through the semantic network, a 
notion that forms the basis of the expert locator type software. This would tackle 
many of the issues that currently impede innovation within AstraZeneca and the 
toolset could be expanded to include the newer branch of social and collaborative 
tools. These could include tools provided by Microsoft within the Office 
Communicator suite (Microsoft, 2007b) and the web based Groove (Groove, 
2007), which could offer secure instant inessaging and document collaboration 
between colleagues within a UK/ Sweden project group for example. 
11.4 CONCLUSION 
At present Tables 11.2 and 11.3 provide a high level overview of what specific 
tools the Knowledge Management toolset should comprise. Allowing fellow 
employees to collaborate and communicate across AstraZeneca's R&D domains 
and externally, with research organisations and universities is the key to driving 
pharmaceutical innovation. The collaborative element of the toolset is designed to 
support innovation and provide the facifities for existing groups of innovators. 
Rather than focusing upon developing new groups, the results indicate that 
AstraZeneca has a large number of different innovative networks (e. g. Medical 
Science, New Opportunities Group, etc. ) which at present lack a focus or hub. 
The toolset is designed to lever the intellectual capital of the organisation and 
provide the focus or hub for these groups or Communities of Practice, while 
additionally providing a supporting framework of collaboration, information/ 
knowledge retrieval and capture to be used as required, in line with Figure 10.8. 
The following chapter finalises the discussion and suggests ways by which the 
effectiveness of a Knowledge Management tool may be assessed. 
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CHAPTER12 
EVALUATING KNOWLEDGE MANAGEMENT 
12.0 INTRODUCTION 
Many authors suggest Knowledge Management is a relatively simple technique with 
which to improve an organisation's innovation capability (e. g. Alavi & Leidner, 2001; 
Zack, 2000). However, many Knowledge Management papers are based upon the 
deployment of technology and to the experienced Knowledge Management practitioner, 
who may have experienced the initial hype of Knowledge Management, it asks the 
question: 
"Will this system really work? And will it deliver thepromised benefits? " 
Davenport & Glaser's (2002) study of Knowledge Management systems, maintains that 
few will deliver upon their promise because they do not connect with the organisation 
and require considerable effort on the part of the knowledge worker to maintain. In many 
cases a Knowledge Management system will fulfil a niche need by providing information 
and knowledge to a specialist sub-set of the organisation. Yet, if a Knowledge 
Management system does instigate, or at least promote a valuable innovation, as in the 
case of AstraZeneca's ontology backed discussion forums (Adelmann & Jashapara, 
2003), it will ultimately be worthwhile. However, measuring the bencfit of a Knowledge 
Management system is notoriously difficult. 
I 
The finding in Chapter 7 is that pharmaceutical innovation is a long-term and 
evolutionary web of interlinked processes. The evaluation requires a detailed, qualitative 
examination and accompanying interpretive philosophical examination of the factors that 
permitted innovation to occur. Without this level of detail, as attained by this research, a 
Knowledge. Management system could appear to possess very little value. 
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Such is the complexity of pharmaceutical innovation that the single ideal Knowledge 
Management tool may simply not exist. Instead, the tool set of Chapter II could form a 
series of interlinked systems that together form a modular approach. Utilising this 
approach would embrace the social and technological aspects of the organisation, but in 
many respects it counters the established view of the "one system fits all" approach. 
When instigating this work within AstraZeneca, the initial emphasis was upon developing 
the ideal Knowledge Management system to allow pharmaceutical innovation, primarily 
by developing and embracing a variety of Knowledge Management tools that could meet 
the needs of the employee and thus allow innovation. However, the results of Chapter 7 
and the Framework of Figure 10.8 now make it clear that these tools must also fit the 
organisational processes. Hence, this in turn complicates the issue of a simple Knowledge 
Management/ Innovation system, by introducing aspects that are rarely considered within 
Knowledge Management tools at present - such as the organisational structure, the allied 
processes that support the organisation, and the intangible assets that help to support the 
employee. 
Tle tool set of Section 11.3 is specifically designed to overcome these problems, yet the 
discussion within this chapter is relevant to other Knowledge Management practitioners 
who are charged with implementing Knowledge Management within an organisation. 
12.1 MEASURING THE EFFECTIVENESS OF KNOWLEDGE MANAGEMENT 
Chapters 6,7 &8 emphasise that the processes and organisational structure are important 
factors, yet few interviewees were aware of the role intellectual capital and particularly 
intangible assets play within the organisation. The literature review of Chapter 3 briefly 
examined intangible assets but since conducting the data analysis, it is clear that they play 
a greater role than previously envisaged within a Knowledge Management system. 
Kaplan & Norton (2001) & Andriessen (2005) denote intangible assets as: 
* The skills, competencies and motivation of the employees 
* Database and information technologies 
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0 Efficient and responsive operating processes 
* Innovation in products and services 
9 Customer loyalty and relationships 
e Political, regulatory and societal approval 
It is clear that many of the results and findings within the conceptual matrices and themes 
of Chapters 6,7 and 8 could be construed as intangible assets. This finding suggests that 
there is a strong link between Knowledge Management, intangible assets and innovation. 
For example, Table 12.1 briefly denotes a selection of results from this study and displays 
the intangible assets of pharmaceutical innovation: 
Table 12.1: Examining a selection of intangible assets within AstraZeneca 
Intangible Assets Example within AstraZeneca 
The skills, competencies and motivation Expert knowledge of Clinical & 
of the employees Discovery scientists; specialist 
physicians' clinical knowledge; molecular 
geneticists' knowledge, etc. 
Database and information technologies PKT; GEL; R&D Portal, etc. 
Efficient and responsive operating New Opportunities Group; Global 
processes Product Team, etc. 
Innovation in products and services Diverging the current portfolio by 
developing innovative drugs; acquiring 
innovative research, etc. 
Customer loyalty and relationships Networking & collaboration between 
biotechnology companies; patient safety 
websitcs to build customer confidence, 
etc. 
Political, regulatory and societal approval Close liaison with the FDA; internal 
politics that can drive favourable 
innovation; internal society of innovative 
cmploYecs, etc. 
Constructing a framework of intangible assets is therefore a relatively easy process from 
the themes and matrices of this study within AstraZeneca. 
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These assets could be used as the basis for a balanced scorecard. That in turn, can be used 
to formulate a strategy for the organisation that acknowledges the intellectual capital of 
the organisation. The balanced scorecard can aid the identification of factors which will 
affect the overall strategy of the organisation and help to bring these to the attention of 
the managers (Spender & Marr, 2005). Yet rarely within the Knowledge Management 
literature will a Knowledge Management tool specifically set out to support the strategic 
objectives of the organisation. This observation is striking, as, on the whole, the research 
showed that Knowledge Management tools and systems commonly support information 
and knowledge sharing only within a defined domain within the organisation (e. g. the 
R&D portal, PKT and departmental discussion forums). 
It is only upon analysing this research, did the researcher witness the apparent disconnect 
between Knowledge Management, innovation and an organisation's strategy - 
particularly on the level of the key performance indicators (KPIs) used by AstraZeneca to 
assess any potential gains from innovation or a Knowledge Management system (see 
Section 7.8). For example, if the definition of intangible assets is refined into three 
further categories (Andriessen, 2005) then the link between knowledge, Knowledge 
Management and strategy is clear: 
1. Strategic competencies - the strategic skills and knowledge required to support the 
organisational strategy 
2. Strategic technologies - the information systems, databases, tools and network 
required to support the strategy 
3. Climate for action - the cultural shifts needed to motivate, empower, and align the 
workforce behind the strategy 
The results of the study of the Knowledge Management tools in Chapter 8 clearly 
demonstrate that elements of these aspects are missing from the existing Knowledge 
Management systems and processes within AstraZcncca. 
For example, employees persistently broached the opinion that their innovative ideas 
were difficult to progress without sufficient managerial backing. 
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While many of the innovative ideas are closely aligned with AstraZeneca's strategy, the 
support to progress their idea from concept to prototype was limited. Hence, it appears 
that the technology and climate to support these innovations through Knowledge 
Management is lacking. A similar observation was also made by Zack (1999) and this 
still appears to be a common finding throughout large organisations in general. 
Knowledge Management within the pharmaceutical industry appears to be driven by 
supporting employees in their daily work and not in supporting the company's innovative 
strategy. Evidently, a fine balance is required whereby the system supports the daily 
activities of the employee in order to generate revenue, yet also allows future revenue to 
be acquired by exploiting the intangible assets and Human Capital of the organisation. 
Therefore, this research suggests that there is a clear distinction between the types of 
Knowledge Management that are needed within an organisation, one to support and one 
to innovate. Innovators frequently complained of having to overcome "process", which 
they determined to be the organisation's management processes and regulations which 
they felt inhibited innovation. This is a factor that could simply be related to trying to use 
tools and systems that are designed to support daily project work rather than support 
innovation, for example GEL, eRooms, etc. This in turn, appears to be due to the fact that 
the measures of success of a system or process are tied to metrics that primarily measure 
financial success. Hence, unless a system or innovation can support an AstraZeneca 
process that has a financial measure, it appears of little value. Furthermore this research 
suggests that the majority of innovative work is largely intangible until it rcaches a 
prototype stage. Only then may it be measured by the existing metrics,. a factor that 
explains why innovation is primarily acquired externally rather than developed. 
The results of Chapter 8 make it is clear that AstraZeneca's "process" can adversely 
affect Knowledge Management systems, particularly when the system exists only to serve 
localised innovative activity. Unless the outputs of a system explicitly aid drug-project 
focused "process" then organisational backing and the "fabled climate for action" will be 
lacking. 
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From a financial perspective it is perfectly rational to invest only in technology that 
directly supports the drug development processes. However, the results of Chapter 6 
imply that a well thought out and reasoned innovation can bypass months of laborious 
work and 'ýprocess 
Therefore, solely supporting existing processes certainly appears financially sound, yet in 
terms of the time taken to reach a viable drug compound, the innovative route may be 
quicker and hence substantially cheaper. One such example of the focus upon "process" 
is the expensive conversion of the GEL (Global Electronic Library) document 
management database to an XML schema for enhanced infori-nation retrieval. The 
redesign of this information repository will make it easier to share regulatory and 
commercial documents both internally and externally with regulatory bodies. Ensuring 
this system is as simple to use as possible is essential for AstraZeneca to comply with 
regulatory bodies, yet it is unclear to what extent achieving this will drive innovation. It 
will certainly aid information retrieval by enhancing the search capability and allowing 
the standalone GEL database to be incorporated into the AstraZeneca global search 
capability. However, it is a large undertaking with little guarantee that the regulatory and 
project documents (mainly Word and PDF) within the database will be of use to the 
innovator. Granted that interviewees commented that there is a need for an overview of 
prior work within AstraZeneca, but interviewees noted that the files within the GEL 
database are simply too complex and detailed to be of use. 
Unless information sources are concise and accurate, this research suggests that an 
innovator will simply contact a colleague through an informal social network instead. 
One employee commented that it would be wonderful to have a global shared folder 
containing presentations of the various disease areas that are researched within 
AstraZcneca. This concise yet effective solution would have saved half a day of a senior 
research scientist's valuable time when they had to give a briefing at an external 
conference. Whether such a folder could be construed as a "Knowledge Management 
system" is a matter of discussion, but the end goal is exactly the same as a complex 
Knowledge Management system - it saves the time of the specialist knowledge worker 
and allows them to focus upon the innovative aspect of their role. 
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Hence, a supportive Knowledge Management system will ultimately allow the worker to 
carry out their job more effectively; however an innovative Knowledge Management 
system should specifically identify and provide the knowledge and information that is 
required to innovate. 
12.2 SUPPORTIVE AND INNOVATIVE KNOWLEDGE MANAGEMENT 
Ibis research suggests the notion that Knowledge Management itself has a distinction, 
between supportive systems and innovative systems. During the researcher's time within 
AstraZeneca the implementation of a supportive software system was analysed. Although 
this was not strictly a Knowledge Management system, the system was innovative in that 
it formed collaborative relationships across the organisation and was linked to the current 
strategy. The novel clinical system named Early Efficacy Enterprise or E3 simplifies the 
process of conducting clinical trials and provides a faster and more efficient means of 
predicting the efficacy of new cancer drugs. While the researcher was discussing the 
implementation of the project with the project manager, it was apparent that this type of 
innovative system fell firmly within the role of a supportive system. 
The efficiency was predicted to rise by 35% and as this type of system directly supported 
the core strategy of the company, resources that had not been available before, were made 
available. The manager acknowledged that gaining initial funding had been difficult, but 
the promised gain in efficiency was tangible and directly supported the progression of 
compounds from Phase II to Phase III clinical trials, thereby attracting senior 
sponsorship. Another major factor was that the project had defined customers who signed 
internal contracts for the service, namely Phase III investigators who, because of the 
project, could manage their budget more accurately and thus record a tangible bcncf it. 
When the project was analysed, II trials had signed up and more were expected; with a 
progression of the system from the oncology TA (Therapeutic Area), to the respiratory 
and inflammation TA (RITA) was expected within the future. 
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Essentially the project acted as an internal consultancy providing a service to internal 
customers and negating the need for expensive external collaborations with Contract 
Research Organisations (CROs). The success of this project led the researcher to attempt 
to discover why exactly this project was so successful over other innovative work. 
If this project is conceptualised within Kaplan & Norton's (2001) framework of 
intangible assets, then it is clear that each intangible can be matched to the software 
system. At this point a leap of faith was required to apply these values to software, but 
essentially an intangible asset typically signifies a concept that has value that cannot be 
measured in financial terms. In this case it is not the tangible value of the software that is 
being assessed, but the intangible value it provides to the organisation as an innovation. 
Table 12.2 illustrates the project in relation to the definitions of an intangible asset, as 
defined by Kaplan & Norton (2001) and Andriessen (2005): 
Table 12.2: Examining the intangible assets of the E' project 
Intangible Assets Example of Intangible Satisfied the definition? 
Definitions asset 
Utilises the skills, Utilises the skills of Yes 
competencies and AstraZeneca's employees 
motivation of the (10 at present) 
employees 
Database and information Provides a template and Yes 
technologies database for analysing and 
sharing clinical trials data 
quickly 
Efficient and responsive Increases the efficiency of Yes 
operating processes the current Phase 11 to 
Phase III business processes 
by 35% 
Innovation in products and Provides an innovative Yes 
services product and a innovative 
customer based service 
Customer loyalty and Creates strong relationships Yes 
relationships for its customers by saving 
them resource 
Political, regulatory and Has strong senior and Yes 
societal approval regulatory sponsorship as it 
clarifies and hastens a 
complex area 
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Hence, the parallels between a successful innovation and the definition of an intangible 
asset are clear. The tangible measure of the 35% increase in efficiency is being driven 
through the development of strong customer loyalty and the utilisation of in-house skills. 
Hence, in terms of innovation, this project has generated value in excess of its original 
remit by exploiting the organisation's intangible assets and by specifically supporting a 
set of crucial business processes that generate future revenue. It would be nalve to 
suggest that a Knowledge Management system can only support the specific business 
processes that generate revenue, as the majority of innovative work, by its very 
definition, is outside the existing processes. Yet it suggests that a Knowledge 
Management system will gain more managerial backing if it directly supports a specific 
process that supports an objective of the organisation's strategy. 
Hence it is important to tailor a Knowledge Management system to directly support the 
existing business processes and support the organisation's strategy. The need to support 
existing work patterns appears to be linked to the fact that the introduction of a 
Knowledge Management system generally calls for change and improvement, rather than 
support. Mertin et al. (2001) demonstrate this point by listing the proposed benefits of a 
Knowledge Management system as: 
1. Cost/ time reduction, increase in productivity 
2. Process improvement 
3. Improvement in the exchange of information 
4. Customer orientation & satisfaction 
5. Transparent organisational structure/ processes 
6. Better decision making and prediction 
Quality improvement 
8. Staff satisfaction 
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9. Competitive advantage and increased market share 
These ýine factors are exclusively based upon changing the existing processes through 
utilising a Knowledge Management system and indicate how disruptive Knowledge 
Management can appear to the management of an organisation. When viewed from this 
perspective, what incentives are there to introduce a system that potentially could 
interfere'with the existing revenue processes of the organisation? In order to be used for 
innovation, a Knowledge Manage4ent system must induce a change in working patterns 
over time, change which may or may not support the existing processes. In a highly risk 
averse environment such as pharmaceutical R&D, the introduction of yet more risk and 
change, will obviously raise eyebrows and require significant effort to prove the benefits 
that may arise through a changq in working patterns. 
For example, a novel Knowledge Management system was studied within AstraZeneca 
and assessed against these factors and the definition of an intangible asset as defined by 
Kaplan -& Norton (200 1) and Andriessen (2005) (Table 12.3). The Knowledge 
Management system was designed to capture the literature and documents that are 
required fbi early stage drug trials. Essentially, the system acted as a central repository 
for information that was deemed -useful. for the employees. The unique aspect was that it 
bypassed the use of private shared drive folders and therefore, all information in the 
system was acc6ssible to others. The system also employed a domain ontology-driven 
searching functionality so aý to aid the user in locating relevant information and the work 
of other employees. 
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Table 12.3: Examining the intangible assets of the a novel Knowledge Management 
system 
Intangible Assets Example of Intangible Satisfied (lie definition? 
Definitions asset 
Utilises the skills, Utilises the skills of Yes 
competencies and AstraZeneca's employees 
motivation of the (I -10 at present) 
employees 
Database and information Provides a template and Yes 
technologies database for analysing and 
sharing information 
Efficient and responsive Is thought to increase the No 
operating processes efficiency of an internal 
department 
Innovation in products and It may provide innovation - No 
services although this is unproven 
Customer loyalty and May creates strong No 
relationships relationships internally, yet 
not externally 
Political, regulatory and Has senior support but lacks No 
societal approval regulatory and 
organisational support 
The results revealed that the system supported an improvement in the exchange of 
information, better decision making and an increase in staff satisfaction for a sub section 
of Clinical scientists. These benefits only resulted through a change in the working 
patterns of the employees to include this system in their daily work. Yet it does not 
directly support one specific process as the E3 system does, instead it helps many. 
Therefore, it is difficult to see how the Knowledge Management system succeeded in 
relation to a number of the intangible assets criteria. On the other hand the E3 system and 
the outputs from the E3 system, satisfy the definition of an intangible asset. Therefore, 
this is a strong argument to ensure that before a system is implemented, there are tangible 
measures of success identified that show how the system will support a current business 
process, even if the system will cause change through innovation. 
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In many respects the research data supports the academic literature which suggests that 
given sufficient time, Knowledge Management systems will also deliver a benefit. Yet, as 
this process is driven by change and not support, it requires time to take affect, time that 
this research has shown, will not be provided unlQss a tangible benefit is perceived. The 
notion that Knowledge Management is strongly linked to change over a period of time, 
appears to be hampering Knowledge Management as a field. Recent research by 
Davenport & Peitsch (2005) also noted that pharmaceutical organisations seek to drive 
drug development by: 
"Changing the way the scientists and technicians operate, in order to create, share and 
use knowledge more efficiently and more effectively ". 
Knowledge Management that is designed for innovation, it would appear, is not based 
upon support for current processes, but instead calls for change and that may explain 
some of the comments fielded by the interviewees: 
"We've been harping on about Knowledge Management and how it can help and very 
little has been actually executed " 
If employees are expected to change to utilise the existing Knowledge Management 
systems and this offers little benefit over collaboration between colleagues in face-to-face 
meetings, then it is clear that the uptake of these systems will be slow, particularly with 
regard to innovation. It is a fair assumption that an employee will change their working 
patterns to utilise a system that supports their current role, but only if the system offers 
them a benefit. The following section explores potential measures to capture the benefits 
of the proposed Knowledge Management tool set of Chapters 10 & 11. 
12.3 MEASURING INNOVATION 
One aspect of this research has been to assess and learn more on measuring the value of 
innovation to an organisation. While there is a wealth of intellectual capital research 
available that proclaims to measure innovation and the intangible assets of a company, 
the reality of applying these measures is rather different, particularly with regard to 
measuring the benefit of Knowledge Management. 
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Chapter 3 analysed relevant research concerning techniques such as the Balanced 
Scorecard, Intellectual Capital statements and so forth. However, what was striking %yas 
that very few papers actually suggest what these measures should be measuring. Instead 
the authors would acknowledge that it is important, yet entirely subjective and these 
measures are dependent upon the context of the intangibles to be measured. Evidently 
this is not overly helpful as it basically states that you must design your own measures. 
However, the results of the conceptual matrices within Chapters 6,7 & 8, do provide 
measures in the form of the "Drivers" and "Required Criteria" for innovation. Overall the 
results provide the measures, listed in Tables 12.4 and 12.5, that could be used to indicate 
the effectiveness of innovative activities within AstraZeneca. 
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Table 12.4: Measuring pharmaceutical innovation 
Area Assessed Assessed Area Metries 
Issues concerning 1. Link between existing Checklist of where the 
the innovation AstraZeneca strategy and innovation "fits" within the 
the innovation organisation i. e. supports a 
particular Therapy Area (TA), 
meets the requirements of the 
GPT, supports a "First in class" 
compound etc 
2. Impact of innovation in Potential cost savings in terms of 
terms of financial resource man hours/ FTE (Full Time 
and revenue generated Employee) saved by using the 
innovation and potential Return 
on Investment (ROI) and 
potential revenue from the 
innovation 
3. Conference presentations/ Number of papers/ conferences/ 
peer reviewed papers/ newsletters/ AstraZeneca 
newsletters produced Innovation Awards 
regarding the innovation 
4. Value and "worth" felt by Questionnaire with Likert Scale 
the employee(s) who to assess employee perspectives 
developed the innovative 
concept - i. e. avoiding a 
"blame culture" 
5. Number of patents Number of patents associated 
developed from the with the innovation - however 
innovation this is a long term undertaking 
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Table 12.5: Measuring the value of information & knowledge for pharmaceutical 
innovation 
Area Assessed- 
Issues concerning 
the use of the 
information & 
knowledge (source) 
Assessed Area 
1. What was the source of 
information/ knowledge? 
e. g. CoP/ decision support 
software/ R&D portal etc 
2. Did the source allow a 
project to progress? 
3. How important was the 
source in terms of 
allowing innovation? 
4. Did the source help to 
66gel" teams? 
5. How many people 
contributed to the source 
and what were their roles? 
6. Did the source help people 
to work more effectively 
together? 
7. Was the source easy to 
find? 
8. Was the source easy to 
use? 
Measures 
t, neCKIISI or pownuai sources, 
for example Knowledge 
Objects, R&D Portal, PKT, 
GEL etc 
Question - Yes or No with free 
text response to capture the 
reasons why 
Question with free text 
response to identify the 
subjective value of the source 
Questionnaire relating to the 
collaborative aspect of the 
information and knowledge 
required (see Section 5.3.3.2 
for examples) 
Number of people and 
checklist to capture their role 
and title 
Survey based upon a Likert 
Scale to gauge how the 
information/ knowledge helped 
to drive innovation 
Survey using a Likert Scale (I- 
5 scale from strongly disagree 
to strongly agree) to gauge how 
easy the information was to 
locate. For example, measure 
the level of agreement with a 
set of statements such as: "I 
found the information source 
___. # 11 
Survey using a Likert Scale to 
assess the ease of which the 
information/ knowledge could 
be used. For example, the level 
of agreement with a set of 
statements such as: "The 
information Ifind is easy to 
understand" 
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The examples provided in Table 12.5 illustrate that many of these measures could consist 
of a simple Likert Scale, survey or checklist. However, this would require retrospective 
assessment after an innovation had sufficiently progressed in the short term. At present 
very little follow up work is conducted concerning the value of an innovation, such as an 
Innovation Award within AstraZeneca, so this would be a beneficial exercise. The longer 
term benefits are rather more difficult to assess due to the long product life cycle of a 
compound. However, short term assessment would be feasible and worthwhile, possibly 
with the inclusion of these assessments at project review or milestones. The use of patent 
data was felt by the interviewees in Chapter 7 to be a poor representation of innovative 
activity. However, a recent article within Eureka (Palmer, 2006) explains how accurately 
mapping the development of patents can aid innovation by producing a roadmap of future 
trends within R&D. Similarly, the knowledge & information reused from software 
systems such as discussion forums, lessons leamt & decision systems and collaborative 
software could be theo'reticafly tracked or mapped, to provide a measure of how effective 
the system is. However, carrying out this in practice would prove onerous, yet could be 
valuable in terms of the evaluation of a Knowledge Management/ IS system within an 
organisation. 
Figure 12.1 illustrates the concept of how innovative information/ knowledge could be 
measured if the Knowledge Management toolset from Figure 10.8 was used as a means to 
innovate 
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AstraZeneca Blot chnology Firm 
CAT 
Department i. e. 
Medical Science Concept 
Knowledge 
Management 
2 Toolset 
68 Primary Level -II 
0 Social Networks 4 
Tollgate (Push/ Pull) 
Secondary Level - 39 Internal/ External 12 01 Knowledge &4 
Prototype Information (Pull) 
14 
Tertiary Level - 
Tollgate 7 
10 
- 
Knowledge & 13 
Information 4 
Capture (Push) 
5 
Innovation 
Figure 12.1: Assessing Information/ Knowledge Flow between organisations with 
regards to innovation 
Measures similar to those identified in Table 12.4 & 12.5 could be used at each point 
denoted by a number within the diagram. 
Knowledge 
Management 
Toolset 
Primary Level - 
Social Networks 
. (Push/ Pull) 
Secondary Level - 
Internal/ External 
Knowledge & 
Information (Pull) 
Tertiary Level - 
Knowledge & 
Information 
Capture (Push) 
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The number signifies the possible measure or measures to be employed. Potential 
innovative measures could include: 
I. The number and details of innovative concepts derived from external sources, 
such as biotechnology firms and universities. It is also important to record where 
within AstraZeneca these innovations are introduced, for example Medical 
Science. 
2. The number and details of the innovative concepts that are approved by the 
internal departmental employees or stakeholders and are then passed on to 
AstraZeneca departments or individuals, who are responsible for progressing the 
innovation further. For example, this may be the progression of a novel 
proteornics study from Medical Science to the GPT. This stage may also record if 
the innovation is passed on to other teams or individuals within a single 
department for further work. This metric seeks to establish the percentage of 
innovations that progress past initial scientific scrutiny once they are acquired 
from external sources. 
3. The number & details of the innovative concepts that pass the tollgates and 
criteria set by internal AstraZeneca groups such as the New Opportunities Group. 
This will provide a percentage measure of how far an innovation has progressed 
and help to identify if the criteria for innovation used by departments and 
AstraZeneca's strategic groups differ. 
4. The number & details of the innovative prototypes that pass initial departmental 
scrutiny and are taken under AstraZeneca's strategy. Again this measure will 
assess how, where and why innovation may either fail or succeed. 
5. The number & details of the innovative prototypes that pass the final set of 
tollgates and make it to an innovation, whether this is a final compound, 
Knowledge Management system or novel FTIM study. Again this measure will 
assess how, where and why innovation may either fail or succeed. 
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Figure 12.1 also illustrates measures that could be used to assess the information and 
knowledge exchange occurring at each stage of the development process: 
6. The source and details of the information and knowledge acquired from the 
Knowledge Management system which have directly contributed to the 
assessment of an innovative concept at a tollgate. It is envisaged that the majority 
of knowledge will stem from the primary level, yet the secondary and tertiary 
levels will provide supportive knowledge and information. The capture of where 
the information and knowledge is obtained from is crucial to demonstrate the 
value of a Knowledge Management system. This is particularly important and 
would help to generate interest in using Knowledge Management systems, such as 
the Knowledge Object system, to support the capture of decision knowledge 
concerning these areas. 
7. The measures used at this stage would be similar to those used at stage 6. Aiming 
to capture where the information and knowledge is being derived from and how 
the decisions were being taken. At this stage of the process it is expected that 
additional information and data will be required to augment the scientific 
research. This would include marketing data to assess the potential of the 
innovation and financial data to support additional investment. Although the 
Knowledge Management system would not provide this, it would still be wise to 
capture how and why this additional data influenced the eventual "Stop/ Go" 
decision. 
8. These measures would assess the use of the social aspects of the Knowledge 
Management system to provide scientific support for an innovation. Potential 
measures include: 
" The number of formal Communities of Practice 
" The total number of participants within the social system, particularly the 
discussion forums 
" The number of regular contributors (knowledge champions) and the 
number of contributors within each community 
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" The number of tools utilised to provide scientific evidence to support the 
innovative concept 
" The number of contributions that directly contribute to supporting or 
disproving an innovation. It is also important to assess when and why an 
innovation may not progress as this can help prevent financial loss and 
compound attrition later on. 
" The percentage of contributions provided by the social tools (Primary 
Level) in comparison to the Secondary and Tertiary levels of the 
Knowledge Management tool set. 
9. These measures would assess the use of the external and internal information 
"Pull" aspects of the Knowledge Management system to provide scientific 
support for an innovation. Potential measures include: 
" The number of available sources 
" The relative use of these sources (e. g. server logs) and hence the relative 
importance of the various sources at the various stages 
The number and details of supporting or disproving scientific evidence i. e. 
academic papers/joumals, in-house reports or external research 
10. These measures would assess the use of the "push" aspects of the Knowledge 
Management system to provide scientific support for an innovation. Potential 
measures include: 
" The number of best practice/ lessons leamt captured 
" The number and location of the decisions captured along the innovative 
process 
" The number of Knowledge Objects created 
" The amount of times the captured information is accessed 
" The where, when and how the captured information and knowledge has 
been used, particularly when it supports an argument for or against 
innovation 
" The percentage of reviews that capture inforniation/ knowledge at each 
stage of an innovative project 
359 
Chapter 12 - Ev! luating Knowledge Management 
11. These measures would assess the use of the social aspects of the Knowledge 
Management system by the external collaborator. The measures would be the 
same as the measures in point 8, yet primarily identify where an external partner 
has contributed the expert knowledge or information. 
12. These measures would assess the use of the information/ knowledge "push" 
aspects of the Knowledge Management system by the external collaborator. The 
measures would be the same as the measures in point 9, yet primarily identify 
where an external partner has contributed the expert knowledge or information. 
13. These measures would be similar to measures in point 10, but would identify if an 
external partner had contributed to/ or used the knowledge or information stores 
within the Knowledge Management system. 
It is hypothesised that building up the knowledge offered by these measures could help to 
identify where collaboration is succeeding and help to refine the toolset software. For 
example, if the majority of decisions are being taken when a concept is first bought into 
AstraZeneca, such as a "Stop/ Go" decision, then tailoring decision support software 
(Level Three) to support these decisions would obviously help. Similarly if sufficient 
data could be gathered to reveal trends then the toolset could be tailored depending upon 
whether the innovative work was a Phase I FTIM (first time in man) study or a protcomic 
study, for example. At present, data is not gathered regarding this aspect and it would be 
interesting to gauge whether different types of collaborative partner required different 
approaches with regards to information/ knowledge exchange. As effective collaboration 
with external organisations is essential for the longevity of AstraZeneca, it makes 
commercial sense to invest in this area and attempt to negate the effects of the mistrust 
and Intellectual Property retention that was evident in the findings of Chapters 6,7 and 8. 
Employing measures to evaluate the impact of a Knowledge Management system would 
also help to gain support for the system and tangibly demonstrate that rather than 
requiring funds, it actually helps to generate revenue. 
An alternative means to measure innovation that is lightly covered within existing 
pharmaceutical research, is via the visualisation of the information and knowledge within 
the organisation, a term commonly referred to as "knowledge mapping". 
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This technique was investigated by the researcher in collaboration with Dr flolger 
Adelmann and employees of the Medical Science department. This exercise led to the 
researcher capturing the outputs from the piggybacking project studied in Chapter 9, 
within a decision capture matrix. This is a novel means of displaying the decisions, 
assumptions and the outcomes relating to each decision, throughout a project. Figure 12.2 
illustrates the capture of the decision, the assumptions that decision was based upon and 
the eventual outcome of the decision: 
Decision Assumptions Outcome 
1. Start both Respiratory and AstraZeneca indications inflammation 
establishedthe early therapeutic 
concept of 2. Choice of management team 
C 
j piggybacking to lead indication establish 
test 2 drugs 3.1ndependent piggybacking study 
simultaneously pricing for AM XXXX & 
established AM YYYY 
Emerging 
respiratory 
clinical 
development 
team requested 
FTE support to 
form a COPD 
team 
The 
piggybacking 
team was formed 
Figure 12.2: Example knowledge mapping of the piggybacking project 
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Figure 12.2 illustrates a cut down version of the original knowledge map, yet the 
technique visually demonstrates that the outcome of one decision can have an impact on 
the decisions taken further down the process. A decision's outcome can impact the 
subsequent decisions made and this method provides a visual means of identifying which 
decisions were key within the project. In the case of the piggybacking project this 
technique revealed that the key decision was the one to develop a separate clinical plan, 
which occurred approximately 6 months into the project. 
Due to privacy issues, the full knowledge map is not available within this thesis, 
however, the full version illustrates that the decision to use two separate clinical plans 
was based upon the outcomes of two previous decisions, all of which were based upon 
assumptions. The decision to develop two separate clinical plans was based upon the 
assumption that the regulatory bodies required two plans, although the experience of the 
project team and the scientific evidence suggested that one plan would be sufficient. 
Hence, the use of the Knowledge Management tool set to clarify this assumption before 
the decision was made could have been beneficial and possibly led to the success of the 
project. Essentially a Knowledge Map in this sense helps to clarify the factors that are 
affecting a project and allow the employees to see where the main influences are 
stemming from. Once a key decision stage has been identified, similar decisions could be 
supported more effectively in the future by the Knowledge Management toolset. The 
decisions shown in this example are a limited version of the original information so as to 
preserve securityi However, the original knowledge map possessed eight key decisions, 
16 assumptions and 8 outcomes of those decisions throughout the project. The 
information was derived using the questions in Appendix 5 as a guide. In addition, the 
piggybacking project yielded a number of valuable indicators of the success of a project. 
These are also defined in Appendix 5 and provide a possible template for identifying 
issues across multiple studies. This work met with a positive response from employees 
within AstraZeneca and Bernard Marr of Cranfield University, and could potentially be 
used to augment the proposed tool set of Chapter 11. Ilowevcr, further research would be 
required before the full potential could be rcalised. 
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The following section now briefly outlines the key findings from this research before 
concluding this chapter. 
12.4 CAN KNOWLEDGE MANAGEMENT TRULY DRIVE 
PHARMACEUTICAL INNOVATION? 
At the minimum this thesis has provided the answer to the "Where? Why? & How? " 
questions as to how Knowledge Management can be used to drive innovation within 
AstraZeneca. From the discussion it is apparent that one simple Knowledge Management 
tool does not fit all situations. A post by the Information Management guru Tom Wilson 
on David Gurteen's website (2002) emphasised the challenges facing Knowledge 
Management: 
'Td guess that the majority of businesses are run in ways that actively prevent 
information sharing and KM in the information sharing sense is not something that can 
be grafted on to an organization - it's not a 'solution'to be bought and implemented, but 
ajundamental change in the ways CEO's [Chief Executive Officers] think about people - 
as knowing, thinking, innovative beings, rather than units in the production process. 
We've got a long way to go. " (Wilson, 2002b) 
This still holds true approximately four years after this statement was made. The 
qualitative results of this research, and particularly the literature review of Chapter 3, 
have shown that Knowledge Management currently revolves around information capture. 
As this chapter has demonstrated, the latest generation of semantic tools and social media 
offers the potential to change this situation'for the better, yet whether these tools have the 
impact they proclaim, remains to be seen. However, it is clear that the chosen toolset 
supports the innovation framework defined in Figure 10.8 and it is theoriscd that, as a 
whole, the toolset can be used to drive pharmaceutical innovation both internally and 
externally. 
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It would appear that allowing fellow employees to collaborate and communicate across 
AstraZeneca's R&D domains and externally within research organisations and 
universities is the key to driving pharmaceutical innovation. Unfortunately, as the results 
of Chapter 6 showed, collaboration is rarely as straightforward as it seems. 
Yet other pharmaceutical companies are using collaboration to good affcct, particularly 
with regards to external research organisation. Eli Lilly is commonly cited as a champion 
of collaborative pharmaceutical R&D, and research by Stach (2006) provides a good 
overview of how they are achieving this success. Primarily, Eli Lilly employ an 
innovation model that actively sources external research that complements their existing 
internal research. This occurs through a specific and funded group labelled the Global 
External Research and Development group (GER&D). To all intents this group would sit 
in the framework of Figure 10.8 within the "Assimilation of Knowledge & Information 
Sources" concept. Although AstraZeneca possess these types of teams at a smaller level, 
it is perhaps necessary to expand this element in order to minimise the role of serendipity 
and ensure that innovative ideas and concepts are immediately tied with the aims of the 
organisation, rather than rely upon the efforts of internal employees to "force" their 
innovative work upon the organisation. 
Eli Lilly then employ a further team labelled the Corporate Business Development group 
to lead negotiations and agree a beneficial contract after a potential innovation has been 
identified. After this has occurred a further group named the Alliance Management group 
take charge of the innovation and collaboration, and progress it through the company to 
create value. This model employs the mantra of "Find-it, Get-it and Crcate-value". A 
mantra that was also raised during the researcher's discussions with Rolls-Royce who 
proclaimed that their equivalent team had a "telephone to God", in order to ensure 
promising innovation is driven and not discarded. It is theorised that the toolsct of Tables 
11.2 & 11.3 would answer the problems currently felt by AstraZcneca's employees and 
essentially informally mimic the formal groups that exist within Eli Lilly at present. 
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In terms of the concept of strategic intangible assets, this research suggests that instead of 
capturing knowledge, a Knowledge Management system may simply have to make 
people aware of what research is taking place, an analogy to the task of Eli Lilly's Global 
External Research and Development group. However, there are many means of achieving 
this, from a simple People Pages/ Expert Locator system to a more in-depth system that 
can provide greater context to the innovation being proposed. 
As Section 6.3 suggests, the greater the contextual element provided, the lesser the 
chance of scientific bias will unduly sway the argument one way. Ilence setting the 
correct scientific context can in many ways reduce the bias present within scientific 
research. 
Providing a greater understanding of related research undeniably helps to define an 
innovative idea, allowing comparison between existing research and the innovation and 
also allowing fellow employees to grasp where the innovative idea has application. 
Unfortunately while setting sufficient context may help, employees noted that bias is 
inescapable in pharmaceutical innovation and this research suggests it is essential for an 
innovation to progress beyond the idea of a concept. So, in many respects, scientific bias 
is a driver of innovation. If an employee can publicise and market an innovation that 
appears to directly support the organisation's strategy and hence is in line with the 
organisations strategic intangible assets, then there is a strong chance the innovation will 
succeed (e. g. the E3 system & the FTIM dosing technology) regardless of scientific bias. 
Hence bias that supports the organisational strategy can in many cases, be acceptable as 
long as the science behind the bias is sound. 
In conclusion to the key findings of the discussion, it is worth noting that pharmaceutical 
innovation is essentially governed by physical rules that dictate the structure of a 
compound. Of these physical rules, Lipinski's "Rule of Five" (Lowe, 2006) set of 
chemical criteria was noted by the Discovery wing of the company to be an over riding 
factor in modem drug production. 
These criteria essentially define the physical properties an orally dosed drug is perceived 
to require such as a being a small molecule (<500g/mol). 
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Even after identifying a valid biological target a suitable compound may not be found, or 
at the minimum a 'best fit' compound adopted. A Clinical Scientist described this as the 
"pinch point" and is worth noting as one of the key criteria that will certainly delay or 
even stop a valid biological target or compound being exploited fully. 
The physical science is an inescapable part of drug development, as modem drug 
development is loaded to focus upon finding small molecules that can be dosed by mouth 
primarily. Yet all employees noted that finding a compound, let alone a small molecule, 
that acts in the right way upon an identified biological target is akin to the proverbial 
needIe in the haystack. 
It is in this area that the Knowledge Management toolset can potentially offer the greatest 
help by identifying and forming alliances with collaborators that possess these types of 
molecules. Once a suitable compound has been discovered Knowledge Management can 
also certainly help, particularly in the application of clinical knowledge. Hence, in 
conclusion, applying the toolset should offer a powerftil benefit to AstraZencca in terms 
of innovative ability and future revenue. 
12.5 CONCLUSION 
The discussion within this chapter raises an number of valid points that shed light upon 
the use of Knowledge Management within an organisation and discusses how Knowledge 
Management can help innovation to align with the organisation's overall strategy. Of 
particular interest is the observation that the successful implementation of the toolsct 
relies upon the tools meeting the requirement of an intangible asset. As Chapter 3 noted, 
Knowledge Management tools often fail to take hold within a company and this is 
principally due the fact that they require change. This research indicates that Knowledge 
Management should integrate with the employees in their daily roles, whether this is in a 
supportive or innovative capacity. 
Finally, if the outputs of the collaborative networks and accompanying Levels of the 
toolset, can be measured using the suggested metrics, then the true value of the toolsct 
could be estimated with regard to innovation. 
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The following chapter concludes the research and revisits the research aims and 
objectives, before suggesting opportunities for further research. 
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CHAPTER13 
SUMMARY, CONCLUSIONS AND 
RECOMMENDATIONS FOR FURTHER WORK 
13.0 INTRODUCTION 
The aim of this chapter is to summarise the findings of the thesis in line with the aims 
and objectives which were defined in Chapter 2. This chapter also provides 
recommendations for further work and draws conclusions from the research as a 
whole. Guidance for future research is also discussed, to be used by the stakeholdcrs 
of this research and Knowledge Management practitioners. 
13.1 RESEARCH OVERVIEW 
The advent of Knowledge Management has bought with it, a considerable amount of 
hype and proclamation. The promise of Knowledge Management is considerable yet 
this thesis has demonstrated that the realities of using Knowledge Management are 
rather more complex. With this in mind, this research was commissioned to examine 
where Knowledge Management could have benefit and how it could be used to 
enhance pharmaceutical innovation within AstraZeneca. The research aim was: 
"ro create and evaluate a Knowledge Management tool set to enhance innovation 
within AstraZcncca. " 
In order to satisfy this aim and develop the tool set the research was split into a 
number of high level objectives: 
1. Identify the general views associated with innovation and pharmaceutical 
innovation 
2. Identify the drivers, the criteria for innovation, the outputs of the innovation 
and the themes associated with innovation, specifically within AstraZcneca 
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3. Examine and evaluate the Knowledge Management strategy and existing tools 
in use across. AstraZeneca R&D 
4. Examine potential Knowledge Management tools that could be used to 
support innovation in AstraZeneca and evaluate their potential use and impact 
to enhance innovation 
5. Test the validity of the Knowledge Management tool set and research by 
publishing the results within AstraZeneca and producing peer-reviewed 
conference proceedings 
6. Deliver the tool set to AstraZeneca R&D 
The majority of these objectives were achieved and the details surrounding this are 
explored in the following section. 
13.2 RESEARCH FINDINGS 
13.2.1 OBJECTIVE 1 
1. "Identify the general views associated with innovation and pharmaceutical 
innovation. " 
The objective consisted of three separate tasks. The first of which was: 
Conduct a review of the literature to identify and understand the general views 
on innovation and innovative processes within the literature. This stage will 
identify what constitutes innovation and what processes are thought to support 
innovation. 
The review of the innovation literature was extensive and formed a substantial part of 
Chapter 3. The study revealed that innovation may be conceived of as an adoption of 
a new system, a product, a process, a service, a program or policy. The definition of 
pharmaceutical innovation would traditionally be the development of a new 
compound or drug. 
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Yet the literature review demonstrated that innovation goes beyond the development 
of a tangible product. The definition of innovation used by the research was "the 
embrace of a novel concept". This was a broad definition yet it provided the research 
with a basis on which to explore innovation within AstraZeneca. The notion of 
pharmaceutical innovation was studied and the processes, drivers and information 
and knowledge that are required were examined and identified. This section 
highlighted areas that the literature deemed important to examine. This included the 
move towards innovation acquisition rather than in-house R&D, and the reliance 
upon accurate knowledge and information at all stages of the drug development 
process. The second and third tasks of Objective I were: 
Conduct an exploratory case study on innovation within AstraZeneca to 
identify the departments and principle innovative employees across 
AstraZeneca R&D. This will take the form of a qualitative case study utilising 
semi-structured interviews 
Clarify and compare the innovative practices of these departments and 
innovators across AstraZeneca with the literature concerning pharmaceutical 
innovation 
These tasks relied upon the development of a semi-structured questionnaire which 
was successfully derived from the literature review of Chapter 3. The results from 
this stage led to Chapter 5 which details the results of this survey within the Medical 
Science department of AstraZeneca, Chamwood. The Methodology Chapter 4 
concluded that the use of a longitudinal case study, coupled with an interprctivist 
approach was a viable research methodology. One of the primary reasons for the 
exploratory study was to evaluate this methodology and decide whether it would 
support the overall research aim. In addition, the tasks within this objective led to the 
development of a research tool in the form of a detailed questionnaire. A research 
framework was also identified with which to assess the innovation and Knowledge 
Management processes within Astra. Zeneca. 
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Furthermore, Chapter 5 identified the basis of the critical factors associated with 
innovation and the use of Knowledge Management. 
13.2.2 OBJECTIVE 2 
2. "Identify the drivers, the criteria for innovation, the outputs of the innovation and 
the themes associated with innovation specifically within AstraZeneca. " 
This objective comprised three tasks, the first of which was: 
Conduct a series of detailed case studies to identify the knowledge and 
inforination needs of the innovative employees and departments within 
AstraZeneca. These will form a set of innovation and knowledge criteria, 
drivers, outputs and themes to be used to develop the Knowledge 
Management tool set. 
Achieving this task formed the bulk of the results of Chapters 6,7 and 8. 
Representative results of the case studies were published and analysed in accordance 
with the data analysis methodology chosen in Chapter 4 and Chapter 5. Meeting this 
objective provided a detailed account of the nature of innovation within AstraZeneca 
and identified many aspects where innovative practice was both aided and hindered. 
The criteria, drivers and outputs of innovation, provide a useful guide to supporting 
innovative activity within AstraZeneca. Furthermore, the information and knowledge 
needs of the employees were also analysed at length. The reliance upon luck, the role 
of regulation and the role of social networks in facilitating pharmaceutical innovation 
were notable contributions to public research. This task also helped to clarify the 
multitude of factors that affect pharmaceutical innovation and provided academics, 
Knowledge Management practitioners and AstraZeneca employees with a greater 
understanding of the problem domain. 
Produce a model of pharmaceutical innovation that reflects innovation 
occurring within AstraZeneca based upon: the identified themes, criteria, 
outputs and drivers of innovation 
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This task was achieved in Chapter 10, where a novel model illustrating the 
interdependence between innovation, knowledge and information was developed. The 
model illustrates the interactions and processes that should be considered when 
supporting pharmaceutical innovation. This model is unique in that it includes aspects 
external to the organisation, which reflect that. the majority of pharmaceutical stems 
from external research. The model also highlights that Knowledge Management can 
function in a marketing role, whereby innovative concepts are essentially announced 
to the organisation. This aspect raises the profile of the innovative individual, thereby 
providing personal gratification, but also highlights novel research to the 
organisational strategists who can develop the concept to an innovation. Encouraging 
this degree of contact from the "grass roots" level employee to the managerial staff, is 
crucial for innovative activity and one that the tool set of Chapter II encourages. 
Clarify and compare the innovative practices of these departments and 
innovators across AstraZeneca with the literature concerning pharmaceutical 
innovation 
This task was satisfied throughout Chapters 3,10,11 and 12. Where possible 
academic literature or practitioners' reports were referred to and compared to the 
research findings. This element will provide AstraZeneca with ideas and suggestions 
for future Knowledge Management related work. It is fair to say that the majority of 
the results grounded existing academic research, yet the innovation criteria and 
themes relating to the use of Knowledge Management tools within the 
pharmaceutical innovation arena certainly help academic research in this area. 
13.2.3 OBJECTIVE 3 
3. "Evaluate the existing Knowledge Management strategy and tools" 
The third objective was to examine and evaluate the Knowledge Management 
strategy and existing tools in use across AstraZeneca R&D. The objective was 
composed of four distinct stages: 
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Conduct a review of the academic and practitioners' literature to identify 
Knowledge Management methods, tools and strategies 
This stage consisted of an extensive review of the existing Knowledge Management 
literature with regards to KM tools, systems and their use within pharmaceutical 
innovation. The review revealed that, although the use of KM was advocated within 
the pharmaceutical arena, few papers have directly studied driving innovation 
through Knowledge Management. This research collated and analysed a substantial 
amount of potentially viable academic and practitioners' reports, in order for the 
findings of this stage to be incorporated into the KM tool set of Chapter 11. This 
stage built upon the results of the prior tasks and focused primarily upon the social 
networking tools, while the importance of utilising ontologies and semantic 
technologies was also discussed. 
9 Define how the value of knowledge and Knowledge Management is assessed 
within the literature 
This stage examined the use of intellectual capital techniques and summarised their 
use within Knowledge Management. This research provided a broad view of the 
measurement of intangibles and was invaluable in identifying how AstraZcneca could 
achieve their greatest return via Knowledge Management. 
Conduct a qualitative case study and consult with employees within 
AstraZeneca, to identify Knowledge Management tools that are being used to 
support innovation 
This process was achieved through semi-structured interviews across AstraZcncca 
with end users, participant observation by the researcher with Knowledge 
Management staff and the use of workshops to discuss the Knowledge Management 
strategy of AstraZeneca. The results of this stage were qualitative in nature and 
formed a rich picture of the use and potential use of Knowledge Management within 
AstraZeneca. The data was again analysed using the representative themes of 
Innovation and Knowledge Management. 
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This stage identified where innovation could be supported by KM tools. These results 
formed the basis of Chapter 8 and led to the evolution of the KM framework of 
Chapter 10 and the definition of the KM tool set in Chapter 11. 
9 Examine how Knowledge Management is and could be evaluated within 
AstraZeneca 
The research found that very little assessment of Knowledge Management currently 
occurs within AstraZeneca, with the assessment being limited to the use of the 
Balanced Scorecard. The methods and discussion presented in Chapter 12 represent a 
novel means of assessing a Knowledge Management system and generated interesting 
discussion concerning this area with Bernard Marr of Cranfield University. 
13.2.4 OBJECTIVE 4 
4. "Examine potential Knowledge Management tools that could be used to support 
innovation in AstraZeneca and evaluate their potential use and impact to enhance 
innovation. " 
e Produce a model of Knowledge Management that could be used to drive 
pharmaceutical innovation within AstraZeneca 
The novel three level model of Knowledge Man4gement was developed and refined 
within Chapter 10. In many respects this descriptive model is unique and offers the 
potential to be instigated in other knowledge intensive industries which are reliant 
upon external collaboration. 
Develop a Knowledge Management tool set from the previous review of the 
literature and the existing Knowledge Management tools within AstraZeneca. 
This stage was successfully achieved in Chapter 11, with the descriptive Innovation 
and Knowledge Management model of Chapter 10 providing the framework and 
structure of the novel prescriptive tool set. The Knowledge Management tools were 
chosen dependent upon the results and themes of the results Chapters 6,7 and 8. 
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This process ensured that the chosen tool sets would meet the needs of the 
employees, the organisational culture and above all, support the existing processes of 
innovation within AstraZeneca. 
13.2.5 OBJECTIVE 5 
5. "Test the validity of the Knowledge Management tool set and research by 
publishing the results within AstraZeneca and producing peer-revie,: Ved conference 
proceedings. " 
Evaluate the results of the research and the Knowledge Management 
recommendations by conducting a series of interviews to seek the opinions of 
the employees responsible for innovating within AstraZeneca. 
This stage was achieved successfully towards the end of the researcher's time within 
AstraZeneca. Personnel involved in Knowledge Management were approached and 
the tool set refined in accordance with their views. Due to time constraints 
encountered at the end of the research phase, this stage does require further research. 
However, as a starting point, the identified tool set would augment existing 
AstraZeneca systems and was deemed to meet the majority of the employee's needs 
by AstraZeneca Knowledge Management employees. 
9 Publish peer reviewed conference papers and present the results to promote 
discussion 
This stage was achieved through the publication and presentation of five conference 
papers relating to pharmaceutical innovation, collaboration and Knowledge 
Management. Valuable and occasionally contentious discussion was generated during 
each presentation, with the discussions validating the selection of the tool set and the 
research as a whole. An additional book chapter concerning the development of a 
Knowledge Management portal has also been reviewed and accepted, with the 
publication date set for late 2007. 
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13.2.6 OBJECTIVE 6 
6. "Deliver the tool set to AstraZeneca R&D. " 
9 Facilitate the implementation of the Knowledge Management tool set 
e Evaluate the Knowledge Management tool set through a series of systematic 
surveys and further case studies. 
The final objective required the implementation of the Knowledge Management 
toolset within AstraZeneca. It is with regret that this stage was simply beyond the 
scope of this research, primarily due to the time constraints associated with 
implementing such systems in a highly regulated environment. However, the 
researcher did support viable Communities of Practice during his time there and 
contributed to the development of novel Knowledge Management systems, which 
have been included within the tool set. Hence, overall, this research has contributed 
valuable and novel research and aided the uptake of Knowledge Management within 
AstraZeneca. Therefore, notable success was achieved in this area even though the 
objective was only partially achieved. 
13.3 LIMITATIONS 
Despite the novelty of this research in developing a viable Knowledge Management 
tool set and modelling pharmaceutical innovation, there remain limitations. The 
primary area is the implementation of the Knowledge Management tool set within 
AstraZeneca. The research aims were ambitious in this regard and with hindsight, 
would have focused upon establishing a series of pilot studies once the requirements 
were outlined. It is believed that this limitation would have been overcome with 
sufficient time. The employees of AstraZeneca will continue with the final objective 
and implement the tool set over the longer term. 
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In many respects the subjective nature of qualitative research could raise concern. 
However, as the methodology review within Chapter 4 discussed, the use of 
qualitative research provides a rich and detailed contextual element which can be 
lacking from quantitative research (Walsham, 1995). The subjective limitation was 
overcome through the use of qualita. tive data analysis techniques that played to the 
strengths of the interpretative approach. With further time, the findings of this 
research could have been accompanied by quantitative analysis, to balance the 
subjective nature of the research. 
The number of participants interviewed, was also a limiting factor and was due to 
limiting the scope of the research to a manageable level and limited access to the 
innovative employees. Ideally a larger employee set, than the 60 employees sampled, 
would have been interviewed with greater access, sufficient time and greater 
resource. This would have enabled filrther validation of the findings and could also 
have highlighted differences in innovative and Knowledge Management practice 
across AstraZeneca with the potential to explore the use of the tool set on an 
international basis, between the UK and Sweden for instance. 
In summary the subjective nature of the research and the eventual limited choice of 
tools, from the myriad of potential Knowledge Management tools, strategies, 
methodologies and techniques will always be contentious. When presenting a paper at 
IRMA (2005), the researcher remarked that the Community of Practice (CoP) may 
not be the panacea to all an organisation's troubles, while this comment was met with 
hostility from a CoP software consultant, the academics amongst the audience 
strongly agreed. It would appear that the only means to satisfy such differences is 
through a process of reasoned "trial and error" where Knowledge Management tools 
are implemented in an organisation and assessed in-situ. 
As this research has shown, the success of a Knowledge Management system is 
largely dependent upon the system supporting existing processes, rather than 
requiring change. 
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An observation that appears to be largely ignored by the majority of Knowledge 
Management literature available, and hence leads to argument and discussion as to 
whether or not Knowledge Management can deliver a tangible benefit at all. Chapter 
12 clarified this issue ftirther and throws greater light upon the highly subjective 
nature of Knowledge Management and as such, is a novel contribution to the existing 
research on this area. However, it should be remembered that the tool set developed 
in this research should be taken as proposition rather than fact and further validation 
is required. 
13.4 RECOMMENDATIONS FOR OTHER ORGANISATIONS 
After presenting a paper at a Knowledge Management conference (OLCK 2006), the 
researcher was asked to contribute a chapter to a book upon the development of 
Knowledge Management portals. This chapter is due to be published in mid 2007 and 
focuses upon the physical tools and strategies that may be used to drive innovation 
(See Parsons et al. 2007). This event is a good validation of the research itself, yet it 
also highlights that this research has considerable applicability to other organisations. 
Aside from the works application within other pharmaceutical companies, the 
commonalities with regards to innovative organisations are evident. Organisations 
such as BAE Systems and Rolls-Royce have already taken great interest in this work 
and it is envisaged that any organisation that relies upon collaboration and 
particularly external collaboration, for example managing supply chains or 
maintaining viable business relationships, would derive value frorn the tool set. 
Furthermore the models and Innovation/ Knowledge Management frameworks 
discussed in this thesis could be used as a guide to successful Knowledge 
Management implementation in other organisations. In particular the research tool of 
Chapter 5 would be valuable to other organisations as a benchmarking tool in its own 
right. The example metrics provided in Chapter 12 also highlight the need to measure 
intangibles and provide examples of how this can be achieved. These measures 
specifically measure a hitherto "grey area" and could potentially help employees gain 
recognition for work that falls outside of the traditional Balanced Scorecard metrics. 
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Finally the literature review of Chapter 3 is a valuable piece of research and reference 
m aterial in its own right for other organisations and researchers interested in 
Knowledge Management and innovation. 
13.5 RECOMMENDATIONS FOR FURTHER WORK 
The author's research has been varied and detailed and has raised a number of 
interesting research avenues: 
The first would be to investigate the implementation of the tool set and 
evaluate its success in driving innovation. From a theoretical perspective and 
limited individual trials of the components, the tool set would appear viable, 
yet it is only upon instigating such systems can the success be measured. 
Although the tool set has been designed to complement the working patterns 
of the innovative employees, it remains to be seen whether the cultural issues 
highlighted in this work will hamper its use. 
* The generic Knowledge Management tool set could be adapted to suit the 
needs of specific departments by the addition of role-specific software with a 
contextual or "pcrsonalisation" clement. This factor arose from discussions 
with Knowledge Management experts within AstraZeneca and academia, 
which concluded that although the employees may require the same sources 
of information, the contextual element surrounding that information may be 
different. 
The research model and frameworks could be adapted to suit other 
organisations and establish whether these models hold true outside of 
AstraZeneca. It is expected that the majority of the concepts will remain 
constant, although the information and knowledge flows will change in 
accordance with the organisations. The concept of luck is also an area that 
requires further investigation both within AstraZcneca and other 
organisations. 
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A conversation with a Rolls-Royce employee hinted that luck plays an 
important a role in their innovative processes, yet the extent of this is unclear. 
This research raises concerns over the reliance of pharmaceutical companies 
on acquiring external research. As a means to bypass the early and risky 
innovative stages, acquiring innovation appears to be well founded, yet it 
would appear that once an innovation is acquired then this early confirmatory 
R&D work is repeated. This is a process that costs considerable resource to 
achieve and may lead to the innovative concept being disregarded due to the 
internal politics of the company. The early R&D stages have strong financial 
drivers to both save money (through early compound attrition) and generate 
future revenue (through a viable compound). Hence, identifying the factors 
that affect the balance between attrition and success would be a valuable 
exercise and one that the Knowledge Management tool set could potentially 
support. 
e The final area for future research concerns the measurement of innovation 
throughout its life cycle. Example measures and means were suggested within 
this thesis yet the actual measurement of innovation, from innovative R&, D 
concept to marketable drug, is a long term project which is worthy of further 
research. 
13.6 OVERALL CONCLUSIONS 
In conclusion, this research has been a fascinating journey through a highly complex 
area that has yielded novel and interesting research. The principle aims of the 
research have been successfully achieved and valuable contributions to academic 
research have been made through the publication of this rescarch. Additionally, 
elements of the tool set are already in use and AstraZencca now possess a strategy to 
further their Knowledge Management work. 
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This thesis has shown that innovative practice within AstraZcneca is a complex 
process, one where employees may have the individual incentive, but require the 
organisational resource to progress their ideas. 
Without the backing of senior management, innovative ideas may fall foul at a 
number of milestones, with resource appearing as a critical success factor within the 
results chapters. If the issue of resource could be overcome, then there is also the area 
of the perceived risks and benefits of an innovative approach and its ability to comply 
with legislation, to be considered. Hence the innovative process is a careful balancing 
act of multiple factors. From the scientific perspective, to the organisational culture, 
to the financial perspective, to the information & knowledge angle amongst others, all 
the areas have a tangible affect upon the eventual success of the innovation. 
Attempting to categorise and manage all of these influences is beyond the scope of 
this work, yet this work has highlighted the factors which the employees are aware of, 
and must address on a daily basis. 
In conclusion, providing employees with the ability to weigh up these factors and 
make a reasoned decision, through the use of the Knowledge Management tool set 
will undoubtedly help to drive innovation within AstraZeneca. Certainly, therc are 
areas of AstraZeneca's innovation policy that are successful and others that are less 
so and this research has helped to determine the factors that arc crucial in driving or 
hindering these processes. Drawing in all these critical sources of knowledge, 
information and data will ultimately allow the innovator to proceed and if all goes to 
plan, help the development of life saving medical drugs. 
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APPENDIX 2 
KM TOOL SET SELECTION 
Table A2.1: Content Management Tools 
Type of Tool Example tool, Value to Representative 
rationale and key driving themes 
themes Innovation 
Storage Databases - access High 
latest information and 
data i. e. SCRIP. 
File repositories - e. g. High 
GEL & eRoom. To 
view what work has 
already occurred Innovation 
within AstraZeneca. Theme: 25 
File-servers & shared Medium 
drives - used for Knowledge Management 
informal information Theme: 19 
sharing outside of a 
defined eRoorn. 
Version control/ out of 
date problems 
however. 
Data warehouses & Medium 
data marts -- to share 
Clinical Trial results, 
useful for gaining 
credibility once a 
concept has been 
launched. 
Authoring Office suites - capture High 
the innovative concept 
i. e. Word/ PowerPoint. Innovation Theme: 24 
Desktop Publishing - High 
to promote the Knowledge 
innovative concept for Management Themes: II 
example FrontPage. 
Graphic suites & High 
multimedia tools - 
gain impact for 
presentations i. e. 
I Photoshop. I 
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Table A2.2: Knowledge Sharing Tools 
Type of Tools Example and Value to Representative 
rationale driving thernes 
innovation 
Distribution Web - essential for High 
external information 
research & access. 
Enterprise portals/ Iligh 
intranets - at present 
important but not 
essential in terms of 
innovation due to 
lack of relevant 
information. 
Extranets - important High 
with regards to Innovation Theme: 9 
tracking down 
information i. e. FDA, Knowledge Management 
PubMed. Themes: 19 
Personalisation - High 
innovators would 
prefer a system that 
"pushes" relevant 
information to them. 
Audio/video High 
streaming - 
teleconferences and 
video conferences are 
essential. 
RSS syndication - Medium 
potentially useful for 
dissemination of 
innovative concepts. 
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Table A2.2: Knowledge Sharing Tools continued 
Connectivity Internet - essential High 
for external 
information research 
& access. 
Security -a balance Medium 
is required between 
open access and 
regulatory security 
issues. 
Authentication - Medium 
essential for a secure 
environment. 
Wireless networking/ High 
mobile computing - 
facilitates mobile 
working and 
gathering of 
information at Innovation Theme: 13 
conferences or "water 
cooler talV. Knowledge 
Management 
Peer-to-peer (P2P) - High 
Theme: 20 
personal folders 
shared across a 
network would be 
useful within 
AstraZeneca to share 
innovative concepts 
quickly. 
Personalization -a High 
system that 
remembers and pulls 
information/ 
knowledge according 
to your requirements 
- similar to the R&D 
portal. 
Audio/video High 
streaming - essential 
to conduct meetings 
and attempt to rnýimic 
a face to face 
environment (as 
I much as possible). 
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Table A2.2: Knowledge Sharing Tools continued 
E-learning Interactive Low 
multimedia - 
functionality is rarely 
used within 
AstraZeneca. 
Computer-based Medium 
training- particularly Innovation Theme: 2 
applicable when 
introducing new Knowledge Management 
software tools etc. Theme: 12 
Web seminars - Medium 
potentially useful for 
disseminating 
information and 
holding discussions. 
Simulations - Low 
technique rarely used 
for innovation if at 
all. 
Learning objects - Low 
insufficient number 
of learning related 
material related to 
I innovation available. 
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Table A2.2: Knowledge Sharing Tools continued 
Collaboration Calendaring - useful High 
to locate and plan 
meetings. 
File sharing - High 
prerequisite of 
innovation and now 
supported by 
eRooms. Innovation Theme: 4 
Meeting support - High 
prerequisite of Knowledge Management 
innovation but few Theme: 18 
employees structure 
meetings effectively 
Application sharing - Iligh 
essential for 
collaboration across 
sites and globally. 
Groupware & High 
decision support 
technology - tools 
such as the Medical 
Science Knowledge 
Objects, have been 
independently shown 
to support innovative 
work. Also relevant 
when confronting 
scientific bias. 
Community Community High 
management - 
essential for a CoP to 
flourish. Innovation Thcme: 4 
Web Logs (Blogs) - Medium 
untested but hold Knowledge Management 
potential. Theme : 18 
Wikis - untested but Medium 
hold potential. 
Social Network High 
Analysis (SNA) - 
useful tool to target 
specific innovators 
with the toolset 
within AstraZeneca. 
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Table A2.2: Knowledge Sharing Tools continued 
Creativity Mind Maps/ Aledium 
Cognitive mapping - 
useful tool for Innovation Theme: 7 
scussion, 
Idea generation - High Knowledge Management 
essential to drive Theme: 17 
innovation yet more 
important at the 
individual level rather 
than the group level. 
Table A2.3: Knowledge Search & Retrieval Systems 
Type of Tools Example and Value to Representative 
rationale driving themes 
Innovation 
Search Search engines - High 
Essential for 
comparative work 
and locating 
information i. e. 
Autonomy, Kartoo 
etc. 
Search agents - Medium 
untested but holds 
potential for 
autonomous Innovation Theme: 25 
information *retrieval. 
Indexing - essential High Knowledge Management 
for rapid information Theme: II 
retrieval i. e. Luccne, 
conversion of GEL to 
XML to facilitate 
indexing. 
Glossaries High 
Important to allow 
cross site and global 
collaboration 
Thesauri - Important High 
to allow cross site 
and global 
collaboration i. e. 
I WordNet. 
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Table A2.3: Knowledge Search & Retrieval Systems continued 
Search Taxonomies/ High 
ontologies - Highly 
important for linking 
disparate 
information, 
knowledge, 
employees and' 
creating riiles to 
manage information. Innovation Theme: 25 
Collaborative Medium 
filtering - untested Knowledge Management 
but holds potential Theme: II 
for - reducing the 
notion of information 
overload. 
The Semantic Web - High 
untdsted but widely 
used in similar 
pharmaceutical 
orgzknisations such as 
Pfizer. 
Analytics Querying more Low 
applicable to data 
management and 
Discovqry. 
Reporting Low 
AstraZeneca use 
Business Objects to 
report data but little 
use for innovative Innovation Theme: 23 
work. 
Multi-dimensional Aledium Knowledge Management 
analysis - the ability Theme: 16 
to interrogate 
multiple sources of 
data (i. e. biorharkcr 
data) could prove 
useful. 
On-line analytical Aledium 
processing - tiseful 
for validating an 
innovati've strategy 
such as clinical trial 
data. 
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TabIe A2.3: Knowledge Search & Retrieval Systems continued 
Workflow Process modelling - High 
essential to 
understand where and 
how the innovation 
should be managed 
(e. g. within the 3D 
grid of AstraZeneca). Innovation Theme: 17 
Process engines - Medium 
backend server Knowledge Management 
software that co- Theme: 21 
ordinates user 
requests, useful for 
semantic web and 
rule based 
information filtering 
ap fications. 
Data mining Statistical techniques Medium 
- applicable only 
once an innovation 
has been tested, 
however would be 
useful to gain Innovation Theme: IS 
credibility by 
analysing existing Knowledge Management 
similar work i. e. "me Theme: I 
too" or "fast 
followee'drugs. 
Neural networks - Medium 
untested but hold 
potential. 
Neural networks - Medium 
untested but hold 
I potential. I 
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Table A2.3: Knowledge Search & Retrieval Systems continued 
Text mining Semantic analysis - High 
important to explore 
large bodies of 
unstructured text. 
Bayesian inference - Medium 
possible use of 
Baycsian networks to Innovation Theme: 
compare innovativc 12 
drugs. 
Natural language Medium Knowledge 
processing (NLP) - Management 
untested, but may be Theme: I 
important when 
extracting machine 
readable knowledge 
from sources across 
AstraZeneca. 
Web mining Collaborative profiling High 
- important means of 
identifying like minded 
individuals and 
progressing 
collaborative groups. 
Intelligent agents - Medium Innovation Theme: 
untested but potentially 25 
useful for uncovering 
knowledge, Knowledge 
information & data Management 
across multiple Theme: 5 
sources. 
Visualization 2D and 3D navigation Ifigh 
- useful means of 
navigating disparate 
information and Innovation Thcmc: 5 
knowledge sources 
across AstraZcncca. Knowledge 
Knowledge/ Ifigh Management 
geographic mapping - Theme: 5 
useful means of 
identifying disparate 
information and 
knowledge sources 
I across AstraZcncca. I 
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Table A2.3: Knowledge Search & Retrieval Systems continued 
Organization Ontology/ Taxonomy Iligh 
development - essential 
for AstraZcncca to 
manage its sources of 
information and 
knowledge. 
Ontology/ Taxonomy High 
acquisition - also 
essential as this 
provides new links Innovation Theme: 3 
between concepts i. e. 
using MESH or Knowledge 
BioWisdom. Management 
Glossaries - Important Ifigh Theme: 9 
to allow cross site and 
global collaboration. 
Thesauri - Important to High 
allow cross site and 
global collaboration i. e., 
WordNet. 
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Table A2.3: Knowledge Search & Retrieval Systems continued 
Reasoning Rule-based expert Medium 
systems - use within 
innovation is unknown 
at present but holds 
potential for future 
work. 
Case-based reasoning - Medium 
use within innovation 
is unknown at present 
but holds potential for 
future work. 
Knowledge-bases/ High 
Knowledge Objects - Innovation Theme: 3 
use within innovation 
is currently being Knowledge 
tested, holds high Management Theme: 
promise. 7 
Machine learning - Medium 
within innovation is 
unknown at present but 
holds potential for 
future work. 
Fuzzy logic - Medium 
application within 
innovation is unknown 
at present but holds 
potential for future 
work. 
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APPENDIX 3 
EXPERIMENTAL MEDICINE 
DISCUSSION FORUM SPECIFICATION 
1.0 INTRODUCTION 
The following report aims to clarify the user requirements of the new Experimental 
Medicine (EM) portal forum. The study is based upon the pilot KM scheme within 
Charnwood EM Department and has gone some way to providing conclusive evidence 
that the EM department has benefited from the use of a threaded message discussion 
group. 
As part of the evolution of Knowledge Management within AstraZeneca, a strategy has 
been outlined which aims to replace the current simple threaded message forum with a 
robust alternative which satisfies the future scope and functional requirements laid out 
within this document. This report firstly concentrates on the novel idea of dynamic 
categorisation, before continuing onto the required functionality of the new forum. These 
requirements were uncovered using ongoing interviews and investigative techniques with 
the staff of the EM department. A finiher final section then outlines a brief synopsis of 
the technology required to fulfil the forums needs. 
2.0 A BACKGROUND TO KM 
The advent of KM has introduced a wide range of strategies and aligned methodologies 
which all proclaim to be the definitive answer to knowledge sharing and creation within 
the business environment. Of these the community-based approach is widely rccognised 
as one of the most valuable adaptations, focusing upon encouraging dialogue and 
communication through the establishment of social networks (Brown, & Duguid, 1991). 
Communities of Practice allow information to be informally shared between colleagues, 
thus encouraging the creation and interaction of knowledge and allowing the reuse of 
existing knowledge and information inherent within the organisation. 
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It is the ability of these networks to utilise asynchronous electronic communication, 
which is their key to success. The arrival and proliferation of the virtual community, a 
medium that undeniably increases knowledge creation (Jordan & Jones, 1997; Nonaka, 
1994; Alavi & Leidner, 2001), has provided a sound foundation for the introduction of a 
KM scheme within the EM department. Koh & Kim (2004) believe their success rests 
upon encouraging these types of interactions: 
* Informal networks 
* Person to Person contact 
9 Encouraged dialogue 
e They bypass traditional hierarchical channels 
4, Information is distributed electronically thus saving time and resource 
It is fair to say that the true use of the Community of Practice has been within the e- 
business arena, they are widely used to increase customer interaction and create a 
business to customer relationship with the site (Hagel & Armstrong, 1997). The 
Community of Practice employed in a similar manner within the EM dcpartmcnt, yet is a 
closed community, where membership is static and new employees are added as they 
start work. It is evident that the driving factors are similar though; a commercial 
community aims to induce value from customer interaction, while the EM community 
induces value through staff-to-staff interaction. The remit of the forum is to provide the 
means to discuss topics and information based upon scientific mattcrs, these discussions 
can then be carried forward to a meeting thus saving valuable facc-to-facc meeting time 
by ensuring all parties have prior exposure to the topics to be discussed. 
The report will deal with aspects of the design and future specification, which will allow 
a greater sense of interaction and information exchange to be carried out. A key point of 
the future design is the offer of a concept labelled as Dynamic Categorisation. The 
concept and rationale behind the idea will be discussed in the following section. 
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3.0 CATEGORISATION AND DYNAMIC CATEGORISATION 
The proposal for the new EM forum includes a novel approach to the current guise of the 
threaded message forum, in that they will offer the opportunity to view the forum without 
static categorisation. A typical web based forum offers distinct categories under which 
users post threads relating to that particular field or topic. Due to the scale of the 
proposed forum and the scope of the users work, the solution of Dynamic Categorisation 
was suggested by Dr Holger Adelmann. As membership within the Global EM groups 
forum is expected to reach approximately 450 users and with such a large user base, the 
potential problems in assigning categories and determining which area or field a post 
should sit under was deemed to be too great. Although forums of this size and larger 
operate within many businesses, this approach may offer a greater return on use and 
value than a traditional view. 
The approach is certainly innovative and an outline of the proposed model is described as 
such. The key idea is that threads are posted onto one main forum, and are not 
compartmentalised by categorisation. Hence the task of extracting meaningful 
information from the forum relies upon the use of an intelligent search facility, which in 
turn is linked to a structured ontology. Hence the design and deployment of these areas 
are crucial, as the failure to correctly design and develop such a system will negate the 
appreciated benefits of the forum. When a user searches for a specific term the ontology 
provides "abstract categorisation" and returns all the týreads linked to the searched term. 
The idea allows the search facility to return threads based upon a single keyword. Tcrms 
that are linked via the ontology to the keyword are located in the titles of the threads and 
duly returned to the user. This allows the return of higher-level conccpts and cnsures the 
results returned reflect the context of the search term. 
The reality and success of the theory rests in the correct development of the ontology and 
the welcome screen, with no visual clue to guide the user through the forum the user must 
have a distinct request that he/ she requires answering or wishes to answer. This has 
obvious drawbacks. 
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A common failing of threaded forums, and one which was seen in the previous EM 
incarnation, is the shielding of information, presenting the user with a search facility and 
nothing else effectively hides all the information from the user. The current model of a 
thread-based forum is particularly successful because the information contained within 
the forum is evident, thread titles allow a browsing user to visualise the information 
within the forum quickly and quickly navigate to their desired topics. However the 
applicability of dynamic categorisation is that it prevents the user being confronted with 
hundreds of threads and hence being overwhelmed by the lack of order and purpose of 
the threads. A large business forum, such as AstraZeneca intranet forums, may contain 
upwards of a thousand threads. Upon accessing the forum the user has little choice but to 
browse or search the forum using a free text facility, to attempt to locate the information 
required. 
A point, which should be carefully considered, is that the average user browses a forum. 
They have no specific goal or information in mind, instead they access the forum to gain 
knowledge and answer posts that are relevant to their field. Prior research and other 
similar case study research by Preece (2001), illustrates that this forms a major part of 
forum participation. Hence without the display of these posts and a notion of where 
relevant posts may lay without specific searching, a user presented with a blank canvas or 
unstructured posts will quickly lose heart and quit the forum. In this sense it is imperative 
to apply a structure to the forum, as without some form of categorisation the users will be 
unable to locate information and comment on posts that may overlap their fields of 
expertise. The key idea is that users must be able to locate and comment upon posts that 
they hold knowledge on, the phrase "we don't know what we know " is applicable here. 
Often people browse and have an area of interest outside of their work remit and these are 
the actions that build a successful community and allow knowledge to be generated. A 
solution to this problem would be the personalisation of the forum views for each user. 
Initially with a standard structure the user's interests and search patterns would generate 
their areas of interest and hence provide the user with a structured and tailored view. This 
approach relies upon: 
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The user declaring their areas of interest- an idea, which could be linked to the 
email expert location system which is currently being developed by 
Loughborough University 
e The ontology backed search returning worthwhile results and making the correct 
links between terminology and fields 
A degree of intelligence within the interaction of the search/ indexer engine, 
which in essence fuses terms together when provided by users and notices 
inferred terminology 
An intermediary answer may be to provide both a standard or limited view of the forum 
and a view that focuses upon dynamic categorisation. This could be accomplished using 
existing technology and supplement the dynamic search page. Adding this fail safe view 
to the novel search page would ensure that users would still utilise the system. After all, it 
must be noted that the traditional threaded discussion forum offers a good rate of success. 
However, once a user had gained in experience and built up areas of interest provided by 
the search/ email system the dynamic page would provide an imminently more tailored 
view. This view would reflect both the users' current interests and posts that may interest 
the user, through a process of inferred categorisation from the search/ indexer. 
The area of dynamic categorisation is innovative and one which may require thorough 
testing and training within a production environment. Though I believe that with 
refinement and if used in conjunction with a standard view the results could be 
worthwhile. The following sections continue to outline some of the more standard 
technical and usability functionality that we would expect to see in a virtual community 
setting. 
4.0 FORUM REQUIREMENTS 
Ilis information has been obtained using unstructured interviews conducted over the 
period of June 2003 to March 2004; the information is based upon 14 current users of the 
EM forum and other staff who are new to both the department and the forum. 
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It is important to recognise that the forum must be operated in conjunction with the 
current structured methodology of knowledge creation and capture present within the 
department. (see Adelmarm et al., 2003) Many aspects relate directly to this methodology 
although these requirements could be tailored to reflect the needs of an altered 
methodology or stand alone community. 
4.1 HIGH LEVEL REQUIREMENTS 
These points outline the basis of the forum. While many appear obvious; highlighting 
them allows each aspect to be taken into account when looking at a replacement forum 
tool. 
The system must provide structured information exchange to be used for the 
creation and retention of relevant knowledge. 
9 The relevant information should be easily identifiable as at present the 
information is often obscured 
* 'Dynamic Categorisation' should be offered 
9 The server must be reliable in order to enhance the site usability and provide faith 
to the users that the system is being supported and backed 
The portal should be standardised with other AstraZeneca sites to maintain a 
consistent 'look and feel' to the intranet, the Clinical PKD or the PKT portal are 
proposed as worthy models 
*A clean uncluttered interface must be used- this is highly important when dealing 
with users who are not technologically minded 
* Time for compulsory basic training must be assigned combined with a dedicated 
support channel 
* Training documents should be available online, ranging from basic to advanced 
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* The system must build upon the pilot study and continue to promote the positive 
aspects previously identified in the separate report 
* The system should provide means for qualitative and quantitative metrics in order 
to track the usability and effectiveness of the forum 
e The forum engine should be modular and use an agreed standard framework so 
that it can easily be incorporated within sites such as the R&D portal. 
4.2 FUNCTIONALITY REQUIREMENTS 
Ile following points outline a baseline measure of the new forums functionality, these 
factors though not exhaustive, are key points that have been discussed and raised with 
both the users and developers. 
4.2.1 FORUM ACCESS AND IDENTIFICATION 
The process of forum access should be simple to utilise for less technologically 
inclined individuals- this should be linked to Windows uscrnames as at present 
Automated attachment of user details when replying and summarising posts, this 
could included a personalised tag, which lists name and contact details such as 
email, telephone and job details. This would be important for obscure usemamcs 
and to gain the context of the post 
Personalisation of the portal and forum should be provided, although maintaining 
a standard look and feel. This may list recent posts first, automatically highlight 
relevant threads and display topics that mirror previous searches. 
4.2.2 POSTING THREADS 
Posting threads should be easily achieved and replying to threads should be self- 
explanatory. The icons used must be evident and visually striking; the current 
forum is an example of poor visual design with these crucial factors being hidden 
within other similar options 
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When posting a thread a simple drop down menu or graphical menu should 
display a choice of post types to the user, this would be Question, Information, 
Comment or Summary. The choice should be mandatory and when replying the 
[RE] default must not be used, users must choose from the list again. Most if not 
all, current forums utilise the [RE] as a default reply so this would have to be 
addressed at the development stage 
Poýts could be colour coded in terms of relevance when posted (see Adelmann et 
al. (2003) for further details). Ideally this would be via a menu and not via I ITM L 
code as is currently used. A similar schema is in use within other AstraZcneca 
forums, and when coupled with the use of the methodology it provides a powerful 
additional visual aid to knowledge creation. However the use of icons may be 
more suited in terms of accessibility issues. 
A menu of commonly used and controlled keywords should be available when 
compiling threads. These should be compliant with the established AZ glossary 
and linked to the terminology of the underlying ontology. 
Users would like the ability to post graphics within the text; this would include 
graphs and figures, which would prove useful when explaining difficult concepts 
within the prose. Drawbacks would include size, formatting (an XML based 
forum would need SVG) and their overuse. Ideally the forum would be able to 
display images and figures created using Microsoft products- all users ufiHse 
these products, so an automated process of conversion or at the least an easy step 
to integrate these should be included. Potentially this could be linked to the 
Clipboard on a drag/drop basis, similar to the E-Room functionality. 
When making a post, the forum should return to the post to show the user what 
has been added- some forums do this while others default to the homepage. 
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Posts should have a rating of importance to them, similar to the exclamation and 
flag used in the MS Outlook products for highlighting urgent threads or more 
mundane topics. When using the dynamic view, these could be displayed 
prominently to the user regardless of the term searched for. This could be tied 
into the proposed expert locator system so as to alert experts whenever a relevant 
critical or important message is posted. 
4.2.3 POSTING LINKS 
Reference papers should be easily introduced into the forum, either as links, 
whole documents or as key parts of text. The ideal would be to link this to an 
existing citation management system such as Reference Manager or Ref Works. 
Users who frequently utilise online medical texts would like the ability to copy 
and paste multiple links into a thread, at present the clipboard functionality of the 
current forum only holds one link. 
4.2.4 SUMMARISING THREADS 
Users requested the ability to automatically export the message information to a 
Word document or PowerPoint file in plain text. This would allow users to easily 
manipulate the information within the forum with a tool they are familiar with. A 
further option would be to automatically export text to a defined template if 
needed. Currently users must copy then paste all information from the web page, 
this inevitably leads to users highlighting extraneous information and the IITML 
formatting. 
e Notification when a summary is completed. At present the system flags when a 
new post have been added, but does not give a purpose or insight into the nature 
of the posts. The Shell oil company use an email newsletter, which summariscs all 
posts to all users at the end of each week. A similar scheme could cmail uscrs 
when a relevant post is summarised. Once again this would be tied in with 
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personalisation of the forum and users who search or post in particular areas, 
would receive summary details of other relevant posts. 
4.2.5 SEARCH FUNCTIONALITY 
* The bare minimum would be a free text search, with the opportunity to search by 
keywords. 
An ontology-linked search to provide context to the search and some degree of 
intelligence, would be preferable and is essential to allow the aspect of dynamic 
categorisation. The search would be linked to RDF/ XML or similar underlying 
metadata to allow complex queries. 
The search capability would allow the concurrent searching of multiple forums, in 
the event of additional forums being made available within AZ. The current idea 
of a single forum should be utilised at present, but there may be links between 
other forums of similar nature in the future. 
Search results should be represented graphically with links between results. The 
tools Kartoo and Spectacle were deemed an ideal vehicle due to the ability of the 
technology to provide logical links between results, without pre-cmpting the user 
to follow a certain path. Representing the results as a Topic Map allows 
convenient navigation through a large return of interesting results. 
* Infonnation should be colour coded in tenns of relevance when searched, it is 
essential that a rating system can be utilised to provide relevance to the results. 
Threads should be ranked and displayed according to their relevance to the 
original query; this could be linked to the relative site of key terms within the 
ontology. 
A brief synopsis of the thread should be included with the results, which could be 
hidden if not required. Kartoo's ability to display this when users hover over a 
link was particularly welcomed. 
403 
App! ndix 3- Forum Specification 
43 MISCELLANEOUS REQUIREMENTS 
RSS news feeds may be incorporated into the view of the forum; these may link 
to similar areas and threads. 
Fresh posts should be highlighted at all times, until the user reads them- the 
ability to flag posts of interest could also be considered. These may be threads 
that detail answers or require answering by the user at a later date when more 
information is available. These threads could be categorised (e. g. "Important 
answer! " or "Return to later") and highlighted within the personalised space of the 
forum view 
Intelligent web agents could be used to crawl the web and return information/ 
links that are relevant to posted threads and discussions 
Support must be provided to the users and the staff who run the system, cither 
extemally or intemally. 
4.4 TECHNOLOGICAL REQUIREMENTS 
The forum must be based on an underlying architecture that provides the degree 
of scalability and stability to allow its use in the future. The current contender is 
NIS SQL Server 2000 and as such, the forum is based upon the use of this 
database 
0 Stability is a key factor 
The forum must be supported by AstraZcneca IS, this will involve utilising a 
package that runs on a Windows platform 
e asp. net using VB was highlighted as the preferred web architecture 
Software that requires user licences may cost a large amount. The potential for 
expansion is considerable so this must be reflected in the cost of the forum 
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Intelligent search facility, fuzzy searches and the ability to learn from user search 
terms 
e The source code should be available for development and refinement 
9 Documentation of the source and build are important to allow furthcr 
development work and effective version control 
5.0 CONCLUSIONS 
The report has set out a specification based on the requirements of the Chamwood EM 
staff and as such can be used to provide a system which reflects the work flow and 
business processes that the staff utilise on a daily basis. The requirements are designed to 
complement existing measures rather than simply replace them and should be used in 
conjunction with a KM methodology to achieve the greatest benefit. The use of Dynamic 
Categorisation is curTently being developed and should be a positive benefit over the 
older system of categorisation. Indeed this will be the first time a structured ontology has 
been used to provide intelligent information searching within EM. If successful the 
technology and KM methodology could be implemented in a wide variety of similar 
areas over AZ, which would allow the company to benefit as a whole. 
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APPENDIX 4 
EXPERIMENTAL MEDICINE GLOBAL FORUM 
BUSINESS LOGIC AND DESIGN 
The following is an excerpt from a report commissioned by AstraZcneca in 
January 2005 to investigate the use of "Dynamic Categorisation" for a threaded 
discussion forum. The primary concept and software associated with "Dynamic 
Categorisation" was created by Dr Holger Adelmann of AstraZeneca and this 
report was commissioned to explain the rationale behind it. The researcher did 
however; contribute discussion and ideas for the concept design and how the 
concept could be exploited within AstraZeneca. 
1.0 INTRODUCTION 
The use of Knowledge Management within Experimental Medicine (EM), 
AstraZeneca Charnwood has led to the important steps of knowledge sharing, 
capture and reuse throughout the department. In order to follow on from these 
successes we have carefully designed and detailed an enhanced knowledge based 
tool to supersede the current EM Knowledge Community. The scope of this report 
is to analyse the business rationale and logic for introducing a new forum, explore 
the functionality and processes which underpin and justify the new forums design. 
This article is expected to evolve with the forum over time, and as such will 
initially capture the design principles, that have led to the novel use of an 
ontology and dynamic categorisation to yield a design which is better suited to 
knowledge generation than the previous incarnate. 
2.0 KNOWLEDGE MANAGEMENT WITHIN EXPERIMENTAL 
MEDICINE 
2.1 APPLYING KNOWLEDGE MANAGEMENT 
Knowledge Management (KM) is now firmly established within the Experimental 
Medicine Department and considerable interest is being generated within 
AstraZeneca and Clinical in particular. 
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In order to explain the success of KM within Experimental Medicine, a detailed 
case study was conducted to explore the staff s perception of KM and how the 
science may benefit their working roles. The case study covered a wide variety of 
experience and job roles and exposed a number of interesting findings which have 
been analysed and discussed to produce the prototype forum. 
At present the EM Department utilises a simple threaded message board that since 
its inception has been plagued by both design and technical issues. The forum 
offers an outdated interface that is far from user friendly and the acts of extracting 
worthwhile information from the forum are often too specialised for the average 
user. A detailed examination of the role and success of the forum highlighted a 
number of failings which could unfortunately only be addressed by the 
development of a suitable replacement. However, it must be noted that the forum 
displayed a remarkable ability to generate and retain information, regardless of the 
interface. The staff felt the forum was providing a tangible benefit to the 
company. 
This is due to the fact that AstraZeneca appears to naturally foster an atmosphere 
which is conducive to knowledge sharing and with the introduction of a suitable 
tool this environment can be encouraged. Evidently we must strive to retain the 
benefit and progress so far achieved, while introducing a system which truly 
reflects the business needs and usability concerns of the EM staff. The new design 
takes account of these failings and when used with a tailored Knowledge 
Management methodology, can actively create and promote a knowledge rich 
environment where users can freely interact and apply their tacit knowledge to 
common problem areas. 
2.2 THE R&D PORTAL PROJECT AND THE KAI FORUMS ROLE 
The use of a Knowledge Management ethos and principle has been combincd with 
the traditional aspects of Information Management, to yield an cxciting 
development within AstraZeneca. The R&D Portal Project stems from the 
companies need to consolidate the vast and ever increasing amounts of 
unstructured data and information which has been collatcd as part of the daily 
work of the company. 
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The proposal is to provide an integrated enterprise portal which will become the 
universal interface for staff to access information and knowledge. The role of the 
portal has evolved from one of a static content management system, to a dynamic 
and responsive environment which encourages interaction and information 
exchange. Knowledge creation is encouraged through the availability of relevant 
documents and the relevant people. The EM KM project is expected to fit within 
the realms of both a knowledge facilitating environment and a knowledge store. 
Initially the forum will occupy the role of a think tank for ideas and practice. For 
instance a physician wanting to know specific details of safety constraints relating 
to a developmental drug would post their question within the forum. Experts 
located across the company would then respond and a web based discussion 
would occur. This would have the probable outcome of a consensus on existing 
data and information regarding the topics. At the minimum the discussion would 
identify that the participants were experts within the field and serve to publicise 
this within the company. The creation of informal networks such as this, allows 
like minded individuals spread over geographically distinct regions to converse 
freely and form alliances. 
2.3 E-ROOM DISCUSSION FUNCTIONALITY 
The R&D portal project is based on a content management system provided by 
Documenturn. This incorporates a variety of Information, Knowledge and Project 
Management tools including eRoom. The remit of the KM forum is essentially 
complementary in operation and aim. 
The eRoom discussion module allows a closed group of staff to gather and discuss 
a specific project area. The fundamental provision of eRoom is to provide a closcd 
envirom-nent where attendees are invited to discuss areas of concern. Related 
documents and folders can be created and hence will prove a very valuable tool 
where project members can collaborate independently of geography and time 
constraints. The KM Forum on the other hand, is very much an open system- 
input is invited from all and membership is not reserved to specific project 
members. 
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In this way we invite external collaboration and encourage the dissemination of 
knowledge and information across the company, as overlapping issues are 
common within drug development and innovation. The functionality of the system 
does show similarities however, yet the eRoom module is rather limited in scope 
beyond that of a simple nested discussion forum. The key difference in the forum 
is the presentation and utilisation of the data sources. The KM Forum utilises a 
novel concept which has evolved from research with the Experimental Medicinc 
department, hence it specifically meets the needs of the pharmaceutical 
community. 
The following section provides an overview and explanation of the novel concepts 
and associated thinking which forms the backbone of the KM Forum. 
3.0 DESIGN OVERVIEW 
The following section discusses the key points of the forum which differ in 
functionality to a normal threaded message forum. It also provides an insight into 
the nature of Dynamic Categorisatioý and the possible further application of this 
approach. 
3.1 DYNAMIC CATEGORISATION 
The most notable innovation is the idea of Dynamic Categorisation developed by 
Dr Holger Adelmann. The concept is unique and seeks to allow the user to tailor 
their view point of the forum according to their areas of interest. All available 
commercial forums centre upon the use of categories to define and manage the 
threads and subjects. The use of categories often causes threads to be assigned to 
incorrect categories. Users may be unsure of where to post a thread if it overlaps 
many subject areas and this often leads to problems with lack of response to posts. 
Users who place a thread in an incorrect category effectively "pigeon hole" their 
thread and a user, who could answer such posts, may fail to visit the category 
resulting in the thread going unanswered. This is a common occurrence and one 
which can be avoided by providing the categories "on the fly" according to the 
preferences and request of the user. 
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A further advantage is the avoidance of the extremely complicated and crucial 
assignment of categories. Within our model we negate the need to reassign 
threads and reorder incorrectly placed threads. The need to continuously check 
and reiterate threads dependent on content is automatically handled by the design, 
so as to supply a list of relevant threads which enable user based discussions 
according to their knowledge and interests. 
In order for the system to function correctly we must ensure that the user is aware 
of the threads that are related to their subject speciality and needs. A user submits 
a keyword and additional supporting information to an intelligent search engine 
which then returns the required categories. 
The engine achieves this by linking with a structured ontology which in this case 
is designed to be applicable to the areas and fields of AstraZeneca and in 
particular the Experimental Medicine Department. The following section covers 
the individual steps which must occur to provide the viewer with a dynamic view 
of the foriun categories. 
4.0 KM FORUM PROCESS OVERVIEW 
The individual principles of the processes are outlined in die Workflow Map 
(Figure 1) and each stage is covered in greater detail in the following section: 
1. Keyword 
If the term is not in the ontology 
2. Stem then the Wordnet search is used 
3. Search 
Word found? 4. Remm 
5. Stem 
Wordnet 
6. Lucene Index 
Select 
7. Return Relevant 
B. Dynamic 
Figure 1: Workflow Map for the forum 
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1. Keyword Search 
The forum is designed to complement and assist users within clinical to locate and 
share information and knowledge on specific subjects rclating to their work. A 
user must enter a keyword or phrase which is indicative of their work, for 
example this may be LFT or Liver Function Test. Hyphenated words are also 
accommodated, though at present phrases asking questions may lead to 
complications. 
2. Snowball Analyser 
The words are initially sternmed using the functionality offered by the Luccne 
Snowball Analyser, this has the effect of reducing words to their constituent parts 
using a specific algorithm. The Snowball sternmer is an amalgamation of 
available sternmers and allows words to be reduced to their constituent parts: the 
stem and the suffix. A stemmed word is the output from the stemmer. The 
stemmed word will have letters removed from the right and these will then be 
presented to the Java based Lucene search engine. An example of a phrase may be 
"conducting a clinical trial" and this is stenuned to "conduct-ing a clinic-al trial". 
Hence the words conduct*, a clinical* and trial will be passed to the next stage 
which is a check against the ontology. For example the search term "ECG" would 
result in the following concepts being stemmed to these constituent parts by the 
Snowball Analyser as illustrated in Fig. 2. 
Eclysis + ECO Analysis + dECG + Analysis + ECO 
Electrocardiogram + hERG + OT + OTC 
Snowball Analyser 
eclysi + ecg +analysi + decg + 
electrocardiogram + hcrg + Qt + Qtc 
Figure 2: String input and stenuried output 
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The initial keyword undergoes a number of checks, the first of which is against 
the ontology. If the search term(s) are within the ontology then the word is 
stemmed and the relevant terms passed to the ontology search. 
However if the terms are not present within the ontology, then a web service 
based using the open source WordNet Java library is invoked. The result is a 
dictionary lookup of the user's keyword against a standard dictionary. Words 
relating to the term are displayed and the user asked to chose a relevant "sense" 
from the presented list 
For example this sets the context -of words such as "tissue" to a medical setting. 
The selected term is then stemmed and searched against the ontology and if found, 
the cycle continues. If a related term in the ontology is not found, then the default 
action at present is to notify the user that "no relevant areas exist and the ontology 
should be updated to reflect this". 
User Search Term: 
"Clinical Test" 
"Not found in Ontology! " 
WordNet Search Returns: "Clinical Trial" 
User selects "Clinical 
Trial" 
Figure 3: WordNet Search 
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3. Ontology Search 
The stemmed words are passed to the KAON Web Service, this is a small Java 
program which operates independently of the asp. net forum and handles requests 
for terminology and ontology lookup. The program was written using the frccly 
available KAON APIs and is documented within the source code. The service 
handles requests via SOAP messages which results in the output of related terms 
to the original keywords entered by the user. Hence from a keyword of ECO the 
following terms are derived, including the related synonyms and sub concepts. 
Keyword: ECO 
QT, QTc, KERG II ECG Analysis, dECG Analysis II ECO, Electrocardiogram 
Retums Related 
Figure 4: The "ECG" keyword returns the related sub concepts and synonyms 
The user's keyword, which in this case is ECG is then passed onto the KAON 
web service, from where related terminology, sub concepts and synonyms are 
retrieved and passed on down the chain. 
4. Return Sub concepts 
KAON is a powerful open source ontology based tool which allows the creation 
and visualisation of a structured ontology. The various higher level concepts and 
sub concepts can be linked and designed to rcflect the logical relationships and 
thought process behind the subject. This approach is particularly uscful in this 
scenario as we reveal the knowledge path a user of the forum would follow. 
A single keyword or key phrase returns words and concepts which are linked. 
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These reflect the existing business processes of the company by including disease 
areas and target areas. By applying the structure at this level we can be assured of 
returning useful information and knowledge to the user when they request posts 
on a specific thread. For instance the keyword ECG will return the synonym 
Electrocardiogram and QT amongst others, QT is strongly linked to safety within 
clinical trials so from a simple starting point we see that a web of inter-rclatcd 
topics emerges offering the user a high chance of locating the required 
knowledge. Figure 4 demonstrates the high level concepts which link from 
"Tissue" and will return areas of interest that are applicable to development 
involving tissue research. 
POP POM Marker 
Marker 
T Tissue issue 
Cell Recruitment Disease 
Figure 5: Visualised Ontology Concepts 
5. Stem Words 
This step is identical in operation to Step 2 and serves to ensure that the search 
terms are stemmed to provide the highest possible return on the initial quM. T'his 
stages results in a comma delimited string. 
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6. Lucene Index Search 
The sternmed concepts and related sub concepts are then passed to Lucene in the 
form of a string, and the index files of Lucene checked against the keywords. 
Lucene is extremely quick at searching documents for key terms and is designed 
to search and index data in the order of millions of documents. This was a crucial 
factor in settling upon Lucene as the chosen search engine. We believe this aspect 
will not be tested by the new forum regardless of the size and growth of the 
forum. A further factor is the ability of Lucene to allow upwards of 250 search 
terms to be searched concurrently when supplied in a comma delimited format. 
Lucene is based on a collection of Java libraries and has been compiled to run as a 
web service utilising SOAP messages. 
By presenting the search functionality as a web service we have allowed the 
search capability to be open to external sites which require an ontology based 
search. Within the present design, Lucene is configured to search XML files as 
the native data store for the forum messages and threads. Although this can easily 
be adapted to search many other file formats including NIS Word, pdf and text 
based files. The potential exists to implement a database driven search through a 
JDBC interface and this is currently being explored as a possible data storage 
solution. 
7. Return Relevant Tbreads 
Lucene returns the file pointer of the relevant threads and these are then passed 
onto asp. net C# code, which then forms the categories governed by the input 
terms. 
8. Dyn=ic Categorisation 
The final stage in the process returns the threads in a structured view by providing 
recent and relevant threads first and related threads in an ordered view, sortcd by 
date and time. The final view of the data is still under development and is 
expected to evolve as users request and functionality is improved to offcr a 
rounded solution. 
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5.0 FUTURE WORK AND CONCLUSION 
The development of the forum is progressing well and the backbone of the forum 
exists within a reliable and ordered code. It is estimated that a prototype will be 
introduced within September 2004 that will utilise the existing ontology driven 
system with a revamped asp. net backend. Work is currently being undertaken to 
utilise C# as the preferred development language so as to provide a stable and 
reusable modular forum. A key facet of the work is the enhanced search 
functionality provided by the use of a relevant ontology to retrieve results. In 
depth discussion has occurred which has concluded that this functionality could 
be applied to other file stores such as MS SQL data stores, Word and pdf 
documents and other common formats. 
In conclusion the KM Forum is an exciting and unique development. Which 
shows substantial promise in fulfilling the ultimate aim of providing a structured 
area for knowledge reuse, information exchange and knowledge creation. 
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APPENDIX 5 
KNOWLEDGE MAPPING 
The following is an excerpt from a report commissioned by AstraZeneca in June 
2005 to investigate the use of knowledge mapping for decision capture. 
1.0 JýNOWLEDGE MAPPING FOR PHARMACEUTICAL INNOVATION 
There are a number of potentially interesting and valuable areas which may be 
mapped by the use of a knowledge led Case Based Reasoning template. When 
attempting to map non-linear processes such as the Piggybacking project, it is wise to 
uncover aspects that directly relate to resource and process management; and the 
novel practices which have led to the key decisions. 
The principle benefit of undertaking the mapping process is that it allows a review of 
the work carried out with the key actors. It is rare within industry for companies to 
conduct such study (Newell ct al. 2002), providing data on unorthodox processes and 
the need of employees to bypass established guidelines in order to complete the 
project. AstraZeneca currently lacks a formulised reflective process when analysing 
project work and the Knowledge Map should aim to uncover the extent of 
organisational and individual based learning. Until now, there was no formal template 
for organisational knowledge capture. Hence valuable knowledge concerning the 
knowledge capabilities of the key players within a defined process can be captured. 
The outcomes of using this template may allow an individual to learn from a project 
and for the organisation to learn of the project. Knowledge mapping will also allow 
individuals skills to be mapped to similar projects once identified. 
2.0 QUESTIONS FOR KNOWLEDGE MAPPING 
Mapping a project can provide an extra level of validity to current AstraZcneca 
processes. A knowledge map may be formed by asking questions such as: 
* Are there certain areas where AZ processes negatively impact upon a project? 
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9 Are project teams offered sufficient resource to reflect upon their work? Or is 
reflection simply not an option? 
* Are deadlines too stringent or do they push a team to fulfil its obligations? 
Are people actively producing new knowledge and innovation? Or are they 
simply rehashing established procedures in a "cut and paste" style? 
* What do we do differently? Is there value in this? 
What do people do best? Are their skills unique? Can we capturc the 
knowledge of skills for future reference? 
* Do we see examples of nested collaborative learning? 
* Do different levels of team interactions stimulate learning and knowlcdge 
interactions throughout the entire project? 
* What are the power relations and hierarchical layers within the projects? flow 
are they affecting the progress and outcome? 
o What management pressure exists? 
e Do we observe vested interests? 
Are there key players or process champions who are essential to drive a 
process forward and create the required knowledge? 
o What skills have we learnt? Are these skills useful and can they and the 
employee be applied elsewhere in similar areas? 
These questions ask what occurs inside a project and can be used to assess the 
knowledge outputs of a project, regardless of whether it meets expectations. In the 
case of the Piggybacking project it maybe that the difficulty in running the two 
projects side by side, was due to the lack of a legitimatiscd business processes that 
facilitate this process. 
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Employees within the projects can adapt and absorb new information in order to 
achieve this task. Yet in this case the established guidelines and time constraints may 
have hindered this process and hence a potentially viable and cost reducing 
methodology was not utilised. The piggybacking example gave the following 
indicators of what areas should be assessed when developing a Knowledge Map: 
Key Information to capture: 
e Project keyword - author, departments, employees involved, dates etc 
9 Map of the process - where and why are the key steps occurring? 
Capture eventual outcome with regards to: 
* Pending i9sues 
9 Best/ Worst Practice 
9 Commonality of assumptions across projects 
* Study Cancellation/ Rejection 
* Outcome - Positive/ Negative 
Capture the factors which lead a project to succeed/ fail: 
* Clinical Development Plan problems 
e Time issues and highlighted hold-ups 
* Unique and common compound safety concerns 
e Safety pathways i. e. what guidelines have to be followcd? 
* Adequate Patient Safety Information for regulatory authorities 
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Novel approaches to Clinical Study techniques - e. g. piggybacking, micro 
plaque delivery approach 
Capture human management and resource problems: 
* Cost & Resource Management I 
o Identifying shared resource and teams 
* Skill Base of Participants 
9 Number of patients required for studies 
o Patient recruitment difficulties 
Departmental audit trail - which departments are using what resourcc, are 
there problems with interdepartmental relations? 
& Success according to TA or application methods 
Process and advantages of using external collaborations- Biotcchs or small 
scale manufacturing 
Capture compound characteristics to find out whether certain compounds more likely 
to succeed: 
* What are the pointers for success? 
9 What are the biomarkers? 
e Chemical similarities between other compounds 
9 Proof of Concept issues 
9 Animal Model Identification issues 
e Problems with application of compound i. e. specificity, target ctc 
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* Predicting success rates - common findings relating to compound efficacy/ 
application at the early stages 
9 Does the project allow cross over with other projects? 
3.0 CONCLUSION 
This report was written to be used as a guide to knowledge mapping. The initial 
results of this exercise are proving valuable. With ftirther research, the technique 
could be aligned with semantic technology to aid information and knowlcdge 
retrieval. 
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